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ABSTRACT
Heparin and related drugs have remained the anticoagulant of choice for medical and
surgical indications. These drugs are comprised of polycomponent sulfated chains of varying
length and biophysical structure with direct and indirect pharmacological effects. Heparins
produce their therapeutic effects by multiple mechanisms involving both the cellular and
humoral targets. These drugs represent natural products which are isolated from mammalian
tissue rich in mast cells. Currently used unfractionated heparins (UFHs) and low molecular
weight heparins (LMWHs) are mostly obtained from porcine mucosal tissue. Other animal
sources including bovine and ovine tissues also provide a source for manufacturing heparins.
While there may be microchemical and biophysical differences, heparin from different origins
produce anticoagulant effects, which can be standardized using various methods which include
the whole blood clotting, global anticoagulant studies and serpin mediated inhibition of such
enzymes as thrombin and factor Xa. The USP method represents a biochemical assay which is
commonly used for potency standardization of heparins whereas the NIBSC standard is used for
the potency standardization of LMWHs.
The global regulatory agencies are currently considering the introduction of bovine and
ovine unfractionated heparins. Worldwide, there are 1.4 billion cattle, 1.9 billion sheep and goats
and 980 million pigs. Both cow and sheep provide potential alternate sources of porcine heparin.
With the advances in technology and manufacturing processes, higher quality bovine and ovine
heparins are now available in various parts of the world and have been shown to exhibit similar
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biologic and clinical profiles compared to porcine products. Standardized UFHs and LMWHs
produce comparable anticoagulant activity and antiprotease activites in vitro. However, their
pharmacokinetics and pharmacodynamics profiling has not been studied. Furthermore, their
mechanisms involving additional cellular and humoral actions have not been studied.
The primary purpose of this dissertation was to compare the structural and functional
characteristics of bovine mucosal (BMH), ovine mucosal (OMH) and porcine mucosal (PMH)
heparins and their depolymerized LMWH counterparts. Furthermore, to test the hypothesis that
“Despite molecular components distribution and minor structural differences, potency referenced
heparins of different animal origins and their depolymerized derivatives may exhibit similar
pharmacological activities”. For this investigation, one batch of each heparin and LMWH source
were utilized. Their activities in biochemical and biological assays were compared in order to
elucidate how their molecular composition and structural attributes affect their pharmacological
actions.
In order to compare the molecular and structural differences of UFHs and LMWHs, such
analytical methods as gel permeation chromatography (GPC) and nuclear magnetic resonance
(NMR) were utilized. Other biophysical methods including light scattering analysis (Photon
correlation spectroscopy and Zeta potential measurements) were used. A comprehensive
profiling of the anticoagulant and antiprotease actions of these agents with reference to serine
protease inhibitors (serpins) mediated modulation of the hemostatic system along with cellular
effects of these agents were investigated in whole blood and defined biochemical systems. The in
vivo behaviors of UFHS and LMWHs have been investigated in terms of multiple PK and PD
parameters in simulated settings and by utilizing a validated non-human primate (Macaca
mulatta) model.
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These investigations have demonstrated that BMH, OMH and PMH exhibit similar
molecular and structural profiles with minor differences. BMH showed weaker anticoagulant and
antiprotease activities compared to OMH and PMH and this weaker effect was not observed
when using potency adjusted-based BMH. The molecular and structural profiles of all LMWHs
were comparable and all produced similar anticoagulant and antiprotease activities at the
functional studies. The in vitro and in vivo neutralization profiles of all heparins were
comparable and both protamine sulfate (PS) and platelet factor 4 (PF4) effectively neutralized
these agents. However, the LMWHs were only partially neutralized in a comparable and an assay
dependent fashion. Studies in platelet-based systems showed that agonist induced platelet
aggregation (AIPA) profile and the heparin induced platelet aggregation (HIPA) antibody
interactions among all heparins and LMWHs from different species were comparable.
In vivo studies in a non-human primate model showed that, the anti-Xa and anti-IIa
effects of OMH and PMH were significantly stronger compared to BMH after IV administration.
However, BMH showed significantly longer half-life (t1/2) compared to PMH and OMH with no
major variations in AUC, Vd and CL parameters between each agent. In regard to LMWHs, all
agents demonstrated similar anti-Xa and anti-IIa effects and comparable PK/PD parameters with
no significant differences. Additional functional PD parameters including endogenous tissue
factor pathway inhibitor (TFPI) release and thrombin generation potential showed comparable
effects with potency adjusted UFHs and LMWHs. The absolute PK parameters as measured by
quantifying glycosaminoglycan (GAG) contents were consistent to the results obtained in the
PK/PD studies.
In conclusion, this dissertation has validated the hypothesis that potency adjusted UFHs
and LMWHs of different origins are comparable in mediating their biologic and pharmacologic
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actions. Thus, the cross-referencing of these drugs with established pharmacopeial standards
provides agents with comparable anticoagulant actions and can be interchanged at comparable
potencies. These studies require clinical validation to demonstrate the bioequivalence which will
harmonize their use.

xxxiv

CHAPTER ONE
REVIEW OF LITERATURE
Blood and Coagulation Process
Blood is a bodily fluid that delivers necessary substances such as nutrients and
oxygen to the cells and transports metabolic waste products away from those same cells.1 It
has four main components; plasma, red blood cells (RBCs), white blood cells (WBCs) and
platelets. Other functions of blood include, transporting hormones and other signals
throughout the body and regulating body pH and core body temperature.1,2
One of the most important functions of blood is coagulation. Coagulation is one part
of the body’s self-repair mechanism (blood clotting by the platelets after an open wound in
order to stop bleeding).1,2 Injuries of blood vessels may cause disruption to the integrity of
our vascular system. The ability of the body to respond to such an injury is known as
hemostasis. This is the process by which blood changes from a liquid to a gel, forming a clot
to stop bleeding and to keep the blood within a damaged vessel. This process involves
vascular constriction, platelet plug formation, and clotting of the blood.1,2
Vasoconstriction is the initial response to a blood vascular injury. Several factors are
involved in vasoconstriction including direct injury to the vascular smooth muscle, reflexes
initiated by local pain receptors, and mediators released by endothelial cells and platelets
which include von Willebrand factor, ADP, and thromboxane.3,4 Vasoconstriction alone can
significantly reduce blood loss for 20-30 minutes, providing time for the formation of a
platelet plug and blood clot.

1
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Numerous platelet adhesive proteins and activators participate in platelet plug
formation.3,4 Von Willebrand factor (vWF) is an adhesive protein which interacts with other
adhesive proteins and activators like collagen, factor VIII, and other clotting factors.
Circulating platelets bind to collagen via the glycoprotein Ia/IIa receptors located on their
surface. Additional circulating vWF further strengthens this adhesion by forming additional
links between the platelets and the collagen fibrils, leading to the activation of platelets.3,4
Platelets contain two different storage granules, α (light) and β (dense). The α storage
granules contain platelet derived growth factor (PDGF), fibrinogen, fibronectin, platelet
factor 4 (PF4), β-thromboglobulin, thrombospondin-1, factor V, platelet activating factor
(PAF), and von Willebrand factor (vWF).5-7 The β granules contain ADP, ATP, histamine,
calcium, and serotonin. Once platelets are activated, the contents of α and β granules are
released and cause various actions such as further platelet aggregation, activation of
additional circulating platelets, and promotion of coagulation.5-7 Aggregating agents, or
agonists, found in the circulation, as well as those released from the platelets themselves,
induce further release of the platelet storage granule contents. Some of these agonists include
ADP, collagen, thrombin, thromboxane (TXA2), platelet activating factor (PAF), serotonin,
epinephrine, fibrinogen, and immune complexes.5-7
Platelets express a variety of receptors for such mediators as the TXA2, serotonin,
epinephrine, collagen and thrombin receptors.8 Additionally, a number of glycoproteins also
present on the membrane surface which serve as receptors for vWF (GP Ib), collagen (GP
Ia/IIa), fibronectin (GP IIb/IIIa), and fibrinogen (GP IIb/IIIa).9
Subsequent to the activation of platelets, aggregates are formed at the injury site
through fibrinogen bridges linking glycoprotein IIb/IIIa receptors which are located on
adjacent platelets. These aggregating platelets create a platelet mesh or plug. Although the
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platelet plug initially arrests blood loss, a fibrin-based clot is necessary in order to stabilize
the mesh and allow it to withstand the shear force of blood flow. This overall process is
facilitated by the coagulation system.9
Blood coagulation is a complex process consisting of the extrinsic, intrinsic, and
common pathways (Figure 1). The extrinsic pathway, or tissue factor pathway, is activated
when the endothelial lining of blood vessels is damaged, which can result from a cut, other
abrasive injuries, or even the rupture of atherosclerotic plaques.10 The opening in the injured
vessel wall exposes tissue factor (TF), a cell surface glycoprotein (45 kDa), to flowing blood.
TF is expressed by sub-endothelial cells, cells surrounding blood vessels, which are not
normally exposed to circulating blood and white blood cells (WBC). TF is the cell surface
receptor for the serine protease factor VIIa (FVIIa).11 Exposure of TF to blood allows for the
formation of an activated TF/FVIIa complex. This TF/FVIIa complex then converts the
protease FX into FXa.11,12
An amplification cascade of events activates the serine proteases of the intrinsic
(contact) pathway.13 Activation of the contact pathway is initiated with the formation of a
complex composed of high-molecular-weight kininogen (HMWK), prekallikrein, and factor
XII (FXII) on a collagen support.13 Both prekallikrein and FXII are converted to their active
forms by the formation of this complex. FXIIa then converts FXI into FXIa, which then
activates FIX. Factor IXa, along with its co-factor FVIIIa, form the tenase complex with the
substrate, FX. The formation of this complex leads to the activation of FX to FXa.14
Together, the extrinsic and intrinsic pathways of coagulation converge at the common
pathway and cause the activation of FX to FXa as shown in Figure 1. Factor Xa is the final
enzyme required for the conversion of prothrombin to its active form, thrombin. Activation of
one molecule of FX leads to activation of thousands of prothrombin enzymes. This process
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occurs when FXa complexes with its co-factor, factor V, and Ca2+on a phospholipid surface
to form the prothrombinase complex. Thrombin, or FIIa, is undoubtedly the most important
enzyme in the coagulation cascade.14 Thrombin’s most critical function in the coagulation
cascade is the conversion of soluble fibrinogen into insoluble strands of fibrin which are the
building blocks for the hemostatic plug or mesh. However, thrombin has many other
functions that are also important for maintaining hemostasis. Initially, thrombin acts to
convert factor XI to XIa, VIII to VIIIa, and V to Va; these are positive feedback mechanisms
by which amplification of the cascade can occur. Subsequently, thrombin can also activate
factor XIII to XIIIa (FXIIIa) which increases the stability of the fibrin clot by crosslinking
fibrin polymers. Finally, thrombin promotes platelet activation and aggregation by activating
protease-activated receptors on platelet membranes.13-15

5

Coagulation Cascade, Chapter 38, Robbins Basic Pathology, 10th Edition

Figure 1. The coagulation cascades: The intrinsic pathway (which has less in vivo significance in
normal physiological circumstances than the extrinsic cascade) is initiated when contact is made
between blood and exposed negatively charged surfaces. The extrinsic pathway is initiated upon
vascular injury which leads to exposure of tissue factor, TF (also identified as factor III), a
subendothelial cell-surface glycoprotein that binds phospholipid. The two pathways converge at the
activation of factor X to Xa. Active factor Xa hydrolyzes and activates prothrombin to thrombin.
Thrombin can then activate factors XI, VIII and V furthering the cascade. Ultimately the role of
thrombin is to convert fibrinogen to fibrin and to activate factor XIII to XIIIa. Factor XIIIa (also
termed transglutaminase) cross-links fibrin polymers solidifying the clot. HMWK: high molecular
weight kininogen.
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Fibrinogen is a high MW protein which is converted by thrombin into fibrin and
consequently formation of a fibrin clot during the coagulation process.16 The fibrin clot is
stabilized by the action of factor XIIIa. Fibrinogen and fibrin have several roles in
coagulation, fibrinolysis, and inflammatory processses.16,17 These functions are regulated by
interactive sites on fibrin/fibrinogen that are unmasked by the conversion of fibrinogen to
fibrin. Once the clot is formed, endogenous mechanisms are triggered to dissolve it through a
complex enzymatic process. This fibrinolytic process results in the dissolution of the fibrinbased clot, leading to the generation of fibrin degradation products. The fibrinolytic process
removes excessive fibrin deposits to improve blood flow following thrombus formation
facilitating the healing process (Figure 2).
Fibrinolysis has two types: primary fibrinolysis and secondary fibrinolysis. The
primary type is a normal body process, whereas secondary fibrinolysis is the breakdown of
clots due to drugs, a medical disorder, or some other cause. Fibrinolysis is important for the
restoration of normal blood flow.16-18 The fibrinolytic system consists of the enzymes
responsible for clot dissolution. Similar to the coagulation factors, the main fibrinolytic
enzyme, plasmin, is produced as a proenzyme, plasminogen, in the liver and activated when
cleaved into its enzymatic form. The breakdown of a clot is a necessary part of the healing
and tissue repair process. Plasmin cleaves the fibrin meshwork, degrading the clot. This
forms fibrin split products, including D-Dimer, which can be detected in the blood as
biomarkers of clot breakdown. Fibrinolysis is regulated by activators such as tissue
plasminogen activator (t-PA) and inhibitors including plasminogen activator inhibitor 1 (PAI1), α2-antiplasmin, and thrombin activatable fibrinolysis inhibitor (TAFI) as shown in Figure
2.19-21
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Figure 2. Fibrinolysis is a process that results in the removal of the fibrin-based clot, leading to fibrin
degradation products and clot lysis. Furthermore, it facilitates the healing process after injury and
inflammation. Plasminogen activators, such as tissue plasminogen activator (tPA) or urokinase,
activate plasminogen to form plasmin. Plasmin enzymatically cleaves insoluble fibrin polymers into
soluble degradation products (FDP), thereby effecting the removal of unnecessary fibrin clot. Blue
arrows denote stimulation, and red arrows inhibition.

Coagulation disorders (inherited or acquired) are disruptions in the body’s ability to
control blood clotting.22 Coagulation disorders can result in either a hemorrhage (too little
clotting that causes an increased risk of bleeding) or / and thrombosis (too much clotting that
causes blood clots to obstruct blood flow).22
Coagulation disorders resulting in bleeding represents hemophilia A (a deficiency of
Factor VIII) hemophilia B (deficiency of Factor IX), Von Willebrand disease (most common
inherited bleeding disorder and it develops when the blood lacks von Willebrand factor) and
other clotting factor deficiencies (Factor II, V, VII, X, or XII) which are important enzymes
for the integrity of the coagulation process as shown in Figure 1. Furthermore, disseminated
intravascular coagulation (DIC) may also result in excessive bleeding where small blood
clots develop throughout the bloodstream and block small blood vessels. The increased
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clotting depletes the platelets and clotting factors needed to control bleeding, causing
excessive bleeding. Liver diseases, vitamin K deficiency and platelet dysfunction (Platelets
are too low or do not work properly) are also common causes of bleeding disorders. Some
bleeding disorders can result in severe bleeding following an accident or injury or it can
happen suddenly and for no reason.22
Hypercoagulable state may be a result of congenital and acquired factors. The genetic
form of this disorder means a person is born with the tendency to form blood clots.23 While,
the acquired conditions are usually a result of surgery, trauma, medications or a medical
condition that increases the risk of hypercoagulable states and clots formation. The common
causes of inherited hypercoagulable conditions include factor V Leiden (the most common),
prothrombin gene mutation and deficiencies of natural proteins that prevent clotting (such as
antithrombin, protein C and protein S).
Additionally, the elevated levels of homocysteine, fibrinogen (dysfibrinogenemia)
and other factors (VIII, IX and XI) are causes of genetic hypercoagulable states.23 Moreover,
the dysfunction of the fibrinolytic system (genetic) including hypoplasminogenemia,
dysplasminogenemia and elevation in plasminogen activator inhibitor (PAI-1) level may also
result in thrombosis. Acquired hypercoagulable conditions include cancer, HIV/AIDS,
obesity, pregnancy and nephrotic syndrome (too much protein in the urine). Furthermore,
some drugs may lead to acquired hypercoagulable states such as oral contraceptives, hormone
replacement therapy, tamoxifen, bevacizumab and prothrombin complex concentrate.23
Such conditions as surgery, cancer, immobilization, hospitalization, patient-related
factors and malignancy may result in venous thromboembolism (VTE).24 VTE includes deep
vein thrombosis (DVT) and pulmonary embolism (PE) and it occurs in ∼1 to 2 individuals
per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States
annually. 24 DVT is a serious condition that occurs when a blood clot forms in a vein located
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deep inside the body. This deep vein blood clot typically forms in the thigh or lower leg but
can also develop in other areas of the body.24 A blood clot that travels to the lungs from deep
veins in the legs or from veins in other parts of the body (DVT) is known as PE. According to
American Society of Hematology (ASH) 2020 guidelines, the management of DVT includes
the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of
an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR range for
patients with VTE who use a vitamin K antagonist (VKA) for secondary prevention, and use
of indefinite anticoagulation for patients with recurrent unprovoked VTE.
Current recommendations include the preference for home treatment over hospitalbased treatment for DVT and PE at low risk for complications and a preference for direct oral
anticoagulants (DOACs) over VKA for primary treatment of VTE.25 Heparins, in particular,
LMWHs have become the standard of care of the management of VTE along with DOACs
such as rivaroxaban, apixaban, betrixaban and dabigatran. Fondaparinux is also used for the
prophylaxis of VTE after surgery. More recently, both the UFHs and LMWHs have also been
used in the management of thrombotic complications observed in COVID-19 patients. 26
Heparin and Related GAGs
The discovery of heparin dates back to 1916 when a medical student named Jay
McLean isolated a fat-soluble anticoagulant compound (phosphatides) from dog livers, when
he was working in the laboratory of William Henry Howell.27,28 In 1918, Dr. Howell termed
this assumed phosphatide “heparin” to reflect its origin. However, by 1922, Dr. Howell’s
research determined that heparin was actually a carbohydrate and not a phosphatide as
originally assumed.27 That same year, heparin became commercially available from a
company known as Henson, Westcott & Dunning.28 Starting the early 1930s, Howell and
other began studying the effects of heparin in humans and those studies were continued
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throughout the 1930s by other laboratories. Until today, heparin continues to be used for the
treatment and prophylaxis of a variety of thrombotic related diseases.29
Heparin has the highest negative charge density of any known biological
macromolecule due to its high content of negatively charged sulphated and carboxylic
groups.30 It belongs to a family of long unbranched polysaccharides known as
glycosaminoglycans (GAGs). It is comprised of repeating units of sulfated glucosamine and
uronic acid (either iduronic or glucuronic) connected by 1-4 linkages (Figure 3). The major
sites of sulfation are the 2-N and 6-O positions on glucosamine residues and the 2-O position
on iduronate residues. The mean degree of sulfation is about 2.0-2.5 per disaccharide unit.30,31
UFH is comprised of molecular components that vary in molecular weight from 2-40
kDa. It is a heterogeneous polymer with several different biological functions, including
inhibition of blood coagulation, inhibition of platelet aggregation, profibrinolytic effects,
release of endogenous mediators such as tissue factor pathway inhibitor (TFPI), and plasma
clearing effects through its action on lipoprotein lipase.32

Diapharma.com/wp-content/uploads/2016/02/heparin-structure

Figure 3. (A) Heparin composed of repeating disaccharide units of D-glycosamine and uronic acid
linked by 1→4 interglycosidic bonds. The uronic acid residue could be either D-glucuronic acid or Liduronic acid. (B) is the pentasaccharide sequence required for antithrombin binding (AT).
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Glycosaminoglycans (GAGs) are linear acidic polysaccharides that are classified into
four distinct families according to the specific disaccharide repetitive units which are
characteristic for the heparin/heparan sulfate glycosaminoglycans, the chondroitin sulfate and
dermatan sulfate galactosaminoglycans, keratan sulfate, and hyaluronic acid. Each GAG is
characterized by the prevalent disaccharide repetitive units, but each single chain generally
contains differently sulfated or acetylated amino sugars and/or uronic acid (Figure 4). The
structural heterogeneity of GAGs and their high negative charge density allow these compounds
to easily interact with proteins. Most of the biological and pharmacological activities of GAGs
are mediated by their ability to bind proteins such as growth factors, enzymes, morphogens, cell
adhesion proteins and cytokines.33

GAGs derived drugs include sulodexide, danaparoid and chondroitin sulfate which
have been used in the management of vascular disorders including chronic venous
insufficiency, and unprovoked thrombosis. Sulodexide represents a mixture of fast-moving
heparin and high MW dermatan sulfate (DS) and it is the only GAG derived agent which has
demonstrated oral bioavailability.34 Danaparoid represents a mixture of heparan sulfate (HS)
and DS with mild anticoagulant activities and is used for the management of anticoagulation
in patients with HIT.35 Several other drugs based on keratan sulfate and hyaluronic acid have
been also developed for various indications.
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Figure 4. GAGs are a family linear polysaccharides consisting of repetitive disaccharide units
composed by a hexosamine (D-glucosamine or D-galactosamine) and an uronic acid sugar (Dglucuronic acid, L-iduronic) or a D-galactose, linked by glycoside linkages. GAGs are classified
according to their structure into four distinct families glycosaminoglycans heparin/heparan sulfate
glycosaminoglycans (A), chondroitin sulfate & dermatan sulfate galactosaminoglycans (B), keratan
sulfate (C), and hyaluronic acid (D).

Origins of Heparin
Heparin (UFH) is a highly sulfated polysaccharide that is manufactured from either
lung or intestinal animal mucosa of mammalian origins. However, the original tissue which
heparin was extracted was dog liver, but this source was not suitable for cultural reasons and
large-scale production.27,28 The use of bovine liver, and then of bovine lung, allowed larger
quantities of drug to be produced, which was first marketed in 1939 as a pharmaceutical
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product in USA. Bovine lung continued as a source of heparin until the mid-1950s, when
porcine (PMH) and bovine intestinal mucosa (BMH) were introduced as alternative sources.
Both sources were subsequently found to be a cleaner and cost-effective source tissue,
requiring fewer steps in the extraction and purification processes than bovine lung heparin.36
Currently, pharmaceutical heparin is obtained primarily from porcine intestinal
mucosa where one pig gut yields in the order of one heparin dose. Although there is a distinct
repeating unit and consistent batch to batch similarities, each heparin batch is composed of
numerous polysaccharide chains that have distinct sequences and lengths regardless of
comparable averaged MW.37 Despite this variability, porcine intestinal mucosa heparin
remains a reliable and very widely used anticoagulant.
In the past, bovine lung and ovine intestines were also used as alternative heparin
sources.38 Porcine intestinal heparin widely replaced bovine heparin (BMH) after the
adoption of the 3rd International Standard by the World Health Organization (WHO) in 1973,
which mandated heparin to be porcine mucosal (PMH) in origin.39 Since then, the use of
ovine and bovine heparins is fairly limited around the world. The main use of bovine
intestinal heparins (BMH) is in the Middle East, whereas ovine intestinal heparin (OMH) has
been used in Asia.40 Porcine intestinal heparin is widely used by the rest of the world. This
shift towards the use of porcine intestinal heparin was primarily due to concerns of bovine
spongiform encephalopathy (mad cow disease) and scrapie through the parental use of
heparin derived from infected animals.40
During the last decade, many groups have attempted to develop bioengineered or
synthetic heparins with defined pharmacokinetics and pharmacodynamics profiles. These
agents do not have any viral or prion impurities (unlike animal-sourced materials), are
bioavailable via alternate routes and produced under current good manufacturing process
(cGMP).41-46 At this point, these agents are not cost-effective for clinical use. Moreover, these
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agents are not readily reversible by PS and will required alternative approaches. Since
porcine heparin is primarily used globally around the world, the risk of supply shortages due
to high demand needs to be addressed. Additionally, the cost of heparin has continually
increased during the past several years.47 Moreover, due to cultural and religious reasons in
some countries, there is a large demand for alternative sources of heparins. Worldwide, it is
estimated that there are 1.4 billion cattle, 1.9 billion sheep and goats, and 980 million pigs.47
With advances in purification technology and manufacturing processes, higher quality bovine
and ovine heparins are now available. Additionally, biological contaminants such as BSE can
be eliminated.48,49 The US FDA and other regulatory agencies such as EMA, are currently
reviewing the possibility of substituting porcine heparin with heparin from other sources.50,51
Several Brazilian and Chinese manufacturers produce bovine and ovine heparins for clinical
use. Bovine and ovine heparins have the potential to fill an unmet need not only for people
with religious constrains but may also provide an alternate source of heparin in worldwide.
Heparin derived from different animal sources or different organs of the same animal
exhibit a number of subtle structural differences. Notably, bovine lung heparin contains much
more trisulfated disaccharide I2S-ANS,6S than porcine mucosal heparin, while bovine
mucosal heparin (BMH) exhibits lower sulfation at the 6-O position of the glucosamine
residues than either bovine lung or porcine mucosal heparins, as well as more sulfation at the
2-O position of the glucuronic acid residue.52-54 Several recent studies have demonstrated the
existence of different AT binding pentasaccharide molecular variants with diverse non-reducing
reducing end extensions; whose molecular ratios provide further fingerprints of the structural
diversity among heparins of different origins.55-57

Biosynthesis of Heparin
Heparin is mainly found in mast cells, where it is synthetized and interacts with
proteins or inflammatory mediators. The studies on its biosynthesis started with
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investigations on how mast cell granule fraction incorporated radioactively labeled UDPsugars into a polysaccharide that was degradable with heparinase.58 The biosynthesis of
heparin occurs primarily in the endoplasmic reticulum and Golgi apparatus of mast cells,59
and it starts with the formation of the linkage region attached to a serine residue on a core
protein, followed by the addition of D-glucuronic acid (1→4) N-acetyl-D-glucosamine
disaccharide units (Figure 5).
The linkage region synthesis is catalyzed by four enzymes that add the individual
monosaccharide to the growing chain, first the attachment of xylose (Xyl) followed by a
stepwise transfer of two galactose (Gal) and one glucuronic acid (GlcA) residues.60 The
enzymes that are involved in this initialization are, a xylosyltransferase, which exists in two
isomeric forms, galactosyltransferases (type I and type II) and glucuronyltransferase, that has
only one form.61-63 Then, the elongation continues with the addition of a N-acetyl-Dglucosamine (GlcNAc), followed by the addition of alternating glucuronate and N-acetylglucosamine residues.60 The elongation of the chain leads to the formation of a
polysaccharide with a molecular weight of 60-100 kDa, whereas, the mean Mw range of the
commercial API heparin lies between 15-20 kDa.
The biosynthesis is mediated by a total of 12 enzymes involved in sulfonation and
epimerization processes (Figure 5). Because of there are isoforms of these enzymes, heparin
results as a heterogeneous polysaccharide. The degree of sulfation and the localization of the
sulfate residues determines the functional activities and biophysical interactions of heparins.
Upon mast cell degranulation, heparin peptidoglycan is transformed to the GAG heparin
through the action of proteases and β-endo glucuronidase. The substrate specificity of the
various enzyme varies according to the organ and the animal species, but the mechanisms of
these differences remain unexplored.64
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Figure 5. Heparin biosynthesis in mast cells, where it is synthetized, and it can interact with proteins
or inflammatory mediators. The biosynthesis is mediated by a total of 12 enzymes involved in
sulfonation and epimerization processes.

Most of the enzymes that are involved in modifying heparin chains have now been
isolated, purified, characterized and molecularly cloned. Some of these enzymes are
produced by recombinant technology at industrial scale. GlcNAc N-deacetylase/Nsulfotransferase (NDST), the glucosaminyl 6-O-sulfotransferases (6OST), and the
glucosaminyl 3-O-sulfotransferases (3OST) each represent a gene family whose members
appear to be expressed in a tissue-specific and developmentally regulated pattern.65 It is now
well known that the sulfation level of heparin chains plays a crucial role in terms of its
anticoagulant activity. These sulfation levels are determined by the expression levels of
specific modification enzymes but how that expression is regulated is not well-known. 66 The
enzymes that most relevant for increasing the sulfation levels of AT binding sites are 3OST
and 6OST enzymes. The AT- pentasaccharide binding sequence contains a critical 3-Osulfated group on the central glucosamine and a critical 6-O-sulfate group on the non-
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reducing end glucosamine. These two sulfate groups are responsible for more than half of the
binding energy of the interaction between heparin and its ligands such as AT. 67
Heparin and related GAGs are ubiquitous and distributed widely in animal tissues.
Cellular systems from simple invertebrates to humans, have the capacity to produce various
heterogenous polysaccharides (GAGs) such as heparin and heparan sulfate (HS). Heparin can
be characterized in terms of disaccharide composition; the disaccharides are distinguished by
the presence of specific sulfated or non-sulfated GlcA/IdoA and GlcN residues. Generally,
the same group of disaccharides exists in most tissues, but their relative content varies. For
example, the disaccharide GlcA-GlcNS3S occurs predominantly in endothelial cells and
connective tissue mast cells, as this unit is a critical substructure in the pentasaccharide
sequence that binds antithrombin (AT).68 In contrast, kidney heparin contains a large amount
of IdoA2SGlcNS3S, but the precise function of this disaccharide in ligand binding is not
known.69
Another approach to characterize heparin structure is in terms of the relative
distribution of the major N-substituents of the GlcN residues: N-acetylated disaccharide units
(NA domains), N-sulfated sequences of variable length (NS domains), and alternating Nacetylated and N-sulfated units (NA/NS domains). Such N-substitution patterns appear to be
characteristic of the cells/tissues from which the HS/heparin are obtained. In particular,
heparin (the mast cell polysaccharide) may be considered essentially a single, unusually
extended NS domain. Since other modifications, such as O-sulfation and epimerization of
GlcA to L-IdoA, depend on prior N-sulfation of GlcN units, the modified disaccharide units
tend to cluster in the NS or NA/NS domains.70
Mechanisms of Actions of Heparin
Heparin primarily mediates its anticoagulant activity mainly through its ability to bind
and to enhance the inhibitory activity of the plasma protein antithrombin (AT). In 1939,
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heparin was shown to mediate its biological functions through a plasma protein, known as
heparin cofactor (HCII).71 The proposal that this heparin cofactor may actually be
antithrombin (AT) was independently made by Seeger and Fitzgerald in 1950s.72 It was not
until 1968 when Abildgaard isolated the plasma component similar to the previously reported
heparin cofactor and renamed it antithrombin (AT).72 Rosenberg and his colleagues then
confirmed that AT was indeed the main heparin cofactor.73,74
AT is a globular glycoprotein produced by the liver that consists of 432 amino acids
with a molecular weight of 58 kDa.75,76 AT is a serine protease inhibitor and is considered
one of the most important anticoagulant molecules in mammalian circulatory systems.
Protease inhibitors of the serpin superfamily play a critical role in regulating proteases in
diverse physiologic processes such as development, wound healing and the immune response.
The family name is an acronym for serine protease inhibitor, but it is now well established
that serpins inhibit proteases of both the serine and cysteine mechanistic classes.77-79 The
main targets of AT are thrombin and factor Xa; however, AT can inhibit several other serine
proteases including IXa, XIa, XIIa, kallikrein, and plasmin. AT binds thrombin in a 1:1
stoichiometric complex.80,81 The complexation of heparin with AT causes an approximate
1000-fold increase in the rate of thrombin inactivation by this serpin.81 As shown in Figure 6,
the interaction between AT and heparin is dependent on a well defined unique
pentasaccharide sequence (Figure 3) within heparin.82,83
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Figure 6. A) UFH main MoA, (B) LMWH main MoA. The main targets of AT are thrombin and
factor Xa of the coagulation cascade. The interaction between AT and heparin is dependent on a welldefined unique pentasaccharide sequence within heparin. The AT/heparin interaction produces a
conformational change in the structure of AT, enabling additional interactions between AT and
heparin, resulting in stronger binding. The strong inhibition of thrombin is due to a template
mechanism of activation, whereby both AT and thrombin bind adjacently on the same heparin chain.
A minimum heparin chain length of 18 saccharides is required for thrombin inhibition by AT. The
AT/heparin interaction produces a conformational change in the structure of AT. This conformational
activation mechanism promotes binding of AT to the active site of factor Xa.

The AT-heparin interaction produces a conformational change in the structure of AT.
This change enables additional interactions between AT and heparin, resulting in a stronger
binding.84,85 After complex formation, the AT interaction reverts to low-affinity binding
resulting in the release of heparin from the covalent AT-factor Xa complex.84,85
Thrombin inhibition occurs through a template mechanism, whereby both AT and
thrombin bind adjacently on the same heparin chain. It is now established that, a minimum
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heparin chain length of 18 saccharides (the pentasaccharide sequence and an additional
adjacent 13 saccharides) is required for thrombin inhibition by AT. Negative charges present
at the extended heparin polysaccharide units bind non-specifically to the exosite (positively
charged region) of thrombin.85 A strong ternary complex between AT, thrombin, and heparin
is formed. This complex produces a substantial increase in the rate of inhibition of thrombin.
Due to the random distribution of the heparin pentasaccharide in heparin, lower MW
fragments of heparin are not be able to bind to or inhibit thrombin. Thus, heparin chains in
the MW range of 5-10 kDa have a progressive increase in mediating thrombin inhibition.85
Besides binding to AT, heparin can also interact with another Serpin known as
heparin cofactor II (HCII). This inhibitor has a considerable sequence homology to AT. HCII
consists of a single-chain glycoprotein which is 480 amino acids in length.86 Unlike AT,
HCII can only inhibit thrombin, where no specific oligosaccharide sequence needed (only
dependent on high negative charge). Heparin catalyzes the formation of the HCII-thrombin
complex, which increases the rate of thrombin inhibition ~1000-fold. HCII can inhibit the
proteolytic enzyme, chymotrypsin.87,88
Protein C is a vitamin K-dependent factor, which is activated by thrombinthrombomodulin complex, forming activated protein C (APC), which in the presence of a cofactor (protein S) acts as an anticoagulant by inactivating factors Va and VIIIa. Additionally,
when complexed with endothelial protein C receptor, exhibits a cytoprotective effect through
modulation of expression of genes related to anti-inflammatory and anti-apoptotic
pathways.89 The activity of APC is mainly regulated by protein C inhibitor (PCI), an inhibitor
from the serpin family. Heparin can modulate PCI activity not only by potentiation of
antithrombin inhibition of thrombin, but also through a direct interaction with PCI. The
inhibition of thrombin leads to a decrease in the activation of protein C, thereby limiting the
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inactivation of FVa and FVIIIa. In addition, heparin has been shown to inhibit the
inactivation of factor Va by APC.90,91
Tissue factor (TF) is the main mediator by which thrombin generation is initiated in
response to vessel damage (extrinsic pathway).92 TF is a 45 kDa transmembrane glycoprotein
which is located at extravascular sites that are not normally exposed to the blood.93 Tissue
factor pathway inhibitor (TFPI) is a pleiotropic serine protease inhibitor. Besides being the
main physiological inhibitor of the extrinsic coagulation pathway, it also has important
influence in lipid metabolism, innate immunity and angiogenesis.94 It has high affinity for
heparin, essential for the expression of its anticoagulant activity; binding and FXa inhibition
studies of heparin oligosaccharides and recombinant TFPI indicated that a dodecasaccharide
is the minimum sugar chain length that will enhance the inhibitory activity of TFPI and that
saccharide units greater than an octadecasaccharide are needed to achieve full potentiation, as
observed with unfractionated heparin.95 Heparin has been shown to release a pool of TFPI
that is bound to glycosaminoglycans on the surface of the endothelium.96 Furthermore,
heparin upregulates TFPI gene expression which causes the elevation of both plasma and
cellular TFPI pools.97,98
Depolymerization of Heparin
Low molecular weight heparins (LMWHs) prepared from heparin through different
depolymerization processes which include chemical, enzymatic and physical approaches.
These agents possess several therapeutic advantages and reduced side effects in comparison
to UFHs.99 Owing to their lower molecular weight compared to the parent heparins, LMWHs
exhibit a more predictable pharmacological profile, better bioavailability and longer halflife.100 The structural heterogeneity that is biosynthetically imprinted, as well as the
introduction of additional chemical characteristics induced by the depolymerization process,
make their structure even more complex than that of heparin.101 Although heparin is the
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standard of care for treatment of various thrombotic diseases, including VTE, DVT, and PE,
it exhibits some pharmacologic disadvantages. LMWHs are an important alternative to UFH
with several advantages, such as higher bioavailability, enhanced safety (less bleeding and
thrombocytopenic potential), greater convenience (fewer injections), and better efficacy
(lower rate of thrombotic events). Some of the most common commercially available
LMWHs are enoxaparin sodium, dalteparin sodium, tinzaparin sodium, ardeparin sodium,
and second-generation LMWH, bemiparin sodium.102
LMWHs are produced by controlled enzymatic or chemical depolymerization of UFH
either by heparinase, a combination benzylation followed by alkaline hydrolysis, nitrous acid
degradation, or peroxidative cleavage.103 Physical methods such as radiation and sonic
degradation are also used. The different methods produce LMWHs with different
biochemical and pharmacological profiles. Therefore, LMWHs are not interchangeable
unless parallel clinical trials have been performed for each specific clinical indication.104
LMWHs consist of short chain polysaccharides, which are approximately one-third the size
of UFH. LMWHs are defined as heparin salts having at least 60% of all chains with a
molecular weight less than 8.0 kDa. On average, LMWHs have molecular weights ranging
between 3.5 to 6.5 kDa.105
The three major approaches for LMWHs preparation are depolymerization by
chemical deamination and β-elimination, either enzymatically or chemically (Figure 7).103
The chemical β-eliminative method to produce enoxaparin (A) is based on cleavage, in
alkaline medium, of the benzyl ester of heparin, which is formed by treatment of the heparin
benzethonium salt with benzyl chloride.106 Under these conditions, β-elimination generates
an unsaturated uronate residue at the non-reducing end and an N-sulfo-glucosamine at the
reducing end. Similarly, in enzymatic depolymerization (B), the action of heparinase I
generates an unsaturated uronate residue at the nonreducing position. However, this residue is
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mostly 2-O-sulfated due to the preference of the enzyme for the -GlcNNS-IdoA2Ssequence.107 Heparin undergoes nitrosylation at the amino group of N-sulfo-glucosamine (C);
the unstable N-nitroso-sulfonamide residues rearrange to generate a carbocation in 2C and the
subsequent ring-contraction and hydrolysis of the adjacent glycosidic bond generate an
anhydromannose residue, that is stabilized by reduction with NaBH4 to form a terminal
anhydromannitol residue.108 The anhydromano residue is a molecular signature for the most
widely used LMWH enoxaparin.
Heparin can also be oxidatively depolymerized using free radicals generated by
different methods such as hydrogen peroxide or ionizing gamma-irradiation (D).109-111 More
specifically, in the case of parnaparin, hydrogen peroxide is decomposed in a water solution
in the presence of catalytic amount of a transition metal of a low oxidation number (copper
II). The strongly electrophilic hydroxyl radical generated by the process easily abstracts
hydrogen from alcohols, ethers, and amides, inducing fragmentation of sugar residues and the
consequent depolymerization of the chain. This cleavage generates oligomers with both even
and odd number of residues.112,113
Depolymerization procedures involved in the manufacturing of LMWHs cause some
structural alterations of the monosaccharide’s units at the site of cleavage and are
characteristic of each depolymerization procedure. Other differences, regarding the
percentage of constituent saccharides and their sulfation pattern, can also be related to both
the process and the structural features of the parent UFH used for the LMWH preparation.114
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Figure 7. Low molecular weight heparins (LMWHs) production strategies. The three major strategies
are β-elimination, either enzymatically or chemically (A & B), depolymerization by chemical
deamination (C) and oxidatively depolymerized using oxygen radicals generated by different methods
such as hydrogen peroxide or ionizing g-irradiation (D).

Because of their lower molecular weight, LMWHs have several distinct
characteristics from UFH. Firstly, in contrast to UFH, which has an anti-FXa/anti-FIIa ratio
equal to 1, LMWHs have a ratio which is greater than 1. This ratio generally increases as the
molecular weight of the compound decreases.115 A greater anti-FXa/anti-FIIa ratio denotes a
reduction in bleeding, which is often a side effect of UFH. Secondly, having smaller
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molecular weight components means LMWHs are better absorbed following subcutaneous
administration. While UFH has a bioavailability of approximately 20 to 30 percent, LMWHs
are virtually 100 percent bioavailable after subcutaneous injection.115 Moreover, the plasma
half-life of LMWHs is two to four times longer than that of UFH; however, this is dependent
on the dose, route of administration, and assay used to detect the anticoagulant activity.116
LMWHs are more predictable anticoagulants because they have a decreased
propensity to bind to plasma proteins, macrophages, and endothelial cells in comparison to
UFH. Consequently, LMWHs are less likely to cause heparin-induced thrombocytopenia
(HIT), can be administered once daily, and do not require continuous monitoring.117
Randomized clinical trials have demonstrated that individual LMWHs used at optimized
dosages are at least as effective as UFH, and probably safer. The convenient once or twice
daily subcutaneous dosing regimen without the need for monitoring, has encouraged the wide
use of LMWHs. It is well established that different LMWHs vary in their physical and
chemical properties due to the differences in their manufacturing methods and these
variances corresponds to variances in their pharmacodynamic and pharmacokinetic
characteristic.118 The World Health Organization (WHO) and the US Food and Drugs
Administration (FDA) regard LMWHs as individual drugs that cannot be used
interchangeably.118
Usually, Low molecular weight heparin dosage does not depend on patient weight and
does not require monitoring due to its predictable bioavailability, longer plasma half-life and
more predictable anticoagulant response in comparison with UFH. While LMWHs are more
expensive than UFH in terms of drug acquisition costs, several pharmacoeconomic studies
have shown that their subcutaneous administration reduces the number of necessary
laboratory monitoring and hospitalization cost.119
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Currently, several generic versions of branded LMWH are available in the market
compared to their innovative counterparts, these agents are cheaper. Many studies have
shown that generic LMWHs not only exhibit similar structural composition but also exhibit
comparable anticoagulant and antiprotease activities in comparison to their branded
counterparts.120 Currently, the FDA approves approximately 250 generic drugs per year. The
generic drug review process (ANDA [Abbreviated New Drug Application]) is clearly defined
by the U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation
and Research. 121 The approval process includes several aspects such as bioequivalence
review (human pharmacokinetics) chemistry, manufacturing, and controls review, plant
inspection and labeling review.
According to the FDA, bioequivalency is a mandatory requirement for generic drugs.
Bioequivalency is a demonstration of acceptable parameters established for bioavailability
(i.e., the extent and rate of drug absorption). Bioequivalency does not require the need of
clinical trials with generic drugs that were originally established by the brand name drug.
These bioequivalence studies usually include assay validation, dissolution studies, and in
vitro and in vivo testing of the generic drugs. Generic interchangeability between a brand
name and generic LMWH has yet to be established. Clearly the data must extend beyond
basic bioequivalence, due to the complex pharmacodynamic profile of LMWHs.122,123 At this
time, there are no clear guidelines for the regulatory bodies for the interchangeability of the
branded LMWHs and it is widely accepted that individual LMWHs are chemically unique
agents and cannot be interchanged therapeutically.
Ultra-low molecular weight heparins (ULMWHs) have been developed as an attempt
to produce safer and more efficacious anticoagulants than heparin and LWMHs. ULMWHs
are obtained by a selective and controlled depolymerization of heparin and have mean
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molecular weights ranging between 2-3 kDa. ULMWHs mainly act through the inhibition of
the coagulation enzyme factor Xa and, to a lesser extent, thrombin .124
Synthetic pentasaccharides represent sole anti-Xa agents without any antithrombin
effects. This agent was initially developed for the prevention of venous thromboembolism
(VTE). Fondaparinux was the first such drug in this class and it mediated its effect through
inhibition of thrombin generation by selectively inhibiting factor Xa. Fondaparinux exhibits
complete bioavailability by the subcutaneous route and is rapidly absorbed, reaching its
maximum concentration approximately 2 h post dosing. It has a terminal half-life of 13 to 21
h, permitting once-daily dosing. Fondaparinux has a linear pharmacokinetic profile that
exhibits minimal intra-subject and inter-subject variability, no individual dose adjustments
are required for the vast majority of the population and there is no need for routine
hemostatic monitoring.125 Several derivatives of pentasaccharides with much longer half-life
have also been developed. However, due to bleeding complications and lack of antidotes,
their clinical development was stopped.
Clinical Uses and Side Effects of Heparin
The clinical use of heparin dates back to the 1937 when it used for the prevention of
post-surgical thrombosis.126 Subsequently, indications were expended to the treatment of
established venous thrombosis and pulmonary embolism.127 Currently, it is used to prevent
blood clots after surgery, during dialysis, and during blood transfusions. The main clinical
indications for heparin are in the prevention and treatment of arterial and venous
thromboembolism, thrombotic stroke, and in certain types of coronary artery syndrome,
mainly unstable angina.127 In addition, a number of additional physiological effects have been
ascribed to heparin since its discovery almost 80 years ago, many of which are independent
from its first-described and best-characterized activity as an anticoagulant.

28
Heparin and heparan sulphate are believed to possess many additional biological
activities that include the ability to modulate embryonic development, neurite outgrowth,
tissue homeostasis, wound healing, metastasis, cell differentiation, cell proliferation and
inflammation.128,129 Heparins side effects are related to their wide variety of biological
activities. Bleeding complications are the most important safety concerns which result
primarily from dosing errors and potency issues.130 This anticoagulant activity is mainly
caused by heparin molecules with high affinity to antithrombin, which amounts to only 3050% of UFH and less than 20% of LMWHs.131 The incidence of bleeding during heparin
therapy is difficult to define, as it depends on numerous parameters including the indication,
dosage, method, and duration of heparin application, the clinical study design and definition
of bleeding, patient characteristics and type of bleeding such as type of surgery and
comedication.132
Non-bleeding complications as well as other biological activities are mediated by
binding of heparin molecules to endogenous proteins other than AT and endothelial cells.
The structural requirements for many of such interactions are not fully understood at this
time.133 Generally, the binding tendency of the negatively charged heparin molecules
increases with their chain length. As is known with UFH, competing binding partners may
even interfere with the high-affinity binding to AT and thus reduce the anticoagulant
effect.134 These non-specific bindings are much less pronounced with LMWHs, which results
not only in improved effect-based pharmacokinetics, but also may explain their reduced risk
of non-bleeding complications.
Heparin-induced thrombocytopenia (HIT) is a catastrophic side effect of this
anticoagulant. The underlying immunogenic mechanism of HIT was only recently identified
as IgG immunoglobulins that target neoepitopes on platelet factor 4 (PF4; a protein released
from activated platelets).135.136 These normally unexposed antigenic sites of PF4 are
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unmasked when PF4 complexes with heparin. Immune complexes of HIT IgG bound to PF4Heparin complexes cross-link platelet FcgIIa receptors producing platelet activation and
release of additional PF4 (Figure 8). In the presence of heparin there is continued formation
of antigenic complexes, rendering a cycle of platelet activation and platelet aggregation
associated with a highly procoagulant condition.135 Sustained platelet activation contributes
to platelet clearance and thrombin generation that can lead to both thrombocytopenia and
HIT-associated thrombosis. Patients suspected of HIT should be tested by an immunoassay
detecting HIT antibodies first, and if positive, the immunoassay result is to be confirmed by a
platelet function test such as the HIPA or the serotonin release assay (SRA).135,136 Periodic
monitoring of platelets is helpful in identifying patients at risk of developing HIT.
Extended usage of heparins may cause serious side effects such as osteoporosis and
skin necrosis.137 Osteoporosis should be monitored in all pregnant or elderly patients who
require long-term heparin anticoagulation (1-2 weeks or longer), although it might be
reversible. In recent years, the most frequent untoward side effects of heparins were reported
to be cutaneous delayed-type hypersensitivity reactions.138 Traditionally, three types of
cutaneous reactions were distinguished: urticarial lesions (immediate hypersensitivity
reactions); erythematous papules and plaques (delayed-type hypersensitivity reactions); skin
necrosis (most serious dermal reactions).139,140 Typically, skin lesions develop > 5 days
following subcutaneous administration and occur at the sites of heparin injection, although
some reports have implicated skin necrosis at sites remote from heparin injection.141
Moreover, these side effects are not life-threatening, they need attention, since they
impair the compliance of the patients and may lead to discontinuation of important
anticoagulant therapy. Minor elevations of potassium levels and liver transaminases are also
observed as well, but they are of little clinical relevance in most patients. In these cases,
routine monitoring of potassium levels is not necessary.
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Figure 8: Heparin-induced thrombocytopenia (HIT) is caused by antibodies that bind to complexes
of heparin and platelet factor 4 (PF4), activating the platelets and promoting a prothrombotic
state. HIT is more frequently encountered with unfractionated heparin (UFH) than with low molecular
weight heparin (LMWH).

The LMWHs exhibit relatively lower side effects in comparison to UFHs in terms of
lesser bleeding, lower potential of generating HIT antibodies and lesser drug interactions.
Moreover, these agents exhibit relatively higher bioavailability after SC administration in
comparison to UFHs. Furthermore, the biological half-life of these agents is much longer in
comparison to UFHs.140 Several LMWHs produced by different methods such as
enoxaparins, fraxiparin, dalteparin, tinzaparin and parnaparin have been developed for
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specific indications at approved dosages. All these agents exhibit structural and functional
heterogeneity and therefor are not interchangeable. However, the generic versions of each of
the branded LMWHs are comparable and approved for clinical use. It is noteworthy that, that
different LMWHs exhibit product specific molecular signature and anti-Xa/anti-IIa ratios.
Unlike UFHs where this ratio is one, the LMWHs exhibit a broad range of this ratio spanning
2-6. For this reason, each of LMWH is considered a distinct drug and standardized
individually. However, the generic versions of individual LMWHs can be standardized using
the established international standard for cross-referencing purposes.
Monitoring of Heparin and Related Drugs
Heparin and related drugs produce their therapeutic effect via multiple mechanisms
targeting the blood and vascular sites which include the coagulation/ fibrinolytic processes,
platelets and endothelial actions. The primary target of heparin’s anticoagulant actions is the
inhibition of FXa and thrombin. Blood- and plasma-based assays are most commonly used
for the monitoring of the anticoagulant effects of heparin and related drugs. The monitoring
approaches are dependent on the dosage, route of administration and type of heparin used.142
For the surgical and interventional procedures, UFHs are used at relatively larger
dosages reaching concentration of up to 10 U/ml. Therefore, whole blood activated clotting
time (ACT) is used to determine the circulating levels of heparins for the individual surgical
procedures.142 This is particularly useful for the post-surgical neutralization of heparins by
PS.142 Several versions of ACT are available and can be used for the accurate assessment of
circulating heparin levels and this method is dependent on the type of activator used. Plasma
based assays, are not useful for the monitoring of these higher levels. Other indirect methods
for measuring heparins at higher levels include PS titration and dye-binding assays.142
The therapeutic monitoring of UFHs was initially carried out utilizing a tilt tube
method and monitoring the clotting of whole blood.142 Currently, the therapeutic monitoring
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of heparin is accomplished by using the aPTT methods. Several versions of aPTT assay are
available and provide sensitive responses in the range of 0-1 U/ml.142 Usually the therapeutic
range is considered at a 2-3 folds increase from the base line values. The aPTT method is
based on the use of contact activators triggering the activation of intrinsic pathway of
coagulation and subsequently detected by optical or clotting methods.142 The aPTT is not
sensitive to monitor the UFHs after SC administration because of the sensitivity range.142
Thrombin time (TT) represents a sensitive method to measure heparin levels in blood
samples.142 This test is carried out by using standardized thrombin reagent in various
configurations. Thrombin reagent supplemented with calcium provides a stronger reagent
capable of detecting higher amounts of heparin. TT is also sensitive to antithrombin agents
and endogenously generated fibrin split products.142
Prothrombinase induced clotting time (PiCT) represents a new global test for the
monitoring of heparins and related anticoagulants which utilizes Russell’s viper venom as an
activation trigger.142 This test is comparable to the aPTT test; however, it measures the
inhibition of various coagulation enzymes at distinct sites. This test is more sensitive to UFHs
and LMWHs in comparison to aPTT reagents.142
The prophylactic monitoring of UFHs is usually not carried out however,
chromogenic based anti-Xa methods are used to detect lower amounts of heparins. Since the
prophylactic dosages are administered via SC route, only low molecular weight components
are absorbed.142 The prophylactic dosage of heparin does not produce any measurable
anticoagulant effects.
Thromboelastography (TEG) represents the assessment of whole blood clotting
profile utilizing a mechanical probe which is primarily capable of detecting viscoelastic
properties of blood.142 TEG represented the first global test for native clotting profile of
whole blood which can provide a composite picture of in vivo processes including the
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contribution of cellular elements. Various versions of this method are now available for the
onsite global testing of samples from patients. This test is very sensitive to heparin and
related drugs.142
LMWHs selectively catalyze the neutralization of Factor Xa which is proportional to
the functional components which bind to AT resulting in the amplification of this effect.
Plasma-based assays and isolated biochemical assays with defined conditions have been
developed.142 The currently recommended USP method is based on the inhibition of FXa by
LMWHs in defined biochemical conditions. This test is performed in conjunction with the
NIBSC standard for the potency evolution of LMWHs. For the clinical monitoring, plasma is
incubated with a known amount of FXa and its inhibition is measured using a specific
chromogenic substrate.142 In this assay, a calibration curves were made which is employed in
calculating the circulating levels of LMWHs.142 Various commercial versions of kits with
standardized reagents such as Biophen series of kits have recently become available. The inhouse methods can also be developed by using standardized agents.142
For safety reasons, complete blood counts (CBC) are also evaluated after the
administration of heparins.142 This information is useful in the assessment of blood loss,
which is reflected as a decrease in the hematocrit, reduced WBCs and platelets.
Thrombocytopenia is monitored by frequent examination of blood smears and monitoring
platelet counts. Patients administered with SC heparins are also monitored for allergic
responses and hematoma formation. 142
Structural Analysis of Heparin
Heparin is a poly-component mixture of oligosaccharides with complex structural
features. The chemical profile plays a pivotal role in determining the biological activity of
heparin.143 Various laboratory methods have been developed to analyze the structural
elements of heparin. These include gel permeation chromatography (GPC), scanning UV
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spectroscopy, heparinase digestion, mass spectrometry, and nuclear magnetic resonance
spectroscopy.144,145 All of these methods are important to understand the molecular and
structural relationships of heparins. The molecular weight profile of heparins is one of the
most important determinants for its biological activity and PK/PD profile.146
Gel permeation chromatography (GPC) is a type of size exclusion
chromatography (SEC), that separates analytes on the basis of size, typically in organic
solvents. The technique is often used for the analysis of polymers and was first introduced in
1955.147 The term gel permeation chromatography was introduced by scientists at Dow
chemical company who investigated the technique and was licensed to Waters Corporation
(Milford, Massachusetts). Subsequently this technology was commercialized for polymer
analysis such as heparin.148 GPC systems and consumables are now also available from a
number of manufacturers. It is often necessary to separate polymers, both to analyze them as
well as to purify the desired product. GPC is widely used to determine the molecular
parameters of heparins such as number average molecular weight (Mn), weight average
molecular weight (Mw), and polydispersity index.149 Additional methods such as viscometry,
ultracentrifugation, and gradient polyacrylamide gel electrophoresis (PAGE) can be used for
further analysis of the molecular weight profile of heparin.150
High-resolution analysis of heparin structure has relied on spectroscopic methods
such as proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) spectroscopy.151
NMR spectroscopy is used to determine the ratio of iduronic acid to glucuronic acid, the
content of N-acetyl-glucosamine, and the patterns and degree of sulfation. Considering its
wide breadth of analysis NMR spectroscopy has emerged as an indispensable method for the
detection and identification of both structural heterogeneities within and between heparin
samples, as well as for the detection and identification of contaminants.152,153 Following the
heparin contamination crisis (2007-2008), 300 MHz 1H-NMR spectroscopy and capillary
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electrophoresis (CE) characterization tests became part of the United States Pharmacopeia
(USP) and European Pharmacopeia (EP) heparin monographs.153 Most of the major heparin
1

H NMR signals have been assigned with 16 characteristic peaks routinely used to confirm

the presence of heparin in the sample.154 Changes to, or a lack of, any of these peaks may
indicate a contaminant or a suboptimal heparin sample. Due to the high charge density of
heparin and other GAGs, they are amenable to electrophoretic migration and separation when
placed within an electric field.155 Separation by capillary electrophoresis (CE) may be
considered similar to that of the reversed-phase high-performance liquid chromatography
(RP-HPLC) technique, but through use of narrow capillaries, allows for very small sample
quantities to be separated. Since the addition of NMR and CE in 2008, the monograph has
been updated, prescribing a higher field strength, that of a 500 MHz NMR spectrometer. This
increases the spectral resolution of the spectrum and therefore its discriminatory power.156
Recently, strong anion exchange high-performance liquid chromatography (SAXHPLC) has replaced CE in the monograph as this technique affords improved separation of
potential contaminants, is more universally available, requires less-specialized training and
doesn’t suffer from reproducibility issues that have been shown in CE.157 Beside SAX-HPLC,
other chromatographic methods are used for the structural analysis and quality control of
heparins such as weak anion exchange (WAX)-HPLC, where the competitive counter-ions
are part of the stationary phase and reversed-phase ion-pair (RPIP)-HPLC, where ion-pairing
reagents are introduced to the mobile phase, modifying the retention of a charged analyte to a
hydrophobic stationary phase.158,159
Additional methods of structural analysis lend themselves to further coupling in the
form of downstream detection methods, such as mass spectrometry (MS).160 MS methods can
be employed downstream, post-depolymerization and separation by other means, but they
may also be employed to separate whole heparin molecules and other GAGs.161 Performing
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hyphenated separations using established methods allows an increase to the sensitivity of the
individual methodologies, for example RPIP-HPLC separation coupled to MS has detected
0.1% and 0.5% over sulfated chondroitin sulfate (OSCS) contamination.162 MS is usually
incorporated in several techniques like LC-MS and LC-MS/MS to study the composition of
the heparin chains, and techniques like GPC-MS that allow for an analysis of oligosaccharide
fragments of these mixtures. MS is an expensive and technically challenging method when
compared to other methods that used to increase the sensitivity of the initial separation
strategies.162 MS coupled with other techniques has been useful in chain mapping and
oligosaccharides distribution of heparin and related agents.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Heparin
Unfractionated heparin is a heterogeneous mixture of polysaccharide chains of
varying length. It is usually administered by continuous IV infusion or SC administration.
The bioavailability of UFHs after SC administration is in the range of 20-30%. To overcome
the low bioavailability associated with the SC route, a higher initial dose of heparin is
required.163 After bolus IV injection, a standard dosage of UFH has a half-life of
approximately 1-2 hours,164 a volume of distribution of 40-70 ml/kg and it is eliminated from
the blood exponentially.165,166 Such first-order kinetics would ordinarily suggest a constant
half-life of the drug, which is independent to the amount of drug injected. However, it is well
known that the half-life of UFH increases in relation to the dose administered.167 Heparin
clearance occurs through the kidney and it is a combination of slower first-order mechanism
and a rapid saturable phase through binding to receptors on endothelial cells and
macrophages where it is depolymerized.167
Low molecular weight heparins are mainly administered via subcutaneous (SC) route.
The bioavailability of LMWHs after SC administration is greater than that of UFH and was
determined to be between approximately 87 - 98 %.168 LMWHs have biological t1/2 (based
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on anti-Xa clearance) nearly double that of UFH, and it is between about 100 and 360 min,
depending on the administration routes (intravenous injection or subcutaneous injection).169
Regarding the anti-Xa/anti-IIa activity half-life (t1/2), the anti-Xa activity t1/2 of LMWHs is
about two to four times longer than for UFHs while anti-IIa t1/2 is only slightly longer for
LMWHs than for UFHs.169
The non-serpin mediated effects of both the UFHs and LMWHs include the release of
endothelial mediators such as TFPI and TPA along with other endothelial products.92,96 Of
these TFPI represents an important measurable parameter which contributes to the observed
pharmacological effects of heparins. TFPI can be measured by quantifying antigen levels in
terms of protein content and the functionality in terms of TF inhibition.92-96 Various forms of
TFPI with differential functionality and TFPI complexes with TF and other endogenous
proteins are found and their levels are affected by heparin. The antigen level measures all
forms of TFPI whereas the functional methods only measure the active forms of this
inhibitor.97,98 Immunoenzymatic methods for the TFPI antigen and functional levels are
commercially available. Heparins are also known to bind to the vascular sites thereby,
modulating the surface charge rendering it non-thrombogenic.96
Neutralization of Heparin
Protamine is arginine-rich/strongly basic (nearly of 67%) and it is commercially
prepared from salmon milt into a dried powder or solution.170 In 1868, protamine was
discovered by Fredrick Miescher as a basic protein bound to nuclear material of Rhine
salmon sperm heads. In 1937, Chargaff and Olsen demonstrated that protamine sulfate could
neutralize the anticoagulant action of heparin.171
Protamine has a mild anticoagulant effect when administered alone. However, when it
is given in the presence of heparin (which is strongly acidic), ionic forces form a stable
complex. In this stable complex an intermolecular charge neutralization occurs, thereby
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causing the neutralization of heparin activity.171 Various factors influence the interaction of
protamine and heparin including individual molecular weight of a given protamine or
heparin, charge type, and charge density.172 Heparin’s affinity for protamine is directly
influenced by many factors such as molecular weight, degree of sulfation, and position of
sulfate residues on the heparin chain.172,173 Dawes and Pepper (1982) determined that degree
of sulfation is the most important determinant of heparin’s affinity to protamine. The binding
of protamine to heparin most likely dissociates heparin from AT, thereby breaking the
heparin/AT complex and neutralizing heparin’s anticoagulant activity.174
Although PS is the only clinical antagonist to neutralize the adverse effects associated
with heparin, its use is associated with certain complications in particular heparin rebound.
Heparin rebound is the reappearance of anticoagulant activity after adequate neutralization
with PS resulting in an excessive postoperative bleeding after surgeries such as cardiac
surgery. After heparin administration, a large proportion binds to plasma proteins and
endothelium which is incompletely removed by PS. After PS is cleared, the protein-bound
heparin dissociates slowly and interacts with AT to produce an anticoagulant effect resulting
in bleeding.172 This phenomenon is called heparin rebound and requires frequent monitoring
necessitating the re-administration of additional dosages of PS. At higher dosages PS itself
may produces mild anticoagulant responses and allergic manifestations.
Other agents that have been evaluated for their ability to neutralize UFHs including
polybrene and PMX-60056.175,177 Polybrene (hexadimethrine bromide), a quaternary
ammonium polymeric salt, is a synthetic heparin antagonist used in clinical laboratories to
neutralize the anticoagulant effects of heparin as well as to determine heparin activity in
human plasma.175 PMX-60056 (small-molecule defensin mimetics) was the clinical lead
compound of a series of small molecule oligomers that interact strongly with heparin and
LMWHs.177
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Platelet factor 4 (PF4) is a natural antagonist of heparin. PF4 has a mean molecular
weight of 7.7 kDa and is 70 amino acids long. It is synthesized by megakaryocytes and stored
in the alpha granules of platelets.178 PF4 is released from platelets upon activation in the form
of a high molecular weight PF4 tetramer, in complex with two chondroitin sulfate
proteoglycan molecules.178 The moment it is released, it is capable of neutralizing the
anticoagulant effects of heparin in plasma. The tetrameric form of PF4 is essential for the
high affinity heparin binding.179 Similar to the case of heparin’s inhibition of thrombin, a
heparin chain length greater than 18 saccharides is required for optimal PF4 binding. Heparin
molecules above 18 saccharides with both anti-thrombin and anti-factor Xa activities can be
completely neutralized by PF4, whereas molecules below 18 saccharides, which retain antifactor Xa activity, are more resistant to neutralization by PF4. A weaker neutralization by
PF4 has been seen for LMWHs in comparison to that of heparin.180
A major complication of heparin’s interactions with platelet factor 4 is its ability to
cause heparin induced thrombocytopenia (HIT). HIT is characterized by a marked decrease in
platelet count (>50%) in association with vascular complications.181 When PF4 is released
from platelets it binds to heparin, resulting in a conformational change in PF4. This complex
is considered a foreign antigen within the body and may be immunogenic. The immune
response is characterized by initial IgM antibody formation and followed by the development
of IgG antibodies. The IgG antibodies form a complex with heparin and PF4 in the
bloodstream. The terminal end of the IgG antibody binds to the Fcγ2 receptor on the surface
of platelets leading to their activation. These activated platelets have a markedly shortened
survival and are acutely consumed in prothrombotic processes, resulting in
thrombocytopenia. HIT generally occurs 5 to 14 days after initiation of heparin therapy.181
Heparinase family of enzymes represent hydrolases which are capable of degrading
heparin and related drugs. The Gram-negative bacterium (Flavobacterium heparinum)
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synthesizes a family of enzymes that degrade glycosaminoglycans. Heparinase-I
(Neutralase™; IBEX Technologies, Montreal, Quebec, Canada) was developed for clinical
usage for the neutralization of the bleeding effects of heparin. This enzyme digests heparin at
its α-glycosidic linkages resulting in non-anticoagulant oligosaccharides. Neutralase was
unsuccessfully developed for the clinical neutralization of heparin in patients undergoing
coronary artery surgery to prevent activation of the coagulation system by the artificial
surfaces of the CPB apparatus.182
Synthetic Heparins and Heparinomimetics
Currently, the UFHs are used in the manufacturing of LMWHs. The supply of the
starting material of the mucosal tissue origin is primarily obtained from porcine, ovine and
bovine sources. The variability of animal-sourced heparin and heparin sulfate, their inherent
impurities, the limited availability of mucosal tissues, and the poor control of these source
materials and their manufacturing processes, all suggest a need for new approaches for
finding substitutes.
Over the past decade, there have been major efforts in the biotechnological production
of glycosaminoglycans, such as mitrin from plants and bacteria. Mitrin is a chemically
engineered anticoagulant polysaccharide prepared from Escherichia coli K5 polysaccharide
to replace heparin.183 Bhaskar and coworkers described the generation of a series of heparinlike products through regioselective sulfation of the capsular polysaccharide from
Escherichia Coli K5. The capsular polysaccharide from E. coli has the same basic structure
as heparin [→4)-β-D-GlcA-(1→4)-α-D-GlcNAc-1(1→].184
The polymeric backbone known as N-acetyl heparosan provides a novel starting
material to develop semi-synthetic heparin-like molecules. To accomplish this, the bacterial
polysaccharide is first converted to sulfaminoheparosan by deacetylation (through
hydrazinolysis) followed by N-sulfation. Controlled O-sulfation of this product results in the
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generation of a series of novel heparin-like oligosaccharide mixtures with varying O-sulfation
patterns and anticoagulant activities. This sulfated oligosaccharide also shows varying
degrees of binding to AT due to the presence of 3-O-sulfated glucosamine unit. Thus,
utilizing these semi-synthetic approaches, anticoagulants with structural identities distinct
from heparin, yet with similar interactions with HC-II and AT, can be developed. These
bacterial polysaccharide derivatives interact with AT and promote its anticoagulant action in
a manner similar to that of heparin.185 Depending on the reaction conditions during their
preparation, the products show different proportions of components with high affinity for AT.
A high affinity fraction of this bacterial polysaccharide was shown to cause conformational
changes in the AT molecule very similar to those induced by high-affinity heparin. The
compositional analysis of these polysaccharide fractions revealed that they have the AT
binding site, the 3-O sulfated GlcN unit, which has previously been identified as the marker
component of the AT binding pentasaccharide sequence in heparin.185 Due to the charge
density of these agents, they may also share other biological activities with heparin including
endogenous release of mediators such as TFPI, modulation of adhesion molecules, interaction
with endothelial cells and anti-inflammatory effects.185
In addition, Linhardt reported the synthesis of an ULMWH, similar to fondaparinux,
using a chemoenzymatic process.186 Instead of preparing the oligosaccharide backbone
through bacterial fermentation, it was enzymatically synthesized by the iterative addition of
UDP-sugars. This was again followed by the use of recombinant O-sulfotransferases and C5epimerase to afford a pure ULMWH in over a 100-fold higher yield than possibly using
chemical synthesis. Additional constructs prepared showed comparable pharmacological
properties as fondaparinux. However, it remains to be seen whether this chemoenzymatic
process can be commercialized to afford new ULMWHs for regulatory agency approval.
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Additional approaches to synthetize heparinomimetics using refined chemoenzymatic
approaches have resulted in the development of high potency octamers and oligosaccharides
of varying lengths.187 Although, attempts have been made to obtain a number of
oligosaccharides solely by using organic synthetic approach. It is technically challenging to
synthesize oligosaccharides larger than hexasaccharides with complex sulfation profiles. As
an alternative approach, improved chemoenzymatic methods have been introduced to
synthesize heparin oligosaccharides with varying chain lengths composed of up to 18 sugar
units. These methods utilize such biosynthetic enzymes as glycosyl transferases, C5epimerase, and sulfotransferases. These methods offer high-throughput and efficienct
synthesis for a wide range of heparin related oligosaccharides.187 More recently, with the
advances in bioengineering and development of selective enzymes with high specificity have
provided tools to produce heparin oligosaccharides of varying length with desirable
biological activities including with high affinity to AT. Moreover, these oligosaccharides are
designed to exhibit desirable PK and PD profiles.187
Another promising approach to develop a synthetic heparin is utilizing the Chinese
hamster ovary (CHO) cells in order to produce heparin with better quality and safety
properties.188 Unlike recombinant proteins that are expressed by a single gene, heparin is
synthesized in a complex metabolic pathway involving over 20 enzymes. Heparin
polysaccharides are uniquely produced in mast cells but because mast cells are particularly
difficult to propagate and maintain, they are not suitable for commercial production.
However, the CHO cell line is an industry standard for producing recombinant therapeutic
products. This familiarity may be an advantage from a regulatory standpoint. Another
advantage is that CHO cells make relatively large amounts of heparan sulfate (HS).
Producing recombinant heparin from CHO cells entails engineering the CHO cells
genetically, to produce HS with the anticoagulant properties of heparin. Further genetic
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engineering could be aimed at reducing other protein binding substructures, for example,
platelet factor 4 (PF-4) binding to reduce the risk of heparin-induced thrombocytopenia
(HIT). However, the major challenges confront the prospect of developing CHO cell lines
that produce recombinant heparin are the complexity of genetically producing HS with the
anticoagulant properties of heparin and the high cost of the final product.188 Furthermore,
semisynthetic heparin-like anticoagulants can be structurally modified by chemical or
enzymatic methods to achieve drugs with desirable biochemical and pharmacological
profiles. It is expected that these agents will exhibit all the biological actions that are
associated with heparins.188
Heparin Supply and Demand
Many factors have contributed to the shortage of PMH and an increased cost of
porcine derived anticoagulants.189 Firstly, the use of UFHs in open-heart surgeries,
hemodialysis and interventional cardiovascular procedures requires large amount of UFHs.
Secondly, PMH is widely used in the manufacturing of LMWHs and ULMWHs. Thirdly,
over 50% of the world’s population of pigs originates from China, which may prove to be
problematic for suppliers in the US health market because of the strained US-China economic
relations. Fourthly, due to religious and/or cultural practices in various parts of the world, the
use of porcine heparins prevents patients from seeking optimal care. Finally, the global pig
population is at risk for viral infections and other diseases. There are about 2 billion pigs
worldwide and over one billion pigs annually (an average of 23 million pigs a week) used in
meat packing industry.189
Recently, an outbreak of African swine fever in China has reduced the availability of
porcine tissues due to profound reduction in big populations. Hundreds of millions of animals
died due to disease or culling resulting in mark reduction of pig population.190 Currently
Chinese authorities and manufacturers are exploring the options to solve this problem
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including the development of vaccines against the viral infections. As the U.S. heparin supply
is dependent on Chinese manufacturers and up to 70% of the U.S. heparin is imported from
China, the U.S. government is concerned on the dependence on one source of heparin raw
material and the potential impact of its shortage on patient usage.189,190 With the advances in
technology and manufacturing processes, higher quality and contaminant-free bovine and
ovine UFHs are now available for clinical and research purposes.189
The earlier development involved the isolation of heparins from other mammalian
sources including the sheep (ovine) and cow (bovine) tissues. The initial clinical batches of
heparins were mainly comprised of bovine lung heparin. As both North and South American
countries have sizable population of cows, large amounts of heparin can be manufactured for
clinical use. More recently, the Brazilian authorities have approved a new monograph for
bovine mucosal heparin. Thus, BMH provides a suitable alternate to PMH.191 Similarly,
sheep are commonly used for the production of wool and meat throughout the world. Sheep
heparin from both lung and mucosal tissues have been also been used in the past. Both OMH
and BMH provide a reasonable and cost-effective substitute for PMH.190,191 Currently most of
the mucosal tissues from these species are used for the manufacturing of casing and animal
feed. Therefore, in view of the current issues, the alternate supply of mucosal tissues from
ovine and bovine sources will provide reasonable and cost feasible substitutes to keep the
supply of the anticoagulants to meet clinical needs.
Mucosal tissues from other farm animals such as goat and buffalo are widely
available and can be used for the manufacturing of heparin and related GAGs. At the present
time, the mucosal tissues from these animals are either discarded or use for the casing
purposes. Currently, several groups are involved in the development of methods to isolate
and characterized heparins from these sources. The data obtained on the BMH and OMH
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suggests that, heparins from goat and buffalo may exhibit comparable biological activities
which can be equeted to those obtained from pig, cow and sheep.
Quality and Manufacturing Control of Heparin
Despite significant advances in analytical approaches, the fine structural details of
heparin are not fully elucidated.192,193 Moreover, the biosynthetic processes involved in the
synthesis of heparin are poorly understood.192 Thus, polydisperse and heterogeneous nature
of heparin represents a major challenge for the pharmaceutical quality control of this complex
drug.
Earlier descriptive monographs for heparin were focused on establishing whether a
given sample exhibited the same anticoagulant activity as a known reference, hence, heparin
quality control was primarily focused on assaying its anticoagulant activity. It was assumed
that GAGs with comparable anticoagulant activity and similar potency were acceptable as
pharmaceutical-grade heparin.
A simple clotting test called the activated clotting time (ACT) was utilized, although
this approach essentially overlooked the structural and functional complexity of heparin and
proven easy to circumvent other activity of heparin.194,195 The selection of potency as a
screening method falsely assumed that, the heparin being assayed was pure heparin and that a
contaminated sample would possess a lower potency and therefore will be rejected. The
limitations of this assumption were realized in 2007-2008 when batches of heparin
demonstrated severe, adverse side effects, resembling the symptoms of anaphylaxis, which
were later established to be due to the presence of OSCS,196 resulting in greater than 200
fatalities in the US alone.197
Following the heparin contamination crisis, new techniques aimed on confirming the
identity of heparin prior to potency screening were made mandatory, resulting in the
addition of two newer techniques to the United States pharmacopeia (USP) monograph and
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to the monographs of many other pharmacopoeias. These methods included 1H NMR
spectroscopy and capillary electrophoresis (CE).198-200 1H NMR offers a high-resolution
technique that can demonstrate the presence of various contaminants and other carryover
GAGs. Almost all of the major heparin 1H NMR signals have been assigned with 16
characteristic peaks routinely used to confirm the presence of heparin in a given
sample.201,202 Alterations to, or a lack of, any of these peaks may indicate a contaminant or a
suboptimal heparin sample. Due to the high charge density of heparin and other GAGs, they
are amenable to electrophoretic migration and separation when placed within an electric
field.203 Separation by capillary electrophoresis (CE) may be considered similar to that of
the reversed phase high performance liquid chromatography (HPLC) technique, but through
use of narrow capillaries, allows for very small sample quantities to be separated.
Besides the techniques employed within the heparin monograph, there are several
other techniques that are well documented for the study of heparin that may be applied to its
quality control and can be broadly separated into three main approaches which include
species separation, structural profile, and size definition.
In regard to species separation, electrophoretic separation is used for the detection of
over sulfated chondroitin sulfate (OSCS) and dermatan sulfate (DS) at the levels of 0.05%
and 0.1%, respectively.204,205 Alternative electrophoretic formats such as polyacrylamide gel
electrophoresis (PAGE) has also been used to distinguish OSCS from heparin post nitrous
acid treatment, where nitrous acid degrades heparin but not OSCS.206 Similarly, such
enzymes as heparinase-I can be used for selective digestion of heparin.
Structural profiling is a crucial methodology for the study of heparin and its quality
control. While 1H NMR spectroscopy is a part of the heparin monograph due to its high
resolution and complete peak assignment, there are several other approaches where NMR
spectroscopy could be utilized, for example employing 13C nucleus, which is able to
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distinguish identical chemical features located in distinct saccharide sequences.207 15N NMR
has also been extensively studied, with some nitrogen microenvironments being assigned,
producing fingerprints of intact and modified heparins.208,209 In addition to the onedimensional (1D) NMR methods, the 2D NMR methods are also used in the study of the
higher-level structure of heparins and are pivotal in first defining OSCS as a
contaminant.210,211 However, 2D NMR methods are too complex, time-consuming, and
expensive for the inclusion in heparin monograph.
The size definition of heparin remains unclear as heparin exists as a heterogeneous
population of varying MW components. Larger heparin molecules possess increased
activity, however, they have larger surface area that increases heparin/protein interaction in
blood stream that may lead to potential side effects.212 The molecular profile of heparins can
be defined in multiple ways, including conventional methods such as ultracentrifugation and
viscosity measurements213,214 and more modern methods such as calibration through use of
standards, utilizing PAGE,215,216 and size exclusion chromatography (SEC)217 or through use
of the Rayleigh theory, whereby the ratio of scattered light intensity to incident light
intensity is used to define MW, such as with static-right-angle-, low-angle- and multi-angle
laser light scattering (SLS, RALS, LALS, and MALS respectively) techniques.218 MW has
also been defined using 13C NMR and MS.219 Size definition when compared to standards is
difficult, as standards are hard to define or acquire, meaning that they are usually created inhouse, leading to variation between labs. The currently available USP standard along with
other reference standards are helpful to harmonize MW profiling.216
A triple detector approach (TDA) has also been utilized, where a RALS detector, a
differential refractive index detector (SLS detection), and a viscometer are used in concert to
accurately define the MW of heparin and may also be used to create uniform standards.220
Molecular weight determination can also be used to screen for contaminants due to the
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resistance of OSCS to depolymerization by bacterial heparinases, resulting in easy
detection.221 Owing to these advanced methods, currently manufactured heparins represent
highly purified, well characterized products which are free of carryover non-heparin GAGs
and free of such contaminants as OSCS.
Biological Standardization of Heparin and Related Drugs
Historically, heparins were standardized in terms of a purely biologic unit “the
minimal amount of material necessary to keep one ml of at blood fluid for 24 hours at 0°C.222
Earlier standardization practices were based on sheep blood recalcification time.
Subsequently, it was realized that it is desirable to define potency in terms of a standard
preparation whereby a unit is defined as the amount of activity contained in a fixed weight of
material.222 In 2008, the heparin monograph was revised and implemented a new potency
assays for heparin; the chromogenic anti-Xa and anti-IIa tests (limited to AT- dependent
actions) instead of the clotting-based assays that can be impacted by contaminants and other
process-related impurities.223
Due to the functional heterogeneity of heparin and its complex chemical structure,
the need for a biological standard for heparin was established and has subsequently been
replaced as necessary when stocks have been exhausted, at intervals of approximately 14
years.224 When establishing a replacement International Standard (IS), it was important to
compare proposed candidate materials with the therapeutic products used at the time.
Standardisation and global harmonisation of units and methods of measurement are essential
for safety and efficacy of this important class of anticoagulants. The World Health
Organization (WHO) and other regulatory authorities had sought a plan that would lead to an
agreed global method for the measurement of biological activity of heparin, based on a single
heparin unit, thus promoting global harmonization.
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The first International Standard for UFH was provisionally accepted by the League of
Nations and established by the WHO in 1947.224 Since then, five additional International
Standards (IS) of UFH have been established and used successfully for assignment of
potency to clinical preparations of UFH. The first and second UFH International Standards,
which were representative of heparin produced during the period of 1940-1950, were derived
from bovine lung materials with specific activities around 140 U/mg. Since then, there have
been two major changes in the characteristics of unfractionated heparin; a change in the
starting material from bovine lung to porcine and bovine mucosa resulting in an increase in
specific activity. These changes have continued to the present day, and most of the heparin
currently used is of porcine mucosal origin and has a specific activity in the range of 180-200
U/mg.224
The stepwise replacement of beef lung with porcine mucosal tissue began in the late
1950s, prompting the establishment of the 3rd International Standard of UFH of porcine
mucosal origin by the World Health Organization in 1973. As noted at the time, the assays of
mucosal material against a lung standard were problematic, with considerable differences
between potencies obtained with different assay methods.225 Differences between anti-Xa and
aPTT methods for lung heparin compared with a mucosal standard were also found and can
be related to differences in molecular weight distribution and polysaccharide components
between the two types of heparin.226,227
In 1984, the 4th International Standard of UFH was established from a porcine
mucosal origin and after sixteen years, a collaborative study was undertaken with the
principal aim of establishing the 5th International Standard of UFH from a large number of
samples of porcine mucosal heparin.224 Finally, the 6th International Standard for heparin
from porcine mucosal origin was approved by the Expert Committee on Biological
Standardization of the World Health Organization in 2013. This standard was also used to
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harmonize the USP standard based on the amidolytic antiprotease assays along with other
methods in an international collaborative study.
The current USP standard is widely used for the cross-referencing of UFHs
employing defined amidolytic anti-Xa and anti-IIa assays. The USP reference is composed of
porcine mucosal heparin which is fully characterized and is provided in highly purified form.
Each ampoule of the current USP reference standard (F01187) contains 9.5 mg of heparin
with a specific activity of 226 U/mg. Most of the APIs originating from porcine mucosal
tissue exhibit comparable potency when manufactured in accordance with the standard
procedures assuring quality requirements by regulatory agencies. Cross-referencing of UFHs
against this standard in USP compliant chromogenic assay for the inhibition of factor Xa and
thrombin in defined biochemical conditions has become a widely acceptable method
harmonizing the standardization practices. Since UFHs exhibit an anti-Xa/anti-IIa ratio of
one, the USP reference-based calibration curves exhibit parallelism. Thus, the USP crossreferencing indirectly provides reliable data on the functionality of UFHs based on the
interaction of AT binding consensus sequences in these anticoagulants.
Regarding LMWH, the measurement of the in vitro anticoagulant activities against an
unfractionated heparin (UFH) standard has given problems of non-parallel assays, wide
variability between laboratories and differences between methods.228 These problems have
been largely overcome by the establishment of a new LMWH standard against which other
LMWHs can be compared. The LMWH standard was calibrated with two separate potencies,
one for anti-Xa and the other for anti-IIa assays.229
The 1st International Standard (IS) for LMWH was established in 1987 and
successfully harmonized potency labelling of commercial low molecular weight products.
The 2nd IS for LMWH was established by the Expert Committee on Biological
Standardization (ECBS) of the World Health Organization (WHO) in October 2003.230 At the
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end of 2012, the 3rd International Standard for LMWH was established by the Expert
Committee on Biological Standardization of the World Health Organization and it has been
used to estimate the anti-Xa and anti-IIa potencies of low molecular weight heparin available
for the clinical use until now.231 Besides the potency standards, additional reference standards
are available for the MW profiling and purity checkup of LMWHs.
In regard to the standardization of synthetic and biosynthetic heparin
oligosaccharides, their potency is usually expressed in terms of anti-Xa and anti-IIa activities.
There is no firm recommendation for the standardization of these agents. Fondaparinux is
usually administered at a fixed gravimetric dosing without any weight adjustments. The antiXa potency of fondaparinux has been cross-referenced using both the USP reference for
heparin and international standard for LMWHs.
The currently developed oligosaccharides of varying length are cross-referenced using
the chromogenic substrate based anti-Xa and anti-IIa methods. Since most of these
oligosaccharides exhibit MW below 5 kDa, it may be useful to assign their potency utilizing
the current LMWH standard. An alternative approach may be to use the commercially
available pentasaccharides (fondaparinux) which has been assigned an anti-Xa potency value.
It is likely that, some of the newly developed oligosaccharides with MW below 5 kDa may
also exhibit anti-IIa properties through HCII requiring standardization for this activity.
Besides the anti-Xa and anti-IIa methods, other biochemical methods such as the binding
constant to AT and oligosaccharides-AT complex inhibition profile for Xa and IIa enzymes
may be recommended.
Bioengineered and recombinant GAGs with comparable MW profile to mammalian
derived heparins can be cross-referenced against the LMWH standard and the USP standard
for UFH depending upon their MW profiles. Eventually, these agents need to be crossreferenced with defined standard of the same origin.

CHAPTER TWO
STATEMENT OF PURPOSE
Unfractionated heparin (UFH) was first used as an anticoagulant in the early part of the
20th century. UFH and low molecular weight heparins (LMWHs) are widely used in the
treatment and prevention of blood clots or thrombi. Furthermore, they have widespread
applications in surgery, in the management of myocardial infarction, in preventing of surface
contact-induced clotting during blood dialysis and as coating material for a range of medical
devices. Most of the heparins are derived from pig mucosa (PMH). However, heparin has also
been manufactured from other mammalian sources such as bovine mucosa (cow, BMH) and
ovine mucosa (sheep, OMH). Although most of the heparins used globally are obtained of
porcine origin, bovine and ovine heparins have also been used in non-Western markets. The
North American and European community primarily use heparins derived from porcine sources,
which are primarily of Chinese origin.
Depolymerized heparins represented by LMWHs such as enoxaparins have become
standard of care for the prophylaxis and treatment of VTE and cardiovascular disorders. These
agents are derived mostly from porcine mucosal tissue and are manufactured using chemical and
enzymatic methods. Bovine and ovine mucosal tissues also provide a source of material to
produce LMWHs. In this dissertation, enoxaparins derived from bovine and ovine origins are
investigated for their biochemical and pharmacologic profile. Thus, this dissertation represents
one of the first comprehensive profiling of enoxaparins of diverse origins.
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UFHs produce their effects via interactions with various endogenous proteins such as
antithrombin (AT) and heparin cofactor II (HCII), the LMWHs primarily mediate their effect via
AT interaction. UFHs and LMWHs mechanism of action relies in large part to specific
pentasaccharide sequence that enables binding to antithrombin. This binding results in a
conformational change in antithrombin that facilitates inactivation of thrombin (factor IIa) and
factor Xa, leading to a significant increase in anticoagulant activity. The degree to which these
agents exert their effects through AT and HCII, as well as other endogenous proteins, determines
how well they inhibit various targets of the coagulation system and the severity of side effects. In
this dissertation additional mechanisms of action such as thrombin generation inhibition and
endogenous release of TFPI are addressed in integrated fashion broadening the scope of the
mechanisms of action of these agents.
One of the purposes of this dissertation is, to investigate the interactions of UFHs and
LMWHs of diverse origins with endogenous proteins such as platelet factor 4 (PF4) which is not
only important for the modulation of the therapeutic action of these agents but also mediates the
generation of neoantigen leading to HIT. Both functional and biophysical approaches have been
utilized to understand the complex mechanism involved in the pathogenesis of HIT. This
dissertation provides a broad and an integrated pharmacokinetic and pharmacodynamic
comparison of UFHs and LMWHs in non-human primate to complement the comprehensive
structural and molecular profiles of these agents. Beside conventional methods, absolute
quantification of GAG components of each agent is compared with their biologic activities.
Since both the UFHs and LMWHs are standardized in defined biochemical assays, crossreferencing of UFHs against a USP standard for potency equivalence to demonstrate the
biosimilarity is addressed in both the in vitro and in vivo settings. The equivalence of
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enoxaparins obtained from various origins pre-standardized by the manufactures is cross
validated using multiple methods.
Livestock farming has provided the sole source of mammalian tissues for the extraction
of biologics such as the UFHs and LMWHs. Currently, in the USA and European community
both of these agents are primarily manufactured by using porcine tissues. The current averaged
population of pigs is approximately one billion which is subjected to fluctuation. However,
worldwide there are 1.4 billion cattle, 1.9 billion sheep and goats which can also provide stating
material to manufacture heparins. Both cow and sheep provide alternate sources of heparin
which are not widely used due to regulatory reasons.
Currently there are some concerns about the shortage of the porcine heparins as they are
widely used in the manufacturing of the low molecular weight heparins (LMWHs). Also, openheart surgeries, hemodialysis and intervention cardiovascular procedures are usually carried out
with anticoagulants and unfractionated heparins. Moreover, due to cultural and religious reasons
in some countries, alternative sources of heparins are needed. The FDA is currently considering
the introduction of bovine and ovine unfractionated heparins. With the advances in technology
and manufacturing processes, higher quality bovine and ovine heparins are now available. In
addition, the viral contaminants such as bovine spongiform encephalopathy (BSE) are
eliminated. Currently bovine and ovine heparins are used in various part of the world and have
been shown to exhibit similar biologic and clinical profiles. Several Brazilian and Chinese
manufacturers provide bovine and ovine heparins for clinical use.
The primary purpose of this dissertation was to compare the structural and functional
characteristics of BMH, OMH and PMH and their depolymerized derivatives (LMWHs).
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Furthermore, to test the hypothesis that “Despite molecular components distribution and
minor structural differences, potency referenced heparins of different animal origins and
their depolymerized derivatives may exhibit similar pharmacological activities”. For this
investigation, one batch of each heparin and LMWH source were utilized. Their activities in
biochemical and biological assays were compared in order to elucidate how their molecular
composition and structural attributes affect their pharmacological actions. The following specific
aims were included for the validation of the stated hypothesis.
Specific Aim 1:
•

To determine the molecular and structural differences among UFHs of different
animal origins and their depolymerized derivatives.

Specific Aim 2:
•

To compare the biochemical mechanisms of action of UFHs of different animal
origins and their depolymerized derivatives.

Specific Aim 3:
•

To investigate the PK and PD of UFHs of different animal origins and their
depolymerized derivatives using non-human primate models.
Significance

This dissertation proposes that bovine and ovine UFHs and their depolymerized products
may be feasible substitutes for porcine counterparts for clinical purposes. The preferential use of
porcine UFH over bovine and ovine counterparts prompted a number of concerns. First, the
shortage of porcine tissues in the world caused an increase in heparin cost. Second, over 50% of
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the world’s population of pigs comes from China, which may prove to be problematic for
suppliers in the US health market because of the strained US-China economic relations. Finally,
due to religious and/or cultural practices in various parts of the world, the use of porcine heparins
prevents patients from seeking optimal care.
The proposed studies will provide guidelines for the interchangeability of heparins from
different origins, thus providing a uniformity in anticoagulant practices globally. In addition,
having potency standardized heparins will facilitate the development of blended products with
similar biological effect as the individual components. The structure activity relationship
component of this dissertation may provide newer information on the molecular interactions of
heparins with not only antithrombin (AT) and heparin cofactor II (HCII), but also with TFPI and
other pharmacophores. This may lead to the development of more defined oligosaccharides with
selected biological profile and improved therapeutic index.
Furthermore, this dissertation will provide a scientific rational to classify heparin
obtained from bovine, ovine and porcine sources as a class of drugs rather than distinct
pharmacological entities with reference to their anticoagulant activities. Biologic potency
adjustment for heparin substances with the anti-Xa and anti-IIa ratio of 1.0, regardless of the
mass per volume considerations will open several options in formulating heparins for wider
applications.
At this time, a large proportion of the mammalian mucosa tissues obtain from bovine and
ovine origins are wasted. These represent a three-times higher amount of mucosal tissue which
can be purposed for the manufacture of heparins. This dissertation will further underscore the
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feasibility of obtaining heparin and related products from diverse origins for not only
anticoagulation but their use in other indications.
In addition, the proposed studies may also be helpful in the development of
bioengineered and synthetic heparins and obtaining glycosaminoglycan (GAG) with predictable
clinical profiles. More importantly, this dissertation will help to harmonize the global regulatory
requirements to consider UFHs and LMWHs as classes of drugs rather than individual drugs
upon cross-referencing with the respective standards.

CHAPTER THREE
MATERIALS AND METHODS
Materials
Heparins and Low Molecular Weight Heparins
Porcine mucosal heparin (PMH, Lot # PH-13353). PMH obtained from Medefil Inc.,
Glendale Heights, IL, USA, was used throughout this dissertation. The active pharmaceutical
ingredient (API) version of PMH was provided in a powdered form and was stored in a
desiccator at room temperature (20 - 25 ºC). PMH was reconstituted in Na2So4 (0.3 M, PH = 5.0)
to obtain a 10 mg/ml solution for the molecular profiling studies and was further diluted in saline
to obtain 1 mg/ml and 100 ug/ml working solutions for additional studies. PMH was found to
exhibit a USP cross-referenced potency in the range of 180-195 USP U/mg.
Bovine mucosal heparin (BMH, Lot # GAG25). BMH obtained from KinMaster
Produtos Químicos, Passo Fundo, Brazil, was used throughout this dissertation. The active
pharmaceutical ingredient (API) version of BMH was provided in a powdered form and was
stored in a desiccator at room temperature (20 - 25 ºC). BMH was reconstituted in Na2So4 (0.3
M, PH = 5.0) to obtain a 10 mg/ml solution for the molecular profiling studies and was further
diluted in saline to obtain 1 mg/ml and 100 ug/ml working solutions for additional studies. BMH
was found to exhibit a USP cross-referenced potency in the range of 130-140 USP U/mg.
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Ovine mucosal heparin (OMH, Lot # OHS-160301). OMH obtained from Ronnsi
Pharmaceutical, Suzhou, China, was used throughout this dissertation. The active pharmaceutical
ingredient (API) version of OMH was provided in a powdered form and was stored in a
desiccator at room temperature (20 - 25 ºC). OMH was reconstituted in Na2So4 (0.3 M, PH = 5.0)
to obtain a 10 mg/ml solution for the molecular profiling studies and was further diluted in saline
to obtain 1 mg/ml and 100 ug/ml working solutions for additional studies. OMH was found to
exhibit a USP cross-referenced potency in the range of 185-200 USP U/mg.
Porcine low molecular weight heparin (P. LMWH, Lot # Lovenox-7LO10). P.
LMWH obtained from Sanofi, Paris, France, was used throughout this dissertation. P. LMWH
was provided as a pre-filled syringe (40 mg/0.4 ml) that was stored in a refrigerator at
temperature (2 - 8 ºC). P. LMWH was diluted in Na2So4 (0.3 M, PH = 5.0) to obtain a 10 mg/ml
working solution for the molecular profiling studies and was further diluted in saline to obtain 1
mg/ml and 100 ug/ml working solutions for additional studies. P. LMWH was found to exhibit
NIBSC cross-referenced anti-Xa and anti-IIa potencies in the range of 93-103 U/mg and 30-40
U/mg respectively.
Bovine low molecular weight heparin (B. LMWH, Lot # RX0015-JCJ-003). B.
LMWH obtained from Ronnsi Pharmaceutical, Suzhou, China, was used throughout this
dissertation. The active pharmaceutical ingredient (API) version of B. LMWH was provided in a
powdered form and was stored in a desiccator at room temperature (20 - 25 ºC). B. LMWH was
reconstituted in Na2So4 (0.3 M, PH = 5.0) to obtain a 10 mg/ml solution for the molecular
profiling studies and was further diluted in saline to obtain 1 mg/ml and 100 ug/ml working
solutions for additional studies. B. LMWH was found to exhibit NIBSC cross-referenced anti-Xa
and anti-IIa potencies in the range of 96-105 U/mg and 30-40 U/mg respectively.
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Ovine low molecular weight heparin (O. LMWH, Lot # EOS-160403). O. LMWH
obtained from Ronnsi Pharmaceutical, Suzhou, China, was used throughout this dissertation. The
active pharmaceutical ingredient (API) version of O. LMWH was provided in a powdered form
and was stored in a desiccator at room temperature (20 - 25 ºC). O. LMWH was reconstituted in
Na2So4 (0.3 M, PH = 5.0) to obtain a 10 mg/ml solution for the molecular profiling studies and
was further diluted in saline to obtain 1 mg/ml and 100 ug/ml working solutions for additional
studies. O. LMWH was found to exhibit NIBSC cross-referenced anti-Xa and anti-IIa potencies
in the range of 94-104 U/mg and 30-40 U/mg respectively.
USP reference standard (Heparin Sodium, Lot # FOI187). USP reference standard
ampoule (9.5 mg - 2144 USP Units) was reconstituted in appropriate volume of diluent to obtain
a 100 U/ml working solution. The Standard working solution was stored at -80 ºC as aliquots and
thawed upon use and diluted to 10 U/ml to cross reference the USP potency of all UFHs in terms
of anti-Xa and anti-IIa activities. This reference standard was developed according to United
States Pharmacopeia (USP) standards (12601 Twinbrook Pkwy, Rockville, MD 20852-1790,
USA).
Heparin narrow range calibrators (NRC). Thirteen NRC calibrators consists of
varying molecular weight were obtained in powdered version from Laboratori Derivati Organic
(LDO, Milano, Italy). Porcine mucosal heparin was fractionated using preparative gel
permeation chromatography to obtain narrow range fractions in the range of (2.1 - 51 kDa),
including 2100 Da, 2400 Da, 2450 Da, 2700 Da, 2870 Da, 4300 Da, 6500 DA, 9400 Da, 15700
Da, 19700 Da, 25000 Da, 35000 Da and 51000 Da. These calibrators were stored in a desiccator
at room temperature (20 - 25 ºC). The NRC method was used for molecular weight
determinations of all agents using gel permeation chromatography method (GPC) on a high-
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performance liquid chromatography (HPLC) system (Waters 845, Millipore-Waters, Lexington,
MA) equipped with Millenniumâ 2000 software designed for polymer analysis.
Coagulation Reagents
Activated partial thromboplastin time (aPTT). The TriniCLOTTM aPTT S kit (Trinity
Biotech USA Inc, Jamestown, NY) was used to determine the aPTT of the test samples. The
following reagents were included in the TriniCLOTTM aPTT S kit: TriniCLOT aPTT CaCl2 (0.02
M) and TriniCLOT aPTT S reagent. The reagent contains purified phospholipids (porcine),
micronized silica (activator), stabilizer, and 0.02% sodium azide as preservative. All reagents
were kept refrigerated (4°C) until use. Each vial of TriniCLOT aPTT CaCl2 (0.02 M) and
TriniClOT aPTT S reagent came ready to use.
Thrombin time (TT) reagent. Purified frozen form of human thrombin (Lot # HT
5528PA) reagent was obtained from Enzyme Research Laboratories (South Bend, Indiana, USA)
at a concentration of 1000 U/ml. The thrombin was diluted with 0.25 M CaCl2 and Xa/IIa buffer
(50mM Tris, 175 mM NaCL, 7.5 mM Na2 EDTA, 800 ml distilled H2O, pH = 8.4, 25 ºC) to yield
5 U/mL solutions.
Prothrombinase-induced clotting time (PiCT) reagent. The PiCT reagent was
purchased from Pentapharm (Basel, Switzerland) and was used in accordance with the
manufacturer instruction. This clot-based reagent utilizes snake venom RVV-V (Russell viper
venom factor V) as an activator.
Factor Xa enzyme and Spectrozyme Xa substrate. Frozen versions of bovine factor Xa
(1.0 mg/ml, Enzyme Research Laboratories, South Bend, IN) were used in anti-Xa activity
assays. Aliquots of factor Xa were reconstituted in appropriate volumes (final factor Xa
concentration of 6µg/ml) in Xa/IIa buffer (50mM Tris, 175 mM NaCL, 7.5 mM Na2 EDTA, 800
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ml distilled H2O, pH = 8.4, 25 ºC) prior to use. The substrate, Spectrozyme FXa (5 µmole/vial)
was obtained from Sekisui Diagnostics (Stamford, CT) and was reconstituted by adding 2 ml of
distilled water to make a 2.5 mM solution. The chromogenic substrate peptide sequence is
mixture (50% - 50%) of Bz-Ile-Glu (gOCH3)-Gly-Arg-pNa (form 1) and Bz-Ile- Glu (gOH)GlyArg-pNa (form 2).
Factor IIa enzyme and Spectrozyme IIa substrate. Human thrombin (Enzyme
Research Laboratories, South Bend, IN) was used in anti-IIa activity assays. Factor IIa was
diluted to 5 U/ml in Xa/IIa buffer (50mM Tris, 175 mM NaCL, 7.5 mM Na2 EDTA, 800 ml
distilled H2O, pH = 8.4, 25 ºC). The substrate, Spectrozyme TH (H-D-Phe-Pip-Arg-pNa, 2HCl)
was obtained from Sekisui Diagnostics (Stamford, CT) and was reconstituted by adding 5 ml of
distilled water to make a 1 mM solution.
Thrombin generation assay (TGA) reagents. Inhibition of thrombin generation was
measured using the Calibrated Automated Thrombogram instrumentation (CAT, Diagnostica
Stago, Parsippany, NJ) on a Fluoroskan Ascent fluorimeter. Fluo-substrate (amino-methylcoumarin, AMC) Fluo-buffer, tissue factor high reagent (mixture of tissue factor and
phospholipids) and a thrombin calibrator were obtained from Diagnostica Stago, Parsippany, NJ
and used for determination of thrombin generation over time in platelet poor plasma (PPP).
Proteins and Enzymes
Heparinase I. Heparinase I (EC 4.2.2.7) was obtained from IBEX Pharma., Montreal,
Canada. This enzyme was obtained from Flavobacterium heparinum. Its molecular weight was
reported to be 42.5 kDa. The potency was designated as >80 IU/mg, where one international unit
(IU) is defined as the amount of enzyme that will liberate 1.0 µmole of unsaturated
oligosaccharides from porcine mucosal heparin per minute at 30 ºC and pH 7. Purity of this
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enzyme was determined by the manufacturer to be greater than 90% by reverse-phase HPLC and
SDS-PAGE analysis. Working dilutions of heparinase-I were prepared at 10 IU and 1 IU before
use. This material was provided as a solution and was stored at -80 ºC until use.
Protamine sulfate (PS). PS was obtained from Sigma Aldrich (P3369-100G, ST. Louis,
MO, USA) in powder form. It had a specific activity of 138 UAH/mg and its mean molecular
weight as determined by HPLC was 4.0 kDa. PS is a cationic polypeptide isolated from salmon
sperm. PS was reconstituted immediately prior to use in normal physiologic saline at a
concentration of 100 µg/ml.
Antithrombin (AT). Human antithrombin (AT) was obtained from Sekisui Diagnostics
(Stamford, CT) in vials containing 2.5 IU. The antithrombin was immunoaffinity purified from
pooled fresh frozen plasma by heparin-Sepharose chromatography and salt-gradient elution.
Working solution of AT were prepared at 1 U/ml in saline and kept at -80 ºC temperature.
Heparin Cofactor II (HCII). Frozen version of Heparin Cofactor II (Lot # KK0818 - 0.1
mg) was obtained from Haematologic Technologies, Inc (CA, USA). HCII was tested prior to
initiation of the manufacturing process and was found negative or nonreactive for anti-HIV-1/2,
HIV-1 RNA, HBsAg, STS, Anti-HCV, HCV RNA and Zika (by investigational NAT). One unit
of this HCII was estimated to inhibit one unit of thrombin. This product was greater than or equal
to 95% pure by SDS-PAGE. The product was stored at -20 ºC until it was reconstituted with
saline to obtain a working concentration of 40 ug/ml.
Molecular Weight Profiling Reagents
The mobile phase used in all the HPLC studies was made using anhydrous sodium sulfate
(0.3 M Na2SO4) and HPLC-grade water from Sigma-Aldrich Inc. (St. Louis, MO). The pH of
this solution was adjusted to 5.0 with 0.5 N H2SO4, filtered and degassed.
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Assays Kits
Heparin anti-Xa and anti-IIa USP kits (Biophen Xa and Biophen IIa) were obtained
from Hyphen BioMed (Aniara; West Chester, Ohio, USA). The anti-Xa and anti-IIa USP kits
reference numbers were 221010 and 221025, respectively. These kits were developed in
compliance with the heparin potency assay described in the USP heparin and the EP heparin
monograph. These are chromogenic assays developed to measure heparins concentrations in
plasma or in purified solutions in terms of their anti-Xa and anti-IIa activities which can be
referenced against USP standard.
Heparin Red kits (Haxthausenweg, Münster, Germany) were used for the quantification
of heparin in citrated plasma by a fluorescence assay. This assay measures the absolute
concentrations of heparin in terms of glycosaminoglycan content. The key component of heparin
red assay is a cationic molecular probe that changes fluoresce intensity when complexed with the
anionic polymers such as heparin. The kit contains 1 vial of Heparin Red® (approximately 0.1
mM solution, 0.5 ml) and 1 vial of Enhancer Solution (50 ml, Dimethyl sulfoxide > 90%, acetic
acid < 10%). The heparin red reagents are stored at refrigerated temperature prior to use.
TFPI antigen levels kits. TFPI antigen levels were determined using a sandwich ELISA
method (Ref # 00261, Diagnostica Stago, Paris, France). This Sandwich ELISA measures the
amount of antigen between two layers of antibodies (capture and detection antibody). TFPI
antigen standards are provided for calibration purposes.
TFPI functional levels kits. TFPI functional levels in the monkey experiments were
determined using ACTICHROME® TFPI kits (Ref # 848, Biomedica Diagnostics, North
Vancouver, Canada). It is a chromogenic assay intended for the measurement of Tissue Factor
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Pathway Inhibitor (TFPI) activity in plasma where TFPI exhibits an inhibitory effect on the
Tissue Factor/FVIIa complex. TFPI functional standards are provided for calibration purposes.
Blood Products
Whole blood. Whole blood was drawn from apparently healthy volunteer donors under an
IRB approved protocol (LU# 9191051098). Blood was drawn using standard double syringe
technique into tubes containing 3.2% sodium citrate. All donors provided informed consent and a
maximum of 40 ml of blood was drawn from each donor.

Blood bank plasma (BBP). Normal human CPDA-1 (citrate phosphate dextrose
adenine) plasma was obtained from the Blood Bank, Department of Pathology, Loyola
University Medical Center, Maywood, IL. This plasma was obtained from blood donated by
normal healthy human volunteers who tested negative for acquired immunodeficiency syndrome
(AIDS) and hepatitis B and C viruses. The fresh frozen plasma packs (n = 5), not more than 30
days old, were thawed at 37 ºC, and then the pooled plasma was aliquoted in volumes of 10 ml
and refrozen at -80oC for a period of not more than two months.
Normal human plasma (NHP). Pooled normal human plasma for use in coagulation
assays was purchased from George King Biomedical (Overland Park, KS). Each pool contained
citrated plasma from 30 or more donors and was certified to return normal values on standard
coagulation tests including PT, aPTT, and fibrinogen and to have levels of coagulation factors II,
V, VII, VIII, IX, X, XI, and XII within the normal range. NHP individual plasma aliquots were
stored at -80ºC prior to use.
Anti-thrombin depleted plasma (AT-DP). Antithrombin depleted plasma was obtained
from Enzyme Research Laboratories (South Bend, IN). This plasma was prepared by
immunoaffinity methods using AT antibodies. This plasma was aliquoted and stored at -80ºC
prior to use.
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Heparin cofactor-II depleted plasma (HC-II DP). Heparin cofactor-II depleted plasma
was obtained from Enzyme Research Laboratories (South Bend, IN). This plasma was prepared
by immunoaffinity methods using HC-II antibodies. Plasma was aliquoted and stored at -80ºC
prior to use.
Normal monkey plasma. Under an IACUC-approved protocol, primates (Macaca
mulatta) were anesthetized with ketamine (10 mg/kg, I.M.) and blood samples were drawn from
the saphenous vein using a 21-gauge ¾ inch butterfly needle and a 5 ml syringe. The blood was
transferred into a 4.5 ml sodium citrate (3.2%) BD Vacutainer® blood collection tube (Becton
Dickinson and Company, Franklin Lakes, NJ). Approximately 15 minutes later, the blood was
centrifuged at 4°C, 3,000 rpm (2,053 x g) for 20 minutes. Plasma from a minimum of 12
primates was pooled and aliquoted in 10 ml volumes. The pooled monkey plasma (NMP) was
frozen in plastic tubes at -80°C for not more than 2 months.
Major Instruments
WatersTM 845 high-performance liquid chromatography (HPLC) system (MilliporeWaters, Milford, MA) was used to determine the molecular profile of the various agents. The
HPLC system consists of a computer, a LAC/E interface module, two 510 HPLC pumps, a 712
WISP auto-injector, a 2404 differential refraction index (RI) detector, and a 2487 ultraviolet
(UV) tunable absorbance detector. The UV and the RI detectors were linked in series, with the
outlet of the tandem columns (TSK G3000SW and TSK G2000SW, TosoHaas, Tokyo, Japan)
attached to the UV detector. Millenniumâ 2000 software designed for polymer analysis was used
to analyze the elution profiles.
Bruker Avance II 600 MHz spectrometer (Bruker BioSpin, Billerica, Massachusetts).
All heparins and LMWHs were investigated using one dimensional (1D) nuclear magnetic
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resonance (NMR) method. 1D 1H and 13C NMR spectra were obtained at 600 MHz on D2O
exchanged heparin (20 mg/mL in D2O) using this Bruker Advance II 600 MHz spectrometer
with TopSpin 3.2 software at 298 K.
ACLTM Elite automated coagulation analyzer (Serial # K000053, Beckman-Coulter,
Miami, FL) was used to determine the antiprotease (anti-Xa and anti-IIa) and anticoagulant
(aPTT and TT) activites for all agents. This coagulation analyzer is capable of processing
multiple samples in a given time and can also generate kinetic data.
A SpectraMax® Plus384 absorbance microplate reader (Molecular Devices, Sunnyvale,
CA) was used to measure clot lysis, kinetics of various assays, and with the ELISA method. This
spectrophotometer system provides rapid and sensitive measurements of a variety of analytes
across a wide range of concentrations. It measures the optical density (OD) of samples at
selected wavelengths (450 nm and 405 nm) in a number of reading modes (endpoint, kinetic and
spectral scan).
STart 4 Hemostasis analyzer (Diagnostica Stago, Paris, France) was used to perform
several clotting-based assays such as PiCT, aPTT and PT assays using whole human blood and
plasma. The instrument uses a mechanical probe to detect clot.
PAP-8E aggregometer analyzer (Bio/Data Corporation, Horsham, PA) was used to
measure the rate and extent of platelet aggregation reactions. It is a light transmission
aggregometry which measures the ability of various agonists to platelets to induce in vitro
activation and platelet-to-platelet activation using platelet rich plasma (PRP). When an agonist is
added the platelets aggregate and absorb less light and so the transmission increases, and this is
detected by the photocell. This instrument is fitted with continuous recording of aggregation
profile in printable form.
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Zetasizer Nano ZS (Malvern; Worcestershire, UK) equipped with a fixed 173°
scattering angle and a 633 nm helium-neon-laser was used to determine heparin/PF4 interaction.
This machine is a high performance two angle particle and molecular size analyzer for the
enhanced detection of aggregates and measurement of small or dilute samples, and samples at
very low or high concentration using dynamic light scattering with 'NIBS' optics. This
instrument provides physicochemical measures in terms of particle size and charge density.
Hemochron 801 ACT machine (Birchwood, Washington, USA) was used to measure
the prolongation of the activated clotting time (ACT) by all agents. This whole Blood
Coagulation System utilizes a mechanical clot detection mechanism in which detection of a
fibrin clot in the blood sample automatically terminates the test, causing the instruments digital
timer to display the coagulation time in seconds. Tubes containing celite activator were used
throughout all studies in this dissertation.
TEG 5000 Thromboelastography Analyzer System (Haemonetics; Braintree,
Massachusetts, USA) was used to determine the impact of all heparins on the kinetic response of
blood clot formation. This hemostasis analyzer system is a diagnostic instrument that provides
comprehensive whole blood hemostasis testing that can help assess bleeding and thrombotic
risks, and also monitor antithrombotic therapies. By providing a more complete picture of the
patients' hemostasis, the TEG system can help facilitate the understanding of hemorrhagic or
thrombotic risk so you can deliver more targeted treatment. Manufacture’s designated activator
comprised of phospholipid was used throughout this dissertation.
Calibrated Automated Thrombogram (CAT, Diagnostica Stago, Parsippany, NJ)
instrument was used to measure thrombin generation potential. CAT system displays the
thrombin generation profile in plasma samples reflecting the onset of thrombin generation (Lag
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time), Peak thrombin representing the maximum amount of thrombin generated and the area
under the curve using a kinetic computed based program. The principle is based on thrombin
catalyzed hydrolysis of fluorogenic substrate upon the addition of such triggering agents as tissue
factor.
Cytation Hybrid Multi-Mode Reader (Model # L43859, Biotek, Winooski, VT, USA)
was used to measure fluorescence signals in the Heparin Red assay. Cytation 5 features a
patented, hybrid optical design, with filter-based fluorescence optics for high transmission and
high sensitivity, and monochromator optics for convenience and assay flexibility. Cytation
Hybrid Multi-Mode Reader has multiple fluorescence measurement modes include fluorescence
intensity, time-resolved fluorescence and fluorescence polarization.
Non-Human Primates
Male (n=6) and female (n=6) non-human primates (Macaca mulatta) (4 - 12 kg) were
used for the studies on the pharmacologic actions of heparins. The non-human primates are part
of a colony currently housed at the Loyola University Chicago Health Sciences Division
according to the institutional IACUC protocols of Loyola University Medical Center. All
experiments were non-terminal and approved by the Loyola University Chicago Health Sciences
Division IACUC. Hematologic profiles and serum chemistry profiles were performed at the
Clinical Laboratory, Department of Pathology at Loyola University Medical Center using a
Beckman Coulter LH 750 Hematology Analyzer (Beckman Coulter Inc, Indianapolis, IN). All
animal studies were carried out in compliance with the guidelines set forth by the Institutional
Animal Care and Use Committee (IACUC), Loyola University Medical Center and the
Principles of Laboratory Animal Care (National Institutes of Health, 2015). These primates were
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checked periodically for physical and laboratory profile of blood parameters such complete
blood counts and were under the care CMF staff.
Methods
Physiochemical Characterization of Heparins
Gel permeation chromatography. The molecular weight profile of each agent was
determined using the method reported by Ahsan et al.232-235 The system was equilibrated using
freshly degassed mobile phase (0.3 M sodium sulfate) until a stable baseline was obtained.
Analysis was carried out by injecting 20 μl of sample (10 mg/ml in 0.3 M sodium sulfate) into
the HPLC system. The flow rate for the mobile phase was 0.5 ml/min and the run time for each
sample was 65 minutes. The internal temperature for the RI detector was set at 35°C and UV
detection was made at 205 nm. Following each run, the elution profile of each sample was
analyzed relative to a previously determined calibration curve.
Calibration of the HPLC system was performed using 13 narrow range calibrators
ranging in molecular weight from 51.0 kDa to 2.4 kDa (10 mg/ml calibrators in 0.3 M sodium
sulfate).236,237 The log molecular weight of each calibrator was plotted against its retention time.
Using the Millenniumâ 2000 software, a third order polynomial regression equation (Log MW =
D0 + D1 (RT) + D2 (RT) 2 + D3 (RT) 3) was fitted to the data points, where MW represents the
calculated molecular weight, RT represents retention time and D0, D1, D2 and D3 represent
coefficients calculated in the curve fitting process. The molecular weight profile of each agent
was determined based on this calibration curve. The molecular weight profile consists of such
parameters as number average molecular weight (Mn, Da), weight average molecular weight
(Mw, Da), Z and Z+1 molecular weights and polydispersity (Mw/Mn). Additionally, for UFH
the fraction of material with molecular weight <8,000 Da, 8,000-16,000 Da, 16,000-24,000 Da
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and >24,000 Da were determined. Additionally, for LMWHs specified distribution profile with
molecular weight representing; molecular weight <2,000 Da, 2,000-8,000 Da, and >8,000 Da
were determined.
In addition, the European Pharmacopeia (EP) method was utilized to determine the
molecular weight profile of all LMWHs throughout this dissertation. 238 In this method the
elution profile of the molecular weight standard provided distinct peaks representing the MW
values of 1800 Da, 2400, Da 3000 Da, 3600 Da, 4200 Da, 4800 Da, 5400 Da and 6000 Da. The
log values of molecular weight of each of these assigned peaks were plotted against their relative
retention times and the Millennium 2000 software was used for calculation the MWs as
outlined above in the NRC method.
Nuclear magnetic resonance (NMR) spectroscopy. NMR analysis was performed on a
Bruker Avance II 600 MHz spectrometer (Bruker BioSpin, Billerica, Massachusetts) with
TopSpin 2.1.6 software (Bruker). Samples were prepared by dissolving approximately 15mg of
heparin in 99.96% D2O and lyophilizing the sample to remove exchangeable hydrogen from the
backbone of the structure. This was repeated 3 times to ensure that the deuterium exchange was
complete. The sample was then re-dissolved in 0.4mL of 99.96% D2O to minimize the HOD
peak in the NMR spectrum. The conditions for 1-dimensional (1D) 1H-NMR spectra were as
previously reported.239-241 Briefly, a wobble sweep width of 12.3 kHz, acquisition time of 2.66 s,
and relaxation delay of 8.00 s were used. Temperature was 298 K. Peaks were assigned based on
previous literature.239 The area of each peak was normalized to that of the total value of all peaks
(excluding the HOD peak).240,241
Chain mapping by LC-MS analysis. Heparin disaccharides were prepared by
exhaustive digestion using a mixture of heparinase I, II, and III (each lyase 0.1 IU/1.0 mg
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sample) in digestion buffer (50 mM ammonium acetate containing 2 mM calcium chloride
adjusted to pH 7.0) at 37 °C overnight. Enzymatic digestion was terminated by boiling samples
for 10 min and removing the denatured enzymes with centrifugation at 10,000 rpm for 10 min.
Supernatants were freeze dried and then re-dissolved for LC-MS analysis. Online RPIP LC
tandem Iontrap MS on an Agilent 1200 LC-Iontrap was used to analyze disaccharides from
NACHs. LC was performed on an Agilent 1200 LC system at 45°C using an Agilent Poroshell
120 EC-C18 (2.7 µm, 2.1 × 100 mm) column. Mobile phase A (MPA) was made up of 38 mM
ammonium acetate and 12 mM tributyl-ammonium acetate in 15% acetonitrile aqueous solution
(pH=6.5).
Mobile phase B (MPB) was made up of 38 mM ammonium acetate and 12 mM tributylammonium acetate in 65% acetonitrile aqueous solution (pH = 6.5). The mobile phase was
passed through the column at a flow rate of 100 µL/min. The gradient program was: 0-8min, 0%
B; 8–15min, 0–80% B; 15–25 min, 80% B; 25–26 min, 80-0% B; 26–40 min, 0% B. The sample
injection volume was 2 µL. The MS parameters were in negative mode as below: scan range
300-700 m/z, nebulizer 40 psi, dry gas 8 L/min, dry Temperature 350 ° C, capillary 1 nA.242
Tetrasaccharides compositional analysis. Tetrasaccharides from heparins of different
animal source were obtained by partial digestion using a mixture of heparin lyases (0.1 IU/1.0
mg sample) in digestion buffer (50 mM ammonium acetate containing 2 mM calcium chloride
adjusted to pH 7.0) at 37 °C for 2h. Enzymatic digestion was terminated by boiling samples for
10 min and removing the denatured enzymes with centrifugation at 10,000 rpm for 10 min.
Supernatants were freeze dried and then re-dissolved for LC-MS analysis. Online RPIP LC
tandem Iontrap MS on an Agilent 1200 LC-Iontrap was used to analyze tetrasaccharides from
heparins. LC-MS parameters and conditions used were the same as described above for the
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disaccharide analysis, except the flow rate was 120 µL/min and mobile phase gradient from 2%
to 30% MPB in 40 min, then rose to 60% MPB in following 15 min.242
Potency Adjustment and Cross Referencing of UFHs and LMWHs
Potency equivalence methods included the cross referencing of heparins and LMWHs of
different origins against their respective standards. For UFHs, USP standard was used in
conjunction with USP compliant amidolytic anti-Xa method. Each of the powdered UFH API is
individually weighed in gravimetric amount to obtain a final working solution of 0-10 ug/ml.
These solutions were used to cross refence against the USP standard solution with a calibration
range of 0-1 U/ml. The anti-Xa potency of each of the heparin was calculated by the Slope Ratio
method using the following formula:
Anti-Xa Potency = [Slope for test heparin/Slope for USP standard] * 1000
Once the potency was determined, the final adjustment to obtained equivalent potency of
100 U/ml working solution were prepared. It’s well known that the potency of BMH is typically
30% less than that of PMH. So, the anti-Xa potency of BMH and PMH were determined to be a
130 U/mg and 200 U/mg respectively. Then, to equate the BMH anti-Xa potency to that of PMH,
the BMH mass/volume was accordingly adjusted to obtain equivalent USP potency in
comparison to porcine heparin.
For the LMWHs, NIBSC standard was used in conjunction with USP compliant
amidolytic anti-Xa method. Each of the LMWH’s API is weighed in gravimetric amount to
obtain a final working solution of 0-10 ug/ml. These solutions were used to cross reference
against the NIBSC standard solution with a calibration range of 0-1 U/ml. The anti-Xa potency
of each of the LMWH was calculated by the Slope Ratio method using the following formula:
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Anti-Xa Potency = [Slope for test LMWH/Slope for NIBSC standard] * 1000
Because of the anti-Xa potency of all LMWHs were comparable and ranged from 95 U/mg to
104 U/mg, no potency adjustment was required. The bovine, ovine and porcine LMWHs were
found to exhibit equivalent potency in all studies carried out in this dissertation.
Global Anticoagulant Assays in Normal Human Blood
Activated clotting time test (ACT).243,244 The manufacturer’s instructions were followed
to perform this assay. Into syringes, 200 µL of 100 µg/mL or 10 U/mL UFH solution or 250
µg/mL or 2.5 U/mL LMWH solution were added. Blood from a healthy human volunteer was
drawn into these syringes and was mixed with the heparin agent (final UFH and LMWH
concentrations were 10 and 25 µg/mL respectively, similar to that used in clinical interventions).
The heparinized blood was placed into a celite ACT tube and was vigorously shaken. The ACT
tube was placed into the ACT machine (Hemachron; Edison, New Jersey, USA) and the time to
clot was recorded. In addition, protamine sulfate (F.C.:10 µg /ml) neutralization profile of all
agents was determined using the same procedures.
Thromboelastography analysis (TEG).245-247 Whole blood from healthy human
volunteers was freshly collected into individual blood collection tubes containing 3.2% sodium
citrate. The whole blood from an individual donor was added to TEG reaction cups containing
heparin to give final concentrations of 0.5, 1.0 and 2.5 µg/mL or 0.25, 0.5 and 1 U/mL (similar to
therapeutic clinical concentrations). In regard to LMWHs, the final concentrations were of 5, 10
and 25 µg/mL or 0.5, 1 and 2.5 U/mL. Calcium chloride (0.25 M) was added to the heparin
supplemented whole blood and the TEG analysis was immediately performed. The clotting
profile was determined and was quantified by measuring the time for clot initiation (R-time),
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time to standard clot firmness (K-time), maximal clot firmness (maximum amplitude), and rate
of clot formation (angle).
Global Anticoagulant Assays in Normal Human Plasma
The selected assays were those commonly used in a hospital laboratory to clinically
monitor therapeutic heparin.248-251 The anticoagulant heparin acts as an inhibitor in these assay
systems, such that a prolongation of the time to clot, or less thrombin generation, indicates
anticoagulation strength of the heparin.
Activated partial thromboplastin time (aPTT). The aPTT assesses the intrinsic and
common pathways of the coagulation systems.252,253 The TriniCLOTTM aPTT S kit (Trinity
Biotech USA Inc, Jamestown, NY) was used to determine the aPTT of the test samples. The
following reagents were included in the TriniCLOTTM aPTT S kit: TriniCLOT aPTT CaCl2 (0.02
M) and TriniClOT aPTT S reagent. The reagent contains purified phospholipids (porcine and
galline), micronized silica (activator), stabilizer, and 0.02% sodium azide as preservative. All
reagents were kept refrigerated (4°C) until use. Each vial of TriniCLOT aPTT CaCl2 (0.02 M)
and TriniClOT aPTT S reagent came ready to use.
When the assay was utilized for human or primate plasma, the assay was performed as
follows. An aliquot of 250 µl of each of the plasma samples were placed into individual test
cups, which were then placed in an ACL test cup carousel in a defined sequence. NHP or NMP
and saline samples were included in every carousel as controls. The reagents were placed in their
appropriate positions (TriniCLOT APTT S reagent in position 2 and CaCl2 in position 3). A
clean ACL rotor was placed in the carousel. The appropriate parameters were set on the machine
before running the test. An aliquot of 50 µl of each of the plasma samples and 50µl of aPTT
reagent were incubated at 37°C for 5 minutes. After 5 minutes of incubation, prewarmed calcium
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chloride was added to trigger coagulation and the clotting times were then measured on an ACL
Elite (Beckman-Coulter, Miami, FL).
Measurement of clotting time was stopped at 300 seconds as clotting times beyond 300
seconds are outside of the linear range of the instrument. UFHs and LMWHs were prepared to a
concentration of 100 µg/mL or 10 U/mL in saline. All agents were serial diluted in pooled
human plasma to achieve a six-point concentration range of 0-10 µg/mL or 0-1 U/mL then was
assayed for anticoagulant activity.
All assays were repeated at least for 3 times (for each concentration of each agent).
Concentration response curves to cover narrow graded ranges at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0,
8.0, 9.0, and 10 ug/ml were determined. Only the linear part of the curve was used for calibration
and cross-calculation purposes. These studies were also carried out in the graded final
concentrations of 0.1-1.0 U/ml. Only the linear part of the curve was used for calibration and
cross-calculation purposes.
Thrombin time (TT). The thrombin time clotting time test (TT) assesses the function of
thrombin in plasma.254 The TT assay was performed on the ACL-300-Plus fast kinetic
coagulation analyzer (Beckman CoulterÒ; Fullerton, California, USA) using a human thrombin
reagent obtained from Enzyme Research Laboratories (South Bend, Indiana, USA). The
thrombin was reconstituted with 0.25 M CaCl2 to yield a 5 U/mL solution. UFHs and LMWHs
were prepared to a concentration of 100 µg/mL or 10 U/mL in saline. Test agents were further
diluted in pooled human plasma to achieve a six-point concentration range of 0-10 µg/mL or 0-1
U/mL, then were assayed for anticoagulant activity. All assays were repeated at least 3 times (for
each concentration of each heparin). Concentration response curves to cover narrow ranges at 110 ug/ml were determined. Only the linear part of the curve was used for calibration and cross-
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calculation purposes. These studies were also carried out in the graded final concentrations of
(0.1-1) ug/ml and 1.0 U/ml. Only the linear part of the curve was used for calibration and crosscalculation purposes.
Prothrombinase-induced clotting time (PiCT). PiCT assay (one stage method) was
utilized to determine the anticoagulant activity of those agents using Diagnostica Stago STart 4
Hemostasis Analyzer.255 Test agents were diluted in pooled human plasma to achieve a six-point
concentration range of 0-10 µg/mL or 0-1 U/mL, then were assayed for anticoagulant activity.
All assays were repeated at least 3 times (for each concentration of each agent). Concentration
response curves to cover narrow ranges at 1-10 ug/ml were determined. Only the linear part of
the curve was used for calibration and cross-calculation purposes. These studies were also
carried out in the graded final concentrations of 0.1-1 U/ml. Only the linear part of the curve was
used for calibration and cross-calculation purposes.
Thrombin generation inhibition Assay (TGA). Inhibition of thrombin generation was
measured using the Calibrated Automated Thrombogram instrumentation (CAT, Diagnostica
Stago, Parsippany, NJ) on a Fluoroskan Ascent fluorimeter.256,257All drugs were supplemented in
normal pooled plasma to obtain concentration ranges from 0 - 10 µg/ml or 0-1 U/mL. Reagents
that were used in this assay including the Fluo-substrate, Fluo-buffer, tissue factor high reagent
(mixture of tissue factor and phospholipids) and a thrombin calibrator. The thrombin generation
assay was carried out in 96-well Immune 2HB transparent round bottom plates.
The thrombin generation potential was measured in terms of the peak thrombin
concentration, lag time and endogenous thrombin potential (ETP) / area under the curve (AUC).
Results were compiled in terms of mean ± SD. Concentration - response curves to cover narrow
ranges at 1-10 ug/ml were determined. Only the linear part of the curve was used for calibration
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and cross-calculation purposes. These studies were also carried out in the graded final
concentrations of 0.1-1 U/ml. Only the linear part of the curve was used for calibration and
cross-calculation purposes.
Antiprotease & Potency Determination Assays
Anti-factor Xa assay in normal human plasma. The inhibition of factor Xa in human
and primate samples was performed on the ACL Elite fast kinetics coagulation analyzer
(Beckman-Coulter, Hialeah, FL), in the following manner. Test samples were prepared by
placing 250 µl of test plasma into individual test cups, which were then placed in an ACL-test
cup-carousel and their positions were recorded. Up to 40 plasma samples could be inserted into
one carousel. Normal human pool plasma and saline samples were included in every carousel as
controls. Bovine factor Xa (1.0 mg/ml) (Enzyme Research Laboratories, South Bend, IN) was
reconstituted with 4 ml (final factor Xa concentration of 6µg/ml) of Xa/IIa buffer (50mM Tris,
175 mM NaCL, 7.5 mM Na2 EDTA, 800 ml distilled H2O, pH = 8.4, 25 ºC) prior to use. The
substrate, Spectrozyme FXa (5 µmole/vial) (Sekisui Diagnostics, Stamford, CT) was
reconstituted by adding 2 ml of distilled water. The reagents were placed in their appropriate
positions (bovine factor Xa in position 2 and Spectrozyme FXa in position 3). A clean ACL rotor
was also placed in the instrument. Once the reagents and samples were in their proper places, the
ACL keypad was used to set the appropriate specifications for the anti-Xa assay. An aliquot of
10 µl of plasma was incubated for 1 minute at 37 ºC, followed by the addition of 100 µl of
bovine factor Xa. After five minutes incubation at 37 ºC, 75 µl of Spectrozyme FXa was added
and the optical density change at 405 nm was measured for 30 seconds.
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The results were processed on an IBM compatible PC. The results were given as optical
density (O.D.) values which were converted to % factor Xa inhibition using the following
equation: % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100].
Anti-factor IIa assay in normal human plasma. The inhibition of factor IIa in human
and primate plasma samples was measured on the ACL Elite fast kinetics coagulation analyzer
(Beckman-Coulter, Hialeah, FL), in the following manner. Test samples were prepared by
placing 250 µl of test plasma into individual test cups, which were then placed in an ACL test
cup carousel and their positions were recorded. Up to 40 plasma samples could be loaded into
one carousel. Normal human or primate pool plasma and saline samples were included in every
carousel as controls. Human thrombin (Enzyme Research Laboratories, South Bend, IN) was
diluted to 5 U/ml in Xa/IIa buffer. The substrate, Spectrozyme TH (Sekisui Diagnostics,
Stamford, CT) was reconstituted by adding 5 ml of distilled water (1 mM). The reagents were
placed in their appropriate positions (thrombin in position 2 and Spectrozyme TH in position 3).
A clean ACL rotor was also placed in the instrument. Once the reagents and samples were in
their proper places the ACL keypad was used to set up the appropriate specifications for the antiII assay. A 10 µl aliquot of plasma was incubated for 1 minute at 37 ºC, followed by the addition
of 100 µl of thrombin. Following one-minute incubation at 37 ºC, 40 µl of Spectrozyme TH was
added, and the optical density change at 405 nm was measured for 30 seconds.
The results were processed on an IBM compatible PC. The results were given as optical
density (O.D.) values which were converted to % factor IIa inhibition by using the following
equation: % Inhibition = [100 - (O.D. sample/O.D. baseline) x 100]
Antiprotease assays in purified AT system. Heparins were diluted to a concentration of
100 µg/mL in saline, and then were further diluted in purified human antithrombin (AT,1 U/ml)
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in place of plasma as the source for AT to achieve a six-point concentration range of 0-10
µg/mL. Each heparin concentration was assayed for its ability to inhibit thrombin and factor Xa
using the modified amidolytic (chromogenic substrate) assays developed in our research
laboratories.258,259 These anti-factor IIa and anti-factor Xa assays were performed on the ACLElite fast kinetic coagulation analyzer (Beckman Coulter; Fullerton, California, USA) using
human thrombin and bovine factor Xa reagent (Enzyme Research Laboratories; South Bend,
Indiana, USA). Spectrozyme TH and Spectrozyme Xa synthetic substrate (Sekisui Diagnostics;
Stamford, Connecticut, USA) were utilized in these studies as well.
These assays that use a purified AT system and eliminate the use of plasma have become
the recommended US and European Pharmacopeia monograph assays for determining potency of
heparin. For each concentration of each heparin the percent inhibition of factor IIa and factor Xa
activity was calculated by calculating the percentage change. Potency of each heparin was
determined by calculating the IC50 value as the amount of heparin which produced 50%
inhibition of factor IIa and factor Xa activity. Concentration response curves to cover narrow
ranges at 1-10 ug/ml were determined. Only the linear part of the curve was used for calibration
and cross-calculation purposes. These studies were also carried out in the graded final
concentrations of 0.1-1 U/ml. Only the linear part of the curve was used for calibration and
cross-calculation purposes.
Antiprotease assays in purified HC-II system. Heparins were diluted to a concentration
range of 0 - 20 µg/mL in Xa/IIa buffer, and 20 ul of heparin cofactor II (20 ug/ml) and 20 ul of
5U/ml Thrombin were added to 20 ul of each agent in 96 well plate. Immediately, the plate was
incubated at 37°C for 1 minute. Then 200 ul of 1 mM Spectrozyme TH was added and the
optical density was monitored for 1 minute at 405 nm using A SpectraMax® Plus384 Absorbance
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Microplate Reader (Molecular Devices, Sunnyvale, CA). Each heparin concentration was
assayed for its ability to inhibit coagulation thrombin using the modified amidolytic
(chromogenic substrate) assays developed in our research laboratories.258,259
For each concentration of each heparin the percent inhibition of factor IIa activity was
determined by calculating the percentage change in the optical density (OD). The relevance
potency of each heparin was determined by calculating the IC50 value as the amount of heparin
which produced 50% inhibition of factor IIa activity.
AT and HC-II depleted plasma studies. Heparins were supplemented in either
antithrombin depleted plasma (AT-DP) (Enzyme Research; South Bend, IN) or heparin cofactorII depleted plasma (HCII-DP) (Enzyme Research; South Bend, IN) to obtain a final
concentration range of 0-50 µg/ml. Each heparin concentration was assayed for its ability to
inhibit thrombin and factor Xa using the modified amidolytic (chromogenic substrate) assays
using standardized.258,259 These anti-IIa and anti-Xa assays were performed on the ACL-Elite fast
kinetic coagulation analyzer (Beckman Coulter; Fullerton, California, USA) using human
thrombin and bovine factor Xa reagents (Enzyme Research Laboratories; South Bend, Indiana,
USA). Spectrozyme TH and Spectrozyme Xa synthetic substrates (Sekisui Diagnostics;
Stamford, Connecticut, USA were utilized in these studies as well. For each concentration of
each heparin the percent inhibition of factor IIa and factor Xa activity was calculated by
calculating the percentage change. Potency of each heparin was determined by calculating the
IC50 value as the amount of heparin which produced 50% inhibition of factor IIa and factor Xa
activity.
The use of serpin depleted plasma differentiates the mechanisms by which the heparins
from various sources mediate their biological actions. Concentration response curves to cover
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narrow ranges at 1-10 ug/ml were determined. Only the linear part of the curve was used for
calibration and cross-calculation purposes. These studies were also carried out in the graded final
concentrations of 0.1-1 U/ml. Only the linear part of the curve was used for calibration and
cross-calculation purposes.
USP compliant anti-Xa and Anti-IIa potency assays. The Biophen Anti-IIa and AntiXa assays from Hyphen BioMed (Aniara; West Chester, Ohio, USA) were developed in
compliance with the heparin potency assay described in the USP Heparin Monograph and the EP
Heparin Monograph.260 The assay was performed according to manufacturer’s instructions.
Biophen anti-IIa and anti-Xa assays are two-step chromogenic methods based on the inhibition
of a constant amount of factor IIa or factor Xa by the tested heparin in the presence of exogenous
AT (stage 1). The excess factor IIa or factor Xa hydrolyzed a specific chromogenic substrate
(stage 2) that leads to a color development. This color was measured at 405 nm using a
SpectraMax® Plus384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA).
Six dilutions of each heparin were prepared using AT-supplemented buffer at
concentrations ranging from 0-10 μg/mL or 0-1 U/mL. The potency of each heparin was
calculated relative to the USP reference standard. USP standard curve was constructed to
estimate the potency of each agent using the slope-ratio method, where the anti-IIa and anti-Xa
potency of each heparin was calculated using this equation:
Anti-IIa or Anti-Xa Potency = [Slope for test heparin/Slope for USP standard] * 1000
In Vitro Neutralization Studies
Protamine sulfate (PS) neutralization studies. PS is the main neutralizing agent used
clinically to reverse the anticoagulation effect of heparin thus reducing the risk of bleeding, for
example after cardiac surgery.261-264 Test agents were supplemented to pooled normal human
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plasma in a concentration range of 0-10 ug/ml and 0-1 U/mL. Freshly prepared protamine sulfate
solution, at a fixed final concentration of 10 µg/mL, was added to each heparin-plasma mixture
which were then assayed for aPTT, TT, anti-IIa and anti-Xa activity. For comparison purposes, a
parallel control using saline in place of protamine sulfate was supplemented (using the same
volume as used for protamine) to each heparin-plasma mixture. PS neutralization indices were
calculated by comparing the PS supplemented and saline supplemented assays.
Heparinase-I digestion studies. Heparinase-I is a heparin-degrading enzyme that cleave
certain sequences of heparin/heparan sulfate specifically.265-271 The digestion profile of both the
heparins and LMWHs can be determined using molecular distribution studies and functional
assays. In these assays, heparins were subjected to heparinase-I digestion in the following
manner: an aliquot of 70 μl of each agent (10 mg/ml) was added to an Eppendorf tube along with
10 μl of CaCl2, 10 μl of either heparinase (10 U) or saline (vehicle control), and an additional 10
μl of saline for a total volume of 100 μl. The solutions were mixed, incubated for 30 minutes at
37°C, and then placed in a 100 °C water bath for 3 minutes. The final heparinase concentration
was 1 U. After digestion, the heparinase/agent or saline/agent solutions were supplemented in
normal human plasma to obtain final concentrations ranging from 0 - 10 μg/ml. Anticoagulant
activity was determined prior to and after the digestion using the aPTT and TT assays.
Furthermore, antiprotease activity was determined prior to and after the digestion using anti-IIa
and anti-Xa assays. Finally, the molecular profile was determined prior to and after the digestion
of each heparin using GPC in a high-performance liquid chromatography (HPLC) system as
mentioned above. Percentage digestion of all heparins and LMWHs was calculated by taking to
account the reduction in the MW.
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Platelet factor 4 (PF4) neutralization studies. These studies were performed on all
UFHs and LMWHs to determine the ability of PF4 to inhibit the anticoagulant and anti-protease
actions of each agent. Frozen PF4 (1 mg/ml) was diluted in saline to obtain a working solution
of (100 ug/ml). Each of the individual agents were thawed and supplemented to pooled normal
human plasma in a concentration range of 0-10 ug/mL or 0-1 U/mL. PF4, at a fixed final
concentration of 10 µg/mL, was added to each heparin-plasma mixture, which were then assayed
for aPTT, TT, anti-IIa and anti-Xa activities. For comparison purposes, a parallel control using
saline in place of PF4 was supplemented to each heparin-plasma mixture. All assays were
repeated at least 3 times.
Platelet Function Profiles
Both heparin and LMWH are known to modulate platelet function such as adhesion,
activation and aggregation. 272-276 Agonist induced platelet aggregation is known to be augmented
at lower concentrations of heparins, whereas at highest concentrations inhibit the aggregation
responses.273 Aggregometry is also used to study HIT antibody mediated aggregation of platelets.
In this study both the augmentation of platelet aggregation induced by various agonists and HIT
antibody mediated responses were measured in the following to approaches.
Agonist induced platelets aggregation (AIPA). Platelet rich plasma (PRP) and platelet
poor plasma (PPP) were prepared by differential centrifugation of citrated whole blood at 800
rpm for 20 minutes from freshly prepared citrated whole blood that was collected from normal
healthy volunteers. PRP was supplemented with heparin at final concentrations of 10, 1 and 0.1
µg/mL or 0.5, 1 and 2.5 U/ml. To this mixture platelet agonists were added. Platelet agonists that
target different receptors/biological pathways within the platelet were used to stimulate platelet
activation.
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The agonists included: ADP, collagen, epinephrine & arachidonic acid. The platelet
activation response at 37°C was monitored for 20 minutes using the PAP-8 Platelet
Aggregometer (BioData; Horsham, Pennsylvania, USA). Changes in light transmission through
the PRP mixture over time was recorded. The platelet aggregation profile was defined in terms of
maximum aggregation (MA), primary slope (PS), area under the curve (AUC), and final
aggregation.
Heparin induced platelets aggregation (HIPA). Apheresis fluid was collected in
conjunction with the therapeutic apheresis procedure to de-load antibody titer in patients with
symptomatic HIT syndrome. These apheresis fluids were screened for the presence of HIT
antibodies by using ELISA method and functionality in 14C serotonin release and platelet
aggregation studies. Five apheresis fluid were selected and pooled and then HIT antibody titer in
terms of immunoglobulins subclasses and HIT aggregation responses were profiled. Ten
milliliter aliquots of the pool were frozen at -80 °C until use. Platelet rich plasma (PRP) was
prepared from health male and female donors utilizing a double syringe, the first few millimeter
was discarded to reduce the activation products such as TF and platelet release proteins.
Platelet rich plasma (PRP) was prepared by centrifuging the citrated blood at 800 rpm
(146 x g) for 20 minutes at room temperature. After separating the PRP, the remaining blood
was spun further at 3,000 rpm (2,053 x g) for 20 minutes to obtain platelet poor plasma (PPP).
PPP was used to adjust the optical density of the PRP in the aggregometer (PAP-8) (BioData
Corporation, Horsham, PA). To test the HIT antibodies responses of each agent, 290 ul of PRP
was supplemented with 160 ul of apheresis fluid and equilibrated for five minutes. Followed by
adding 50 ul of heparins at various concentrations (10 ug/ml, 100 ug/ml and 1 mg/ml) to achieve
final concentrations of 1, 10 and 100 µg/ml.
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Similarly, UFHs of different origins were tested at potency adjusted stock concentrations
of 5, 10 and 25 U/ml to achieve 0.5, 1 and 2.5 U/ml concentrations. The 1 and 10 µg/mL heparin
concentrations represent the range of clinical dosages, and the 100 µg/mL heparin concentration
is used as an assay control (excess antigen) that has a negative response in tests with true heparin
antibody-dependent platelet activation.277 The platelet activation response was monitored for 30
minutes at 37°C on the PAP-8 Platelet Aggregometer. Results were recorded in terms of slope
and % aggregation. For the compilation of the results, 30 mins aggregation point was used.
Multiple platelet donors (n=10) were used, and the results were compiled as mean +/- SD.
Parallel controls for both heparin and HIT antibody were obtained by substituting saline in
respective proportions.
Characterization of Heparin/PF4 Interaction
Since the recent understanding of the key role that platelet factor 4 (PF4) plays in the
pathogenesis of HIT, scientists are looking to determine qualities about the interaction of PF4
with heparin that are associated with the pathology of HIT.278-281 For the evaluation of the
immunogenicity of UFHs and LMWHs from various animal origins, the potential of these agents
to form complexes with human PF4 was investigated using photon-correlation spectroscopy
(PCS) and Zeta-potential (Zp) measurements in conjunction with Ronzoni institute (Milano,
Italy). These studies were carried essentially in the same experimental settings as previously
published. The PF4, from human platelets (hPF4), was purchased from ChromaTec, Greifswald,
Germany (freeze-dried in Hanks’ balanced salt solution [HBSS]).282 In order to perform the
evaluation of PF4/heparin interaction, titration of protein by the samples was performed at
different Protein/Heparin Ratio (PHR), calculated as follow:
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Photon-correlation spectroscopy (PCS) studies. To analyze hPF4/heparin complex
size, the solution obtained by mixing 40 µl hPF4 (1 mg/mL in HBSS) with suitable volume of
HBSS and heparin solutions was transferred to a disposable folded capillary cell at room
temperature and analyzed 60 minutes post-mixing. The molar ratios between protein and heparin
concentration (PHR) were determined considering the average molecular weight value (Mw) of
each sample, measured by high performance–size exclusion chromatography with triple detector
(HP-SEC-TDA) and the molecular weight of the hPF4 tetramer (31.2 kDa).282
Zeta potential (Zp) measurements. Each sample of freeze-dried hPF4 in HBSS was
dissolved in deionized water to obtain a protein concentration of 1 mg/mL. In order to measure
the Zp of hPF4/heparin complexes, the solution obtained by mixing 40 µl hPF4 (1 mg/mL in
HBSS) with a suitable volume of water and heparin solutions was transferred to a disposable
folded capillary cell (Malvern, Worcestershire, United Kingdom) at room temperature and
analyzed 10 minutes post-mixing.282
The PCS and Zp of PF4/heparin complexes were measured using the Zetasizer Nano ZS
(Malvern, Worcestershire, United Kingdom) with a fixed 173 degree scattering angle and a 633
nm helium–neon laser. Data were analyzed using Zetasizer software version 7.11 (Malvern,
Worcestershire, United Kingdom). For Zp experiments, the statistical evaluation was carried out
using Origin software where the Zp data were fitted versus the logarithm of PHR with a
sigmoidal equation that allows for the determination of the PHR at which Zp = 0 mV, the neutral
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state of the complex. The Tables (1- 4) below show the PF4 and heparin and LMWH molar
ratios that were used for PCS and Z-potential studies. Heparins were used in a contention range
of 0.08 - 0.25 uM whereas the LMWHs were used in a concentration range of 0.25 – 1.455 uM
for both the PCS and Zp studies. The PF4 concentration was kept constant throughout these
studies at a 1.6 uM level.
Table 1. PF4 and heparin molar ratios that were used for PCS studies. PHR; protein heparin ratio:

Table 2. PF4 and LMWH molar ratios that were used for PCS studies. PHR; protein heparin ratio:
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Table 3. PF4 and heparin molar ratio that were used for Z-potential studies. PHR; protein heparin ratio:

Table 4. PF4 and LMWH molar ratios that were used for Z-potential studies. PHR; protein heparin ratio:

In Vitro Studies in Pooled Monkeys’ Plasma
In this investigation, non-human primate model was utilized to determine the
pharmacokinetics (PK), pharmacodynamics (PD) and protamine neutralization profiles of all
agents. In addition, several functional assays such as anticoagulant and antiprotease assays were
performed in pooled monkeys’ plasma and normal human plasma to compare the activities of all
agents. The pooled monkey plasma was prepared from 12 non-human primates using the
standard methods and frozen in plastic tubes at -80°C for not more than 2 months as mentioned
earlier in blood products section (1.6). Furthermore, 1-2 mL of whole blood was drawn from
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each monkey into a syringe and was placed into an EDTA tube, this discarded blood was used
for the complete blood count (CBC).
The CBC for each primate was determined using Hematology Analyzer Workstation
(Beckman Coulter 628134 UniCel DxH 800) to monitor the hematologic profile of each primate
in terms of various parameters. The CBC profile of each primate was tabulated in terms of such
parameters as cell counts including RBC and platelet along with WBC. Other parameters
including hemoglobulin, hematocrit and differential analysis of leukocytes. The composite
results of the hematologic profile of the primates were tabulated and reviewed by the CMF staff
to insure the physiologic status of the colony (Appendices B13 & B14).
In Vivo Studies in Non-Human Primates
PK/PD profile in non-human primate model. The PK/PD studies in primates were
carried out in accordance with an approved IACUC protocol. These studies were carried out in a
cross over design in individual groups of 4 primates for each agent. Rhesus monkeys (Macaca
mulatta) ranging in weight from 6.4 to 10.8 kg were used in these investigations.283-286 Primates
were anesthetized by the intramuscular administration of ketamine (10 mg/kg) and xylazine (1-2
mg/kg) based on their most recent charted weight. Following attainment of the appropriate depth
of anesthesia (assessed by a lack of response to foot pinch), primates were freshly weighed to
accurately determine the dose of the test agent. The procedure room was maintained at an
ambient temperature of 78◦F to minimize the chance that primates would become hypothermic
while under anesthesia. A baseline blood sample was collected by venipuncture of the saphenous
vein. UFHs were administered at a dose of either 0.5 mg/kg or at adjusted USP potency of 100
anti-Xa U/kg intravenously while LMWHs were administered at 1 mg/kg subcutaneously. All
heparins were administered via the contralateral saphenous vein. Additional blood samples were
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collected at 15, 30, 60, and 120 min post-UFHs administration (Figure 9). For the LMWHs,
additional blood samples were collected at 2, 4 and 6 hours after the administration of each agent
(Figure 10).

Figure 9. Schematic of experimental protocol for monkey PK/PD studies and blood draw points.
Primates (n=4) were administered UFHs at a dose of 0.5 mg/kg or 100 U/kg as an IV bolus. 15 minutes
following the administration of the drug, a second blood sample was collected. Additional blood samples
were collected at 30-, 60- & 120-minutes post drug administration.

Figure 10. Schematic of experimental protocol for monkey PK/PD studies and blood draw points.
Primates (n=4) were administered LMWHs at a dose of 1 mg/kg as an IV bolus. 2 hours following the
administration of the drug, a second blood sample was collected. Additional blood samples were collected
at 4 and 6 hours post drug administration.

All blood samples were collected using a double syringe technique, employing a 21gauge butterfly needle. After an initial ∼1 ml volume (discard blood) was collected, the syringe
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was changed, and a 2.7 ml sample was drawn and placed into a tube containing 0.3 ml 3.2%
sodium citrate. Citrated blood samples were centrifuged at 1,100 x g for 15 min. The supernatant
platelet poor plasma was harvested, and aliquots of plasma were stored frozen at -80°C until
analysis of circulating drug levels. In-vitro concentration-response curves were made by
supplementing the various UFHs and LMWHs into pooled primate plasma. Plasma
concentrations of the various agents were plotted against corresponding optical densities in the
factor IIa or factor Xa assays using graphing software, SigmaPlot for Windows version 12.3
(Systat Software, San Jose, CA) and best-fit curves were made.
The drug concentration in each primate blood sample in terms of anti-IIa and anti-Xa
activities was determined by extrapolation. The area under the plasma concentration time curve
(AUC), elimination half-life (t1/2), systemic clearance (Cl) and volume of distribution (Vd) were
calculated from the extrapolated plasma concentrations using the non-compartmental method of
PKSolver® add-in software for Microsoft Excel.287 All results were presented as mean ± SD.
Absolute PK parameters using the Heparin Red Kit®. The Heparin Red Kit is used for
the quantification of heparin in citrated blood plasma by a fluorescence assay (Figure 11).288,289
The absolute heparin concentration in primate plasma samples were measured according to the
manufacture instructions. 20 μL aliquots of the primate plasma samples were added into
microplate wells immediately followed by 80 μL of the mixture (Heparin Red dye + Enhancer
solution). The microplate was introduced in the plate reader, shaken at high speed for 3 minutes
and measurement of fluorescence was initiated. Individual calibration curves were made using
the same drugs which were injected to the monkeys by plotting drug concentrations in μg/mL
against fluorescence intensity. Then we determine the heparin concentration in monkey’s plasma
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from fluorescence intensity and comparison with calibration curves. Triplicate determination was
done for all samples.

Figure 11. Schematic representation of fluorescence quenching of the molecular probe Heparin Red in
the presence of polyanionic polysaccharides due to the formation of non-fluorescent aggregates.
Fluorescence (Heparin Red® assay) is measured with the microplate reader Biotek Synergy Mx (Biotek
Instruments, Winooski, VT, USA), excitation at 570 nm, emission recorded at 605 nm, spectral band
width 13.5 nm, and read height of 8 mm.

Thrombin generation inhibition assay (TGA). This assay was performed using the
Calibrated Automated Thrombogram assay (CAT, Diagnostica Stago, Parsippany, NJ) on a
Fluoroskan Ascent fluorimeter. Assay was performed as described above in section (2.4.4).
Results in terms of various parameters such as peak thrombin, area under the cure and lag time
were compiled in terms of the mean ± SD.
Tissue factor pathway inhibitor (TFPI) antigen level assay. TFPI antigen levels were
determined by using a commercially available Sandwich ELISA method (Diagnostica Stago,
Paris, France) as shown below (Figure 12). Monkeys samples at different time points were added
to Micro-plate wells that were pre-coated with TFPI capture antibody (Fab’ fragments from
mouse anti-TFPI monoclonal antibody) and blocked. Then, all samples were incubated in the
wells, where the TFPI protein was bound by the immobilized capture antibody. Wells were

94
washed to remove unbound non-specific sample matrix. A detector antibody (mouse anti-TFPI
monoclonal antibody-peroxidase conjugate, lyophilized) was incubated in the wells for 30
minutes where it binds to the captured TFPI then the wells were again washed to remove
unbound detector antibody. Finally, colorimetric detection (addition of the substrate orthoPhenylenediamine and urea peroxide) was then performed. The enzymatic reporter conjugated to
the detector antibody (Peroxidase) catalyzed a detection substrate producing a signal which was
proportional to the quantity of the TFPI antigen levels.

Figure 12. Diagrammatic representation of the quantification of TFPI antigen levels using sandwich
ELISA method.

Tissue factor pathway inhibitor (TFPI) functional level assay. TFPI functional levels
were measured in all primate plasma samples using the commercially available
ACTICHROME® TFPI kit (Biomedica Diagnostics, North Vancouver, Canada).
ACTICHROME TFPI measures the ability of TFPI to inhibit the catalytic activity of the
TF/FVIIa complex as it activates Factor X to Factor Xa. It is a two-stage chromogenic assay. In
the first stage, samples were incubated with TF/FVIIa and the residual TF/VIIa activity
converted FX to FXa. In the second stage, the FXa activity generated cleaved
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SPECTROZYME® FXa, a highly specific chromogenic substrate for Factor Xa. The cleaved
substrate released a para-nitroaniline (pNA) chromophore into the reaction solution. The solution
absorbance was read at 405 nm and compared to those values obtained from a standard curve
constructed using known TFPI activity levels.
In vivo protamine sulfate neutralization profile in non-human primate. Protamine
sulfate (PS) single dose vials were obtained from Fresenius Kabi pharmaceutical company
(Melrose Park, IL, USA). For these experiments, four Rhesus monkeys were used for each group
(n=4) as mention above. A baseline blood sample was collected by venipuncture of the
saphenous vein prior to the administration of any test agent. Primates were administered UFH at
a dose of 0.5 mg/kg and 100 U/kg or LMWHs at a dose of 1 mg/kg as an IV bolus. 15 minutes
following the administration of each agent, a second blood sample was collected, and primates
were immediately treated with a 1 mg/kg IV dose of protamine sulfate or an equivalent volume
of saline. Additional blood samples were collected at 15-, 45- & 120-minutes post protamine
sulfate administration (Figure 13). These experiments detailed here were non-terminal. As such,
following a minimal two-week drug washout period, a primate may be used in another treatment
group.
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Figure 13. Schematic of experimental protocol for monkey protamine neutralization and blood draw
points. Primates were administered UFH at a dose of 0.5 mg/kg and 100 U/kg or LMWH at a dose of 1
mg/kg as an IV bolus. 15 minutes following the administration of the drug, a second blood sample was
collected, and primates were immediately treated with a 0.5 mg/kg IV dose of protamine sulfate or an
equivalent volume of saline. Additional blood samples were collected at 15-, 45- & 120-minutes post
protamine sulfate administration.

Data Processing and Statistical Analysis
The experimental data obtained in this dissertation is presented as the mean ± standard
deviation (SD) or mean ± standard error of the mean (SEM) and is indicated as such throughout
this document. The results obtained from the biochemical experiments were analyzed using a
two-way analysis of variance (ANOVA) followed by a Bonferroni multiple comparison test.
This analysis was used to determine statistically significant differences between the
effects of various heparins and LMWHs. Potency comparisons (IC50) were compared using a
one-way ANOVA followed by a Tukey multiple comparison test. Other data were analyzed
using one of the following statistical tests as such: Students t-test (unpaired), one-way ANOVA
with a Tukey multiple comparison test, Pearson’s chi-square test and Fisher’s exact test. In all
cases a p value < 0.05 was considered statistically significant. Computed p values were presented
for each analysis. Graphs with data and error bars were drawn using Microsoft Excel (Microsoft
® Corporation, Redmond, WA) or GraphPad Prism 8.0. for Windows (GraphPad Software, San
Diego, CA).
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For the PCS and Zeta potential studies, the statistical evaluation is carried out using
Origin software where the Zp data was fitted vs the logarithm of PHR with the sigmoidal
equation:
(TOP – BOTTOM)
Y= BOTTOM + --------------------------------1+10[(LOGIC50 - X) * HILLSLOPE]
Where:
Y = Zp (mV)
X = logarithm of PHR

The sigmoidal regression equation calculates the PHR value of the curve that corresponds to the
Zp=0, neutrality status of the complex. which is characteristic of each heparin sample. For the
monkey’s studies, previous in vivo studies in this lab involving I.V. administration of
anticoagulant agents to NHP have shown that, an n=4 for each group is sufficient to measure the
anticoagulant effects. Statistical analysis, graphs with data and error bars were performed using
GraphPad Prism Version 8.0.
Ethical Aspects
All animal protocols were approved by the Institutional Care and Use Committee
(IACUC, appendices C1 and C2) at Loyola University Medical Center. The human whole blood
from normal healthy volunteers for validation studies and for obtaining plasma preparations was
drawn under an IRB approved protocol (Appendices B11 and B12). Whole blood was drawn
from healthy male and female individuals who were apparently free of any drug intake and who
have reviewed and signed informed consents. The blood was drawn in standardized laboratory
conditions under the supervision of certified medical technologist or a physician.
In regard to the non-human primate studies, baseline samples were used to measure the
complete blood count (CBC) which were recorded and reported to CMF. Whenever warranted,
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appropriate dietary supplementation (e.g., folic acid, iron supplements) were provided to
identified primate. The non-human primate housing in the CTRE CMF consists of two dedicated
rooms and one procedure room. To assure isothermic conditions during the procedures for the
entire duration of the blood draws, primates remained in the procedure room. The ambient
temperature in the procedure room was maintained at 78°F. Following the last blood draw,
primates were returned to their normal housing room and were kept under observation until full
recovery.

CHAPTER FOUR
RESULTS
Physicochemical Characterization of Various UFHs and LMWHs
Heparin has a complex molecular structure with a broad MW range of (1.8 kDa - 44 kDa). The
chemical profile plays a pivotal role in determining the biological activity of heparin and its
derivatives. Various laboratory methods have been developed to analyze the structural
components of heparin. These methods include gel permeation chromatography, scanning UV
spectroscopy, heparinase digestion profiles of the depolymerized components, mass
spectrometry, and nuclear magnetic resonance spectroscopy. All are useful tools to understand
the underlying structure-activity relationship (SAR) of heparins from different animal origins. In
this investigation, we used HPLC analysis (UV & RI Detector) and NMR methods on all agents
to characterize their physicochemical properties.
Gel Permeation Chromatography (GPC)
Molecular weight profiles. The molecular weight profiles for bovine, ovine and porcine
heparins and their depolymerized products were determined by gel-permeation chromatography
(GPC) in a high-performance liquid chromatography (HPLC) system. The molecular weight of
each sample was determined by a narrow range calibration (NRC) method as previously
described in the ‘Materials and Methods’ section. The elution profiles for UFHs and their
depolymerized products (LMWHs) were obtained using the gel permeation chromatographic
method and are represented on Figure 14 for the UFHs whereas LMWHs profiles are depicted
on and Figure 15. The weight profiles of both the UFHs and LMWHs were calculated by
99
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utilizing the calibration curves constructed using thirteen MW standards which have been
discussed in the Material and Methods. Individual calibration curves for both the UV and RI
methods were employed (Appendices).
A.

UV Chromatograms

B. RI Chromatograms

Figure 14. Elution profiles of BMH (black), OMH (blue) and PMH (green) as measured by gel
permeation chromatography (GPC) using the NRC method. Both the UV 205 nm (A) and RI (B)
detector methods were used. Panel A, shows the UV profile whereas the panel B, shows the RI profile.
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A. UV Chromatograms

B. RI Chromatograms

Figure 15. Elution profiles of B. LMWH (black), O. LMWH (blue) and P. LMWH (green) as measured
by gel permeation chromatography (GPC) using the NRC method. Both the UV 205 nm (A) and RI (B)
detector methods were used. Panel A, shows the UV profile whereas the panel B, shows the RI profile.
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The elution profiles using the UV detection method are shown in Figure 14A, while
Figure 14B shows the elution profiles using the RI detection method. The calculated molecular
weights were comparable between the UV and RI detectors for the UFHs. The elution time for
each sample is defined as the time between the start of separation (the time at which the solute
enters the column or the beginning of the peak) and the time at which the sample fully elutes
(end of the peak). OMH showed the broadest peak, with elution time of approximately 20
minutes, indicating higher degree of heterogeneity compared to the BMH and PMH. PMH had
elution time which spanned approximately 16 minutes, which relatively a narrow peak indicating
that it has a higher degree of homogeneity compared to the other agents. The trends were similar
between the UV and RI profiles.
The molecular weight profiles for PMH, OMH and BMH obtained with the UV and RI
detectors for the NRC method are tabulated in Table 1. Since heparins are heterogeneous in nature,
the molecular weights of the various agents determined by GPC represent average molecular
weights cross referenced to the NRC curves.
As seen in Table 1, BMH exhibited the highest mean of weight average molecular weight
(Mw) of 21634±654 Da as measured by UV detection when using the NRC method. The PMH
and OMH exhibited slightly lower means of weight average molecular weight (Mw) of
17311±604 Da and 18911±580 Da, respectively. The number average molecular weight (Mn) of
the various heparin exhibited the same rank order as shown in Tables 1. The values of average
molecular weights (Mw & Mn) of all heparins obtained by RI detector were comparable to the
UV detector with the same rank order as seen in Table 1.
BMH had slightly higher polydispersity index (Higher molecular weight) of 1.39±0.13 as
measured by UV detection compared to all other UFHs when determined by the NRC method.
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PMH and OMH had comparable polydispersity index of 1.21±0.12 and 1.22±0.11
respectively. The polydispersity values of all UFHs determined using RI detector were
comparable to those obtained by UV detector with the same rank order. Polydispersity is a
measure of the homogeneity of the fractions making up the heparin sample. For each of the
heparins, the polydispersity decreased as the molecular weight decreased. The overall data of
these studies showed that, BMH, OMH and PMH have comparable molecular weight profiles.
Additional MW parameters and MW distribution data were compiled as shown below.
Additional MW parameters. MP; peak molecular weight, Mz; Z average molecular weight, Mz+1; Mz+1
molecular weight
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Molecular weight distribution of various UFHs as determined by the UV and RI detectors:

In regard to LMWHs, all agents showed almost superimposable chromatograms with the
same elution profiles as measured by both detectors (Figure 15). All LMWHs had comparable
elution times which spanned approximately 15 minutes, which relatively narrow peaks
indicating that the have higher degree of homogeneity compared to the UFHs. The trends were
similar between the UV (Panel A) and RI (Panel B) profiles for all LMWHs as shown in Figure
15. The molecular weight profiles for all LMWHs obtained with the UV and RI detectors for the
NRC method are tabulated in Table 2. All LMWHs exhibited very comparable Mw and Mn
parameters as measured by UV and RI detections when using the NRC method. Weight average
molecular weights (Mw) were 4114±79 Da (B. LMWH), 4139±84 Da (O. LMWH) and 4171±75
Da (P. LMWH). Furthermore, number average molecular weights (Mn) of all LMWHs ranged
from 3447 Da to 3499 Da as measured by the UV method (Table 2). The same trend was shown
when determined by the RI detector). The polydispersity index (PDI) values of all LMWHs were
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very close (Table 2) and were lower compared to the UFHs indicating that LMWHs are more
homogenous mixtures compared to the UFHs. Additional MW parameters and MW distribution
data were compiled as shown below.
Additional MW parameters. MP; peak molecular weight, Mz; Z average molecular weight, Mz+1; Mz+1
molecular weight:

Molecular weight distribution of various LMWHs as determined by the UV and RI detectors:

Heparinase-I (HP-I) digestion. Heparinase-I is one of the most extensively studied
glycosaminoglycan lyases. Enzymatic degradation of heparins by heparin lyases not only largely
facilitates heparin structural analysis but also can be used to produce low molecular weight
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heparin (LMWH). In these experiments, heparinase-I (1 U/ml final concentration) was incubated
with all agents (10 mg/ml, pH = 5.0) at 37°C for 30 minutes and then the molecular weight
profiles were determined.
In Figures 16 & 17, Panels A show the elution profiles for the non-digested samples,
while Panels B show the elution profiles for the heparinase digested samples using the UV
detection and RI detection methods, respectively. As seen in Figures 16 & 17, heparinase-I was
clearly capable of depolymerizing the various heparins as evident by the shift to the right of each
peak and subsequent decrease in mean molecular weight for all agents (Figures 16B & 17B).
Additionally, the post-digested average weight molecular weights (Mw) as measured by UV
detector for all heparins were comparable and ranged from 3086±163 Da to 3312±189 Da which
demonstrates similar profiles of heparinase-I digestion (Table 3). The same trend was noted
when the RI detector was used (Table 3). The calculated molecular weights for pre and post
heparinase digestion samples were comparable with the UV and RI detectors. The results for the
pre and post heparinase digestion of BMH, OMH and PMH obtained with the UV and RI
detectors for the NRC method, are tabulated in Table 3. All post heparinase digestion heparins
(UFHs) showed comparable molecular weight profiles as determined by UV and RI detectors.
HeparinaseI digestion Index of BMH (85%), OMH (82%) and PMH (83%) heparins were
comparable when using UV detection. The same trend was noted when using RI detection
(Table 3).
Figures 18 & 19 show chromatograms for various LMWHs pre and post Heparinase-I
digestion as measured by the NRC method. Panel A shows the elution profiles for the nondigested samples, while Panel B shows the elution profiles for the heparinase digested samples
using the UV detection and RI detection methods, respectively. As seen in Figures 18 & 19,
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heparinase-I partially depolymerized all LMWHs as evident by the slight shift to the right of
each peak and subsequent slight decrease in mean molecular weight for all agents (Panels A&B).
Furthermore, the post-digested average weight molecular weights (Mw) as measured by UV
detector for all LMWHs were comparable and ranged from 2249±134 Da to 2289±111 Da which
demonstrates similar profiles of heparinase-I digestion (Table 4).
The same trend was noted when the RI detector was used (Table 4). In addition, the
calculated molecular weights for pre and post heparinase digestion samples were comparable
with the UV and RI detectors. The results for the pre and post heparinase digestion of B.
LMWH, O. LMWH and P. LMWH obtained with the UV and RI detectors for the NRC method,
are tabulated in Table 4. All post heparinase digestion LMWHs showed comparable molecular
weight profiles as determined by UV and RI detectors. Heparinase-I digestion Index of B.
LMWH (44%), O. LMWH (45%) and P. LMWH (43%) agents were comparable when using
UV detection. The same trend was noted when using RI detection (Table 4).
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A. Pre-heparinase-I digestion

B. Post-heparinase-I digestion

Figure 16. Heparinase-I digestion of BMH (black), OMH (blue) and PMH (green) as measured by GPC
using the NRC method. Pre (A) and Post (B) heparinase-I elution profiles were determined using the UV
detection method. Heparinase-I (1 U/ml final concentration) was incubated with all heparins (10 mg/ml,
pH = 5.0) at 37°C for 30 min.
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A. Pre-heparinase-I digestion

B. Post-heparinase-I digestion

Figure 17. Heparinase-I digestion of BMH (black), OMH (blue) and PMH (green) as measured by GPC
using the NRC method. Pre (A) and Post (B) heparinase elution profiles were determined using the RI
detection method. Heparinase-I (1 U/ml final concentration) was incubated with various heparins (10
mg/ml, pH = 5.0) at 37°C for 30 min.
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A. Pre-heparinase-I digestion

B. Post-heparinase-I digestion

Figure 18. Heparinase-I digestion of B. LMWH (black), O. LMWH (blue) and P. LMWH (green) as
measured by GPC using the NRC method. Pre (A) and Post (B) heparinase-I elution profiles were
determined using the UV detection method. Heparinase-I (1 U/ml final concentration) was incubated
with all LMWHs (10 mg/ml, pH = 5.0) at 37°C for 30 min.
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A. Pre-heparinase-I digestion

B. Post-heparinase-I digestion

Figure 19. Heparinase-I digestion of B. LMWH (black), O. LMWH (blue) and P. LMWH (green) as
measured by GPC using the NRC method. Pre (A) and Post (B) heparinase-I elution profiles were
determined using the RI detection method. Heparinase-I (1 U/ml final concentration) was incubated with
all LMWHs (10 mg/ml, pH = 5.0) at 37°C for 30 min.

112
Nuclear Magnetic Resonance (NMR) Analysis
UFHs and LMWHs of various origin were investigated using one dimensional (1D)
nuclear magnetic resonance (NMR) method. 1D 1H and 13C NMR spectra were obtained at 600
MHz on D2O exchanged heparin (20 mg/mL in D2O) using a Bruker Advance II 600 MHz
spectrometer (Bruker Bio-Spin, Billerica, Massachusetts) with TopSpin 3.2 software at 298 K.
All of the reported results in the following section were obtained on powdered APIs version of
both, the UFHs and LMWHs.
1

H NMR Spectra - UFHs. Figure 20 represents the 1H-NMR spectral profiles of the

various UFHs, whereas the following compilation shows the peak assignment/residue in these
agents.
The peak assignment/residue of 1H-NMR spectra of various heparins using one dimensional (1D) nuclear
magnetic resonance (NMR) method:
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The A-S assignments represent nineteen individual peaks in the porcine heparin in this
analysis. These peaks were used to compare the structure of BMH and OMH preparations. The
IdoA2S and GlcA contents were slightly lower for OMH and BMH compared to PMH which
was determined by the relative intensities. There was more GlcNAc in PMH than in OMH and
BMH, which was demonstrated by the relative intensity of the peak at 1.96 ppm (peak S) which
corresponds to the N-acetyl protons of the GlcNAc residue. In addition, no unidentified peak was
observed in OMH compared to PMH. However, for BMH, there were 2 extra peaks, one peak C’
(GlcNS) between peak C (GlcNY6S) and peak D (IdoA) and one peak before peak F (IdoA) that
were not present in PMH and OMH. Furthermore, PMH and OMH have clear peak B
(GlcNY3S6X), which is not present in BMH proton spectrum (Figure 20).
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Figure 20. Shows the proton NMR spectra (1H Spectrum) of various heparins prepared from porcine
(upper), bovine (middle) and ovine (lower) sources. 1H NMR experiments were performed on the samples
for 32 scans with a five second relaxation delay.
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13

C NMR Spectra - UFHs. Figure 21 shows the carbon 13 NMR spectra for PMH, BMH

and OMH. 13C proton decoupled NMR experiments were performed on the samples and peak
assignments were noted and complied below.
The peak assignment/residue of 13C NMR Spectra of various heparins using one dimensional (1D) nuclear
magnetic resonance (NMR) method:

The A-G peaks represent seven components detected by this method that were used to
compare BMH, OMH and PMH preparations. For the most part, the 13C NMR spectra of the
OMH and PMH were comparable (Figure 21). In contrast, the 13C NMR spectrum of BMH was
different (the region between 50 to 100 ppm) as shown in Figure 21. Furthermore, the BMH 13C
spectrum had clear peak for GlcNY at 59.71 ppm that was not present in PMH and OMH spectra
(Figure 21).
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Figure 21. Shows the carbon NMR spectra (13C Spectrum) of various heparins prepared from porcine
(upper), bovine (middle) and ovine (lower) sources. 13C decoupled NMR experiments were performed on
the samples for 2000 scans.
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1

H NMR Spectra - LMWHs. Figure 22 represents the 1H-NMR spectral profiles of the

various LMWHs, whereas the following compilation shows the peak assignment/residue in these
agents.
The peak assignment/residue of 1H-NMR spectra of various LMWHs using one dimensional (1D) nuclear
magnetic resonance (NMR) method:

The A-Q assignments represent seventeen individual peaks in the porcine LMWH
spectrum that were used to compare it to those of the bovine LMWH and ovine LMWH
preparations. For bovine LMWH, GlcNAc content was slightly higher compared to porcine and
ovine LMWHs. In addition, no unidentified peak was observed in ovine LMWH compared to
porcine LMWH. However, in the bovine LMWH proton spectrum, there was a clear GlcNS peak
that was not present in porcine and ovine LMWHs spectra. In addition, the proton NMR
spectrum of bovine LMWH was different compared to the ovine and porcine ones (the region
between 3 to 5 ppm) as shown in Figure 22.
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Figure 22. Shows the proton NMR spectra (1H Spectrum) of various LMWHs/Enoxaparins prepared
from porcine (upper), bovine (middle) and ovine (lower) sources. 1H NMR experiments were performed
on the samples for 32 scans with a five second relaxation delay.
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13

C NMR Spectra - LMWHs. Figure 23 shows the carbon NMR spectra. 13C proton

decoupled NMR experiments were performed on the samples and peak assignments and were
noted and complied below.
The peak assignment/residue of 13C NMR Spectra of various LMWHs/Enoxaparins using one
dimensional (1D) nuclear magnetic resonance (NMR) method:

The A-G peaks represent seven components detected by this method that were used to
compare bovine, ovine and porcine LMWH preparations. The 13C NMR spectra of the ovine and
porcine LMWHs were comparable (Figure 23). In contrast, the 13C NMR spectrum of bovine
LMWH was different (the region between 50 to 100 ppm) as shown in Figure 23. Furthermore,
the bovine LMWH 13C spectrum had a clear peak for GlcNY at 59.71 ppm that was not present
in porcine and ovine LMWHs spectra. The porcine and ovine LMWHs showed 13C NMR
spectra that were clearly similar to each other but distinctly different from bovine LMWH 13C
NMR spectra (Figure 23).
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Figure 23. Shows the carbon NMR spectra (13C Spectrum) of various LMWHs/Enoxaparins prepared
from porcine (upper), bovine (middle) and ovine (lower) sources. 13C decoupled NMR experiments were
performed on the samples for 2000 scans.
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In addition, the relative amounts of key saccharide components were determined by
integration of the peaks in the 1H-NMR spectra (Table 5). In Figure 24, BMH heparin exhibited
lower GlcNX3S6X (2.6%) compared to PMH (7.5%) and OMH (6.8%) agents. In contrast, all
LMWHs showed comparable N-Acetylglucosamine 6-sulfate which is an essential component of
the pentasaccharide binding sequence for the interaction with antithrombin.

Figure 24. Composition of various heparins and LMWHs using NMR Integration method.

Furthermore, the 3-O sulfation % of each heparin was determined to see if there are
differences which may affect their anticoagulant activity. 3S% was calculated from 1H NMR
spectra using the below equation1:

PMH and OMH had comparable 3S% as calculated using the above equation; 3S% were
9.9% and 11.8% respectively (Figure 25). On the other hand, BMH showed lower 3S% (6.3%)
compared to other UFHs, which may contribute to its lower anticoagulant activity (Figure 25).
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However, all LMWHs exhibited comparable 3S% as follows; P. LMWH (27.5%), B. LMWH
(22.3%) and O. LMWH (24.4%) which may explain the similar anticoagulant activities of
LMWHs from different animal sources (Figure 26).

Porcine Heparin

Bovine Heparin

Ovine Heparin

Figure 25. 3S% Determination of Various UFHs. It shows the proton NMR spectra (1H Spectrum) of
various heparins prepared from porcine (upper), bovine (middle) and ovine (lower) sources. 1H NMR
spectra were used to determine 3S% in all agents.
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Figure 26. 3S% Determination of Various LMWHs. It shows the proton NMR spectra (1H Spectrum) of
various LMWHs/Enoxaparins prepared from porcine (upper), bovine (middle) and ovine (lower) sources.
1
H NMR spectra were used to determine 3S% in all agents.
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Disaccharide and Chain Mapping Analysis
Disaccharide compositional analysis was performed using an LC-MS approach following
heparin lyase I, II, III treatment (B. Yang, et al, 2011). The disaccharide compositional analysis
of all agents is presented in Figure 27. The disaccharide compositional analysis shows that
BMH had significantly lower TriS% of 44.5% (associated with the antithrombin binding
sequence) compared to PMH (78.0%) and OMH (81.7%). The overall degree of sulfation of
each agent was determined using the following equation:
Degree of Sulfation = (% OS/100 x 1) + (% NS/100 x 1) + (% 6S/100 x 1) + (% NS/100 x 1) +
(% NS6S/100 x 2) + (% NS2S/100 x 2) + (% 2S6S/100 x 2) + (% TriS/100 x 3)

BMH exhibited a lower degree of sulfation (64.4%) compared to PMH (90.2%) and OMH
(93.2%). However, all LMWHs showed comparable degree of sulfation; P. LMWH (93.8%), B.
LMWH (87.4%) and O. LMWH (93.0%). Furthermore, the 6S% was calculated from the
disaccharide analysis of these agents. BMH showed lower 6S% of 54.6% compared to PMH
(84.0%) and OMH (91.4). Porcine, bovine and ovine LMWHs showed comparable 6S% of
91.6%, 91.8% and 90.4%, respectively.

Figure 27. Shows the disaccharide compositional analysis of all agents as determined by LC-MS method.
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In addition, the degree of acetylation, that is another crucial factor for the anti-Xa and
anti-IIa activities of these agents, was determined from the 1H NMR using the following
equation:
% NAc = [int. 3/3) / (int. 2)] x 100
(int.2; GlcNS, int.3; CH3Ac)

All LMWHs exhibited comparable degree of acetylation, 3.1% (P. LMWH), 3.9% (B.
LMWH) and 3.9% (O. LMWH). However, UFHs showed different degree of acetylation ranged
from 2.7% to 8.3%.
Bottom-Up Disaccharide Analysis
A bottom-up analysis was performed using online hydrophilic interaction
chromatography (HILIC) FTMS to analyze the oligosaccharide fragments of LMWHs generated
by heparin lyase II digestion. More than 40 oligosaccharide fragments of UFHs and LMWH
were quantified and used to compare heparins/LMWHs prepared from different animal sources.
The quantified fragment structures included unsaturated disaccharide/ oligosaccharides arising
from the prominent repeating units of these LMWHs, 3-O-sulfo containing tetrasaccharides
arising from their antithrombin binding sites, 1,6-anhydro ringcontaining oligosaccharides
formed during LMWH manufacture, saturated uronic acid oligosaccharides coming from the
non-reducing ends of some chains, and oxidized linkage region oligosaccharides coming from
the reducing ends of some chains. This bottom-up approach provided rich detailed structural
analysis and quantitative information with high accuracy for the UFHs on Figure 28 and for the
LMWHs Figures 29 respectively.
Panel A on Figure 28 shows a relative quantitation of fragments that were detected by
bottom-up analysis of digested commercially available porcine LMWH (Clexane and Lovenox)
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and UFHs (PMH, BMH & OMH) where the reducing ends contain a 1, 6-anhydro group. The
tetrasaccharides derived from the heparin linkage region are also shown in Figure 28. Panels B
& C on Figure 28 show relative quantification of fragments detected in bottom-up analysis of
digested porcine LMWH (Clexane and Lovenox) and UFHs (PMH, BMH & OMH) where nonreducing ends are saturated and unsaturated, respectively.
The Bottom-Up analysis of all UFHs from different animal sources showed comparable
relative quantification of the 40 oligosaccharide fragments (Figure 28). BMH exhibited
significantly lower [1,0,1,0,2], [1,0,1,0,3] and [0,1,1,1,3] oligosaccharide fragments compared to
other UFHs (Panel A&B on Figure 28). [1,0,1,0,2] stands for deltaUA-GlcN disaccharide with 2
sulfation groups, [1,0,1,0,3] stands for deltaUA-GlcN with 3 sulfation groups and [0,1,1,1,3]
stands for GlcA-GlcNAc disaccharide with 3 sulfation groups. In contrast, BMH showed
significantly higher [0,1,1,1,2] oligosaccharide fragment compared to PMH and OMH
counterparts; [0,1,1,1,2] stands for GlcNAc-GlcA disaccharide with 2 sulfation groups (Panel B
on Figure 28). In Panel B on Figure 28, OMH exhibited significantly higher [0,3,4,0,5]
oligosaccharide fragment compared to PMH and BMH counterparts; [0,3,4,0,5] stands for GlcNGlcA-GlcN-GlcA-GlcN-GlcA-GlcN dp7 with 5 sulfation groups.
Panel A on Figure 29 shows a relative quantitation of fragments that were detected in
bottom-up analysis of commercially available porcine LMWH (Clexane and Lovenox) and
LMWHs (porcine, bovine & ovine) where the reducing ends contain a 1,6-anhydro group. The
tetrasaccharides derived from the heparin linkage region are also shown in Panel A. Panels B &
C on Figure 29 show a relative quantitation of fragments detected in bottom-up analysis of
commercially available porcine LMWH (Clexane and Lovenox) and LMWHs (porcine, bovine
& ovine) where the non-reducing ends are saturated and unsaturated, respectively. As shown in
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Figure 29, The Bottom-Up analysis of all LMWHs from different animal sources showed
comparable relative quantification of the 40 oligosaccharide fragments. Figure 10C showed that,
B. LMWH exhibited significantly lower [1,0,1,0,3] oligosaccharide fragment compared to
porcine and ovine counterparts. [1,0,1,0,3] stands for deltaUA-GlcN with 3 sulfation. On the
other hand, B. LMWH showed significantly higher [0,1,1,1,2] and [1,0,1,0,2] oligosaccharide
fragments compared to porcine and ovine counterparts. [0,1,1,1,2] stands for GlcNAc-GlcA
disaccharide with 2 sulfation groups and [1,0,1,0,2] stands for deltaUA-GlcN disaccharide with
2 sulfation groups (Panels B&C).
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Figure 28. Bottom-Up Disaccharide Analysis of Heparins. It shows the bottom-up analysis of various
heparins that was performed using online hydrophilic interaction chromatography (HILIC) FTMS to
analyze the oligosaccharide fragments of LMWHs generated by heparin lyase II digestion. More than 40
oligosaccharide fragments of LMWH were quantified and used to compare heparins prepared from
different animal sources.
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Figure 29. Bottom-Up Disaccharide Analysis of LMWHs/Enoxaparins. It shows the bottom-up analysis
of various LMWHs that was performed using online hydrophilic interaction chromatography (HILIC)
FTMS to analyze the oligosaccharide fragments of LMWHs generated by heparin lyase II digestion. More
than 40 oligosaccharide fragments of LMWH were quantified and used to compare LMWHs prepared
from different animal sources.
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Top-Down Disaccharide Analysis
Top-down analysis was performed to characterize and compare the LMWHs from
various animal sources. Bioinformatics software (GlycReSoft 1.0) was used to automatically
assign structures within 5 ppm mass accuracy. As shown in Figure 30, all LMWHs have almost
the same fragments percentages of unsaturated disaccharide/oligosaccharides arising from the
prominent repeating units of these LMWHs, saturated uronic acid oligosaccharides coming from
the non-reducing ends of some chains and 1,6anhydroamino ring-containing oligosaccharides
formed during LMWH manufacture. This top-down analysis suggests that, the manufacturing
and quality control processes of these LMWHs from various UFHs were very close and with
high standards.
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Figure 30. Top-Down disaccharide analysis of LMWHs/Enoxaparins as determined by LC-MS method.
Bioinformatics software (GlycReSoft 1.0) was used to automatically assign structures within 5 ppm mass
accuracy.
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Functional Profiling Studies of UFHs and LMWHs
The effect of various heparins and LMWHs on anticoagulation and antiprotease activities
were determined using well-defined biochemical systems in which various unfractionated
heparins and LMWHs from different animal sources were supplemented in various matrices at
various concentrations, in order to determine the anticoagulant and antiprotease properties of
these agents.
Global Anticoagulant Assays (Human Blood)
These assays are commonly used in a hospital laboratory to clinically monitor heparin,
typically in a surgical or interventional setting. All agents were supplemented to freshly
collected human whole blood then were tested immediately by assay systems commonly used
to clinically monitor heparin therapy.
Activated clotting time assay (ACT). The anticoagulant effects of various heparins
(PMH, OMH and BMH) in whole blood as measured by ACT assay are shown in Figure 31. At
a final concentration of 10 ug/ml, OMH and PMH heparins significantly (*p <0.05, **p <0.02)
produced stronger effects prolonging the ACT compared to BMH heparin. OMH and PMH
produced stronger effects prolonging the ACT in the range of 322±12.8-329±8.7 seconds
compared to BMH (254±10.8 seconds) as shown in Figure 31A. However, all heparins at a
final concentration of 1 U/ml, exhibited comparable effects prolonging the ACT in the range of
311-318 seconds (Figure 31B). All LMWHs at a final concentration of 25 ug/ml exhibited
comparable effects prolonging the ACT in the range of 311±9.8-318±12.5 seconds 215±11.8223±9.9 seconds as shown in Figure 32. All ACT values of all heparins and LMWHs are
tabulated in Table 6.
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A. ACT assay – UFHs (ug/ml)

B. ACT assay – UFHs (U/ml)

Figure 31. Comparative anticoagulant effects of various heparins in whole human blood as measured by
the ACT system (n = 5-7). Heparins in ug/ml (A) and heparins in U/ml (B). All agents were
supplemented in the whole blood of final concentrations of 10 µg/ml (A) and/or 1 U/ml (B). Saline was
used as a negative control. At a final concentration of 10 ug/ml, PMH and OMH heparins significantly
(*p <0.05, **p <0.02) produced stronger effects prolonging the ACT compared to BMH heparin. At a
final concentration of 1 U/ml, all heparins showed comparable anticoagulant effects. ACT; activated
clotting time. All results represent the mean ± SD.
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Figure 32. Comparative anticoagulant effects of various LMWHs in whole human blood as measured by
the ACT system. All LMWHs were supplemented in the whole blood of final concentrations of 25 µg/ml
(n = 5-8). Saline was used as a negative control. All LMWHs (porcine, bovine and ovine) at a final
concentration of 25 ug/ml exhibited comparable effects prolonging the ACT. ACT; activated clotting
time. All results represent the mean ± SD.

Thromboelastography (TEG) analysis. TEG assay was used to assess the complete
global and kinetic response of blood clot formation and the overall coagulation status. Figure
33 shows the composite thromboelastogram of various heparins compared at 1.25 ug/ml (A)
and 0.125 U/ml (B). At 1.25 ug/ml, OMH and PMH exhibited similar effects on the TEG
system (Figure 33A). However, BMH produced a weaker anticoagulant effect in this assay
system (Figure 33A). At 0.125 U/ml, all heparins showed similar anticoagulant effects in the
TEG system as shown in Figure 33B. At 1.25 ug/ml (Figure 33A), OMH and PMH produced
stronger effects compared to BMH agent and the r-time values of OMH (31.4±6 mins) and
PMH (31.2±5.5 mins) were higher than with BMH (17.5±2.5 mins). The k-time data followed
the same pattern, OMH (16.5±1.6 mins) and PMH (16.6±2.3 mins) exhibited comparable and
stronger effects compared to BMH agent (10.1±1.5 mins). The rank order in the angle was
found to be BMH > OMH = PMH. The MA value for BMH (54 ±7.2 mm) was higher
compared to PMH (43.1±3.4 mm) and OMH (45.6 ±6.8 mm) agents. At 0.125 U/ml (Figure
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33B), all heparins exhibit similar anticoagulant effect as well as comparable TEG parameters
including r-time, k-time, angle, and MA which ranged from (25 – 26.9 mins), (12.6 – 13 mins),
(19.5 ±2.2-20.5±3.2 degree) and (46.1±5.2-48.1±8.2 mm) respectively.
Figure 33C shows the composite thromboelastogram of various LMWHs compared at
2.5 ug/ml. At 2.5 ug/ml, all LMWHs produced similar anticoagulant effects in this assay
system (Figure 33C) as well as comparable TEG parameters including r-time, k-time, angle,
and MA which ranged from (23.4±3.2-24.4±2.8 mins), (12±1.9-13.2±3.1 mins), (17.4±1.219.2±3.2 degree) and (43.2±7.2-45.3±3.2 mm) respectively. The TEG parameters including rtime, ktime, angle, and MA were compiled from five individual donors for each of these agents
as shown below.
Comparison of the TEG profile of various heparins and LMWHs in whole human blood (n = 5). FC,
final concentration; TEG, Thromboelastography. All results represent the mean ± SD:

.
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Figure 33. Comparative anticoagulant effects of various heparins and LMWHs in whole human blood
(n=5) as measured by the TEG system. All heparins were supplemented in the whole blood of final
concentrations of 1.25 µg/ml (A) and 0.125 U (B). All LMWHs were supplemented in the whole blood of
final concentrations of 2.5 µg/ml (C). Saline was used as a negative control. TEG; Thromboelastography,
S; saline, P; porcine, B; bovine, O; ovine. All results represent the mean ± SD.
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Global Anticoagulant Assays (Citrated Blood Bank Plasma)
Activated Partial Thromboplastin Time (aPTT) assay. The anticoagulant effects of
PMH, OMH and BMH as measured by aPTT are shown in Figure 34. All heparins were
supplemented in BBP over a concentration range of 0 to 10 µg/ml (Figure 34A and Table 7 or
Figure 34B and Table 8). At the equigravemetric concentrations (ug/ml), OMH and PMH
exhibited significant (*p ≤ 0.05) anticoagulant effects at concentrations of 2.5 and 5 µg/ml
compared to BMH (Figure 34A). At 2.5 ug/ml concentration point, OMH and PMH heparins
significantly produced stronger effects prolonging the aPTT (≥ 300 seconds) compared to BMH
heparin (207±10.9 seconds). At concentrations above 5 µg/ml BMH produced significantly (*p
≤ 0.05) longer clotting times compared to baseline values, while the OMH and PMH provided
comparable results at all concentration points. Furthermore, at the potency-based
concentrations (U/ml), all heparins produced similar anticoagulant effects at all concentration
points as shown in Figure 34B and Table 8.
All LMWHs were supplemented in BBP over a concentration range of 0 to 10 µg/ml
(Figure 34C). All LMWHs exhibited similar prolongation of aPTT (similar anticoagulant
effect) at all concentration points as shown in Figure 34C and Table 9. In general, heparins
(UFHs) significantly (p ≤ 0.05) produced longer clotting times compared to LMWHs at
concentrations above 2.5 ug/ml.
Thrombin time (TT) assay. In this project, TT clotting time assay was used to assess
the effect of various heparins and LMWHs on thrombin using human plasma. All heparins
were supplemented in BBP over a concentration range of 0 - 10 µg/ml (Figure 35A and Table
7) or 0-1 U/ml (Figure 35B and Table 8). At the gravimetric-based concentrations (ug/ml),
OMH and PMH significantly (*p ≤ 0.05) prolonged the TT at concentration of 2.5 µg/ml
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compared to BMH (Figure 35A). At 1.25 ug/ml concentration point, OMH and PMH heparins
significantly (*p ≤ 0.05) produced stronger effects prolonging the TT (≥ 300 seconds)
compared to BMH heparin (82±6.4 seconds). At concentrations above 1.25 µg/ml BMH
produced significantly (*p ≤ 0.05) longer clotting times compared to baseline values, while the
OMH and PMH provided comparable results at all concentration points (Table 7). At the
potency-based concentrations (U/ml), all heparins produced similar anticoagulant effects (TT
prolongation) at all concentration points as shown in Figure 35B and Table 8.
All LMWHs were supplemented in BBP over a concentration range of 0 - 10 µg/ml
(Figure 35C). All LMWHs exhibited similar prolongation of TT (similar anticoagulant effect)
at all concentration points as shown in Figure 35C and Table 9.
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Figure 34. Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the aPTT
assay (n=3). All heparins were supplemented in the BBP over a concentration range of (0 - 10) µg/ml (A)
or (0 – 1) U/ml (B). All LMWHs were supplemented in the BBP over a concentration range of (0 - 10)
µg/ml (C). Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal
heparin, OMH; ovine mucosal heparin, LMWH; low molecular weight heparin, BBP; blood bank plasma.
All results represent the mean ± SD.
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Figure 35. Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the TT assay
(n=3). All heparins were supplemented in the BBP over a concentration range of (0 - 10) µg/ml (A) or (01) U/ml (B). All LMWHs were supplemented in the BBP over a concentration range of (0 - 10) µg/ml
(C). Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal heparin,
OMH; ovine mucosal heparin, LMWH; low molecular weight heparin, BBP; blood bank plasma. All
results represent the mean ± SD.

140
Prothrombinase-induced clotting time (PiCT) assay. This assay was also carried out
in order to determine the anticoagulant activity of all agents (Figure 36 and Table 10). Heparins
were diluted in pooled human plasma to achieve a six-point concentration range of 0-10 ug/ml
or 0-1 U/ml, while LMWHs were diluted in pooled human plasma to achieve a six-point
concentration range of 0-10 ug/ml. As shown in Figures 36A&B, all gravimetric-based
heparins as well as potency-based heparins produced comparable anticoagulant effects (PiCT
prolongation) at all concentration points. At their highest concentrations, gravimetric-based
heparins and potency-based heparins produced prolongation of PiCT by range of 269-280
seconds and 245-254 seconds respectively. In terms of LMWHs, all agents exhibited similar
effects prolonging the PiCT at all concentration points and it ranged from 175 to 184 seconds at
their highest concentrations (Figure 36C).
Thrombin generation inhibition assay (TGA). Figure 37 depicts the
thrombokinetograms obtained in the thrombin generation (TGA) assay. All heparins (ug/ml and
U/ml) produced a concentration-dependent inhibition of thrombin generation and the inhibitory
effects were comparable at all concentration points as shown in Panels A&B. The peak
thrombin values of gravimetric-based heparins were found to be comparable and ranged from
59±3.5 to 65±4.5 nM. The potency adjusted-based heparins also showed a similar trend and the
peak thrombin values ranged from 63±4 to 74±6 nM respectively. In regard to LMWHs, all
agents exhibited a concentration-dependent inhibition of thrombin generation and the inhibitory
effects were comparable at all concentration points as shown in Panels C. The peak thrombin
values of all LMWHs ranged of 97±9 - 100±8 nM. The comparative thrombin generation
inhibitory profile of all heparins was investigated in normal human plasma in a concentration
range of 0 - 10 ug/ml (Figure 38A and Table 11) and 0 - 1 U/ml (Figure 38B and Table 12),
which represents the therapeutic range of these agents. While LMWHs were investigated in
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normal human plasma samples in a concentration range of 0 - 10 ug/ml (Figure 38C and Table
13). The thrombin generation profile was measured in terms of peak thrombin, AUC, and the
lag time (Figure 38). All TGA profile parameters of all agents (heparins and LMWHs) are
tabulated in the table below
In terms of peak thrombin, all gravimetric-based heparins (ug/ml) produced comparable
thrombin inhibitory effects with the exception of BMH, which showed significantly (*p ≤ 0.05)
weaker inhibition of thrombin at 1.25 ug/ml concentration (Figure 38A). This weaker effect
was not observed when potency-based heparins (U/ml) were used as shown in Figure 38B.
Figure 38C shows that, all LMWHs exhibited similar thrombin inhibition effects at all
concentration points with minor differences. In terms of AUC, all gravimetric-based heparins
(ug/ml) produced concentration-dependent decreases in the AUC, with BMH exhibiting the
weakest effect at 5 ug/ml concentration (Figure 38A).
All potency-based heparins (U/ml) and LMWHs (ug/ml) exhibited the same trend in the
AUC values with minor differences as shown in Panels B&C respectively. In terms of lag time,
all gravimetric-based heparins (ug/ml) produced a concentration dependent increases in the lag
time values. BMH (ug/ml) produced significantly (*p ≤ 0.05) weaker prolongation of the lag
time at its highest concentration (10 ug/ml), whereas OMH and PMH produced more
pronounced effects on lag time (Figure 38A). All potency-based heparins (U/ml) and LMWHs
(ug/ml) exhibited the same trend in the lag time values with minor differences as shown in
Panels B&C respectively.
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Figure 36. Comparative anticoagulant effects in pooled human plasma as measured by the PiCT assay
(n=4). All heparins were supplemented in the normal human plasma over a concentration range of (0 10) µg/ml (A) or (0 – 1) U/ml (B). All LMWHs were supplemented in the normal human plasma over a
concentration range of (0 - 10) µg/ml (C). Significance was set at (*p ≤ 0.05). PMH; porcine mucosal
heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, LMWH; low molecular weight
heparin. All results represent the mean ± SD.
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Figure 37. Thrombokinetograms of various heparins and LMWHs as obtained by the TGA assay.
Inhibition of thrombin generation was measured by Fluoroskan ascent fluorimeter, calibrated automated
thrombogram (CAT; Diagnostica Stago). All heparins were supplemented in normal pooled plasma over
a concentration range of (0 - 10) µg/ml (Panel A) or (0 – 1) U/ml (Panel B). All LMWHs were
supplemented in normal pooled plasma over a concentration range of (0 - 10) µg/ml (Panel C).
Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal heparin,
OMH; ovine mucosal heparin, LMWH; low molecular weight heparin.
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Figure 38. Comparative thrombin generation inhibitory (TGA) profile of various heparins and LMWHs
in terms of peak thrombin (nM), area under the curve (AUC, nM*min), and lag time (mins). Inhibition of
thrombin generation was measured by Fluoroskan ascent fluorimeter, calibrated automated thrombogram
(CAT; Diagnostica Stago). All heparins were supplemented in normal pooled plasma over a
concentration range of (0 - 10) µg/ml (Panel A) or (0 – 1) U/ml (Panel B). All LMWHs were
supplemented in normal pooled plasma over a concentration range of (0 - 10) µg/ml (Panel C).
Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal heparin,
OMH; ovine mucosal heparin, LMWH; low molecular weight heparin. All results represent the mean ±
SD.
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Antiprotease & Potency Determination Assays
The inhibition of factor Xa and thrombin by various UFHs and LMWHs in various
matrices was studied. Antiprotease actions of these agents were determined by amidolytic
assays, which utilized substrates for factor Xa (Spectrozyme Xa) and thrombin (Spectrozyme
TH). Optical density changes were used to determine the percent inhibition by each agent as
compared to blood bank plasma (BBP). In addition, the USP potency was determined in
accordance with the specifications and directions provided by the manufacturer (HYPHEN
BioMed).
Anti-Xa and Anti-IIa assays in blood bank plasma (BBP). As seen in Figure 39, the
gravimetric-based OMH and PMH when supplemented in BBP exhibited comparable factor Xa
inhibition activity at all concentration points (Panel A). OMH and PMH inhibited factor Xa at
the highest concentration (10 µg/ml) by 92.9±2.2 % and 96±3.5 % respectively. In contrast,
BMH (ug/ml) exhibited significantly (*p ≤ 0.05) the lowest anti-Xa activity compared to other at
2.5 ug/ml and at higher concentrations (Panel A). BMH inhibited factor Xa at its highest
concentration by 84.7±3.4 %. However, potency-based heparins produced similar anti-Xa
activity at all concentration points as seen in panel B. As shown in panel C, all LMWHs
exhibited similar factor Xa inhibition activity at all concentration points with minor differences.
All LMWHs inhibited factor Xa at their highest concentrations by a range of 76.5 % to 77.8 %
as seen in panel C. The percentage inhibition of factor Xa for all heparin and LMWHs agents
were noted at Tables 14, 15 & 16.
In terms of the anti-IIa activity, the gravimetric-based OMH and PMH significantly
inhibited factor IIa (thrombin) to a greater extent than BMH at all concentration points (Panel
A). At the concentration of 10 µg/ml, OMH and PMH inhibited factor IIa by 89.2±03.7 % and
85±2.5 % respectively, while the BMH inhibited factor IIa by 76±3.3 % at the same
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concentration (Panel A). Nevertheless, all potency-based heparins exhibited comparable
thrombin inhibition activity at all concentration points and no significant differences were noted
(Panel B). The same trend was noted among all LMWHs which exhibited similar factor IIa
inhibition activity at all concentration points with minor differences. All LMWHs inhibited
factor IIa at their highest concentrations by a range of 45.2 % to 46.6 % as seen in panel C. All
LMWHs produced significantly weaker anti-IIa activity compared to heparins and the
percentage inhibition of factor Xa for all heparin and
LMWHs agents were noted at Tables 14, 15 & 16.
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Figure 39. The inhibition of factor Xa and thrombin in blood bank plasma (BBP) as measured by the
amidolytic anti-Xa and anti-IIa assays (n=4). All heparins were supplemented in normal pooled plasma
over a concentration range of (0 - 10) µg/ml (A Panel) or (0 – 1) U/ml (B Panel). All LMWHs were
supplemented in normal pooled plasma over a concentration range of (0 - 10) µg/ml (C Panel).
Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal heparin,
OMH; ovine mucosal heparin, LMWH; low molecular weight heparin. All results represent the mean ±
SD.

Anti-Xa & Anti-IIa assays in purified AT system. As shown in Figure 40, all heparins
were supplemented in a purified AT system over a concentration range of 0 - 10 µg/ml (A) or 0 1 U/ml (B) and were mixed with a known amount of thrombin or factor Xa. While all LMWHs
were supplemented in a purified AT system over a concentration range of 0 - 20 µg/ml (C) and
were mixed with a known amount of thrombin or factor Xa. The potency of each agent is
presented in terms of IC50 as shown in Table 17. Briefly, concentration verses percent inhibition
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was plotted, and the linear portion of each curve was used to determine the IC50 value by
extrapolating the concentration required to produce 50% inhibition.
Figure 40A shows that, the gravimetric-based PMH (ug/ml) and OMH (ug/ml) when
supplemented in AT system, exhibited the highest anti-Xa potency with IC50 values of 2±0.12
ug/ml and 1.9±0.15 ug/ml respectively. While BMH (ug/ml) was significantly (*p ≤ 0.05)
weaker to inhibit factor Xa with IC50 value of 3.3±0.09 µg/ml (Panel A). The same trend was
noted in the inhibition of thrombin (factor II) by the same heparins. PMH (ug/ml) and OMH
(ug/ml) showed the highest anti-IIa potency with IC50 values of 2.1±0.12 and 2.2±0.18
respectively, while the BMH (ug/ml) was significantly (*p ≤ 0.05) weaker to inhibit factor IIa
with IC50 value of 3.4±0.21 (Panel A). In terms of the potency-equated heparins, all agents
produced similar factor Xa and thrombin inhibition activity with IC50 values ranged of 0.20 0.22 U/ml and 0.27 - 0.285 U/ml respectively (Panel B). In addition, all LMWHs (ug/ml)
exhibited comparable anti-Xa and anti-IIa activities with minor differences in the IC50 values
which ranged from 3.7 - 3.95 ug/ml and 14.6 - 14.8 ug/ml respectively (Panel C).
Anti-IIa assays in purified HCII system. The IC50 values of all agents were determined
in another SERPIN system called HCII as shown in Figure 41. Unlike AT purified system, all
gravimetric-based heparins produced comparable inhibition effects of thrombin (factor II) with
IC50 values ranged from 4.2 – 4.5 ug/ml (Figure 41A). The same trend was noted with the
potency-based heparins (Figure 41B) and LMWHs (Figure 41C), where the IC50 values ranged
from 0.41 U/ml to 0.43 U/ml and 13.9 ug/ml to 14.2 ug/ml respectively. The potency of each
agent is presented in terms of IC50 as shown in Table 18.
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Figure 40. Potency (IC50) comparison for various heparins and LMWHs when supplemented in purified
AT system as measured by the amidolytic anti-Xa and anti-IIa assays (n=3). All heparins were
supplemented in AT system over a concentration range of (0 - 10) µg/ml (A Panel) or (0 – 1) U/ml (B
Panel). All LMWHs were supplemented in AT system over a concentration range of (0 - 20) µg/ml (C
Panel). Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal
heparin, OMH; ovine mucosal heparin, LMWH; low molecular weight heparin. All results represent the
mean ± SD.
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Figure 41. Potency (IC50) comparison for various heparins and LMWHs when supplemented in purified
HCII as measured by the amidolytic anti-IIa assay (n=3). All heparins were supplemented in HCII system
over a concentration range of (0 - 20) µg/ml (A) or (0 – 2) U/ml (B). All LMWHs were supplemented in
HCII system over a concentration range of (0 - 20) µg/ml (C). Significance was set at (*p ≤ 0.05). PMH;
porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, LMWH; low
molecular weight heparin. All results represent the mean ± SD.

AT and HCII depleted plasma studies. All agents were supplemented in either
antithrombin depleted plasma (AT-DP) or heparin cofactor-II depleted plasma (HCII-DP) and
then anti-Xa and anti-IIa activities were measured by the amidolytic anti-Xa and anti-IIa assays
(Figure 42). All heparins and LMWHs when supplemented in AT-DP showed no anti-Xa and
anti-IIa activities compared to their activities in the BBP as shown in Panels A&B. However,
when they were supplemented in HCII-DP, they showed somewhat weaker anti-Xa and anti-IIa
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activities compared to their activities in the BBP (Panel C&D). The anti-Xa and anti-IIa
activities decreased by a range of 32% - 45% compared to their activites in the blood bank
plasma (Panels C & D). The percentage inhibition of factor Xa and thrombin for all heparins and
LMWHs in AT-DP and HCII-DP were noted at Tables 19, 20, 21 & 22.
USP compliant anti-Xa and Anti-IIa potency assays. In these assays, the USP potency
of all agents was determined in accordance with the specifications/directions provided by the
manufacturer (HYPHEN Biomed) and all agents were supplemented in the external buffer over
a concentration range of 0-10 µg/ml. As shown in Figure 43A&B, PMH and OMH agents
showed comparable anti-Xa and anti-IIa potencies compared to the BMH counterpart. USP
potency results of all heparins as determined by the chromogenic anti-Xa and anti-IIa assays
were noted in Tables 23.
The USP potency of PMH as measured by anti-Xa assay was 185±1.4 U/mg, whereas
the OMH exhibited comparable potency of 189±2.8 U/mg. In contrast, the USP potency of the
BMH was significantly (*p ≤ 0.05, **p ≤ 0.05) lower (136±2.1 U/mg) compared to PMH and
OMH as shown in Figure 43 A. Figure 43 A. The USP potency as measured by anti-IIa assay
showed the same trend (Figure 43B). OMH and PMH exhibited comparable potencies of
189±3.2 U/mg and 184±3.4 U/mg respectively. However, the BMH produced significantly (*p ≤
0.05, **p ≤ 0.05) lower potency of 135±4.3 U/mg compared to others. The anti-Xa/anti-IIa
ratios for all heparins were comparable and were around one.
On the other hand, all LMWHs exhibited similar NIBSC potencies as measured by antiXa and anti-IIa assays as shown in Figure 43 C&D. The USP anti-Xa and anti-IIa potencies of
all LMWHs ranged from 96.5 to 99.3 U/mg and from 37.6 to 39.3 U/mg respectively. The USP
anti-Xa potency of all LMWHs was more than the double of their USP anti-IIa potency as
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shown in Figures 43C&D. USP potency results of all LMWHs as determined by the
chromogenic anti-Xa and anti-IIa assays were noted in Tables 24.
In terms of potency-based heparins (Figure 44A&B), these heparin solutions were
prepared by cross refencing against the USP standard solution with a calibration range of 0-1
U/ml. All these heparins produced similar anti-Xa and anti-IIa USP potencies.
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Figure 42. The inhibition of factor Xa and thrombin in AT-DP (Panel A&B) and HCII-DP (Panel C&D)
as measured by the amidolytic anti-Xa and anti-IIa assays (n=3). All agents were supplemented over a
concentration range of (0 - 10) µg/ml. PMH; porcine mucosal heparin, BMH; bovine mucosal heparin,
OMH; ovine mucosal heparin, LMWH; low molecular weight heparin, AT; antithrombin, HCII; heparin
cofactor II, DP; depleted plasma. All results represent the mean ± SD.

154

Figure 43. Comparative USP potencies as measured by the chromogenic anti-Xa and anti-IIa assays
(n=4). Heparins (A&B) and LMWHs (C&D). All agents were supplemented in the external buffer over a
concentration range of 0-10 µg/ml. The potency of each agent was calculated by cross-referencing to the
reference standards for USP (Heparins) or NIBSC (LMWHs). *; p < 0.05, **; p < 0.03, PMH; porcine
mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, LMWH; low molecular
weight heparin, USP; United States Pharmacopeia, NIBSC; National Institute for Biological Standards
and Control. All results represent the mean ± SD.

Figure 44. Comparative USP potencies as measured by the chromogenic anti-Xa and anti-IIa assays
(n=3). Anti-Xa (A) and Anti-IIa (B). All heparins were supplemented in the external buffer over a
concentration range of 0-1 U/ml. The potency of each agent was calculated by crossreferencing to the
reference standard for USP. PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine
mucosal heparin, USP; United States Pharmacopeia. All results represent the mean ± SD.
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In Vitro Neutralization Studies of Various UFHs and LMWHs
Heparins and LMWHs are widely used anticoagulants for interventional and surgical use.
As such, the ability to reverse the biological effects of heparins is very important. The
anticoagulant and bleeding effects of heparins are clinically neutralized by protamine sulfate. In
this project, we used several neutralizing agents such as protamine sulfate (PS), heparinase-I
(HP-I) and platelet factor 4 (PF4). The neutralization effects were measured using the APTT, TT
(5U Ca2+), anti-Xa and anti-IIa assays, which were previously discussed in the ‘Materials and
Methods’ section. The data represent the mean ± standard deviation of three independent
experiments.
Protamine sulfate (PS) neutralization studies. Figure 45 shows the in vitro
neutralization of PMH, OMH and BMH by PS as determined by the anticoagulant assays (aPTT
and TT) and antiprotease assays (Anti-Xa and anti-IIa). As shown in Figure 45A, PS was able to
completely neutralize the anticoagulant effects of all heparins at all concentration points.
However, in the TT assay (B), PS (10 ug/ml) was able to completely neutralize the anticoagulant
effects of the different concentrations of heparins at or below 5 μg/ml. As shown in Figures
45C&D, the same trend was observed for the amidolytic anti-Xa and anti-IIa assays. PS was able
to completely neutralize the different heparins at almost all concentration points. The results for
the PS neutralization profile of PMH, BMH and OMH agents, are tabulated in Tables 25, 26 and
27.
At potency-based heparin solutions, PS (10 ug/ml) was able to completely neutralize the
anticoagulant effects of the different concentrations of heparins at or below 0.5 U/ml (Figures
46A&B). At the highest concentration (1 U/ml), PMH and OMH were completely neutralized by
PS, however, BMH was partially (*p ≤ 0.05) neutralized compared to others (Figure 46A). In the
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TT assays (Figure 46B), PS failed to neutralize all heparins at their highest concentration (1
U/ml). In terms of the anti-Xa and anti-IIa, all heparins were completely neutralized by PS at all
concentration points, however, BMH was partially (*p ≤ 0.05) neutralized by PS at
concentrations above 0.5 U/ml as shown in
Figures 46C&D. The results for the PS neutralization profile of potency adjusted PMH, BMH
and OMH agents, are tabulated in Table 28, 29 and 30.
In terms of LMWHs, all agents were supplemented at 0 to 10 µg/ml range and PS was
added to the LMWH solutions to obtain a final antagonist concentration of 10 ug/ml (Figure 47).
In the aPTT and TT assays, PS was able to completely neutralize all LMWHs at all
concentration points (Figures 47A&B). However, PS partially neutralized all LMWHs with the
same degree at all concentration points in both, the anti-Xa and anti-IIa assays (Figures
47C&D). The results for the PS neutralization profile of all LMWHs (porcine, bovine and ovine)
are tabulated in Table 28, 29 and 30.
Furthermore, the PS neutralization profiles of all agents were determined in whole
human blood as measured by the ACT system (Figure 48). All gravimetric-based heparin
solutions (10 ug/ml) were completely neutralized (ACT = 144-146 seconds) by PS compared to
the control (Saline, ACT = 137±3.3 seconds) as noted in the potency-based heparin solutions (1
U/ml), both PMH and OMH were completely neutralized (ACT = 139-144 seconds) compared
to saline (138 seconds), however BMH (1 U/ml) was partially neutralized (*p ≤ 0.05, ACT =
193±8 seconds) compared to the control (ACT = 138±4.3 seconds) (Figure 48B). In terms of
LMWHs, PS was able to partially neutralize all LMWHs (**p ≤ 0.01, ACT = 179-182 seconds)
compared to the saline (137±3.5 seconds) as depicted in Figure 48C. All PS neutralization data
of all heparins and LMWHs as determined by ACT system are shown below.
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PS Neutralization data as determined by ACT system in whole human blood:
Agents
Agent + Saline
Agent + PS
Sec
Sec
PMH – 10 ug/ml
331.4±15
144±8
BMH – 10 ug/ml
253.6±17
145.6±9
OMH – 10 ug/ml
328.8±19
144±6
PMH – 1 U/ml
296.8±13
144±7
BMH – 1 U/ml
299.6±12
192.6±8
OMH – 1 U/ml
307.4±15
139±5
P. LMWH - 25 ug/ml
224.6±12
182±9
B. LMWH – 25 ug/ml
223.4±10
180.6±6
O. LMWH – 25 ug/ml
215.8±14
179.4±7

Figure 45. Comparative neutralization profile of various heparins using PS as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D). All
agents were supplemented in BBP over a concentration range of 0 to 10 ug/ml. PS was added to the
heparin supplemented plasma to obtain a final PS concentration of 10 ug/ml. Significance was set at (*p
≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin,
PS; protamine sulfate, BBP; blood bank plasma. All results represent the mean ± SD.
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Figure 46. Comparative neutralization profile of various heparins using PS as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D). All
agents were supplemented in BBP over a concentration range of 0 to 1 U/ml. PS was added to the heparin
supplemented plasma to obtain a final PS concentration of 10 ug/ml. Significance was set at (*p ≤ 0.05).
PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, PS;
protamine sulfate, BBP; blood bank plasma. All results represent the mean ± SD.
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Figure 47. Comparative neutralization profile of various LMWHs using PS as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D). All
agents were supplemented in BBP over a concentration range of 0 to 10 ug/ml. PS was added to the
heparin supplemented plasma to obtain a final PS concentration of 10 ug/ml. Significance was set at (*p
≤ 0.05). P. LMWH; porcine low molecular weight heparins, B. LMWH; bovine low molecular weight
heparin, O. LMWH; ovine low molecular weight heparin, PS; protamine sulfate, BBP; blood bank
plasma. All results represent the mean ± SD.
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Figure 48. Comparative neutralization profile of various heparins (A and B) and LMWHs (C) using PS
in whole human blood as measured by the ACT system. All agents were supplemented in the whole
blood of final concentrations of 10 µg/ml (A) and 1 U/ml (B). All LMWHs were supplemented at a final
concentration of 25 ug/ml and saline was used as a negative control (n = 5). *; p < 0.05, **; p < 0.01,
ACT; activated clotting time, PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH;
ovine mucosal heparin, PS; protamine sulfate, S; saline. All results represent the mean ± SD.
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Heparinase-I (HP-I) digestion studies. The neutralization/digestion profiles of various
heparins and LMWHs by heparinase-I (HP-I) as determined by the anticoagulant assays (aPTT
and TT) and antiprotease assays (Anti-Xa and anti-IIa) are shown in Figures 49 & 50. HP-I was
able to completely neutralize the anticoagulant (Figures 49A&B) and the antiprotease (Figures
49C&D) activites of all heparins at all concentration points.
As shown in Figure 50, HP-I was able to completely neutralize all LMWHs at all
concentration points as determined by the anticoagulant assays (aPTT and TT) and amidolytic
assays (anti-Xa and anti-IIa) as noted in Panels A, B, C & D respectively. The results for the
heparinase-I neutralization profile of all heparins and LMWHs, are tabulated in Tables 34-39.
Platelet factor 4 (PF4) neutralization studies. Figure 51 shows the in vitro
neutralization of PMH, OMH and BMH solutions (ug/ml) by PF4 as determined by the
anticoagulant assays (aPTT and TT) and amidolytic assays (anti-Xa and anti-IIa). In the aPTT
assay, PF4 was able to completely neutralize all heparins at concentration points (Figure 51A).
In terms of the TT assay, PF4 completely neutralized all heparins at and below 5 ug/ml
concentration points and failed to neutralize all heparins at their highest concentration of 10
ug/ml (Figure 51B). As seen in Figures 51C&D, all heparin solutions (ug/ml) were completely
neutralized by PF4 at and below 5 ug/ml concentration points, however, at their highest
concentration of 10 ug/ml, PF4 partially neutralized all heparins with the same degrees. The
results for the PF4 neutralization profile of all heparins (ug/ml), are tabulated in Tables 40,
41&42.
Figure 52 shows that, all potency-based heparin solutions (U/ml) exhibited the same PF4
profiles of gravimetric-based heparin solutions (ug/ml) in the anticoagulant (aPTT & TT) and
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the amidolytic (anti-Xa & anti-IIa) assays. The results for the PF4 neutralization profile of all
heparins (U/ml), are tabulated in Tables 43, 44 & 45.
On the other hand, LMWHs exhibited similar PF4 in all assays (Figure 53). PF4 was able
to completely neutralize all LMWHs as determined by the anticoagulant’s assays (Figures
53A&B). However, all LMWHs solutions (ug/ml) were partially neutralized by PF4 at all
concentration points as measured by the amidolytic anti-Xa and anti-IIa assays (Figures
53C&D). The results for the PF4 neutralization profile of all LMWHs, are tabulated in Tables
46, 47&48.
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Figure 49. Comparative neutralization profile of various heparins using HP-I as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D).
HP-I (1 U/ml final concentration) was incubated with various heparins (10 mg/ml, pH = 5.0) at 37°C for
30 min. Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal
heparin, OMH; ovine mucosal heparin, PS; protamine sulfate, HP-I; heparinase-I. All results represent
the mean ± SD.
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Figure 50. Comparative neutralization profile of various LMWHs using HP-I as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D).
HP-I (1 U/ml final concentration) was incubated with various LMWHs (10 mg/ml, pH = 5.0) at 37°C for
30 min. Significance was set at (*p ≤ 0.05). P. LMWH; porcine low molecular weight heparins, B.
LMWH; bovine low molecular weight heparin, O. LMWH; ovine low molecular weight heparin, PS;
protamine sulfate, HP-I; heparinase-I. All results represent the mean ± SD.
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Figure 51. Comparative neutralization profile of various heparins using PF4 as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D). All
agents were supplemented in BBP over a concentration range of 0 to 10 ug/ml. PF4 was added to the
heparin supplemented plasma to obtain a final PF4 concentration of 10 ug/ml. Significance was set at (*p
≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin,
PF4; platelet factor 4, BBP; blood bank plasma. All results represent the mean ± SD.
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Figure 52. Comparative neutralization profile of various heparins using PF4 as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D). All
agents were supplemented in BBP over a concentration range of 0 to 1 U/ml. PF4 was added to the
heparin supplemented plasma to obtain a final PF4 concentration of 10 ug/ml. Significance was set at (*p
≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin,
PF4; platelet factor 4, BBP; blood bank plasma. All results represent the mean ± SD.
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Figure 53. Comparative neutralization profile of various LMWHs using PF4 as determined by the
anticoagulant and the antiprotease assays. aPTT assay (A), TT assay (B), anti-Xa (C) and anti-IIa (D). All
agents were supplemented in BBP over a concentration range of 0 to 10 ug/ml. PF4 was added to the
heparin supplemented plasma to obtain a final PF4 concentration of 10 ug/ml. Significance was set at (*p
≤ 0.05). P. LMWH; porcine low molecular weight heparins, B. LMWH; bovine low molecular weight
heparin, O. LMWH; ovine low molecular weight heparin, PF4; platelet factor 4, BBP; blood bank
plasma.
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Platelet Function Profile of Various UFHs and LMWHs
Both heparin and LMWH are known to modulate platelet function such as adhesion,
activation and aggregation. In these studies, both the augmentation of platelet aggregation by
various agonists and the HIT antibody-mediated responses were measured using aggregometry
methods as described in the “Material & methods” section.
Agonist induced platelet aggregation (AIPA) assay. Figures 54&55 depict the
effect of various concentrations of heparins; (10, 1 and 0.1 ug/ml) and (1, 0.5 and 0.1 U/ml) on
the platelet aggregation in presence of various activators (agonists) such as ADP, AA, collagen
and epinephrine. All heparins produced comparable effects (aggregation % & aggregation rate)
on platelet aggregation at all concentrations in both, gravimetric and potency-equated basis as
shown in Figures 54&55 respectively. All the agonists under same condition produced similar
aggregation response. However, the epinephrine showed slower onset of aggregation compared
to the others. In terms of LMWHs, all agents exhibited the same trend at all concentrations as
shown in Figure 56. The comparative effects of various concentrations of heparins and LMWHs
on agonist induced platelet aggregation (AIPA) are tabulated in Tables 49, 50 & 51.
Heparin induced platelets aggregation (HIPA) assay. The effects of various heparins
and LMWHs on HIT antibody mediated platelet aggregation are depicted in Figure 57. All
heparins (ug/ml and U/ml) produced significant (p ≤ 0.05) platelet aggregation responses
compared to the control (saline) at concentrations of (10 and 1 µg/ml) and (1 and 0.5 U/ml) as
shown in Figures 57A&B. However, none of the heparins
exhibited a platelet aggregation response at neither 0.1 µg/ml nor 0.1 U/ml concentrations.
These results suggest that all heparins have a similar HIT profile at the same concentrations.
However, LMWHs exhibited significantly (p ≤ 0.05) weaker platelet aggregation responses
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compared to heparins at 10 ug/ml and 1 ug/ml concentrations as noted in Figure 57C. Results
from these studies are compiled in Tables 52, 53&54.
Figure 58 depicts the effect of various heparins and LMWHs pre- and post- heparinase-I
digestion on HIT positive antibody platelet aggregation. All pre heparinase digestion samples
showed comparable platelet aggregation responses at concentrations of (10 & 1 µg/ml) and (1 &
0.5 U/ml), however all agents showed no HIT response at 0.1 µg/ml and 0.1 U/ml. All post
heparinase digestion samples exhibited no platelet aggregation responses at all concentrations.
These results suggest that, heparinase-I completely neutralizes heparins and LMWHs from
various animal sources. Results from these studies are compiled in Table 55&56.
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Figure 54. The effect of various heparins on agonist induced platelet aggregation (AIPA). Heparins were tested at final concentrations of 10 ug/ml
(Panel A), 1 ug/ml (Panel B) and 0.1 ug/ml (Panel C). Saline was used as a negative control while various agonists like ADP, AA, collagen and
EPI were used as positive controls. ADP; adenosine di-phosphate, AA; arachidonic acid, EPI; epinephrine, AGG; aggregation, PMH; porcine
mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin. The results represent the mean ± SD (n=5 platelet donors).
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Figure 55. The effect of various heparins on agonist induced platelet aggregation (AIPA). Heparins were tested at final concentrations of 1 U/ml
(Panel A), 0.5 U/ml (Panel B) and 0.1 U/ml (Panel C). Saline was used as a negative control while various agonists like ADP, AA, collagen and
EPI were used as positive controls. ADP; adenosine di-phosphate, AA; arachidonic acid, EPI; epinephrine, AGG; aggregation, PMH; porcine
mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin. The results represent the mean ± SD (n=5 platelet donors).
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Figure 56. The effect of various LMWHs on agonist induced platelet aggregation (AIPA). LMWHs were tested at final concentrations of 10
ug/ml (Panel A), 1 ug/ml (Panel B) and 0.1 ug/ml (Panel C). Saline was used as a negative control while various agonists like ADP, AA,
collagen and EPI were used as positive controls. ADP; adenosine di-phosphate, AA; arachidonic acid, EPI; epinephrine, AGG; aggregation, P.
LMWH; porcine low molecular weight heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH; ovine low molecular weight
heparin. The results represent the mean ± SD (n=5 platelet doners).
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Figure 57. The effect of various heparins and LMWHs on HIT antibody mediated platelet aggregation. Heparins were tested at final
concentrations of 10 ,1 and 0.1 ug/ml (Panel A) and at final concentrations of 1, 0.5 and 0.1 U/ml (Panel B). LMWHs were tested at final
concentrations of 10 ,1 and 0.1 ug/ml (Panel C). Saline was used as a negative control while AA was used as a positive control. AA; arachidonic
acid, AGG; aggregation, PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, LMWH; low molecular
weight heparin. The results represent the mean ± SD (n=10 platelet donors).
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Figure 58. The effect of various heparins and LMWHs pre- and post-Heparinase-I digestion on HIT positive antibody platelet aggregation.
Heparins were tested at final concentrations of 10 ,1 and 0.1 ug/ml (Panel A) and at final concentrations of 1, 0.5 and 0.1 U/ml (Panel B). LMWHs
were tested at final concentrations of 10 ,1 and 0.1 ug/ml (Panel C). Saline was used as a negative control while AA was used as a positive control.
AA; arachidonic acid, AGG; aggregation, PMH; porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, LMWH;
low molecular weight heparin. The results represent the mean ± SD (n=5 platelet donors).
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Characterization of Heparin/Platelet Factor 4 (PF4) Interaction
In order to perform the evaluation of PF4/heparin interaction, titration of protein by the
samples was performed at different Protein/Heparin Ratio (PHR), calculated as follow:

Photon Correlation Spectroscopy (PCS) studies. For the PCS experiments, the
obtained titrations results are shown in Figure 59, while data are compiles below (PHR for
which the maximum aggregate size was achieved).

Figure 59. PCS titrations results. For each experiment, a 60-second delay was followed by the injection of
1 or 2 µl of respectively UFHs and LMWHs, for a total of 19 titration points spaced 240 seconds apart;
sample cell was maintained at 25°C under stirring, 1000 rpm. HBSS solution was used as reference buffer
and loaded in the instrument reference cell. Z-Average; particle diameter, PHR; protein-heparin ratio.
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Photon Correlation Spectroscopy (PCS) Titrations Results:

As depicted in Figure 59, The size of particles follows a bell-shaped curve with a
maximum achieved at different PHR values varying average molecular weight; in particular, 9.0
for PMH, 6.4 for BMH and OMH, and 2.0 for the three LMWHs were obtained. Comparing the
three UFHs, lower concentrations, so a higher PHR, of porcine UFH are needed to form the
large complexes as compared to the other heparins; moreover, ovine heparin forms slightly
larger aggregates compared to others. The three samples showed the formation of the ultra large
complexes (ULCs) and the size of all complexes was quite similar, however, PMH produced
somewhat a larger complex compared to
others.
On the other hand, the three LMWHs resulted with very similar both titration curves and
size of the complexes reached at the PHR of maximum aggregation (2.0); very slightly higher
the B. LMWH size, but we cannot consider it significantly different, since under these
conditions the measurement is more instable due to the several equilibria that are present among
the different structures in solution that increase the polydispersity index of the measurement
(Figure 59). Another important observation is that LMWHs did not form ULCs and reached the
maximum of aggregation only at much lower PF4-heparin ratios in respect of UFHs, so these
sample would be predicted to be less likely to provoke antibody formation.
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Zeta potential measurements. The Zp of complexes was measured using conditions
analogous to those of the PCS experiments, whereby increasing amounts of heparin were
incubated with a fixed concentration of hPF4. The only significant difference was in the solvent
used for solutions preparation; the use of water instead of HBSS was mainly due to exclude any
interference of the salt on Zp evaluation. A sigmoidal equation was fitted to the Zp versus the
logarithm of PHR data to obtain the PHR value of the curve that corresponds to the neutral state
of the complex (Zp = 0). The PHR values at which Zp = 0 (mV) for each agent are reported
below, while the fitted curves are shown in Figure 60.

Figure 60. Zeta Potential Titrations results of various heparins (A) and LMWHs (B). A sigmoidal
equation was fitted to the Zp versus the logarithm of PHR data to obtain the PHR value of the curve that
corresponds to the neutral state of the complex (Zp=0). The PHR values at which Zp=0 mV for each
heparin. Zp; zeta-potential, PHR; protein-heparin ratio.
Zeta Potential Titrations Results:
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Comparing the UFHs, in accordance with the PCS result, PMH exhibited the higher PHR
of maximum aggregation (approximately 13). BMH differs from PMH and OMH samples in
terms of the higher concentration required to obtain the neutrality of charge (PHR = 9.0), even
though its maximum complex size was the smaller. The only parameter significantly different is
the degree of sulfation (DS), which is lower for the BMH than the others, but anyway for all
UFHs samples the Zp=0 are reached at PHR at least not so different, taking into account that the
standard deviation (SD) calculated on the Zp=0 obtained by titrating five times (n=5) the same
porcine UFH is ± 4.2, confirming that also the sulfate groups play an important role in the
PF4/heparin interaction.
For LMWHs, very slight differences were observed with Zp=0 PHR values as shown above.
The Zp=0 PHR values were 3.6 for P. LMWH, 3.4 for B. LMWH and 3.0 for O. LMWH. Both
PCS and Zeta potential studies demonstrated that all UFHs have comparable PF4 binding and
aggregation. The same trend was observed among all LMWHs. However, there were significant
differences between UFHs and LMWHs in PCS and Zp measurements as mentioned above.
In Vitro Studies in Pooled Monkeys’ Plasma
All heparins were supplemented in human and monkey plasmas to determine the
differences as measured by the aPTT assay, anti-Xa assay, anti-IIa assay and absolute GAG
contents (Heparin Red kit). As shown in Figure 61, all heparins exhibited similar anticoagulant
(aPTT assay) and antiproteases (anti-Xa and anti-IIa) activities in both human and monkey
plasmas.
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Figure 61. In vitro supplantation of various heparins in monkeys’ plasma All heparins were
supplemented in human and monkey plasma over a concentration range of (0 - 10) µg/ml. Panel A;
aPTT, Panel B; anti-Xa and Panel C; anti-IIa. Significance was set at (*p ≤ 0.05). All results represent the
mean ± SD (n=3).

Furthermore, all heparins exhibited comparable recovered GAG contents in both human
and monkey plasmas as determined by the Heparin Red kits as depicted in the compiled data
below.
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The recovered concentrations of various heparins in both human and monkey plasmas as measured by
Heparin Red method:

.

In Vivo Studies in Non-Human Primates
Non-human primate models were used to study the pharmacodynamic (PD) and
pharmacokinetic (PK) properties of various heparins and LMWHs in an in vivo model similar to
humans. To elucidate how molecular weight and structure contribute to the PD/PK properties,
various heparins and LMWHs were given to primates intravenously (IV) and/or subcutaneously
(SC) at doses previously described in the ‘Materials and Methods’ section. The PK/PD and the
in vivo PS neutralization profiles of various PMH, OMH and BMH and their depolymerized
derivatives were assessed using a variety of clotting and amidolytic based assays.
PD profile as determined by anti-Xa, anti-IIa and aPTTassays. Concentrationresponse curves were made by supplementing various heparins and LMWHs in pooled baseline
primate plasma over a concentration range of 0 to 10 µg/ml.
Best-fit curves were made and the drug concentration in plasma samples collected at
various time points following drug administration was determined by extrapolation using the
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measured percent inhibition of factor Xa and thrombin. The results are presented as the mean ±
SD and compiled data for the individual experiments can be found in Tables 57-66.
In Figure 62, Panel A shows the plasma concentration-time courses and the anti-Xa
activity expressed as % inhibition, at various time points of various heparins (0.5 mg/kg). PMH
and OMH exhibited similar anti-Xa activity in terms of anti-Xa potency and factor Xa %
inhibition at all time points (Panel A). At 15-, 30- and 60-minutes post-drug administration,
BMH led to significantly (p ≤ 0.05) lower level of anti-Xa potency compared to PMH and OMH
as shown in Panel A. The peak plasma concentration achieved following administration of BMH
(1.5±0.3 U/ml) was significantly (p ≤ 0.05) lower than after the administration of the PMH
(2.2±0.2 U/ml) and OMH (2.3±0.3 U/ml) agents. At 30- and 60-minutes post-drug
administration, BMH led to significantly (p ≤ 0.05) lower level of factor Xa inhibition compared
to PMH and OMH as shown in Panel A. Peak anti-Xa activity for PMH and OMH agents were
(88.5±3.1 % Inh) and (90.5±5.5 % Inh) respectively. However, the peak anti-Xa activity for the
BMH was the lowest (79.3 ±4.3 % Inh) as shown in Tables 57& 60.
The time course of the amidolytic anti-IIa activity of all heparins (0.5 mg/kg IV) are
shown in Panel B. PMH and OMH exhibited similar anti-IIa activity in terms of anti-IIa potency
and factor IIa % inhibition at all time points (Panel B). At 15-, 30- and 60minutes post-drug
administration, BMH led to significantly (p ≤ 0.05) lower level of anti-IIa potency compared to
PMH and OMH. The peak plasma concentrations following administration of BMH (1.3±0.2
U/ml) was significantly (p ≤ 0.05) lower compared to PMH (2±0.2 U/ml) and OMH (2.3±0.3
U/ml) agents. At 30- and 60-minutes post-drug administration, BMH led to significantly (p ≤
0.05) lower level of factor IIa inhibition compared to PMH and OMH as shown in Panel B. Peak
anti-IIa activity for PMH and OMH agents were (89±3.1 % Inh) and (92.5±5.5 % Inh)
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respectively. However, the peak anti-IIa activity for the BMH was the lowest (80 ±3.3 % Inh) as
shown in Tables 57& 60.
Panel C depicts the aPTT response curves after 0.5 mg/kg IV administration of various
heparin to primates (n=4). PMH and OMH showed comparable anticoagulant effects at all time
points. However, BMH produced significantly (p ≤ 0.05) weaker prolongation of the clotting
time compared to PMH and OMH at 15-, and 30 minutes post drug administration. Maximal
effects for PMH (38.8±2.3 sec) and OMH (39.8±1.0 sec) were seen at 15 minutes post drug
administration, while the BMH demonstrated maximal anticoagulant effect of 33.9±2.9 sec
(Tables 57&60).
As seen in Figure 63, Panel A shows the plasma concentration-time courses and the antiXa activity expressed as % inhibition, at various time points of various heparins (100 U/kg). All
potency-adjusted heparins exhibited similar anti-Xa activity in terms of anti-Xa potency and
factor Xa % inhibition at all time points. The peak plasma concentrations achieved following the
IV administration of PMH, BMH and OMH were (1.5±0.3 U/ml), (1.47±0.2 U/ml) and
(1.45±0.3 U/ml) respectively. In terms of factor Xa % inhibition, the peak anti-Xa activity for
PMH, BMH and OMH agents were (92.5±4.1 % Inh), (93.2±6.5 % Inh) and (90.5±3.1 % Inh),
respectively (Tables 58&61).
The time courses of the amidolytic anti-IIa activity of all heparins (100 U/kg IV) are
shown in Panel B. PMH, BMH and OMH exhibited similar anti-IIa activity in terms of anti-IIa
potency and factor IIa % inhibition at all time points. The peak plasma concentrations following
administration of various heparins (100 U/kg) were comparable and ranged from 1.34 to 1.41
U/ml. In addition, the peak anti-IIa activity of all heparins were similar; PMH (93±4.1 % Inh),
BMH (92±2.1 % Inh) and OMH (90±3.5 % Inh) (Tables 58&61).
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In terms of the anticoagulant effects of all heparins (100 U/kg) as measured by the aPTT
assay, all agents produced comparable anticoagulant effects at all time points (Panel C).
Maximal effects for PMH (39±3.3 sec), BMH (38.8±2.8 sec) and OMH (38±3.2 sec) were seen
at 15 minutes post drug administration (Tables 58&61).
Figure 64 shows the pharmacodynamic effects of 1 mg/kg SC of various LMWHs
administered to primates as measured by the amidolytic anti-Xa / anti-IIa and the anticoagulant
aPTT assays. Panel A shows the plasma concentration-time courses and the anti-Xa activity
expressed as % inhibition, at various time points of various LMWHs. All LMWHs exhibited
similar anti-Xa activity in terms of anti-Xa potency and factor Xa % inhibition at all time points
(0-, 2-, 4- and 6-hours). The peak plasma concentrations achieved following the IV
administration of P. LMWH, B. LMWH and O. LMWH were (1±0.12 U/ml), (0.9±0.1 U/ml)
and (0.9±0.14 U/ml) respectively. In terms of factor Xa % inhibition, the peak anti-Xa activity
for P. LMWH, B. LMWH and O. LMWH agents were (84.9±3.1 % Inh), (86.6±3.5 % Inh) and
(88±5.1 % Inh), respectively (Tables 59&62).
The time courses of the amidolytic anti-IIa activity of all LMWHs (1 mg/kg IV) are
shown in Panel B. All LMWHs exhibited similar anti-IIa activity in terms of anti-IIa potency
and factor IIa % inhibition at all time points. The peak plasma concentrations following
administration of all LMWHs were comparable and ranged from 0.15 to 0.18 U/ml. In addition,
the peak anti-IIa activity of all heparins was similar; P. LMWH (43±3.1 % Inh), B. LMWH
(43.5±4.1 % Inh) and O. LMWH (46±2.5 % Inh) (Tables 59&62).
In terms of the anticoagulant effects of all LMWHs (1 mg/kg) as measured by the aPTT
assay, all agents produced comparable anticoagulant effects at all time points (Panel C).
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Maximal effects for P. LMWH (40±2.3 sec), B. LMWH (39±2.1 sec) and O. LMWH (41±31
sec) were seen at 2 hours post drug administration as depicted in Tables 59&62.

Figure 62. The pharmacodynamic effects of 0.5 mg/kg IV of various heparins administered to primates
as measured by the amidolytic anti-Xa / anti-IIa and the anticoagulant aPTT assays. Panels A & B show
the plasma concentration-time courses of each agent as determined by effects on anti-Xa and anti-II
activities respectively. Panel C shows the anticoagulant effect of various heparins as measured by the
aPTT method. Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine
mucosal heparin, OMH; ovine mucosal heparin, IV; intravenously. The results represent the mean ± SD
(n=4).
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Figure 63. The pharmacodynamic effects of 100 U/kg IV of various heparins administered to primates as
measured by the amidolytic anti-Xa / anti-IIa and the anticoagulant aPTT assays. Panels A & B show the
plasma concentration-time courses of each agent as determined by effects on antiXa and anti-II activities
respectively. Panel C shows the anticoagulant effect of various heparins as measured by the aPTT
method. Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH; bovine mucosal
heparin, OMH; ovine mucosal heparin, IV; intravenously. The results represent the mean ± SD (n=4).
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Figure 64. The pharmacodynamic effects of 1 mg/kg SC of various LMWHs administered to primates as
measured by the amidolytic anti-Xa / anti-IIa and the anticoagulant aPTT assays. Panels A & B show the
plasma concentration-time courses of each agent as determined by effects on antiXa and anti-II activities
respectively. Panel C shows the anticoagulant effect of various LMWHs as measured by the aPTT
method. Significance was set at (*p ≤ 0.05). P. LMWH; porcine low molecular weight heparins, B.
LMWH; bovine low molecular weight heparin, O. LMWH; ovine low molecular weight heparin, SC;
subcutaneously. The results represent the mean ± SD (n=4).
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Pharmacodynamics (PD) profile as determined by TGA assay. The
pharmacodynamic effects of various heparins and LMWHs administered to primates as
measured by the TGA assay as depicted in Figures 65&66.
Figure 65 shows the thrombokinetograms of various heparins (Panels A&B) and
LMWHs (Panel C) in non-human primates. All heparins (ug/ml and U/ml) produced complete
inhibition of thrombin generation at 15-, 30- and 60-minutes poste drug administration as shown
in Panels A&B. However, at 120-minutes post drug administration (0.5 mg/kg), PMH and OMH
showed comparable thrombin inhibitory effects where the thrombin generation values ranged
from 55±4.5 nM to 67±7 nM. Whereas BMH (0.5 mg/kg) at the time point showed significantly
(p ≤ 0.05) weaker thrombin inhibitory effect (150±15 nM) compared to others as shown in panel
A. In regard to LMWHs (1 mg/kg), all agents exhibited comparable inhibition of thrombin
generation at all time points as shown in Panels C. The peak thrombin values of all LMWHs
were at 6-hours post drug administration and ranged of 100±6-119±11 nM.
The thrombin generation profile was measured in terms of peak thrombin, AUC, and the
lag time and all TGA profile parameters of all agents (heparins and LMWHs) are tabulated in
Table 63 (UFHs; 0.5 mg/kg), 64 (UFHs; 100 U/kg) & 65 (LMWH; 1 mg/kg).
In terms of peak thrombin, all gravimetric-based dosages of heparins (0.5 mg/kg)
produced comparable thrombin inhibitory effects with the exception of BMH, which showed
significantly (p ≤ 0.05) weaker inhibition of thrombin at 120 mins post drug administration
(Figure 66 A). This weaker effect at 120 mins was abolished when used potency-adjusted
dosages of heparins (100 U/kg) as shown in Figure 66B. Figure 66C shows that, all LMWHs
exhibited similar thrombin inhibition effects at all concentration points with minor differences.
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In terms of AUC, all gravimetric-based dosages (0.5 mg/kg) and potency-adjusted
dosages (100 U/kg) of heparins produced comparable AUC values at all time points, with the
weakest effect at 120 mins time points (Figure 66A&B). All LMWHs (1 mg/kg) exhibited the
same trend in the AUC values with minor differences as shown in Figures 66C.
In terms of lag time, all gravimetric-based dosages (0.5 mg/kg) and potency-adjusted
dosages (100 U/kg) of heparins produced similar lag time values at all time points with minor
differences (Figures 66A&B). All heparins produced maximal prolongation of the lag time at 15
mins time points (Figures 66A&B). All LMWHs (1 mg/kg) exhibited comparable lag time
values at all time points with maximal lag time prolongation at 2- and 4-hours post drug
administration as shown in Figures 66C.
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Figure 65. The thrombokinetograms of various heparins and LMWHs administered to primates as
measured by the TGA assay. Panels A & B show the thrombokinetograms of 0.5 mg/kg and 100 U/kg
IV of various heparins administered to primates. Panel C shows the thrombokinetograms of 1 mg/kg
SC of various LMWHs administered to primates. Significance was set at (*p ≤ 0.05). TGA; thrombin
generation inhibition assay, IV; intravenously, SC; subcutaneously, PMH; porcine mucosal heparin,
BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, P. LMWH; porcine low molecular weight
heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH; ovine low molecular weight
heparin, SC; subcutaneously.
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Figure 66. The pharmacodynamic effects of various heparins and LMWHs administered to primates as
measured by the TGA assay. Panels A & B show the TGA parameters of 0.5 mg/kg and 100 U/kg IV of
various heparins administered to primates. Panel C shows the TGA parameters of 1 mg/kg SC of various
LMWHs administered to primates. Significance was set at (*p ≤ 0.05). TGA; thrombin generation
inhibition assay, AUC; area under the curve, IV; intravenously, SC; subcutaneously, PMH; porcine
mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, P. LMWH; porcine low
molecular weight heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH; ovine low
molecular weight heparin, SC; subcutaneously. The results represent the mean ± SD (n=4).
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PD profile as determined by TFPI antigen and functional levels assays. In this study,
TFPI antigen levels were measured at varying time points after the administration of heparins
and LMWHs (1 mg/kg) from various sources (Figure 67 and Table 66).
Figure 67A shows the TFPI antigen levels in primates after 0.5 mg/kg IV PMH, BMH
and OMH dosages. Following a gravimetric dosage, BMH-treated primates exhibited a
significantly lower TFPI level at 15- and 30-mins (p < 0.05) than OMH and PMH, with a
maximum value of 210±39 ng/ml at 15 mins post drug administration (Figure 67A). PMH and
OMH showed comparable TFPI levels at all time points with maximum values of 264±24 ng/ml
and 255±42 ng/ml respectively at 15 mins post 0.5 mg/kg drug administration (Figure 67A).
In a second set of experiments, PMH, BMH and OMH were administered at potency
adjusted dosages (100 U/kg). Administration of potency adjusted dosages of each UFH resulted
in comparable TFPI antigen levels at all time points with maximum values ranged from 245±13
ng/ml to 257±31 ng/ml at 15 mins post 100 U/kg drug administration (Figure 67B). Figure 67C
depicts that, all LMWHs produced comparable TFPI antigen levels at all time points with
maximum values ranged from 97±9 ng/ml to 102±12 ng/ml at 15 mins post 1 mg/kg drug
administration.
Furthermore, the estimation of pharmacokinetic parameters calculated from TFPI antigen
release assay after IV administration of 0.5 mg/kg heparins to non-human primates were
determined. all agents demonstrated a comparable half-life with a range of (85 - 97 mins) and no
significant differences in area under the curve were noted among all agents (AUC = 17306 –
18720 ng/ml*min). At the potency-equated dosages (100 U/kg), all agents demonstrated a
comparable half-life with a range of (90 - 101 mins) and no significant differences in area under
the curve were noted among all agents (AUC = 19030 – 20435 ng/ml*min). In addition, all
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LMWH at 1 mg/kg SC dosages showed comparable half-life with a range of (2.3 – 2.5 hrs) and
no significant differences in area under the curve were noted among all agents (AUC = 450 – 476
ng/ml*hr).
Additionally, the TFPI functional levels were measured in all primate plasma samples
using the commercially available ACTICHROME® TFPI kit as shown in Figure
68 and Table 67. Figure 68A shows the TFPI functional levels in primates after 0.5 mg/kg IV
PMH, BMH and OMH dosages. All heparins (PMH, BMH and OMH) showed comparable TFPI
functional levels at all time points with maximum values of 2.03±0.13 U/ml, 2.13±0.22 U/ml
and 2.08±0.21 U/ml respectively at 15 mins post 0.5 mg/kg drug administration. The same trend
was noted at potency adjusted dosages (100 U/kg) of each UFH, TFPI functional levels at all
time points were comparable with maximum values ranged from 2 U/ml to 2.1 U/ml at 15 mins
post 100 U/kg drug administration (Figure 68B).
Likewise, all LMWHs at 1 mg/kg dosages exhibited similar TFPI functional levels at all
time points as depicted in Figure 68C. The TFPI functional levels of all LMWHs were
comparable at all time points (0, 2, 4 and 6 hours) and exhibited the maximal effect (TFPI
functional level range: 1.76 – 1.83 U/ml) at 2 hrs post drug administration.
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Figure 67. The pharmacodynamic effects of various heparins and LMWHs administered to primates as
measured by the TFPI antigen release level assay. Panels A & B show the TFPI antigen release profile of
0.5 mg/kg and 100 U/kg IV of various heparins administered to primates. Panel C shows the TFPI
antigen release profile of 1 mg/kg SC of various LMWHs administered to primates. Significance was set
at (*p ≤ 0.05). TFPI; tissue factor pathway inhibitor, IV; intravenously, SC; subcutaneously, PMH;
porcine mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, P. LMWH;
porcine low molecular weight heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH;
ovine low molecular weight heparin, SC; subcutaneously. The results represent the mean ± SD (n=3).
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Figure 68. The pharmacodynamic effects of various heparins and LMWHs administered to primates as
measured by the TFPI functional level assay. Panels A & B show the TFPI functional profile of 0.5
mg/kg and 100 U/kg IV of various heparins administered to primates. Panel C shows the TFPI functional
profile of 1 mg/kg SC of various LMWHs administered to primates. Significance was set at (*p ≤ 0.05).
TFPI; tissue factor pathway inhibitor, IV; intravenously, SC; subcutaneously, PMH; porcine mucosal
heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, P. LMWH; porcine low
molecular weight heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH; ovine low
molecular weight heparin, SC; subcutaneously. The results represent the mean ± SD (n=3).
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PK parameters as determined by anti-Xa and anti-IIa assays. The estimation of
pharmacokinetic (PK) parameters calculated from plasma concentration-time curves using the
anti-Xa assay after IV administration of 0.5 mg/kg heparins to non-human primates are shown in
Figure 69A. At the indicated dose, BMH (96±11 mins) demonstrated a significantly (p < 0.05)
longer half -life (t1/2) compared to PMH (59 ± 8 mins) and OMH (56 ± 6 mins). No differences
in area under the curve (AUC) were noted among all agents {AUC = 185-210 (ug/ml) *min}
and although BMH appeared to have a larger volume of distribution (Vd), no significant
differences were noted among all heparins {Vd = 37-46 ml/kg}. Furthermore, no differences in
systemic clearance (Cl) were noted between each agent as shown in Figure 69A.
The estimation of PK parameters calculated from plasma concentration-time curves
using the anti-IIa assay after IV administration of 0.5 mg/kg heparins to non-human primates are
shown in Figure 69B. At the indicated dose, BMH (105±12 mins) demonstrated a significantly
(p < 0.05) longer half -life (t1/2) compared to PMH (58±6 mins) and OMH (60±5 mins). No
differences in area under the curve (AUC) and volume of distribution (Vd) were noted among all
agents. All heparins (0.5 mg/kg) exhibited AUC and Vd ranged of {158-178 (ug/ml) *min} and
{37-47 ml/kg} respectively. In addition, no differences in systemic clearance (Cl) were noted
among all heparins.
In both anti-Xa and anti-IIa assays the relative concentration 15 mins after the
administration of OMH and PMH were higher than BMH. In anti-Xa assay, Cmax of PMH (2.3±
0.14 U/ml) and OMH (2.2±0.21 U/ml) heparins were significantly (p < 0.05) higher compared to
the BMH (1.5±0.21 U/ml). The same trend was noted in the anti-IIa assay, where the Cmax of
PMH and OMH were 2±1.9 U/ml and 2.2±2.3 U/ml respectively. In contrast, the BMH showed
lower Cmax of 1.2±0.14 U/ml compared to the others. The results for the pharmacokinetic
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parameters of PMH, BMH and OMH as determined by. The anti-Xa and anti-IIa methods are
tabulated in Table 68.
The estimation of PK parameters calculated from plasma concentration-time curves
using the anti-Xa and anti-IIa assays after IV administration of 100 U/kg heparins to nonhuman
primates are shown in Figure 70. Figure 70A depicts the PK parameters as determined by the
anti-Xa assay where, BMH (97.5±13 mins) demonstrated a significantly (p < 0.05) longer half life (t1/2) compared to PMH (61 ± 5 mins) and OMH (57 ± 4 mins). No significant differences in
area under the curve (AUC) were noted among all agents {AUC = 147-156 (ug/ml) *min} and
although BMH appeared to have a larger volume of distribution (Vd), no significant differences
were noted among all heparins {Vd = 58-64 ml/kg}. Furthermore, no differences in systemic
clearance (Cl) were noted between each agent as shown in Figure 70A.
The same trends were noted when the PK parameters were measured by the antiIIa assay
as seen in Figure 70B. At the indicated dose (100 U/kg), BMH (89±8 mins) demonstrated a
significantly (p < 0.05) longer half -life (t1/2) compared to PMH (56±4 mins) and OMH (60±7
mins). No differences in area under the curve (AUC) and volume of distribution (Vd) were noted
among all agents. All heparins (100 U/kg) exhibited AUC and Vd ranged of {140-152 (ug/ml)
*min} and {57-65 ml/kg} respectively. In addition, no differences in systemic clearance (Cl)
were noted among all heparins (Figure 70B).
In both anti-Xa and anti-IIa assays the relative concentration 15 mins after the
administration of PMH, BMH and OMH were comparable. In anti-Xa assay, Cmax of all heparins
were ranged from 1.43 U/ml to 1.49 U/ml. The same trend was noted in the antiIIa assay, where
the Cmax of all heparins were comparable and ranged from 1.34 U/ml to 1.42 U/ml. The results
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for the pharmacokinetic parameters of PMH, BMH and OMH as determined by. The anti-Xa and
anti-IIa methods are tabulated in Table 69.
In terms of LMWHs, the estimation of PK parameters calculated from plasma
concentration-time curves using the anti-Xa and anti-IIa assays after SC administration of 1
mg/kg LMWHs to non-human primates are shown in Figure 71. All PK parameters of all
LMWHs were comparable with no significant differences as measured by the anti-Xa (Figure
71A) and anti-IIa (Figure 71B). PK parameters ranges of all LMWHs as determined by the antiXa were t1/2 {3.8-4.1 hrs}, AUC {71-77 (ug/ml) *hr}, Vd {78-84 ml/kg} and Cl {18.5-21
ml/kg/hr} (Figure 71A). Additionally, PK parameters ranges of all LMWHs as determined by
the anti-IIa were t1/2 {1.7-1.9 hrs}, AUC {21-23 (ug/ml) *hr}, Vd {118-121 ml/kg} and Cl {5760 ml/kg/hr} (Figure 71B). The results for the pharmacokinetic parameters of P. LMWH, B.
LMWH and O. LMWH as determined by the anti-Xa and anti-IIa methods are tabulated in Table
70.
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Figure 69. Estimation of pharmacokinetic (PK) parameters calculated from plasma concentration-time curves using the anti-Xa (A) and anti-IIa
(B) assays after IV administration of 0.5 mg/kg of various heparins to non-human primates. Significance was set at (*p ≤ 0.05). PMH; porcine
mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, IV; intravenously. The results represent the mean ± SD (n=4).
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Figure 70. Estimation of pharmacokinetic (PK) parameters calculated from plasma concentration-time curves using the anti-Xa (A) and anti-IIa
(B) assays after IV administration of 100 U/kg of various heparins to non-human primates. Significance was set at (*p ≤ 0.05). PMH; porcine
mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, IV; intravenously. The results represent the mean ± SD (n=4).
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Figure 71. Estimation of pharmacokinetic (PK) parameters calculated from plasma concentration-time curves using the anti-Xa (A) and anti-IIa
(B) assays after SC administration of 1 mg/kg of various LMWHs to non-human primates. Significance was set at (*p ≤ 0.05). P. LMWH; porcine
low molecular weight heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH; ovine low molecular weight heparin, SC;
subcutaneously. The results represent the mean ± SD (n=4).

200

201
Absolute quantification and PK parameters (Heparin Red Kits®). The absolute
amount of heparin in primate plasma samples were measured using Heparin Red kit (a
fluorescence assay) according to the manufacturer instructions (Figures 72 and Table 71). All
gravimetric-based heparin dosages (0.5 mg/kg) show comparable GAG contents at all time
points, with a maximal content of a range (7.5- 7.85 ug/ml) at 15 mins time point as shown in
Figure 72A. At the potency-adjusted heparin dosages (100 U/kg), PMH and OMH exhibited
comparable GAG contents at all time points with a maximal GAG contents of a range (7.6-7.8
ug/ml) at 15 min time point as shown in Figure 72B. However, BMH showed higher GAG
contents compared to others which was significantly (p < 0.05) higher at 15 mins (9.7±1.2) and
30 mins (6.5±0.57) time points. On the other hand, all LMWHs showed comparable GAG
contents profile at all time points with a maximal GAG contents of a range (5.3-5.6 ug/ml) at 2
hours after drug administration (Figure 72C).
The absolute PK parameters were determined using data derived from the Heparin Red
method after IV administration of 0.5 mg/kg heparins to non-human primates (Table 72). At the
indicated dose, PMH, PMH and OMH produced comparable half -life (t1/2) which ranged from
39 mins to 44 mins as noted in Table 72. No significant differences in AUC, Vd and Cl were
noted among all agents with a range of {AUC = 458-504 (ug/ml) *min}, {Vd = 62-64 ml/kg}
and {Cl = 1-1.1 (ml/kg/min)} respectively.
At the potency-adjusted heparin dosages (100 U/kg), BMH demonstrated a significantly
(p < 0.05) higher AUC {624±13 (ug/ml) *min} and slower Cl {1.6±0.19 (ml/kg/min)} compared
to PMH and OMH as noted in Table 72. Furthermore, no significant differences in t1/2 and Vd
were noted among all agents and ranged of {41-48 mins} and {121-132 (ug/ml) *min}
respectively.
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In terms of LMWHs (1 mg/kg), all agents showed comparable PK parameters as noted in
Table 72. PK parameters ranges of all LMWHs were t1/2 {2.1-2.2 hrs}, AUC {2325 (ug/ml)
*hr}, Vd {131-133 ml/kg} and Cl {41-43 ml/kg/hr}.

Figure 72. Absolute quantification of GAGs content using Heparin Red kit after IV administration of 0.5
mg/kg or 100 U/kg of various heparins and after SC administration of 1 mg/kg of various LMWHs to
non-human primates. Significance was set at (*p ≤ 0.05). GAG; glycosaminoglycan, PMH; porcine
mucosal heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, LMWH; low molecular
weight heparin, IV; intravenously, SC; subcutaneously. The results represent the mean ± SD (n=4).
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In vivo PS neutralization studies (anti-Xa and anti-IIa assays). The time courses of
the amidolytic anti-Xa and anti-IIa activities of PMH, BMH and OMH (100 U/kg & 0.5 mg/kg)
post I.V. administration of saline (control) and PS (0.5 mg/kg) are shown in Tables 73&74
respectively. Administration of potency adjusted dosages (100 U/kg) of each UFH followed by
saline I.V. injection resulted in comparable drug levels through all time points as determined by
anti-Xa and anti-IIa assays with a maximum value of 1.2±0.2 U/ml and 1.26±0.25 U/ml
respectively (Table 73 & Figure 73). However, the gravimetric dosage (0.5 mg/kg) of BMH
exhibited a significant lower drug levels at 15 and 45 mins (p <0.05) post drug administration as
determined by anti-Xa assay; 0.81± 0.09 U/ml & 0.56±0.02 U/ml respectively (Table 73 &
Figure 73). In addition, Figure 73B shows the plasma concentration-time courses for each agent
as determined by their effects on anti-IIa activity. BMH-treated primates exhibited a significant
lower drug levels at 15 and 45 mins (p <0.05) post drug administration; 0.79±0.12 U/ml &
0.58±0.09 U/ml respectively compared to the potency adjusted dosages (Table 74 & Figure 73).
PMH, BMH and OMH at various dosages showed comparable PS neutralization profiles at all
time points as determined by both assays. However, slightly higher residual levels observed in
the BMH (100 U/kg) treated primates as determined by both assays (Panels A&B on Figure 73).
Furthermore, Figure 73 shows AUC for protamine sulfate (PS) neutralization time
curves of various UFHs post I.V. injection at a dose of 0.5 (mg/kg) as determined by various
antiprotease assays. BMH at 0.5 mg/kg showed significant smaller AUC (p <0.05) of 105±7.9
(U/kg)*min post saline I.V. injection compared to others as measured by both assays. All UFHs
at 100 U/kg dosages showed comparable AUC post saline injection of a range of (150.8±14.5) –
(171±11.8) (U/kg)*min as determined by anti-Xa assay (Figure 73A) and a range of (150.5±9.9)
– (165.6±16.4) (U/kg)*min as determined by anti-IIa assay (Figure 73B). Neutralization %
(AUC reduction %) for PMH (100 U/kg), BMH (100 U/kg), OMH (100 U/kg) and BMH (0.5
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mg/kg) as determined by anti-Xa were comparable and they were 76.5±2.3 %, 73.9±4.6 %,
77.8±2.8 % and 75±3.3 % respectively (Panel A). Similar neutralization % (AUC reduction %)
were observed when heparin levels were determined using an anti-IIa assay, they were 75.8±3.1
%, 74.1±2.6 %, 77.9±1.8 % and 79±2.3 % for PMH (100 U/kg), BMH (100 U/kg), OMH (100
U/kg) and BMH (0.5 mg/kg) respectively (Panel B).
The time courses of the amidolytic anti-Xa and anti-IIa activities of various LMWHs (1
mg/kg) post I.V. administration of saline (control) and PS (0.5 mg/kg) are shown in Tables 75
&76 respectively. Administration of various LMWHs followed by saline I.V. injection (Control)
resulted in comparable drug levels through all time points as determined by anti-Xa and anti-IIa
assays with a maximum value of 1.31±0.19 U/ml and 0.32±0.01 U/ml respectively (Table 75 &
Figure 74). All LMWHs were partially neutralized by PS by the same degree as determined by
both assays (Figure 74). 15 minutes post PS administration, plasma concentration of all LMWHs
were comparable and ranged from 0.91±0.14 U/ml to 0.97±0.13 U/ml and from 0.14±0.03 U/ml
to 0.16±0.02 U/ml as determined by anti-Xa (Panel A) and Anti-IIa (Panel B) assays
respectively. The same trend was observed at all time points (Figure 74 & Table 76).
AUC for protamine sulfate (PS) neutralization time curves of various LMWHs post I.V.
injection at a dosage of 0.5 (mg/kg) as determined by various antiprotease assays is shown in
Figure 74. All LMWHs at 1 mg/kg dosages showed comparable AUC post saline injection of a
range of (149.5±5.8) – (153.5± 7.1) U/kg*min as determined by anti-Xa assay and a range of
(34.3± 2.3) – (35.6± 4.9) U/kg*min as determined by anti-IIa assay. All LMWHs at 1 mg/kg
dosage were partially neutralized post PS I.V. injection as determined by both assays. They
showed comparable neutralization % profile (AUC reduction %) of a range of (18±2.3-20±3.8
%) and (54±3.8 - 56.9±6.8 %) as determined by anti-Xa and anti-IIa assays respectively (Figure
74).
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Figure 73. Comparative neutralization profile of various dosages of UFHs post PS I.V. injection at a dose
of 0.5 (mg/kg) as determined by various antiprotease assays in non-human primates (n=4). Anti-Xa assay
(Panel A) and Anti-IIa assay (Panel B). Significance was set at (*p ≤ 0.05). PMH; porcine mucosal
heparin, BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, LMWH; low molecular weight
heparin, IV; intravenously, PS; protamine sulfate. The results represent the mean ± SD (n=4).
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Figure 74. Comparative neutralization profile of 1 mg/kg dosages of LMWHs post PS I.V. injection at a
dose of 0.5 (mg/kg) as determined by various antiprotease assays in non-human primates (n=4). Anti-Xa
assay (Panel A) and Anti-IIa assay (Panel B). Significance was set at (*p ≤ 0.05). P. LMWH; porcine low
molecular weight heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH; ovine low
molecular weight heparin, IV; intravenously, PS; protamine sulfate, N%; neutralization %. The results
represent the mean ± SD (n=4).

In vivo PS neutralization studies (Heparin Red Kits®). The absolute GAG contents of
PMH, BMH and OMH (100 U/kg & 0.5 mg/kg) post I.V. administration of saline (control) and
PS (0.5 mg/kg) are shown in Tables 77&78 respectively. Administration of potency adjusted
dosages (100 U/kg) of PMH and OMH followed by saline I.V. injection resulted in comparable
drug levels through all time points with a maximum value of 8.22±0.9 ug/ml and 7.76±0.9 ug/ml
respectively. However, BMH at
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100 U/kg showed slightly higher maximal concentration of 8.8±0.9 ug/ml compared to other
agents (Table 77 & Figure 75A). All heparins at various dosages showed comparable PS
neutralization profiles at all time points as determined by the Heparin red method. However,
slightly higher residual levels observed in the BMH (100 U/kg) treated primates. 15 mins post
PS administration, all heparins showed comparable drug concentrations ranged from 1.24±0.9 to
1.43±0.7 ug/ml while BMH (100 U/mg) showed slightly higher drug concentrations of 1.69±0.3
ug/ml at the time point (Table 77 & Figure 75A).
Neutralization % (AUC reduction %) for PMH (100 U/kg), BMH (100 U/kg), OMH (100
U/kg) and BMH (0.5 mg/kg) were 77.1±2.3 %, 71.9±3.6 %, 77.8±3.8 % and 79±3.3 %
respectively as shown in Figure 75A.
The absolute GAG contents of various LMWHs (1 mg/kg) post I.V. administration of
saline (control) and PS (0.5 mg/kg) are shown in Tables 79&80 respectively. All LMWHs were
partially neutralized by PS by the same degree as determined by Heparin
Red method (Figure 75B). 15 minutes post PS administration, plasma concentration of all
LMWHs were comparable and ranged from 3.32±0.93 ug/ml to 3.45±0.83 ug/ml and the same
trend was observed at all time points (Figure 75B & Table 80). Nevertheless, P. LMWH, B.
LMWH and O. LMWH showed comparable neutralization % profile (AUC reduction %) of
40±2 %, 42±3 % and 39±2 % respectively as depicted in Figure 75B.
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Figure 75. Comparative neutralization profile of various dosages of heparins (Panel A) and LMWHs
(Panel B) post PS I.V. injection at a dose of 0.5 (mg/kg) as determined by various antiprotease assays in
non-human primates (n=4). Significance was set at (*p ≤ 0.05). PMH; porcine mucosal heparin, BMH;
bovine mucosal heparin, OMH; ovine mucosal heparin, P. LMWH; porcine low molecular weight
heparins, B. LMWH; bovine low molecular weight heparin, O. LMWH; ovine low molecular weight
heparin, IV; intravenously, PS; protamine sulfate, N%; neutralization %. The results represent the mean ±
SD (n=4).

CHAPTER FIVE
DISCUSSION
Heparin was first discovered by Jay McLean while working in William Henry Howell
laboratory in 1916.290 Heparin is a complex pharmaceutical agent, that has been used
clinically since the early part of the 20th century in the prevention and initial treatment of
thrombosis.290 Heparin is second only to insulin as a natural therapeutic agent used in many
indications including, but not limited to, kidney dialysis, surgery, cardiac-invasive
procedures, treatment of heart attack, cardiac arrhythmia, acute coronary syndrome,
pulmonary embolism, stroke, and deep-vein thrombosis, prevention of blood clotting, and
anticoagulant coating of devices.290 Recently, heparin has been used as an anticoagulant agent
to treat patients with the SARS-Cov-2 virus that causes COVID-19 to control blood clot
formation which clogs blood vessels preventing blood oxygenation.291
Heparin is a linear, highly sulfated polysaccharide consisting of alternating
glucosamine and uronic acid monosaccharide residues. Heparin does not possess a defined
single structure or organized template like proteins or nucleic acids. Rather it is a complex
material composed of random sequences of various saccharide chains with various lengths
and various degrees of sulfation with an average molecular weight ranging between 1.5 to
30 kDa.292
The FDA approved the original New Drug Application (NDA) for heparin drug product
in 1939 and this heparin was sourced from cows (bovine lung).33 In the 1940s, additional
heparins were approved by the FDA, but these heparins were sourced from porcine intestinal
mucosa (PMH). There have been about 60 years of safe and effective use of bovine lung
heparin in patients in the US.33 However, because of the spread of bovine spongiform
209
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encephalopathy (BSE or “Mad Cow” disease) in Europe in 1990s concerns were raised on the
possible introduction of transmissible spongiform encephalopathy agents into bovine lung
heparin. Although there has not been a documented or suggestive transmission of BSE to
humans from a medical product of bovine origin, this led to the removal of bovine lung
heparin from the US market in the late 1990s with replacement by porcine mucosal heparin
(PMH).33
In 2008, some samples of porcine heparin were found to be contaminated with oversulfated chondroitin sulfate (OSCS) resulting in the deaths of many patients throughout the
world. Since then, FDA has worked diligently and continuously to provide additional
analytical assessments of heparin to further safeguard heparin drug products and related
heparin supply chains.33 Currently, the FDA and other regulatory agencies are interested in
alternative sources to porcine heparin to diversify and enable a proactive approach to address
possible shortages or contamination of the global porcine heparin supply.
It is well known that bovine mucosal heparin or BMH exhibits weaker anticoagulant
activity (110-130 U/mg) compared to heparin obtained from porcine origin (180-190 U/mg).
In the last decade, many approaches have been used in the scientific community to produce
BMH with comparable anticoagulant activity to the PMH counterparts. One of these
approaches was the enzymatic modification of animal-sourced heparins. It is well known that
heparin contains a pentasaccharide sequence that allows it to interact with antithrombin III
(AT) and inhibit blood coagulation proteases, such as factor IIa (thrombin) and factor Xa.
Linhardt group has already done some enzymatic modification of BMH in order to increase
its anticoagulant activity to be comparable with the PMH.293 The anticoagulant activity of
BMH has been increased through increasing the level of sulfation at specific areas within the
AT binding sites using 3-O sulfotransferase enzymes. This approach had few limitations such
as the resulting heparin had a very high level of sulfation that may enhance binding to PF4
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and thus might increase the incidence of the HIT side effect.293 In addition, the enzymatic
modifications of BMH significantly increased the cost of the product. So, more chemoenzymatic modification studies are required to enhance BMH USP activity without
enhancing the risk of HIT (PF4 binding) and also to produce a cost-effective product.293
It is well known that heparin is a heterogeneous and polydisperse polymer.292 Its
purification processes play a very important role in determining the molecular weight range
and the ionic property which can result in preparations with improved anticoagulant
potencies. A previous study has shown that, it is possible to separate and purify BMH via ionexchange chromatography using a specific column in order to improve its anticoagulant
activity to be comparable to PMH.294 This approach is very promising; however, it is not
cost-effective. More studies are needed in order to improve the anticoagulant activity of
BMH using specific fractionation columns without increasing the cost of the product.
Furthermore, bioengineered/synthetic heparins approaches were used to avoid animalsourced heparins in order to prevent any animal-contamination and to secure the heparin
supply. Although, modern biotechnological methods are available to bring more advanced
manufacturing processes for heparins, there are no bioengineered anticoagulant products in
the market that are cost effective and readily reversible. Additional studies should be
conducted in order to overcome these limitations.45
Additional mammalian sources such as sheep (ovine) mucosal tissue have also been used
to manufacture heparin. 153,295 The ovine heparin exhibits comparable structural and
functional properties to porcine heparin.295 The ovine heparins also mediate their
anticoagulant effects primarily via thier interactions with AT. Because of the substantial
availability of ovine mucosal tissue, there is strong interest developing ovine heparin for
clinical purposes.
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The LMWHs (depolymerized versions of UFHs) are manufactured by fractionation,
enzymatic, chemical and physical depolymerization of UFHs. Enoxaparin represents the most
commonly used LMWHs for broad clinical indications. This LMWH was initially derived
from porcine mucosal tissues, however, similar LMWHs can also be manufactured by using
bovine and ovine heparins.296,297 The enoxaparins produced from bovine, ovine and porcine
UFHs have been shown to exhibit comparable structural and functional profiles.296,297
NMR and other analytical approaches utilizing heparin digesting enzymes have provided
unique approaches to characterize both UFHs and LMWHs. The role of AT rich chains in
bovine and porcine UFHs has been reported in terms of the prevalence of these
oligosaccharides consensus chains.54 Additional structural comparisons using NMR and chain
mapping have also been reported by several groups for the UFHs and LMWHs.295,298 Only
limited data on the biological activities on heparins of diverse origins is available.
The UFHs of different origins are conventionally standardized in terms of either USP
referenced or EP referenced potencies. These standards are provided by pharmacopeial
organizations and have gone through periodic revisions and refinements. The Argentinean
and Brazilian regulatory agencies have also introduced bovine mucosal heparin standards to
cross references BMH obtained from bovine mucosal origin.299 The USP has also considered
a dedicated monograph for BMH however, this monograph is still under preparation. Current
standards primarily based on AT mediated anti-Xa and anti-IIa activities. Enoxaparins and
related LMWHs are standardized in refence to a well characterized international standard
which is provide by WHO affiliated organization (NIBSC, London, England). Additional
standards for LMWHs are also available through USP.
Cross-referencing of both the UFHs and LMWHs against common standards provides an
approach to harmonize the potency standardization of the anticoagulant effects of both UFHs
and LMWHs. Despite the MW distribution and microchemical differences, the potency
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standardized heparins are projected to produce comparable anticoagulant responses. The USP
and EP standards have been effectively used in the standardization of UFHs during the past
decade. Similarly, the NIBSC standard for LMWHs has proved useful in potency designation
for enoxaparins and other LMWHs. Regardless of species origin, the UFHs are usually
standardized against standard which have been developed from both porcine and bovine
origins. The clinical dosing of the UFHs including the PS neutralization takes into account
the anticoagulant effects which are based on their potency in terms of circulation levels as
U/ml. Similarly, the LMWHs are also administered in designated units in fixed and mass
based dosing. Thus, one of the main purposes of this dissertation was to demonstrate the
comparability of UFHs in gravimetric and potency adjusted studies.
While the data on the isolation, purification and characterization of heparins has been
extensively generated since the discovery of heparin, the studies on the mechanisms of
actions and pharmacological profiling have been rather limited. Both the UFHs and LMWHs
exhibit marked molecular and functional heterogeneity. The anticoagulant actions along with
the protease modulatory actions are primarily mediated by AT and HCII. The relative
proportion of AT binding components range from 20-30% whereas, the HCII binding chains
represent a higher proportion. The role of non-AT binding chains is not fully understood.
Therefore, additional studies on the mechanisms involved in the mediation of anticoagulant
effects are needed. Such newer tests as the prothrombinase induced clotting time (PiCT) and
thrombin generation inhibitory effects represent assays providing additional information on
the mechanisms of actions.255-257
The interaction of both the UFHs and LMWHs with endogenous proteins also plays an
important role in the overall biological responses. In particular, the interaction of PF4 with
both the UFHs and LMWHs is impotent from the standpoint of the neutralization of their
biological effects. Furthermore, the heparin/PF4 complexes also lead to the generation of
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heterogeneous antibodies some of which lead to heparin induced thrombocytopenia (HIT).
Most of the studies in such interactions have been carried out with PMH and porcine LMWH.
This dissertation represents an integrated approach where heparins from diverse origins are
compared in well-defined studies for their interaction with PF4 with refence to their
neutralization profile and antibodies generation.
Most of the pharmacokinetic (PK) studies with both the UFHs and LMWHs have been
carried out in conjunction with clinical trials utilizing indirect methods to quantify circulating
levels of these agents.300-301 Similarly, the PK studies in animal models have been reported
utilizing global anticoagulant assays and anti-Xa/IIa assays.300-301 Labeled heparins with
different detector probes have also been used to study the PK of heparins.302 More recently,
the PK of UFHs in terms of absolute levels as measured by LC-MS method has also been
reported.303 This method is based on the detection of heparin disaccharides units to quantify
the circulating levels of heparins. The absolute levels of heparins measured by this method
reflect the true concentration of heparin which is not influenced by endogenous factors such
as fluctuation in coagulation proteins and other factors which can modulate the anticoagulant
effects of these agents. Moreover, the PK/PD studies of UFHs and LMWHs have not been
reported in a comparable experimental setting. In this dissertation, all UFHs and LMWHs of
diverse origins have been studied in primates in a cross-over manner.
Dye binding assays have been used to quantify heparins in various experimental settings.
Toluidine blue and related dyes have been conventionally used to stain heparin to detect the
chromatographic separation. Toluidine blue is also used to quantify heparin and related GAG
levels in biological fluids. More recently, a highly sensitive fluorescence quenching method
was developed to quantify heparin and related GAG in biological fluids.288,289 Initially
developed for the in vitro detection and quantitation of GAG in biological fluids, additional
modified assays known as Heparin Red have become available to measure both UFHs and
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LMWHs in plasma and other biologic fluids.288,289 In the PK/PD studies reported in this
dissertation, Heparin Red-based method was used to quantitate circulating heparins in the
primate’s studies. The absolute quantification of heparin by this method along with indirect
quantitation of heparins using anti-Xa/IIa and clot-based aPTT assays represent the very first
approach to compare the absolute levels of these drugs with indirectly measured levels.
UFHs and LMWHs represent GAG with common structural features with the repeating
disaccharides units composed of D-glucosamine and uronic acid linked by 1→4
interglucosidic bonds. Species-based differences in the degree of sulfation and other minor
structural features exist among the UFHs of different origins. However, the anticoagulant
actions of these agents are mainly mediated via their interaction with AT. On the other hand,
depolymerization processes cause process-based structural changes in the LMWHs. In the
case of enoxaparins, these molecular signatures include generation of double bond in the
terminal sugar and the formation of anhydromano groups.
The structure of both the UFHs and LMWHs is extensively studied using biophysical
methods including NMR and mass spectroscopy.153,241 Enoxaparins prepared by using
heparins of different origins have been usually standardized in pharmacopeial assays. Species
specific microchemical differences in enoxaparins do not influence their antiprotease and
anticoagulant effects. Thus, the standardization and cross-referencing of both the UFHs and
respective enoxaparins in reference to pharmacopeial standards may result in comparable
pharmacological effects in reference to their anticoagulant and thrombotic actions. Therefore,
this dissertation seeks to provide supportive data that valid cross-referencing of these against
a defined standard may result in biosimilar products with predictable anticoagulant actions.
In this dissertation, comparative studies on bovine, ovine and porcine heparins and their
depolymerized products were carried out to demonstrate the biochemical, biophysical and
pharmacological activities of these agents in validated in vitro assays and the PK/PD
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behaviors were investigated in a primate model. The primary purpose of this investigation
was to test the hypothesis that “Despite molecular components distribution and minor
structural differences, potency referenced heparins of different animal origins and their
depolymerized derivatives may exhibit similar pharmacological activities”. Although, the
comparative integrated studies on these agents have been carried out to establish the
sameness of these agents, observed differences in the agents have also been compiled in
various sections and discussed in the light of other reported data. Thus, the integrated
discussion below aims to approach each section in an objective fashion in support of the
primary hypothesis of this study that cross-referencing of heparins with a known standard
may harmonize their dosing and potentially interchanging these drugs for specific indications.
Physicochemical Characterization of Various UFHs and LMWHs
Gel permeation chromatography (GPC). As UFHs and LMWHs are heterogeneous
in nature, their average molecular weights can be determined by using GPC or size exclusion
chromatography (SEC). SEC separates the components of the different heparins based on
MW, while offering the advantages of minimal sample preparation and a rapid turnaround
time.149
In this dissertation, in order to obtain MW profiling of these agents, data from the size
exclusion profile of each agent was used in conjunction with a wide range of NRC calibrators
consisting of 13 well defined calibrators ranging from 2.1- 51 kDa.149 These narrow range
calibrators were obtained from preparative chromatographic methods and their MW were
established using biophysical methods. The MW profiles were determined utilizing the UV
and RI detectors in a single study. The MW characteristics were obtained using a third order
polynomial equation. The data was compiled in terms of various parameters, however for
comparative purposes, the mean of the average molecular weight (Mw) was used.
Distribution profile of each of these agents in various ranges of the MW were also compiled.
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Molecular weight (MW) profiles. The Mw value of BMH (21634±654 Da) was
slightly higher compared to PMH (17311±604 Da) and OMH (18911±580 Da) as determined
by the UV detector. The same trends were noted by the RI detector. The polydispersity index,
which is a measure of heterogeneity, was slightly higher for OMH (1.35±0.07) than for other
agents as determined by the UV detector and the same results were obtained by the RI
detector. BMH showed slightly higher proportion of longer chains in (> 12 kDa) range in
both the UV and RI methods. The MW distribution profile showed variable distribution
patterns in the lower ranges. However, when the chain distribution (< 7.5 kDa) the OMH
showed a much higher prevalence of these components (19-26%) as measured by both the
UV and RI methods in comparison to PMH and BMH (< 10%). Thus, the distribution profiles
represented origin-based patterns. The distribution profiles of the chain components of each
heparin may be useful in product characterization.
Despite the differences in the distribution profile of the components, overall, these
studies demonstrated a comparable average molecular profile of OMH and PMH in
comparison to BMH with slightly higher MW. The other MW distribution parameters were
also comparable for OMH and PMH with some variations noted in the BMH, in particular the
polydispersity index.
In regard to LMWHs, all agents showed comparable MW profile in terms of Mw and
Mn as determined by both detectors (UV and RI). The polydispersity index (PDI) values of
all LMWHs were very close and were lower compared to the UFHs indicating that LMWHs
are more homogenous mixtures compared to the UFHs. These results were consistent to
previously published studies.
It is interesting to note that, the MW profiles obtained using the UV detector resulted
in slightly lower values in comparison to the RI detector for the UFHs. In the case of
LMWHs, the UV obtained MW values proportionally lower than those obtained by the RI
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detector. This difference may be due to the compositional differences in these heparins, in
particular the LMWHs where a double bond is generated due to the manufacturing process.
The pharmacopeial methods recommend the use of UV detector for MW profiling of
LMWHs. The current referenced standard for LMWHs is based on a heparinase digested
products which generates double bonds in the oligosaccharides components which can be
used as calibrators. In the studies reported in this dissertation, the MW profiling of both the
UFHs and LMWHs was carried out in reference to narrow range calibrators (NRC). These
calibrators represented well characterized fractions of heparin in the range of 2-50 kDa. The
results obtained from the EP method for enoxaparins were comparable to those obtained in
the UV detector studies on LMWHs.
Heparinases digestion and benzylation followed by alkaline hydrolysis mediated
cleavage of UFHs results in the generation of double bonds. 103,104 The EP method for the
MW profiling of LMWHs utilizes this characteristic of double bond containing
oligosaccharides for the cross-referencing of the MW of these agents.238 This approach is
only valid for the cross-refencing of the LMWHs and is not valid for UFHs. For this reason,
the studies included in this dissertation are mainly based on the NRC calibration approach.
Heparinase-I degradation. Heparinase-I is one of the most extensively studied
glycosaminoglycan lyases. Enzymatic degradation of heparins by heparin lyases not only
largely facilitates heparin structural analysis but also can be used to produce low-molecularweight heparin (LMWH). Heparinase-I specifically cleaves heparins between the 2-sulfoiduronate and 2,6-disulfo- glucosamine residues.304
Overall, heparinase-I was clearly capable of depolymerizing the various heparins and
LMWHs as evident by the shift to the right of each peak and subsequent decrease in mean
molecular weight for all agents. The same observations were noted in terms of MW
distributions; post HP-I digestion, a decrease in higher molecular weight chains and an
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increase in lower molecular weight chains of all agents. Additionally, the similar postdigested mean molecular weights (ranging from 3 to 3.3 kDa) for UFHs and for LMWHs
(ranging from 2.2 to 2.4 kDa) demonstrates a similar degree of heparinase-I digestion.
Moreover, the heparinase digestion indices for all heparins were comparable. Therefore, each
of the three UFH’s were digested by heparinase-I in a similar fashion, suggesting a
comparable amount of 2-sulfo-iduronate 2,6-disulfoglucosamine linkages in the various
heparins. In addition, all LMWHs showed similar heparinase digestion indices which is an
indicative of comparable amount of 2-sulfo-iduronate 2,6-disulfoglucosamine linkages in all
LMWHs.
The HP-I digestion profile of the UFHs and LMWHs were comparable in both UV
and RI detector-based elution profile. The relative digestion of heparins is dependent on the
concentration of HP-I used, in these studies, the HP-I was constant at 1 U/ml. At this
concentration, HP-I produced strong depolymerization of all agents, it resulted in a
significant reduction in the MW of the UFHs (80-82%), similarly, the LMWHs were digested
in a comparable fashion (50-55%).
The oligosaccharides chains resulting from UFHs digestion represented slightly
higher MW distribution (3.1-3.4 kDa) in comparison to LMWHs with lower MW distribution
(2.0-2.2 kDa). This data suggests that, the depolymerization of UFHs resulted in the
generation of oligosaccharides chains comprised of 4-10 hexose units, whereas the LMWHs
digestion was comprised of tetra and hexa saccharides. The digestion profile was comparable
for the bovine, ovine and porcine UFHs/LMWHs.
The relative digestion of UFHs was greater than 80% whereas, LMWHs showed a
50% digestion of the chains. These differences are apparently due to MW of these agents,
where the UFHs showed comparably 3-4 times higher MW than LMWHs. These results
clearly suggest that, regardless of origin the heparins represent an indistinguishable substrate

220
for HP-I. Moreover, this enzyme can also be used to prepare depolymerized heparin of
desirable MW. A LMWH known as tinzaparin is prepared by the digestion of porcine
mucosal heparin.305 It is likely that biosimilar versions of tinzaparin can also be derived by
using bovine and ovine UFHs.
Nuclear magnetic resonance (NMR) analysis. Nearly 100 tons of heparin is
annually produced worldwide primarily from porcine intestinal mucosa (PMH).306 Sizable
amounts of bovine intestinal mucosa and ovine intestinal mucosa heparins are also prepared
but are not approved for clinical use in most countries. These heparins, sourced from bovine
and ovine tissues, exhibit specific MW and structural characteristics which are not easily
distinguishable by molecular profiling and other physiochemical methods.54,307,308 NMR
provide an extremely useful tool to investigate the structural characteristic of UFHs and
related GAGs. NMR is also capable of identifying structural alterations happened during the
manufacture of heparins. This technology is now routinely used for the quality assurance of
both the UFHs and LMWHs.
In this dissertation, one-dimensional 1H NMR and 13C NMR analysis was carried out
to compare the structural characteristics of UFHs and LMWHs of different origins. Although,
there is reported structural variation in the AT-binding pentasaccharide sequences,307,308 all
heparins have unique, well-conserved residues, such as a central 3-O-sulfoglucosamine,
critical for the biological activities mediated by the inhibition of serine proteases such as
factor Xa and thrombin.309 During the biosynthesis of heparins, some unsubstituted AT
precursor sites remain in heparin due to incomplete action of the 3-O-sulfotransferase
enzyme.309 For this reason, 60-70% of the oligosaccharides chains don’t exhibit affinity to
AT.
Previous studies have shown that, in the anomeric region of the 1H NMR spectra, the
signals of 3-O-sulfo-N-acetylglucosamine and 3-O-sulfo-N-sulfoglucosamine residues are
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useful for distinguishing heparins derived from different spices.153,241 Additionally, the
relative amounts of iduronic acid and glucuronic acid residues are partially based on the
origin of heparin. 153,241 Moreover, differences in sulfation at several specific positions
(position 6 of glucosamine residues, position 3 of glucosamine, and position 2 of the iduronic
acid) were found among PMH, OMH and BMH.153,241 NMR has provided detailed
information on these structural differences and therefore offers a useful approach for the
detailed structural analysis of heparins.
Overall, the 1H NMR spectra of PMH, OMH and BMH appeared mostly comparable,
however some structural differences were noted, and which were consistent with previously
published studies.153,241 For the most part, OMH was structurally similar to PMH in contrast
to BMH which exhibited certain species-specific molecular signatures. Furthermore, PMH
was found to contain considerably more N-acetylated glucosamine residues than either OMH
or BMH as determined by the relative intensity of the peak at δ 1.96 in the 1H NMR spectra.
The spectral profiling of various peaks for the BMH, OMH and PMH was compared
in terms of specific sugar residue assignments categorized as peaks A-S. The peak D
(IdoA2S) was slightly higher and peak S (GlcNAc) was slightly lower for OMH compared to
others and no unidentified peak was observed. However, in BMH, there was one additional
peak between peak C (GlcNY6S) and peak D (IdoA2S) and one peak next to peak F (IdoA)
which were not present in PMH and OMH. In addition, peaks intensity from peak I to peak P
were significantly different compared to those in PMH and OMH. Peak S intensity was also
higher than that in OMH. However, this univariate spectrum evaluation does not provide
enough information for the unambiguous characterization of heparin’s species of origin.
In a previous study, the correlation of NMR spectra of heparin showed that PMH and
OMH were similar in their structural profile.153,241 In general, the 1H-NMR spectra of PMH
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and OMH were almost identical and both can meet USP specification for heparin, which have
been published in the pharmacopeia forum.
The 13C NMR spectra for PMH and OMH were almost identical. However, the level
of 6-O-sulfation of the glucosamine residues of OMH was slightly higher. A lower degree of
acetylation was found in OMH in comparison to PMH and BMH. The 13C-NMR spectrum of
BMH was significantly different from that of PMH and OMH, especially in the region
between 50 to 100 ppm. Peak D and peak E represent glucosamine 6-O-sulfation and
glucosamine 6-OH, respectively. BMH had a lower degree of 6-O sulfation compared to
PMH and OMH as evidenced by the higher intensity of peak E.
In contrast to UFHs, the structural differences in the 1H NMR analysis of LMWHs
were relatively minimal. In particular, 1H-NMR spectra showed that B. LMWH, GlcNAc
content was slightly higher compared to P. LMWH and O. LMWH. In addition, no
unidentified peak was observed in ovine LMWH compared to porcine LMWH. Moreover, the
proton NMR spectrum of bovine LMWH was slightly different compared to the ovine and
porcine ones (the region between 3 to 5 ppm) as shown in Figure 22. This data was consistent
with previously published studies.296,310 Overall, despite comparable profiles microstructural
differences were noted in proton NMR analysis which were more prominent in B. LMWH.
The same observations were noted in the 13C NMR spectra of all LMWHs, where the
13

C NMR spectra of the ovine and porcine LMWHs were comparable. In contrast, the 13C

NMR spectrum of bovine LMWH was slightly different (the region between 50 to 100 ppm)
as shown in Figure 23. Furthermore, the bovine LMWH 13C spectrum had a clear peak for
GlcNY at 59.71 ppm that was not present in porcine and ovine LMWHs spectra. These
observations were also consistent with the previously published studies. 296,310
The NMR analysis also provided a tool to analyze major saccharide components of all
heparins included in these studies. BMH heparin exhibited lower GlcNX3S6X (2.6%)
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compared to PMH (7.5%) and OMH (6.8%) agents. All LMWHs showed comparable NAcetylglucosamine 6-sulfate which is an essential component of the pentasaccharide binding
sequence for the interaction with antithrombin.309 In addition, PMH and OMH had
comparable 3S%. The 3S% for PMH and BMH were 9.9% and 11.8% respectively. On the
other hand, BMH showed lower 3S% (6.3%) compared to other UFHs, which may contribute
to its lower anticoagulant activity.309 Whereas, all LMWHs exhibited comparable 3S% as
follows; P. LMWH (27.5%), B. LMWH (22.3%) and O. LMWH (24.4%) which may explain
the similar anticoagulant activities of LMWHs from different animal sources.296,310 These
observation suggests that the 3S% profiles of UFHs distinguishes BMH from PMH and OMH
such differences are not noted in depolymerized counterparts of UFHs.
In addition to the structural characteristics of the heparin, the NMR analysis (1H and
13

C) of these agents did not reveal the presence of any impurities including the solvent and

other reagents used in the production of these agents. The NMR analysis also did not provide
any evidence of oversulfated chondroitin sulfate (OSCS) and other heparinoids such as
dermatan sulfate and heparan sulfate. The results on the structural characteristics of these
agents included in this dissertation are consistent to other reported studies. 296,310
The studies reported in this dissertation were carried out on randomly selected batches
of UFHs and LMWHs of various origins. Although not included in this dissertation, the
structural analysis of UFHs consistently shown comparable results indication the batch
consistency and the uniformity of manufacturing processes of both of these groups of
anticoagulants studies. UFHs were found to be free of the carryover GAGs including heparan
sulfate, dermatan sulfate and chondroitin sulfate. The absolute GAG levels as measured by
fluorescence quenching methods were also comparable at the gravimetric level for both
UFHs and LMWHs. However, USP adjusted BMH exhibited proportionally higher GAG
value in comparison to PMH and OMH. This is suggestive of the AT binding consensus
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sequence density in the component chains of BMH. Interestingly, this difference was not
noted in the enoxaparin derived from bovine UFH. The manufacturing process of
enoxaparins involves benzylation followed by alkaline hydrolysis of the high MW chains
constituting UFHs. It is conceivable that, during this process random molecular
rearrangement may occur resulting in products of comparable structural characteristics.
Chain mapping and structural fragment characterization analysis. In addition to
NMR characterization of heparins, complementary methods including disaccharide chain
analysis, top-down and bottom-up analysis are used to further characterize these agents. 311,312
These methods included the use of specific heparin digesting enzymes to generate defined
heparin fragments which are further characterized by physiochemical methods. Additional
analysis is carried out using mathematical modeling and other calculations to define the
composition of each UFHs and LMWHs. In the studies presented in this dissertation, detailed
structural characterization of the agents was carried out using validated chain mapping
methods.
In this investigation, disaccharide compositional analysis was performed using an
LC-MS approach following heparin lyase I, II, III treatment.312 The disaccharide
compositional analysis showed that BMH had significantly lower TriS% of 44.5% (AT
binding sequence) compared to PMH (78.0%) and OMH (81.7%). This may explain the
lower anticoagulant effect oh BMH compared to others. In addition, the overall degree of
sulfation of each agent was measured which is essential in determining the anticoagulant
activites of these agents.311 BMH exhibited a lower degree of sulfation (64.4%) compared to
PMH (90.2%) and OMH (93.2%). However, all LMWHs showed comparable degree of
sulfation; P. LMWH (93.8%), B. LMWH (87.4%) and O. LMWH (93.0%). In addition, the
degree of acetylation, which is another important factor for the anti-Xa and anti-IIa activities
of these agents, was determined and found to be consistent with previously published
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studies.311 Furthermore, in this analysis UFHs showed different degrees of acetylation ranged
from 2.7% to 8.3%.310All LMWHs exhibited comparable degree of acetylation, 3.1% (P.
LMWH), 3.9% (B. LMWH) and 3.9% (O. LMWH).
The structural information obtained using the disaccharide analysis is useful in
explain the structure-activity relationship (SAR) of UFHs and LMWHs. Previous studies
have reported the anticoagulant activities of N-deacetylated heparin and N-desulfated heparin
with those of standard heparin in an animal model.311 These observations are consistenet to
the structural attributes which determine the anticoagulant actions of these agents.311 Relative
reduction in the biological activities of heparin was noted showing that, the N-deacetylated
heparin retained 23% of the anticoagulant activity, 34% of the anti-Xa activity and 23% of
the anti-IIa activity of standard heparin. Whereas the N-desulfated heparin retained only 1.5%
of the anticoagulant activity, 0.095% of the anti-Xa activity and 0.92% of the anti-IIa activity
of the original heparin.311 These functional results underscore the importance of N-acetylation
and N-sulfation of UFHs and LMWHs and contribute to AT binding and other anticoagulant
activities.
A bottom-up analysis was performed using online hydrophilic interaction
chromatography (HILIC) FTMS to analyze the oligosaccharide fragments of heparins
generated by heparin lyase II digestion. More than 40 oligosaccharide fragments from these
agents were quantified and used to compare UFHs and LMWHs obtained from different
animal sources. Multiple quantified fragments of specific structures including 1) unsaturated
disaccharide/oligosaccharides generated from the prominent repeating units of these heparins,
2) 3-O-sulfo containing tetrasaccharides generated from their antithrombin binding sites, 3)
1,6-anhydro ring-containing oligosaccharides formed during enoxaparin manufacture, 4)
saturated uronic acid oligosaccharides originating from the non-reducing ends of some chains
and 5) oxidized linkage region oligosaccharides coming from the reducing ends of some
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chains. The fragmentation profiles may exhibit minor batch to batch variations which may be
due to the production processes. However, statistically such variations do not impact on the
final analysis. This bottom-up approach provided a robust detailed structural analysis and
quantitative information with high accuracy for both the UFHs and LMWHs.312 The bottomup disaccharide unit analysis showed that all heparins from different animal sources have
comparable oligosaccharide fragments contents after lyases digestion which was consistent
with the previously published data.312 The same observations were noted in the bottom-up
disaccharides analysis of all UFHs and LMWHs.310 The bottom-up analysis of heparins
provide a finger printing of the disaccharide units and its helpful in the manufacturing and
quality control of these agents.
The top-down analysis was performed to characterize and compare the LMWHs from
various animal sources. All LMWHs exhibited similar fragments percentages of 1)
unsaturated disaccharide/ oligosaccharides originating from the prominent repeating units, 2)
saturated uronic acid oligosaccharides coming from the non-reducing ends of some chains
and 3) 1,6-anhydroamino ring-containing oligosaccharides formed during enoxaparins
manufacture. This data suggests that, the manufacturing and quality control processes of
enoxaparins obtained from UFHs of different origins were similar and utilized standardized
depolymerization processes.
Taken together, the disaccharides and chain mapping analysis complemented with
bottom-up and top-down analysis of the structurally defined fragments provide a unique tool
to compare these agents and to assure their origin.
In Vitro Functional Studies of Various UFHs and LMWHs
Whole blood anticoagulant effects of various UFHs and LMWHs. The therapeutic
effects of UFHs and LMWHs are predominately due to their interactions with a diversity of
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plasma proteins including factor Xa and thrombin. The ability of heparins to bind to and
inhibit such serine proteases is predominately mediated by cofactors such as AT and HCII.
ACT assays are commonly used in a hospital laboratory to clinically monitor heparin,
typically in a surgical or interventional setting.243,244 Heparin prolongs the ACT time as a
function of its concentration. The anticoagulant heparin acts as an inhibitor in these assay
systems, such that a prolongation of the time to clot indicates anticoagulation strength of the
heparin. All agents were supplemented to freshly collected human whole blood then were
tested immediately by assay systems commonly used to clinically monitor heparin therapy.
Ethical board approval was obtained to allow for blood collection blood from healthy
volunteers after signing an informed consent document. The gravimetric-based OMH and
PMH heparins significantly (p ≤ 0.05) produced stronger effects prolonging the ACT
compared to BMH (ug/ml) heparin. These results are consistent with the previously reported
study.313 However, all potency adjusted UFHs (1 U/ml) exhibited comparable effects
prolonging the ACT at the range of 311-318 seconds. Potency adjustment of BMH resulted in
a comparable anticoagulant effect of this agent similar to the PMH and OMH. This suggests
that whole blood ACT can also be used for comparing and adjusting the anticoagulant
potency of UFHs. The original anticoagulant potency assignments were based on sheep
whole blood recalcification time prolongation by UFH.314 The ACT in various versions is
commonly used for the monitoring of the anticoagulant actions of UFHs and their titration by
PS.
Unlike UFHs, at equivalent gravimetric levels, all LMWHs at a final concentration of
25 ug/ml exhibited comparable effects prolonging the ACT at the range of 215-223 seconds.
This is due to the fact that, all these agents have been standardized in reference to
international standard in terms of anti-Xa U/mg. Moreover, the manufacturing process for
LMWHs are harmonized and less heterogeneous in comparison to UFHs.
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In addition, the anticoagulant activity was assessed in human whole blood using TEG,
an assay which uses whole blood to assess the complete global and kinetic response of blood
clot formation and the overall coagulation status.245-247 Anticoagulants (inhibitors of clotting
such as UFH & LMWH), have marked effects on the parameters of the clot formation
assessed by the TEG. The clotting profile was determined and was quantified by measuring
the time for clot initiation (R-time), time to standard clot firmness (K-time), maximal clot
firmness (maximum amplitude), and rate of clot formation (angle). The gravimetric- based
OMH and PMH exhibited similar effects on the TEG system in terms of all parameters.
However, BMH (ug/ml) produced a weaker anticoagulant effect in this assay system
compared to others. Adjusting the potency of all UFHs resulted in comparable anticoagulant
activity of all agents in terms of clot initiation (R-time), time to standard clot firmness (Ktime), maximal clot firmness (maximum amplitude), and rate of clot formation (angle).
On the other hand, at the equivalent gravimetric levels of 2.5 ug/ml (0.25 U/ml), all
LMWHs produced comparable anticoagulant activity as measured by various parameters.
This observation further validates that, pre-standardization of LMWHs results in products
with comparable anticoagulant activity.
Our results clearly underscore the importance of whole blood-based assays such as
ACT and TEG in comparing heparins of different origins and suggest that these methods can
be used for anticoagulant potency adjustment of these products. The inclusion of these
methods in potency adjustment along with the conventional methods may provide additional
data where the relative contribution of cellular components of blood is taken into account.
Global anticoagulant assays in human plasma-based systems. The conventional
anticoagulant activities of heparins are usually measured by activated partial thromboplastin
time (aPTT). In addition to this method, thrombin time (TT) can also be used for measuring
the anticoagulant effects of heparins. These two methods are commonly used in a hospital
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laboratory to clinically monitor therapeutic heparin.248-251 Beside these two assays, a newly
developed method known as prothrombinase induced clotting time (PiCT) was also used to
determine the anticoagulant effects which measures the effects of these heparins through
different mechanisms.255 The integrated anticoagulant profiles as measured by these 3
methods provided a broad screening of the global anticoagulant effects of UFHs and
LMWHs.
The aPTT method was used to assesses the intrinsic and common pathways of the
coagulation systems.252,253 In the aPTT assay, the anticoagulant effects of the gravimetricbased OMH and PMH heparins were comparable and both exhibited significant stronger
anticoagulant effects in comparison to BMH. At concentrations above 10 ug/ml all UFHs
produced maximal anticoagulant effects which were indistinguishable. The concentrations of
heparin needed to double the aPTT from the baseline values for OMH (1.21 ug/ml) and PMH
(1.25 ug/ml) were lower compared to the BMH (1.9 ug/ml). These results are consistent with
the previously reported study.313 In contrast, all potency adjusted-based heparins exhibited
comparable anticoagulant effects at all concentrations points which were consistent with the
whole blood-based anticoagulants studies. The LMWHs produced relatively weaker
anticoagulant effects in comparison to UFHs. No differences were noted in the anticoagulant
effects of these agents between the bovine, ovine and porcine enoxaparins. These results
clearly suggest that, pharmacopeial adjusted heparins exhibit comparable anticoagulant
activities in these aPTT assay.
Thrombin time (TT) assay was used to measure the conversion of fibrinogen to fibrin
following the addition of a known amount of thrombin into plasma.254 In the current studies,
thrombin was supplemented with calcium chloride to lower the sensitivity of the assay
allowing for strong antithrombin drugs to produce a measurable effect. The gravimetric-based
solutions of OMH and PMH showed comparable anticoagulant effect and both exhibited
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significant clotting time prolongation at the 1.25 ug/ml concentration, while BMH exhibited
significantly weaker anticoagulant effects at this concentration in comparison to PMH and
OMH. All agents produced maximal responses at concentration of > 2.5 ug/ml. When the
UFHs were compared in USP adjusted solutions produced a comparable anticoagulant
response. The anticoagulant effects of LMWHs were weaker in comparison to the UFHs,
however all of these agents produced comparable anticoagulant effects. These results are
consistent with the previously reported study.313 Potency adjustment of these agents resulted
in comparable anticoagulant effect.
Beside the aPTT and TT clotting-based methods, one stage PiCT assay was utilized to
compare the anticoagulant activity of these agents employing a mechanical clot-base method
(STart 4 Hemostasis Analyzer).255 This method is a prothrombinase based test which relies
upon the use of an enzyme isolated from the venom of the Russell viper (Daboia russelli) to
activate Factor V and has been developed to monitor the anticoagulants of heparins,
LMWHs, the direct thrombin and Xa inhibitors.255 The activation of the coagulation system
in this test involves different sites in the coagulation cascade in comparison to the aPTT test.
Unlike the previous clotting-based methods, all gravimetric-based heparins as well as
potency-based heparins produced comparable anticoagulant effects in a concentration range
of 0-10 ug/ml. At 10 ug/ml, the maximal response was comparable
in all UFHs and ranged from 269-280 seconds. Potency adjusted UFHs also produced
comparable anticoagulants effects in the concentration range and results were almost
superimposable. At 1 U/ml, these agents produced similar anticoagulant effects which ranged
from 245 to 254 seconds. It is interesting to note that unlike the aPTT assay in the PiCT test,
the mass adjusted and USP potency adjusted UFHs produced similar anticoagulant effects.
BMH was comparable with both the OMH and PMH responses.
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The relative proportion of protease generated in this assay is different in compassion to the
aPTT assay which utilizes the contact activation. The anticoagulant responses measured in
the PiCT assay were slightly weaker in comparison to the aPTT assay.
All LMWHs exhibited relatively weaker anticoagulant response in comparison to
UFHs in this assay (*p ≤ 0.05). The anticoagulant responses were concentration dependent
and were comparable for all agents producing similar anticoagulant effects at 10 ug/ml which
ranged from 175 to 184 seconds. Interestingly, the anticoagulant response measured in this
assay was stronger in comparison to the aPTT assay. This data suggests that, chain
composition and MW of heparins may contribute to the inhibition of thrombogenesis in this
assay.
Thrombin generation assay (TGA) provides a global test for the measurement of
endogenous processes leading to the formation of thrombin. This assay represents a
cumulative response to activators resulting in the generation of various proteases and their
modulations by activators and inhibitors.256,257 Endogenous factors including clotting
proteins, inhibitors such as AT and TFPI along with other protein modulators contribute to
thrombin generation which is measured utilizing kinetic analysis. This assay also provides
additional information on endogenous thrombin generation potential which is a reflection of
the overall protease activation network leading to the formation of thrombin. The kinetic
profile can be analyzed by various methods and in this dissertation the software utilized
provided such values as peak thrombin, AUC representing total amount of thrombin
generated and the time taking to generate thrombin in terms of lag time. TGA is a relatively
sensitive method in contrast to the global anticoagulant assays such as aPTT and PiCT. The
comparative thrombin generation inhibitory profiles of these agents were investigated in
normal plasma samples at various concentrations ranges at 0-10 ug/ml and 0-1 U/ml.
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All UFHs produced a concentration-dependent inhibition of peak thrombin when
compared in a mass/ml concentration. The BMH produced slightly higher values of thrombin
indicating weaker inhibitory effects. When these agents were compared at USP potency
adjusted levels, all agents produced superimposable inhibitory effects. In contrast to UFHs,
all LMWHs produced relatively weaker inhibition of peak thrombin values reaching a
maximum thrombin inhibition at 10 ug/ml. No differences were observed among various
LMWHs. The AUC profiles of the mass adjusted heparins showed a concentration-dependent
inhibition of total thrombin generated, OMH and PMH produced comparable responses
whereas, at concentration of grater that 2.5 ug/ml BMH showed weaker inhibition. This
weaker effect was not observed when potency-based heparins (U/ml) were used. In regard to
AUC, all gravimetric-based heparins (ug/ml) produced concentration-dependent decreases in
the AUC, with BMH exhibiting the weakest effect at 5 ug/ml concentration. In terms of lag
time, all gravimetric-based heparins (ug/ml) produced a concentration-dependent increases in
the lag time values. BMH (ug/ml) produced significantly (*p ≤ 0.05) weaker prolongation of
the lag time at its highest concentration (10 ug/ml), whereas OMH and PMH produced more
pronounced effects on lag time. This weaker effect of BMH (ug/ml) was not observed when
potency adjusted-based heparins (U/ml) were tested. The LMWHs showed a relativity weaker
inhibitory response of various parameters as compared to UFHs. Bovine, ovine and porcine
LMWHs exhibited similar TGA profiles in terms of peak thrombin, AUC and the lag time. In
contrast to the clot-based anticoagulant assays where differences were noted between massbased solutions of BMH, PMH and OMH, the TGA assay did not reveal any significant
differences among these agents. This data suggests that, the TGA may be sensitive to non-AT
mediated effects of the chain components in UFHs. A previous report has compared the
effects of various anticoagulants on the thrombin generation assay.315 These thrombin
generation parameters were product specific and did not relate to their anti-Xa activities.
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Antiprotease assays in human plasma-based systems. Beside the clot-based assays,
the antiprotease assays provide additional data on the mechanism of action of heparins. Both
the anti-Xa and IIa assays are amidolytic methods that use factor Xa or IIa specific substrates
with a measurable chromophore. Both factor Xa and IIa cleave the respective chromogenic
substrate, releasing a para-nitro aniline (PNA) which is detectable by both kinetic and endpoint optical methods. The release of PNA is directly proportional to the amount of factor Xa
or IIa present.259 In these assays, the inhibitory effects of heparins can be measured in
different matrices. The mass based OMH and PMH supplemented at various concentration in
BBP exhibited comparable factor Xa and thrombin inhibition activities at all concentration
points. OMH and PMH inhibited factor Xa and thrombin at the highest concentration (10
μg/ml) in a range of (92.9±2.2% -96±3.5%) and (85.2±3.7%-89±2.5%) respectively. In
contrast, BMH when compared at similar mass/ml level exhibited significantly the lowest
anti- Xa and anti-IIa activities compared to others at 2.5 ug/ml and at higher concentrations
(*p ≤ 0.05). BMH inhibited factor Xa and thrombin at 10 ug/ml and exhibited lower degrees
of inhibition (84.7±3.4% and 76±3.3% respectively). The overall results from these global
amidolytic antiprotease studies demonstrate that the BMH was consistently weaker than
PMH and OMH. However, all USP potency-based heparins (U/ml) produced similar anti-Xa
and anti-IIa activities at all concentration points. This data suggests that, by increasing the
mass/volume of BMH, the AT contents of BMH become equivalent to PMH and OMH.313 On
the other hand, all LMWHs (bovine, ovine and porcine) inhibited factor Xa and thrombin at
comparable levels and no differences were noted. In contrast to UFHs, the relative inhibition
of thrombin was lower than the factor Xa with the LMWHs. This data clearly indicates that,
the AT binding components were different in the LMWHs in comparison to UFHs. For this
reason, the anti-Xa/anti-IIa ratio differs between UFHs and LMWHs.
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Antithrombin (AT) is the primary serpin which binds to a specific chain in heparins
and results in the amplification of the anti-Xa and anti-IIa activities. Purified buffer system
supplemented with AT provides an approach to determine the true inhibitory effects of
heparins which are independent of the effects of other plasma proteins which can modulate
the inhibitory effects. Thus, this method provides a clear profile for the relative amounts of
the AT binding chains in heparins.
In the purified assay, all agents were diluted to obtained stock concentrations of 100
μg/ml or 10 U/ml in saline, and then were further diluted in purified AT (1 U/ml) solution in
a range of 0-10 ug/ml and 0-1 U/ml. The supplementation of heparins into purified AT
system provides a defined biochemical approach and has been recommended by EP and USP
monographs. The potency of each agent was determined by calculating the IC50 value as the
amount of heparin which produced 50% inhibition of factor IIa and factor Xa activity. As
expected, BMH (ug/ml) exhibited significantly (*p ≤ 0.05) higher IC50 values (weaker
potencies) compared to the PMH and OMH in both amidolytic assays (anti-Xa and anti-IIa),
however, all potency adjusted-based UFHs showed comparable IC50 in both methods.301
In regard to LMWHs (ug/ml), all agents exhibited comparable anti-Xa and anti-IIa
activities with minor differences in the IC50 values. While potency adjusted UFHs exhibited
comparable IC50 values in both the anti-Xa and anti-IIa assays, the LMWHs exhibited
relatively higher IC50 values of the anti-IIa effects. The inhibitory profile in the purified
system were consistent with the results obtained from plasma-based studies.303,316
Heparin cofactor-II (HCII) is a serpin which is capable of binding to the heparins
chains and mediate the inhibition of thrombin. The inhibitory effects of both the UFHs and
LMWHs on the inhibition of thrombin was also measured in HCII supplemented system. In a
concentration range of 0-10 ug/ml, the BMH, PMH and OMH produced comparable
inhibitory effects with IC50 values ranged from 4.2-4.5 ug/ml. This is in contrast to the IC50
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values obtained in the AT supplanted system for the inhibition of thrombin where BMH
exhibited relatively higher value. This data suggests that, the HCII binding chain prevalence
is comparable in UFHs obtained from various origin. At the potency adjusted level, all UFHs
produced comparable IC50 values. The LMWHs obtained from different origins also showed
comparable IC50 values which were higher in comparison to those obtained with UFHs. This
data suggests that, the chain length and MW contribute to the interaction with the HCII.
Furthermore, the degree of sulfation also contributes to the interaction of HCII with heparin
components.
To further demonstrate the serpin dependence of the anti-Xa and anti-IIa effects of
heparins, plasma depleted from AT and HCII were used. These plasma preparations provided
an integrated approach to determine the relative contribution of each of these Serpins in the
mediation of the antiprotease effect of heparin. All agents were supplemented at a
concentration range of 0-10 ug/ml in either the antithrombin depleted plasma (AT-DP) or in
heparin cofactor-II depleted plasma (HCII-DP). The anti-Xa and anti-IIa activities were
measured by the amidolytic assays. All heparins and LMWHs when supplemented in AT-DP
did not exhibit any anti-Xa and anti-IIa activities. These observations were in contrast to the
results obtained with intact human plasma. This data suggests that, AT is the main mediator
for the antiprotease activities of UFHs and LMWHs.81
However, when UFHs and LMWHs were supplemented in HCII-DP, they showed
measurable anti-Xa and anti-IIa activities which were relatively weaker in comparison to the
intact human plasma. This may be due to, the presences of the AT in the HCII-DP. These
results clearly suggests that, AT is the main mediator for the antiprotease actions of heparins
and HCII partially contributes to the thrombin inhibitory effects of these agents.87,88
These studies in the purified AT and HCII systems along with the complementary
studies with the depleted plasmas, clearly underscore the importance of AT in the mediation
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of the antiprotease actions of heparins. Moreover, these results are supportive of the
hypothesis that, potency adjustment based on USP method is dependent on the adjustment of
AT binding of the chain components in heparins.
The commercially available USP compliant amidolytic assays for the cross-refencing
of heparins with pharmacopeial standards are based on the using of purified AT in buffer
systems to study the inhibitory profiles of factor Xa and thrombin. These are biochemically
defined assays and are not influenced by plasma proteins and other biological contaminants.
Throughout this dissertation work, validated amidolytic assays for the anti-Xa and anti-IIa
activites of heparins were developed in collaboration with Hyphen Biomed (Paris, France).260
These methods are now available commercially in the form of complete kits. The studies
reported in this dissertation utilized the 6th USP reference standard (Heparin sodium,
lot#FO1187). This standard was comprised of 9.5 mg of porcine mucosal heparin with the
total of 2144 units per ampoule (226 U/mg). In this investigation, standard was diluted to
obtained concentrations of 1000 U, 100 U and 10 U per ml. The calibration curves were
constructed representing the linear range of the factor Xa and thrombin inhibitory responses.
The UFHs were cross-referenced at mass/ml (ug/ml) concentrations to obtained referenced
potency.
The LMWHs included in this dissertation research were all pre cross-referenced and
standardized against the 3rd LMWH (NIBSC) standard. All LMWHs were provided at the
designated potency in a range of 95-104 U/mg. All LMWHs were used at an assumed
potency of 100 U/mg.
The anti-Xa and anti-IIa USP potencies of PMH and OMH were comparable and
ranged from 185±1.4 to 189±2.8 U/mg and from 184±3.21 to 189±3.4 U/mg respectively. In
contrast, the anti-Xa and anti-IIa USP potencies of the BMH were significantly (*p ≤ 0.05)
lower (132±2.1-134±2.1 U/mg) compared to PMH and OMH. On the other hand, all LMWHs
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exhibited comparable USP potencies in the anti-Xa (96.5 to 99.3 U/mg) and anti-IIa (37.6 to
39.3 U/mg) based assays. Unlike heparins, the anti-IIa activities of LMWHs were much
lower than UFHs. The anti-Xa/Anti-IIa ratios for the UFHs were consistently in a range of
0.95-1.0, whereas LMWHs exhibited a much higher anti-Xa/anti-IIa ratios in a range of 2.592.64. The anti-Xa and anti-IIa potencies measured in the purified systems are consistent with
the results generated in human plasma-based studies.259 The pharmacopeial assays based on
the use of purified reagents provide defined biochemical systems which kinetically analyzed
for computational purposes.
The anti-Xa and anti-IIa ratios of unfractionated heparin of various origins are near
unity regardless of the potency. For this reason, the unfractionated heparins can be cross
referenced in these assays. On the other hand, the anti-Xa and anti-IIa ratios of low molecular
weight heparins range from 2-4. Therefore, each of the different low molecular weight
heparins is considered a distinct drug entity. While the anti-Xa activity can be used to assign
a potency for branded low molecular weight heparins, it cannot be used for claiming product
equivalency unlike unfractionated heparins.
The anti-IIa method is recommended for cross referencing unfractionated heparins.
However, in the studies reported in this dissertation, anti-Xa methods are preferred. This is
because of the reason that anti-IIa method only measures chains composing of more than 18
saccharide units. Although small in proportion, unfractionated heparins contain sizable
amounts of oligosaccharides, below the molecular weight of octadecasaccharide.
In Vitro Neutralization Studies of Various Heparins and LMWHs
Heparins are widely used for surgical and interventional purposes at a relatively high
dose. After these procedures, the residual amounts of heparins required neutralization.
Furthermore, heparin associated bleeding is also seen with dosage errors and the
accumulation of these agents due to clearance disorders. Various approaches to neutralize
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heparins have been used, PS represents the only clinically used antagonist of heparins and its
widely used after surgical procedures.171-173 PS is highly cationic polymer capable of
complexing with anionic heparin chains. Beside PS, other polybasic proteins such as PF4 is
also capable of neutralizing heparin anticoagulant effects. Recombinant PF4 has been
developed for clinical purposed with limited success.173 Moreover, the complex formed
between PF4 and heparin may generate antibodies leading to thrombocytopenia. Heparinase-I
(HP-I) is a flavobacterial enzyme capable of digesting both UFHs and LMWHs.41,266 HP-I
produces depolymerized heparin fragments with much lesser anticoagulant effects. This
enzyme has also been tested in clinical trials for the neutralization of heparins with limited
success.272 The neutralization profile of heparins provides another approach to characterize
the composition of these agents and demonstrate similarities or compositional differences in
these agents.
In the studies reported in the dissertation, all three approaches were used to compare
the neutralization profile of heparins obtained from different animal origins. Thus, the
objective of these studies was to determine the neutralization profiles of various heparins
with such agents, such as protamine sulfate (PS), heparinase-I (HP-I) and platelet factor 4
(PF4). The neutralizing profile of both the UFHs and LMWHs were determined by
comparing various clotting and antiprotease activities. The neutralization profile of each of
the heparins with PS was determined in human plasma-based systems supplemented at
concentrations range of 0-10 ug/ml or 0-1 U/ml. PS was used at a fixed concentration of 10
ug/ml.
In the global anticoagulant such as aPTT and TT assays, PS was able to completely
neutralize the anticoagulant effects of the different heparins (ug/ml) at concentrations below 5
ug/ml. However, only partial neutralization of the anticoagulant effects was observed at a
higher concentration of 10 ug/ml. In antiprotease assays, PS was able to completely
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neutralize the effects of these agents at concentrations below 5 ug/ml. However, at 10 μg/ml,
the neutralization effects of PS were variable. BMH produced relatively lower anticoagulant
and antiprotease effects in comparison to PMH and OMH, yet its neutralization at 10 ug/ml
was slightly lower in the aPTT, anti-Xa and anti-IIa assays. Interestingly, in the TT assay at
10 ug/ml concentrations PS failed to neutralize the anticoagulant effects for UFHs. This may
be due to the relative sensitivity of TT reagent. Stronger TT reagent with concentration of 10
U/ml may provide deferential neutralization profile for UFHs.
At the potency adjusted heparin concentrations of 0-1 U/ml, PS (10 ug/ml) was able
to completely neutralize the anticoagulant effects of all UFHs at concentrations of or below
0.5 U/ml. Yet, at the highest concentration (1 U/ml), PMH and OMH were almost completely
neutralized by PS, however BMH was only partially neutralized at this concentration (*p ≤
0.05). Similar to the mass adjusted studies, in the TT assay none of the UFHs were
neutralized at 1 U/ml concentration.
Despite the lower anticoagulant and antiprotease effects of BMH in various assays, its
neutralization profile was different at high concentration of 10 ug/ml and 1 U/ml with 10
ug/ml PS. These differences were much more pronounced in the USP adjusted
concentrations. This is most probably due to the increase of the mass of the BMH to increase
the biologic activity of this agent. These observations are supportive of the clinical data
CABG surgeries where BMH required higher amounts of PS for its neutralization.217
Compared to UFHs, all LMWHs exhibited relatively weaker yet comparable
anticoagulant effects in the aPTT and TT assays in a concentration range of 0-10 ug/ml.
These effects were completely neutralized by PS at 10 ug/ml. All of the LMWHs exhibited
comparable and anti-Xa effects which were partially neutralized by PS. The LMWHs
produced relatively weaker anti-IIa effects which were similar with all agents and were
partially yet comparably neutralized by PS. The is probably because, all LMWHs have small
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charge density and small chain lengths (less than 18 saccharides) which lead to a weak PS
binding (the18 saccharides chain is essential to stabilize the heparin/PS complex).318,319
Additionally, the higher length chains composed of greater than 18 saccharides units exhibit
both the anti-Xa and anti-IIa activities in comparison to lower MW chains which are only
exhibit anti-Xa activities. Moreover, the molar concentrations of LMWHs are 3-4 time higher
in comparison to UFHs. Thus, the complexes formed between PS and UFHs/LMWHs
represent different proportions which contribute to the observed neutralization profiles.
Activated clotting time is the method for monitoring heparins at surgical and
interventional concentrations in the range of 1-5 U/ml (10-50 ug/ml). The neutralization
profile of UFHs was studied at 10 ug/ml and 1 U/ml with 10 ug/ml PS.
In both the gravimetric-based studies, both the PMH and OMH produced stronger
anticoagulation effects (>300 seconds) in comparison to BMH (255 seconds). However, PS
completely neutralized (ACT = 144-146 seconds) these effects which reached near normal
control values (Saline, ACT = 137±3.3 seconds). At the potency adjusted at 1 U/ml, all UFHs
produced comparable anticoagulant effects, however supplementation of PS at 10 ug/ml
resulted in a comparable neutralization of PMH and OMH. Whereas the potency adjusted
BMH showed lesser neutralization effects.
This data is consistent to the data in the global anticoagulant assay where BMH was
only partially neutralized in the potency adjusted studies. The partial neutralization of BMH
reflects the relatively higher amounts of the components chains in the BMH in comparison to
PMH and OMH at potency adjusted levels. These studies suggest that potency adjusted
BMH, while producing comparable anticoagulant effects may require higher amounts of PS
for their neutralization.
Unlike the UFHs, LMWHs of different origins at 25 ug/ml (2.5 U/ml) produced
comparable prolongation of the ACT. However, the anticoagulant effects of these agents
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were weaker than those observed with UFHs a lower concentration of 10 ug/ml and 1 U/ml.
PS produced partial neutralization of the anticoagulant effects of these agents in a comparable
fashion. The relative neutralization of the anticoagulant responses with LMWHs by PS was
much weaker due to the concentration used at 10 ug/ml. Increasing PS concentration to 25
ug/ml may result in a higher degree of neutralization. These results strongly suggest that, PS
is more efficient for the neutralization of UFHs in contrast to LMWHs. Despite, the weaker
neutralization of these agents by PS, it is still recommended for the control of bleeding
associated with LMWHs.320
PF4 is a polybasic cytokine belonging to the CXC chemokine family and has a mean
molecular weight of 7.7 kDa (70 amino acids).178 PF4 is synthesized by megakaryocytes and
stored in the alpha granules of platelets and released from activated platelets.178 PF4 exists
mainly as a tetramer under physiological conditions and binds to heparin with a very high
affinity in a 1:1 ratio and its tetrameric form is essential for the heparin binding.179 Heparin’s
interactions with PF4 may lead to both thrombocytopenia and HIT-associated thrombosis.280
Moreover, PF4 is capable of neutralizing heparin and related agents as measured by
functional assays. For this reason, recombinant PF4 was developed for the neutralization of
heparin.321 The neutralization profile of UFHS and LMWHs was also studied in similar
conditions as the one used for PS neutralization.
The anticoagulant activities of all mass based UFHs were completely neutralized in
the aPTT assay. However, at higher concentration of 10 ug/ml, PF4 did not neutralize the
anticoagulant effect in the TT assay. Similarly, in the anti-Xa and anti-IIa assays PF4
completely neutralized these effects at concentration of 5 ug/ml. However, only partial
neutralization was noted at 10 ug/ml. These results are interesting when compared to the
results obtained from PS neutralization studies. PF4 was more effective in neutralizing the
anticoagulant effects as measured by aPTT assay in comparison to PS. In the USP potency
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adjusted studies, PF4 neutralization profile was comparable to those observed in the mass
adjusted studies. Thus, for the most part PF4 exhibits similar neutralization effects in various
assays used for the comparison of UFHs.
On the other hand, LMWHs exhibited similar PF4 neutralization profiles in all of the
anticoagulant and antiprotease assays. PF4 was able to completely neutralize all LMWHs as
determined by the anticoagulant (aPTT and TT) assays. However, all LMWHs solutions
(ug/ml) were partially neutralized by PF4 at all concentration points as measured by the
amidolytic anti-Xa and anti-IIa assays. These results were comparable to the PS
neutralization results. This is probably because, both PS and PF4 interactions with heparins
are exclusively charge dependent.171,179 Both the PS and PF4 are highly basic in nature and
exhibit comparable MW profile. In the monomeric form, PF4 provides the same molar
proportions for the complexation as PS.
HP-I is a heparin-degrading enzyme that cleaves certain sequences of heparin/heparan
sulfate specifically. 41 HP-I is an enzyme purified and characterized from Flavobacterium
heparinum. It is one of the most extensively studied glycosaminoglycan lyases. Heparinases
have aided in the understanding of important physiological roles of heparin, which include
anticoagulation, angiogenesis, etc.266 Additionally, heparinases themselves have therapeutic
and diagnostic applications such as heparin detection and removal.272 Moreover, HP-I is also
been used for the preparation of LMWHs.216 Enzymatic degradation of heparin by heparin
lyases not only largely facilitates heparin structural analysis but has also been shown to
exhibit heparin neutralization effects in animal models and limited clinical trials.216
The cleavage of heparin by HP-I occurs at the linkage regions between the GlcNS6S
(1→4) IdoA2S and GlcNS3S6S (1→4) IdoA2S residues.46 Xiao et al (2011) demonstrated
that the GlcNS3S6S (1→4) IdoA2S linkage, which is found mainly within the AT binding
site, is more susceptible to cleavage by heparinase-1 than the other major heparin
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disaccharide repeating unit GlcNS6S (1→4) IdoA2S. For this reason, HP-I at 1 U/ml
completely neutralized the anticoagulant and antiprotease activities of the mass adjusted
UFHs. Although the USP adjusted UFHs were not profiled for the HP-I neutralization, it is
expected that this enzyme will produce comparable neutralization of all UFHs because of its
cleavage of the AT binding oligosaccharides sequence in contrast to the ionic interactions
with PS and PF4.
All of the LMWHs at a concentration of 0-10 ug/ml were completely neutralized by HP-I
at 1 U/ml. In comparison to UFHs, these agents produce weaker anticoagulant and antiXa/IIa effects. However, the AT binding consensus sequence is comparable to UFHs and
susceptible to cleavage resulting in a complete loss of the anticoagulant and antiprotease
actions.
The concentration of HP-I used in the studies reported in this dissertation is relatively
high at 1 U/ml. Additional studies using lower amount of HP-I may provide differential
neutralization data on both the UFHs and LMWHs. As discussed before, HP-I digestion of
both the UFHs and LMWHs results in the generation of oligosaccharides mainly comprised
of 4-8 hexose units. The results on the functional studies suggests that, these oligosaccharides
are devoid of AT binding sequences because of the site-specific cleavage resulting in the loss
of affinity to this serpin.
Platelet Function Profile of Various UFHs and LMWHs
Both UFHs and LMWHs are known to modulate platelet functions such as adhesion,
activation and aggregation. 272-276 Agonist induced platelet aggregation (AIPA) is known to
be augmented at lower concentrations of heparins, whereas the higher concentrations inhibit
the aggregation responses.273 Aggregometry is also used to study HIT antibody mediated
aggregation of platelets. In this study both the augmentation of platelet aggregation by
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various agonists and HIT antibody mediated responses were measured in the following
studies.
Agonist induced platelet aggregation (AIPA) assay. The effect of UFHs on AIPA
was studied at systems supplemented with 10, 1 and 0.1 ug/ml and at potency adjusted
concentrations of 1, 0.5 and 0.1 U/ml. Such agonists as ADP, collagen, arachidonic acid and
epinephrine were used. Saline was used as a control to compare the modulation of the
responses of heparins. In these studies, all UFHs produced comparable effects (aggregation %
& aggregation rate) on platelet aggregation at various gravimetric and potency-equated basis
concentrations. Similarly, the different LMWHs did not produce any modulation of platelet
aggregation profiles when supplemented at 10, 1, 0.1 ug/ml.
Both UFHs and LMWHs are known to produce augmentation of platelet aggregation with
such agonist as ADP. However, in these studies reported here in this dissertation neither, the
UFHs nor LMWHs of different origins did not produce any augmentation of AIPA.
These data are not consistent to the previously published studies where, UFHs shown
to augment platelet aggregation at a higher level than LMWHs.322 The observed differences
in the two studies may be due to the experimental conditions and the concentration of
agonists used. It is noteworthy that, at 10 ug/ml there was no reduction on the platelet
aggregation responses with various agonist with both the UFHs and LMWHs. This may be
due to the use of relatively higher concentrations of the agonists used in this study.
Heparin induced platelet aggregation (HIPA) assay. One manifestation of
heparin’s interactions with platelet factor 4 (PF4) is its ability to generate antibodies to the
heparin/PF4 complexes leading to heparin induced thrombocytopenia.180-182 These antibodies
are generated due to the formation of neoantigen which lead to the IgG, IgA and IgM
antibodies.180-182 The IgG immune complex then binds to the FcγRII receptors on circulating
platelets and induces platelet activation, promotes thrombin generation, and platelet
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aggregation. Activation of platelets induces the release of microparticles and ultimately leads
to a reduction in the number of platelets causing thrombocytopenia.180-182 Aggregometry
based methods have been used to complement HIT diagnosis in conjunction with platelet
counts. Additionally, patients suspected of HIT are tested by an immunoassay which detect
HIT antibodies. If this test is positive, additional studies to confirm HIT diagnosis can be
carried out using 14C Serotonin Release Assay (SRA).323 The aggregation-based methods
provide a functional approach to study the HIT antibody mediated responses. This method is
also useful to screen the relative effects of UFHs and LMWHs in experimental settings.
In these studies, the ability of various UFHs and LMWHs to promote a HIT response
was examined in platelet aggregation assays in which platelet rich plasma from normal
donors was mixed with heparins and serum collected from known HIT positive patients. The
aggregation response was used as an index for the potential to cause HIT. At gravimetricbased and potency adjusted-based UFHs produced concentration dependent increase in the
aggregation responses. There were differences noted in the BMH, OMH and PMH
preparations.
On the other hand, all LMWHs exhibited significantly (p ≤ 0.05) weaker platelet
aggregation responses compared to heparins at all concentrations in the range 0.1-10 ug/ml.
At 10 ug/ml, all LMWHs produced less that 30% platelet aggregation which was markedly
lower than the responses obtained with UFHs. This may be due to the charge density and
MW distribution of the LMWHs which is much lower than UFHs. These observations
suggest that LMWHs are less likely to produce HIT responses in comparison to UFHs.275
Nevertheless, at relatively higher concentration the LMWHs nay also mediate HIT responses.
The HIT antibody mediated aggregation studies were also carried out in conjunction
with HP-I digestion studies. The aggregation responses were studied in identical experimental
settings as previously described. HP-I depolymerization of both the UFHs and LMWHs
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resulted in a complete loss of the aggregation responses of these agents in the presence of
HIT antibodies. This suggests that the HP-I treatment of heparins resulted in smaller
fragments incapable of forming the complexes to mediate their effects. As observed, in the
MW profiling of these heparins after HP-I digestion, these results are consistent. Moreover,
the functionality of heparins after digestion with HP-I is markedly reduced. Therefore, the
platelet activation responses with heparins are dependent on the MW profiles and other
physiochemical properties.
Characterization of Heparin/PF4 Interaction
It is well known that PF4 and heparin interactions are exclusively charge dependent;
optimal PF4/heparin complex formation occurs when the two polymers are present at certain
molar amounts associated with charge neutralization.132–135 Changes in molar amounts of PF4
or heparin leading to excess of one component or another results in charge imbalance and
increased repulsive forces that affect complex assembly. The PF4 /heparin complex can lead
to an immune mediated reduction of platelets leading to a heparin-induced thrombocytopenia
(HIT). HIT represents a catastrophic adverse reaction with the use of this anticoagulant. HIT
is caused by antibodies that recognize the heparin and PF4 complexes. Although the immune
reaction is common (8%- 50%), clinical complications of thrombocytopenia and thrombosis
are far less frequent, affecting ~ 3% of patients exposed to the drug in various clinical
settings.136,137
Until recently, it was widely believed that the heparin of bovine origin exhibits a
higher degree of thrombocytopenia. This assumption was only based on the fact that, the
earlier reports used bovine lung heparin and compared it with PMH. Bovine lung heparin has
relatively higher degree of sulfation in comparison to the BMH. Almost all of the bovine
heparin preparations are now obtained from intestinal mucosal tissues. Moreover,
manufacturing processing have greatly improved. BMH is widely used in southeast Asian
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countries without any major signals for HIT syndrome. While the clinical data on the
comparison of the two agents is limited, the biophysical studies reported in this dissertation
did not demonstrate any differences between the BMH, OMH and PMH. It is unlikely that,
the immunogenic potential of these agents can be differentiated in clinical settings.
Two different HIT types are known, a relatively common nonimmune, clinically
harmless type I and a rare immune-mediated, serious HIT-type II. The first type, caused by
direct interaction of heparin with the platelet membrane resulting in enhanced platelet
aggregation, occurs in approximately 10% of patients treated with heparins, usually within
the first few days of treatment.138 Heparin-induced thrombocytopenia type II, typically
occurring 10 to 14 days following the initiation of heparin therapy in about 5% of treated
patients.
Biophysical tools have gained an important role to complement immunological and
functional assays for better understanding the interaction of heparin with PF4.147 This
allowed identification of those features that make PF4 immunogenic (e. g. a certain
conformational change induced by the polyanion, a threshold energy of the complexes, the
existence of multimeric complexes, a certain number of bonds formed by PF4 with the
polyanion) and to characterize the morphology and thermal stability of complexes formed by
the protein with polyanions.
In this investigation, PCS and Zeta-potential methods were utilized to characterize the
interactions of various UFHs and LMWHs with PF4. PCS and Zp techniques, have been
optimized to distinguish between UFHs and LMWHs.155 It is well known that a lower molar
quantity of heparin is needed to reach the maximum complex with PF4 in comparison to the
molecular weight. However, Mw is not the only parameter that plays a role in the
PF4/heparin interaction, also the polydispersion index and the sulfation degree (DS) have
significant contribution in this interaction.
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BMH exhibited the highest Mw heparin analyzed which reached the maximum
aggregation at the higher PHR with each technique used, so requiring the smaller
concentration. Moreover, it’s Zp=0 is obtained at a PHR not so different from the other two
UFHs which exhibited at least 10 % lower MW. In fact, both PMH and OMH have a higher
DS, so it is reasonable to state that this parameter can increase the electrostatic interaction
with the PF4, leading to a less heparin concentration needed for PF4 charges saturation.
Similarly, the three LMWHs exhibited the same PCS derived maximum values of
aggregation along with very similar complexes size, and quite the same null Zp PHR values.
These results are in accordance with the Mw distribution and DS profiles of the LMWHs.
In regard to PCS and Zeta Potential evaluations, the largest complexes should occur at
the molar ratios that lead to charge neutralization, but differences are observed as the result of
the different approaches used for the calculation of PHR at maximal aggregation utilizing
experimental data and a mathematical extrapolation. The PHR obtained from Zp is always
higher than the PCS values. PHR at null Zeta potential is the most quantitative parameter,
whilst PHR for maximum size is a robust, but semi-quantitative parameter due to the low
resolution of the concentration range of the test solutions and the maximum complex size is
more qualitative. Nevertheless, these parameters are necessary to understand the
complexation profile of a heparin material with PF4.
It is noteworthy to mention that, only one technique is not sufficient for a complete
description of the PF4/sample interaction. On the contrary it is more useful to obtain a
broader picture by taking into account different methods together. In this sense, PCS and Zp
evaluation can be reasonably considered orthogonal methods for PF4/heparin interaction
study, in particular for the discrimination between UFHs and LMWHs. Regarding the
different sources, only the PMH samples seem to differentiate from the BMH and the OMH,
in terms of decreased concentrations needed to obtain the maximal aggregation which is
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consistent with various approaches used. There is no convincing report which provides
evidence that heparins of different origins differently bind with PF4.160,161
In the PCS titration studies, the UFHs have higher PHR ratios in comparison to
LMWHs. The size of particles follows a bell-shaped response of both the UFHs and
LMWHs. In particular BMH and OMH exhibited comparable values of 6.4 which was lower
than PMH exhibiting a value of 9. All LWMHs samples exhibited considerably lower values
of 2.
In the Zeta-potential measurements studies, the PHR values of the UFHs considerably
higher (9-13) in contrast to those obtained with LMWHs (3.0-3.6). These data suggests that,
the stability of these complexes depends on the charge density and MW of these agent.
Complexes formed with LMWHs and PF4 requires relatively higher concentration of these
agents in comparison to those formed with UFHs. For this reason, the LMWHs do not cause
HIT responses with the same magnitude as UFHs. Additionally, LMWHs do not form ultra
large complexes with PF4 as evident in these studies. This data clearly suggests that, there
were significant differences between UFHs and LMWHs in PCS and Zp measurements.
While the UFHs show minor species dependent variations in these measurements, all of the
LMWHs exhibited comparable results.
Based on the molecular interactions of both the UFHs and LMWHs with PF4, it can
be stated that, the origin of these agents does not impact on their immunogenic potential. It is
indeed true that, the complexes formed with the UFHs have different biophysical behavior in
comparison to those formed with LMWHs. This has been demonstrated in both clinical and
experimental settings. The functional studies carried out showed stronger HIT antibody
mediated aggregation with UFHs in comparison to LMWHs. Furthermore, there was no
difference in the functional antibody response by each group of agents.
Pharmacokinetic and Pharmacodynamic Studies in Primates
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The structural and functional studies to compare the heparins of various origins in
various standardized methods provided a comprehensive account of the biochemical and
biophysical characteristics of these agents. These studies demonstrated individual profile of
each class of the UFHs and LMWHs. In the potency adjusted studies, the UFHs showed
comparable activities as measured by several methods. The LMWHs were pre standardized
and exhibited comparable profiles. To further validate these observations, a primate model
(Macaca mulatta) was utilized. This model has been extensively used in the study of the
anticoagulant drugs such as heparins. 297,301
Primates are related and genetically similar to human. Human DNA is on average
96% identical to the DNA of primates. The plasma protein composition and blood cellular
profile of primates are comparable to that of human. Coagulation factors, platelets count, and
other laboratory parameters are also found to be comparable. Physiologically, primates
provide a relevant model to study the in vivo behavior of heparins.
To compare the anticoagulant and antiprotease responses of the human and primate
plasmas, validation studies were carried out to demonstrate the similarities in the two
matrices in standard laboratory assays. Citrated human and monkey plasma pools were
supplemented with UFHs at graded concentrations 0-10 ug/ml.
All heparins exhibited similar anticoagulant (aPTT assay) and antiproteases (anti-Xa
and anti-IIa) activities in both human and monkey plasmas. The GAG content in the two
plasma systems were quantitated by using a fluorescence quenching method utilizing Heparin
Red assay. In these studies, all agents exhibited comparable results and the recovery of GAG
contents was found to be 96% -103% in both human and monkey plasmas. These studies
demonstrate that, UFHs exhibited comparable anticoagulant and antiprotease profiles in
primate and human plasmas. Moreover, the red dye method provided identical results with
UFHs suggesting the sameness between these agents.
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In order to evaluate the pharmacodynamics (PD) and pharmacokinetic (PK) profiles
of various heparins in non-human primates, various UFHs and LMWHs were administered to
primates intravenously (IV) and/or subcutaneously (SC) at designated doses previously
described in the ‘Materials and Methods’ section. The PK/PD profiles along with the in vivo
PS neutralization profiles of all agents were assessed using a variety of clot-based, amidolytic
anti-Xa/anti-IIa assays and TGA along with quantitating absolute GAG concentration assays.
Since heparins from various animal sources (pig, cow and sheep) exhibit product specific
variations in MW composition, the impact of these differences was determined in terms of
their PK/PD profiles. Differential responses in various assays may be due to the binding to
plasma proteins, in particular with AT and HCII.71-74 Furthermore, the vascular effects of
these agents may also differ in terms of TFPI release.
At the gravimetric-based dosages (0.5 mg/kg, IV), all UFHs exhibited measurable
inhibitory effects as determined by both the anti-Xa and anti-IIa assays. All three drugs
significantly prolonged the aPTT and TT clotting assays with strong anticoagulant activity
observed at 15 minutes post-administration. At this point anticoagulant activity was stronger
for OMH and PMH than for BMH. Administration of the various heparins at an IV dose of
0.5 mg/kg produced a significant inhibition of factor Xa and thrombin at 15 minutes. This
effect gradually decreased during the study period for all 3 agents. OMH and PMH had a
significantly stronger anti-Xa and anti-IIa effects compared to BMH up to 60 minutes postadministration. However, all agents exhibited comparable anti-Xa and anti-IIa effects at 120
minutes whereas the plasma concentration-time courses of all agents followed the same
trends. Overall, the OMH and PMH consistently showed comparable and stronger effects at
all time points in contrast to BMH.
Upon potency adjustment (100 U/kg, IV), all UFHs produced comparable
anticoagulant and antiprotease activites in all assays. These results were consistent with the

252
previously published studies.301 These results further underscore the proposal that potency
adjusted UFHs are similar in mediated their biological responses.
Since, the LMWHs are commonly used in SC regimen, the PK/PD studies of these
agents were carried out at a fixed dosage of 1 mg/kg. All LMWHs exhibited similar plasma
concentration-time courses for the anti-Xa/anti-IIa activities measured as % inhibition and
circulating levels by using this data during the entire course of the study. Moreover, the
anticoagulant effects of all LMWHs as measured by the aPTT assay were comparable at all
time points. It is interesting to note that, the trough levels of the anti-IIa and aPTT reverted
back to near baseline, however that ant-Xa activity-based levels remained elevated. This may
be due to the longer half-life of the lower molecular chains which may have followed a
different absorption and elimination kinetics. These data were consistent with the previously
published studies. 297,301
The pharmacodynamic effects of various heparins and LMWHs administered to
primates were also measured by the TGA assay. All heparins (0.5 mg/kg and 100 U/kg)
produced similar TGA parameters (Peak thrombin, AUC and Lag time) and complete
inhibition of thrombin generation at 15-, 30- and 60-minutes poste drug administration.
However, at 120-minutes post drug administration (0.5 mg/kg), PMH and OMH showed
comparable thrombin inhibitory effects where the thrombin generation values ranged from
55±4.5 nM to 67±7 nM. Whereas BMH (0.5 mg/kg) at this time point showed significantly (p
≤ 0.05) weaker thrombin inhibitory effect (150±15 nM). Such a difference in the studies
carried out at 100 U/kg was not noted. This data once again supports the notion that, potency
adjusted BMH produces comparable inhibition of protease generation and related assays.
In regard to the LMWHs (1 mg/kg, SC), all agents exhibited comparable TGA
profiles in terms of Peak thrombin, AUC, Lag time and inhibition of thrombin generation at
all time points. The thrombin generation inhibitory profile was consistent to the anti-Xa
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activities and remain sustained during the 2 to 4 hours, however gradual increase in thrombin
generation was noted at 6 hours. This method provides an overall anticoagulant status and is
highly sensitive to investigate the biological effects of heparins. Consistent with the other
assays results, the potency adjusted UFHs and LMWHs showed similarities in their
biological effects.
The PK/PD parameters as measured by the antiprotease and anticoagulant assays
mostly represent Serpin mediated responses of heparins in plasma. Both the UFHs and
LMWHs produce several indirect pharmacological effects which are mediated through their
actions on endothelial lining. Heparins release a potent inhibitor of TF from the endothelial
known as TFPI.95,96 In this investigation, TFPI antigen and functional levels were measured at
varying time points after the administration of UFHs (0.5 mg/kg and 100 U/kg) and LMWHs
(1 mg/kg) from various animal origins. Following a gravimetric dosage, BMH-treated
primates exhibited a significantly (p ≤ 0.05) lower TFPI antigen levels at 15- and 30-mins
than OMH and PMH, with a maximum value (210±39 ng/ml) at 15 mins post drug
administration. In contrast, potency adjustment dosages of all UFHs resulted in comparable
TFPI antigen levels throughout the entire period of the study with a maximal value at 15
minutes (265±39 ng/ml).
The functional TFPI levels were also measured utilizing a chromogenic assay which
specifically measures the inhibition of TF. UFHs when compared at a mass-based dosage did
not reveal any differences in the functional TFPI levels between the BMH, OMH and PMH.
These results differ from those obtained in the TFPI antigen level studies. This is may be due
to the chain composition of the UFHs where most of the components are composed of greater
that 14 saccharide units.95 Moreover, in the functional TFPI assay only the full-length form of
this inhibitor is measured in contrast to the antigen-based assay where both the truncated and
preexisting complexed TFPI epitope are measured. In the studies with the LMWHs, The
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TFPI antigen release profile was comparable with all 3 agents, however the functional levels
were lower when compared to UFHs. These data showed that, potency adjusted UFHs in the
IV studies and LMWHs in the SC studies produced comparable release of TFPI antigen and
functional levels.
Although the PK/PD studies of heparins are usually carried out using the anti-Xa
methods, these assays provide only limited information in the overall biological effects of
these drugs. The studies reported in this dissertation represented an integrated approach
where such additional functional tests as TGA and TFPI activities are also included to profile
their effects. The inclusion of these assays provides a multiparametric approach to
characterize their therapeutic effects.
The PK parameters of heparins in terms of the usual profile including biologic t1/2,
Cmax, Vd and Cl are obtained by taking into account the anti-Xa inhibitory actions. Such
parameters can also be calculated by using anti-IIa methods which only reflects the
oligosaccharides components with greater than 18 hexose units. However, the anti-Xa
method derived concentration represents the total chains with both the anti-Xa and anti-IIa
activities. It should be noted that, these methods are functional methods and represent only
those chains with Serpin affinity.
It is established that bovine heparins exhibit lower anticoagulant activity than porcine
and ovine heparins.313 Structural analysis of these agents has shown this reduced activity of
bovine heparin is associated with differences in the sulfation pattern and presence of
antithrombin-binding regions.54 Even with improved heparin manufacturing process, the
potency of bovine heparins does not reach at comparable level to that of porcine heparin.
Attempts to enhance the potency of bovine heparin included site specific sulfonation and
MW fractionation of bovine heparins.307,309 Administering a greater amount of bovine heparin
by weight and adjusting the potency by antiprotease and anticoagulant approaches results in
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in a comparable biologic effect with BMH. It has recently been shown that use of the 6th
International Standard for Unfractionated Heparin, which is derived from a porcine heparin,
is suitable for cross-referencing and adjustment of the potency of bovine heparins.324 In the
current study, we utilized the USP heparin activity standard to normalize concentrations of
bovine, ovine and porcine heparins for comparing the PK parameters of these agents along
with studies at mass adjusted dosages.
The PK parameters calculated from plasma concentration-time curves using the
chromogenic anti-Xa and anti-IIa assays after IV or SC administration of heparins to nonhuman primates were determined. The estimation of PK parameters of both the gravimetricbased and potency adjusted-base dosages of OMH and PMH were comparable when
determined by the anti-Xa and anti-IIa assays. However, BMH exhibited a significantly (p ≤
0.05) longer half -life (t1/2) compared to PMH and OMH. Furthermore, no differences in area
under the curve (AUC) were noted between each agent. Although BMH appeared to have a
slightly higher volume of distribution (Vd), no significant differences were noted between all
of the UFHs studied. Additionally, no differences in systemic clearance (Cl) were noted
among all UFHs as determined by both the anti-a and anti-IIa methods.
Several previous studies have been reported on the PK parameters where LMWHs
derived using either Beta-elimination/alkaline hydrolysis or nitrous acid-based
depolymerization processes.325,326 LMWHs derived from bovine intestinal heparin utilizing
Beta-elimination methods have been studied for the PK profile using the anti-Xa and anti-IIa
assays.296,297 Depolymerized versions of LMWHs derived from bovine and porcine intestinal
mucosa met the specifications for Lovenox in terms of MW distribution and potency.296,297
Previous studies have demonstrated that LMWH produced from porcine, ovine and bovine
heparins by nitrous acid depolymerization were comparable in terms of their composition and
functional activities.326 Recent studies suggest that bioequivalent LMWHs can be generated
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by using standardized manufacturing processes for a given products such as enoxaparins used
in this investigation.
In these studies, the estimation of PK parameters calculated from plasma
concentration-time curves of all LMWHs using the anti-Xa and anti-IIa assays after SC
administration of 1 mg/kg to non-human primates were calculated. LMWHs obtained from
various sources exhibited comparable PK parameters in terms of t1/2, Cmax, AUC, Vd and Cl
as determined by both the anti-Xa and anti-IIa assays.325,326 No significant differences were
noted among these agents. This is due to the fact that, all of the LMWHs were previously
standardized to demonstrate a potency of 100 U/mg.
These studies described here demonstrated that, USP potency adjusted UFHs and
LMWHs derived from ovine, bovine and porcine origins exhibit comparable anticoagulant,
antiprotease, and PK profiles suggesting their bioequivalence. Based on these results, it is
projected that, the PK behavior of potency adjusted heparins will be comparable in human
subject to those observed in the primates. Recently completed studies on enoxaparins
obtained from ovine and porcine sources have shown similar PK parameters in human
studies.297
The absolute amount of heparin concentrations in primate plasma samples were
measured using Heparin Red kit (a fluorescence assay) in an accordance to the manufacture
instructions. The absolute amount of GAG contents was determined by cross-referencing the
circulation amounts of heparins with each of the individual calibration curves. The recovery
validation studies were carried out with each agent by supplementing known amounts and
subsequent quantification.
At all gravimetric-based UFHs dosages (0.5 mg/kg, IV), all agents showed
comparable GAG contents at all time points, with Cmax values in a range of 7.50-7.85 ug/ml
at 15 mins time point. The elimination kinetics exhibited superimposable patterns. At the
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potency adjusted UFHs dosages (100 U/kg, IV), PMH and OMH exhibited comparable GAG
contents at all time points with a maximal GAG contents in a range of 7.6-7.8 ug/ml at 15
min time point. However, BMH showed relatively higher GAG contents profile compared to
others which was significantly (p < 0.05) higher at 15 mins (9.7±1.2) and 30 mins (6.5±0.57)
time points. On the other hand, all LMWHs showed comparable GAG contents profile at all
time points with a maximal GAG contents in a range of 5.3-5.6 ug/ml at 2 hours after drug
administration.
In addition, in this investigation the absolute PK parameters were determined using
the Heparin Red method after IV administration of 0.5 mg/kg or 100 U/kg UFHs to nonhuman primates. At the gravimetric-based dosages, all agents produced comparable PK
parameters in terms of t1/2, AUC, Vd and Cl. However, potency adjusted-based BMH,
demonstrated significantly (p ≤ 0.05) higher AUC and slower Cl compared to PMH and
OMH. Furthermore, no significant differences in t1/2 and Vd were noted among all agents.
This data is consistent with the potency adjustment process where, higher amounts of BMH
(30-35%) are required to achieve a comparable potency of PMH and OMH. For this reason,
the PK measurements derived from the functional methods do not show any differences
between various UFHs. The practical implication of these findings is that potency adjusted
BMH IV dosing may require proportionately higher amounts of PS for their neutralization.
This observation has also been clinically validated in CABG surgery.317
All LMWHs (1 mg/kg, SC) showed comparable PK parameters in terms of t1/2, Cmax,
AUC, Vd and Cl, when the absolute GAG-based concentrations were used for their
determination. These data were consistent with the PK parameters obtained by functional
anti-Xa and anti-IIa assay.
It is interesting that potency adjusted BMH showed higher GAG amounts whereas the
enoxaparin prepared from BMH did not exhibit this behavior. Thus, the depolymerization
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processes used in the preparation of enoxaparins results in structural modification in the
digested chains in which the AT binding sequences become uniformly distributed. Moreover,
all the depolymerized heparins are standardized to exhibit comparable functional potency
ranging from 95 U/mg to 110 U/mg.
One of the advantages of using heparins for clinical anticoagulation is due to the
neutralization of these agents by PS which can be used to control bleeding associated with
their use. PS is a polycationic polymer rich in basic amino acids such as proline, histidine and
arginine.171-173 PS is used for the neutralization of UFHs and LMWHs such as enoxaparin,
318,319

however its neutralization of LMWHs is not as effective as with UFHs. Other

polycationic substances including PF4 have also been tested for their ability to neutralize
UFHs.319 However, the results have been inconclusive and the use of PF4 may lead to heparin
induced thrombocytopenia (HIT). Additionally, a catatonically modified polysaccharide
antidote to neutralize UFHs has been reported in non-clinical settings.327 There have been
several other antidotes with diverse chemical structures which have been proposed for the
neutralization of UFHs.327 Heparinases are members of a class of enzymes which can degrade
heparin with varying specificities.41Heparinase-I is a flavobacterial enzyme which has been
tested in both preclinical and clinical settings for the neutralization of UFHs.266,272 Despite
these developments, PS remains the sole antagonist for the control of bleeding and
neutralization of circulating heparin following surgical procedures.
The studies reported in this dissertation describe the in vivo neutralization of UFHs
and LMWHs obtained from bovine, ovine and porcine sources following their administration
at equigravemetric and potency-adjusted dosages. This study represents the first integrated
investigation on the in vivo neutralization profile of UFHs and LMWHs in a primate model.
This model has been extensively used in the study of the PK of heparins following both IV
and SC administration.297,301 In this investigation, LMWHs produced by benzylation followed
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by alkaline hydrolysis were used for the neutralization studies. A previous publication has
reported on the comparison of UFHs and LMWHs produced by using mucosal tissue of
bovine, ovine and porcine origins.297,301
The neutralization profile of UFHs from various origins was investigated at a dosage
of 100 U/kg after IV administration and at a gravimetric dosage of 0.5 mg/kg IV. In this
study, PS administered at a dose of 0.5 mg/kg effectively neutralized all three UFHs in an
identical manner as measured by anti-Xa, anti-IIa and absolute GAG contents assays.
Since all LMWHs exhibited a comparable in vitro potency of 100 U/mg, these agents
were administered at 1 mg/kg intravenously and their neutralization was studied after
administration with PS at a dose of 0.5 mg/kg. The LMWHs were only partially neutralized
in the anti-Xa and anti-IIa profiles in contrast to UFHs. The relative neutralization of the antiXa activity was much weaker in contrast to the anti-IIa activities of LMWHs. At the same
time the elimination of the anti-IIa actions after PS neutralization was faster than that
observed with the anti-Xa assay. This observation suggests that, the higher MW chains
responsible for the anti-IIa activity were more effectively complexed with PS in contrast to
the lower molecular weight chains which only exhibits anti-Xa activity. This data is
consistent to previous findings where differential neutralization of LMWHs was reported.328
BMH at the 0.5 mg/kg dosage showed lower anti-Xa and anti-IIa activities in
comparison to PMH and OMH at comparable dosages of 100 U/kg (equivalent to 0.5 mg/kg).
Therefore, the anti-Xa and anti-IIa activities of BMH were lower in comparison to PMH and
OMH. However, unlike the LMWHs, PS completely neutralized the anti-Xa and anti-IIa
effects of UFHs which were sustained during the study period of two hours. There were no
differences observed between the different UFHs studied in terms of the extent of
neutralization. This observation is in discordance with the previous findings where BMH
required higher amounts of PS for the neutralization of bleeding in CABG (Coronary artery
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bypass graft).317 However, in this clinical trial relatively higher dosages of PMH and BMH
were used. In this clinical study, higher amounts of PS were required to neutralize UFHs
which were dosed at comparable level.
In the current study, PS was used at a fixed dosage of 0.5 mg/kg with both the UFHs
and LMWHs. The average molar concentration of UFH components was much lower than the
average molar concentration of LMWHs. This may be one reason for the marked differences
in the neutralization profile of the two groups of heparins. Regardless of these differences, the
relative neutralization of UFHs and LMWHs from various origins was comparable. It would
be of interest to determine the impact of higher dosages of protamine on LMWH
neutralization. Although LMWHs are usually administered subcutaneously, these agents have
also been administered intravenously for surgical and interventional procedures. Limited
available data suggests that intermittent bleeding complications with LMWHs may be
manageable by repeated administration of PS.320
The PK profile of the UFHs of different origins showed comparable trends and the
AUC for both the anti-Xa and anti-IIa activities were similar for the potency adjusted agents.
BMH at 0.5 mg/kg showed a proportionately lower AUC with both the anti-Xa and anti-IIa
assays. This is due to the lower potency of this anticoagulant in comparison to PMH and
OMH. PS administration resulted in comparable reductions of the anti-Xa and anti-IIa
activities of all heparins.
The PK profile of the LMWHs was comparable in the anti-Xa and anti-IIa assays,
however unlike heparins, the LMWHs exhibited markedly reduced anti-IIa activities. The
AUC values for the anti-Xa activities after PS administration showed comparable trends
however unlike UFHs, only showed partial decrease in the range of 20-30% for the anti-Xa
activity. While minor differences were noted however these were not statistically significant.
The anti-IIa effects as calculated on the basis of the AUC were comparable among the
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LMWHs tested but were much lower when compared to the anti-Xa activity. The anti-IIa
activity of each LMWH was equally neutralized (~40-50%) by PS.
The absolute GAG contents assay showed similar trends as compared to the anti-Xa
and anti-IIa assays. Administration of potency adjusted dosages (100 U/kg) of PMH and
OMH followed by saline I.V. injection resulted in comparable drug levels through all time
points. However, BMH at 100 U/kg showed slightly higher maximal concentration of 8.8±0.9
ug/ml compared to other agents. All UFHs at both dosages (gravimetric-based and potency
adjusted-based) showed comparable PS neutralization profiles as determined by the Heparin
red method. However, slightly higher residual levels observed in the BMH (100 U/kg) treated
primates compared to others. Moreover, the neutralization % (AUC reduction %) for all
UFHs (0.5 mg/kg and 100 U/kg) were comparable and ranged from 72±3.6% to 79±3.3%.
All LMWHs were partially neutralized by PS to almost the same degrees as
determined by this method. Nevertheless, P. LMWH, B. LMWH and O. LMWH showed
comparable neutralization % profile (AUC reduction %) ranged from 39±2 % to 42±3 % and
these results were consistenet with those generated by the anti-Xa and anti-IIa assays.
The studies reported in this investigation were carried out with IV dosing of both the
UFHs and LMWHs. Thus, this data is relevant to surgical and interventional indications for
these agents. LMWHs are mostly used SC and the absorption profile follows a different PK
profile which will require periodic administration of PS which is only administered IV and
follows much faster elimination kinetics. The preliminary results presented in this dissertation
suggest that additional studies are needed to develop effective protocols for the neutralization
of the SC administered LMWHs by PS.
Project Limitations
This dissertation represents a comprehensive and integrated approach to validate the
hypotheses that, potency adjusted heparins exhibit comparable biologic profiles utilizing a
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multiple array of biophysical, biochemical and pharmacological approaches. Owing to the
diversities of these approaches, individual validations of methodologies used was required.
There were several limitations which should be taken into considerations for the continuation
of the future research in this area.
One of the major limitations of this study is the use of only one batch of each agents
for the comparison of the UFHs and LMWHs in both the in vitro and in vivo studies. Batch
to batch variations are usually noted in biologic products and for that reason, standardization
procedures are used. The inclusion of multiple batches for these studies would have provided
information on the variability in both the function and biologic studies. Such an approach can
be undertaken as an independent project because of the large number of studies to obtain
reasonable data. A previous report has summarized the data on the multiple batches of UFHs
of different origins demonstrating minimal variations.313 Despite the use of single batches in
the current studies, the data obtained was found to be consistent with the other reported
studies.
The cross-referencing of UFHs and LMWHs was primarily carried out using the USP
recommended anti-Xa and anti-IIa methods. Because of the anti-Xa and anti-IIa ratio is near
unity for UFHs, studies reported in this dissertation only anti-Xa method-based adjustment
were made for UFHs. In this case, this does not make any difference. Moreover, the anti-Xa
method provides a cumulative estimation of the functional pharmacophore which is the AT
binding site in heparins chains regardless of the MW. The anti-Xa method has been widely
used to pre-standardize LMWHs.
Another limitation of this study is, that all LMWHs were assumed to exhibit a
potency of 100 U/mg. Therefore, all studies in LMWHs were carried out at mass adjusted
concentrations which were directly proportional to the U/mg potency. Evidently, in all studies
the LMWHs exhibited comparable biological response in particular in the anti-Xa assay, the
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concentration curves were almost superimposable. This validated the fact that, these agents
were pre-standardized against the first international standard. Regardless of this, for the
preclinical development, cross validation of the potency is important.
In the HP-I digestion studies, only the results of the higher concentration of this
enzyme at 1 U/ml are included in this dissertation. Additional data by using lower
concentrations of these enzymes may have provided differential depolymerized-based finger
printing of these chains for individual characterization. Complementary data
with heparin digesting enzymes obtained in conjunction with chain mapping is consistent to
the data obtained at higher concentration of HP-I. In future studies, additional studies can be
carried out by using HP-I at lower concentrations to validate the data presented in this
dissertation.
UFHs are used in broad range of high concentrations (1-10 U/ml) in interventional
and cardiovascular surgical procedures. ACT methods have been used to determine the
circulating levels of heparins these procedures. One of the limitations of these studies was,
the use of only celite ACT at relatively lower concentrations of UFHs at 1 U/ml and 10
ug/ml. These studies should be carried out in a broader range (2.5-7.5 U/ml) of UFHs and
their respective neutralization by PS at varying concentrations to mimic clinical usage.
However, the reported studies in this dissertation provided a valid data on the importance of
the potency adjustment on the anticoagulant responses as measured by the ACT.
The in vitro PS neutralization studies were carried out at a fixed concentration of PS
of 10 ug/ml. In some of the assays particularly in the case of anti-Xa, PS was not capable of
neutralizing the effects of heparins at higher concentrations. This was particularly true with
LMWHs where PS neutralization was minimal due to the disproportional molar ratios.
Therefore, PS should have been used at higher concentrations to deflect the molar proportions
with LMWHs. Despite this limitation, the data presented herein provided comparable
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neutralization of the mass-based concentrations of heparins. In the case of UFHs, it provided
clinically relevant data for the increased amounts of PS needed for the neutralization of
potency adjusted BMH.
In the AIPA studies, the reported results did not reveal any activation of platelets by
either UFHs or LMWHs. This is due to the fact that, the agonist used produced supra
maximal aggregation responses. Such studies should have been carried out in a submaximal
aggregation response which could have been augmented by heparins. Other experimental
factors such as platelet counts, and donor selection may have also contributed to this
outcome. However, these studies clearly demonstrated that, UFHs and LMWHs do not inhibit
platelet aggregation at a concentration range of 0-10 ug/ml.
For the HIT antibody meditated platelet aggregation studies, only three concentrations
were used in the range of 0-10 ug/ml. These are relatively low concentrations and for the
parabolic responses, these studies should have been carried out in a concentration range of 0100 ug/ml. Modified methods have recently become available to perform such studies in a
smaller volume of samples and will provide useful information.
In regard to the PK/PD profiles of these drugs, a few experimental limitations should
be mentioned. The PK/PD studies carried out in individual group of animals with only 4
primates included for each agent. A larger group comprised of 6 -8 animals is usually
included in such studies. There is inter-animal variability (i.e., hepatic function, age, sex, and
weight) which may contribute to the group variations. The duration of the PK/PD studies was
relatively short in both the IV and SC studies. Moreover, the number of blood draws were
limited to 6 samples per study. The UFHs were only studied in the IV protocols whereas, the
LMWHs were studied in the SC studies. It would have been preferable to carry out these
studies in both regimen at variable mass and potency adjusted dosages. Regardless these
limitations, the data presented in this dissertation showed comparable PK/PD behavior of
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UFHs at potency adjusted IV dosages. The LMWHs also provided comparable PK/PD data in
the SC studies.
The neutralization studies were carried out at a fixed dosage of PS (0.5 mg/kg) with
both the UFHs and LMWHs in primates. A higher PS dosage of 1-2 mg/kg may have
provided additional insight of the neutralization of the LMWHs. The duration of the study
was also limited to a 2-hour period, which precluded determining whether the extent of
heparin rebound differs with the various heparins. Such a study may have provided relevant
data in a time period of 12 hours. Additionally, in this study only anti-Xa and anti-IIa
activities were monitored. Global anticoagulant assays such as the activated partial
thromboplastin time (aPTT) and thrombin generation inhibition (TGA) assays may provide
additional information of the relative neutralization of UFHs and LMWHs. Despite these
limitations, these studies clearly showed that, potency adjusted UFHs were effectively
neutralized by PS. However, the LMWHs were only partially neutralized by PS at the
dosages studied. Nonetheless, the neutralization profile of all LMWHs were comparable at
the dosages studied. An increased dosage of PS may provide more effective neutralization of
these agents for the IV settings.
The absolute concentration of UFHs and LMWHs were measured using Heparin Red
assay and cross-referencing the circulating levels against each of the agent studied in the
PK/PD investigation. Other methods such as the LC-MS based approaches may provide
complementary data and further validate the data generated in this dissertation.
The integrated biological studies reported herein are primarily based on the PK/PD
analysis. However, the antithrombotic and bleeding profiles using valid animal model were
not carried out. Such studies will further underscore that, potency adjusted heparins will
exhibit comparable effects.

266
Despite these limitations, this dissertation has clearly validated that heparins and
related drugs can be cross-referenced against their respective standards to provide more
uniform biological outcomes. While different pharmacopeial standards are available, the USP
reference standard is widely used globally for cross-referencing UFHs. The LMWHs are
cross-referenced against an established international standard and have provided a uniform
approach in potency designation of these agents. The use of these standards and the dosing of
heparins at cross-referenced equivalent potency therefor provide a rational approach in
demonstrating the biosimilarity of these agents. The data presented in this dissertation has
therefore validated the primary proposal and the hypothesis that potency adjusted heparins
will produce comparable biological effects and warrant clinical validation.
Clinical Implications
Heparins and GAG are widely present in mammalian tissues such as lung and
intestine. Sizable quantities of mammalian tissues can be obtained from meat packing plants
to manufacture heparins from bovine and ovine sources. Most of the heparins used in the
Western hemisphere is obtained pig mucosal tissue. The data presented in this dissertation
clearly suggests that, heparins can be derived from bovine and ovine sources and upon crossreferencing exhibit comparable anticoagulant activities. Moreover, depolymerization
processes provide comparable LMWHs exhibiting biosimilar profiles.
This data is also supportive of the proposal that standardized UFHs and their products
can be blended and are likely to exhibit comparable anticoagulant and antithrombotic effects
in reference to the single sourced heparin. Drugs of biological origins such as insulin and
growth factors have been manufactured in standardized conditions and commercialized in
blended form. This will alleviate the problem associated with single sourced heparin.
Moreover, it will provide a purposeful use of tons on mucosal tissue of mammalian origins
which is currently wasted.

267
The data provided in this dissertation is also helpful in providing the guidelines for the
effective neutralization of the bleeding and other undesirable effects of heparins. It also
points out to the necessity of optimizing the approaches for the neutralization of LMWHs.
More importantly, the results obtained on the biophysical interactions of heparins and
PF4 indicate that despite certain structural differences, the complexes formed are comparable
between these polymers. Furthermore, the HIT mediated platelet aggregation studies reveal
that, there is no difference among these agents in mediating such responses. This is in
contrast to the widely believed notion that bovine heparins produced stronger HIT responses.
The PK/PD responses of the heparins as studied by using the functionally derived
concentrations further validate that, potency adjusted heparins will provide predictable
responses. Therefore, dosing of these agents can be harmonized and some of the functional
assays included in this study can be used for optimal monitoring of heparins.
Notably, the use of primate model in the study of PK/PD profile of heparins provide a
comparable information which can be easily translated into projected human responses.
Therefore, this will minimize the necessity of carrying out human trails which will be helpful
in fast tracking for the approval of biosimilar heparins of different origins.
Finally, based on the data provided in this dissertation it can be concluded that,
porcine mucosal sourced heparins should not be considered as the sole anticoagulants.
Heparins from cow and sheep demonstrate anticoagulant effects which can be optimized to
exhibit comparable pharmacological profiles, offering logical interchangeable substitutes.
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CHAPTER SIX
SUMMARY
This dissertation addresses a wide array of the biochemical and pharmacological
investigations on unfractionated heparins and their depolymerized derivatives derived
from different animal sources. The experimental approaches molecular and structural
characterization, biochemical and pharmacological profiling in functional assays were
used to identify an approach for the harmonization of their anticoagulant effects. A
summary of results from the major experimental protocols included in this dissertation is
provided below in separate sections.
Physicochemical Characterization of Various UFHs and LMWHs
1. BMH, OMH and PMH heparins exhibited comparable molecular weight (MW) profiles as
determined by the size exclusion chromatography. The MW profile of all agents ranged
of 17.3±0.6 kDa-21.6±1.6 kDa. The depolymerized counterparts of UFHs exhibited
comparable MW profiles in the range of 4114±79 Da-4139±84 Da. UFHs and LMWHs
were found to be degraded by heparinase-I (HP-I) resulting in oligosaccharides
containing 4-10 hexose units.
2. Nuclear magnetic resonance (NMR) analysis showed that, the degree of sulfation of PMH
was higher compared to OMH whereas, BMH has the lowest degree of sulfation. This
analysis also showed that, the degree of acetylation of OMH was higher compared to
PMH whereas, BMH has the lowest degree of acetylation. The degree of sulfation and
acetylation of all LMWHs from various animal sources were comparable. None of the
heparins exhibited any signals related to the presence of over sulfated chondroitin sulfate
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(OSCS) and dermatan sulfate (DS).
3. Disaccharide compositional analysis revealed lower TriS % with the BMH in comparison
to PMH and OMH. All LMWHs showed comparable TriS % levels. The UFHs showed a
broader range of the degree of acetylation whereas the LMWHs lower degree in a
relatively narrow range.
4. Bottom-Up LC-MS analysis of oligosaccharides fragments showed that, all UFHs and
LMWHs from different animal sources have comparable fragmentation profiles however,
minor variations were noted. In the Top-Down analysis all LMWHs exhibited similar
oligosaccharides composition in terms of unsaturated disaccharide/oligosaccharides,
saturated uronic acid oligosaccharides, and 1,6-anhydroamino group oligosaccharides.
In Vitro Functional Studies of Various UFHs and LMWHs
1. The global anticoagulant and antiprotease effects of the gravimetric-based BMH were
consistently lower than PMH and OMH except in the PiCT test where all gents showed
comparable results. Upon adjustment of the USP potency of all UFHs, all agents
exhibited comparable responses. Pre standardized LMWHs when compared at
gravimetric levels, exhibited similar global anticoagulant and antiprotease effects.
2. In the purified AT supplemented system at gravimetric levels, PMH and OMH produce
comparable inhibitory effects in anti-Xa and anti-IIa assays which were stronger than
BMH however, upon potency adjustment all agents exhibited comparable inhibition in
terms of IC50 values. On the other hand, all LMWHs produced similar inhibition of these
enzymes.
3. The USP complaint chromogenic based anti-Xa/anti-II assays provided comparable USP
potency of OMH and PMH (185-190 U/mg) whereas, BMH exhibited relatively lower
values (134-140 U/mg). Upon potency adjustment, all UFHs exhibited comparable
results. All LMWHs exhibited comparable USP anti-Xa (96.5-99.3 U/mg) and anti-IIa
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4.

(37.6-39.3 U/mg) activities. The anti-Xa/IIa ratio for all UFHs were comparable and
ranged (0.98-1.1), these ratios were much higher with LMWHs (3.2-3.5) and yet
comparable.
In Vitro Neutralization Studies of Various Heparins and LMWHs

1. Protamine sulfate (PS) neutralization studies of at gravimetric levels of UFHs showed
that, all agents were comparably neutralized to almost the same degrees in all assays.
However, upon potency adjustment, BMH required increased amounts of PS for its
neutralization. All LMWHs exhibited partial assay dependent neutralization by PS which
was prominent with the anti-Xa assays.
2. Heparinase-I (HP-I) studies showed that, the anticoagulant and antiprotease activities of
all UFHs and LMWHs from diverse animal origins (bovine, ovine and porcine) were
completely neutralized by this enzyme.
3. Platelet factor 4 (PF4) neutralization studies demonstrated that, the anticoagulant
activities of all gravimetric-based UFHs were comparably neutralized in all assays.
However, upon potency adjustment, BMH required increased amounts of PF4 for its
neutralization. All LMWH preparations (ug/ml) were partially neutralized by PF4 as
measured by the amidolytic anti-Xa and anti-IIa assays.
Platelet Function Profile of Various Heparins and LMWHs
1. Agonist induced Platelet aggregation (AIPA) studies showed that, all UFHs produced
comparable effects (aggregation % & aggregation rate) on platelet aggregation at various
concentrations of gravimetric and potency-equated based levels. The same trends were
noted in AIPA studies for LMWHs which demonstrated similar effects (aggregation % &
aggregation rate) on platelet aggregation at various concentrations. All LMWHs showed
similar aggregation compared to UFHs with relatively slower rate of aggregation.
2. Heparin-induced platelet aggregation (HIPA) studies showed that, all gravimetric-based
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and potency adjusted-based UFHs produced comparable responses in HIT antibody
mediated aggregation at the same concentrations. LMWHs produced comparable
responses which were relatively weaker in comparison to UFHs.
Characterization of Heparin/Platelet Factor 4 (PF4) Interaction
1. Photon-correlation spectroscopy (PCS) studies showed that, BMH and PMH preparations
formed comparable ultra large complexes (ULCs) with PF4. Whereas OMH formed
relatively larger aggregates. All LMWHs formed comparable complexes with PF4 and
unlike UFHs, these agents did not form ULCs reaching maximal aggregation at much
lower PF4-heparin ratios.
2. Zeta potential (Zp) measurement studies showed that, all UFHs derived from various
animal origins reached Zp=0 (Neutral state of complex) at comparable PHR ratios which
ranged from 9 to 12.9. However, all LMWHs reached Zp=0 (Neutral state of complex) at
much lower PHR ratios which ranged from 3 to 3.6.
In Vivo Studies in Non-Human Primates
1. Pharmacodynamic (PD) profiles as determined by various anticoagulant and antiprotease
assays showed that, at gravimetric based dosage (0.5 mg/kg, IV), OMH and PMH
produced comparable effects which were relatively stronger than BMH. Upon potency
adjustment, all UFHs produced comparable anticoagulant and antiprotease effects. All
LMWHs at mass-based dosing (1 mg/kg, SC) produced comparable PD effects.
2. Pharmacodynamic (PD) profiles as determined by the TGA assay showed that, all UFHs
(0.5 mg/kg and 100 U/kg) produced comparable thrombin inhibitory effects and TGA
parameters in terms of peak thrombin, AUC and Lag time. All LMWHs (1 mg/mg, SC)
produced similar TGA profiles.
3. Pharmacodynamic (PD) profile as determined by the TFPI antigen assay showed that, at
gravimetric based dosages (0.5 mg/kg, IV) BMH produced relatively lower TFPI antigen
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levels compared to OMH and PMH. The overall TFPI antigen levels of OMH and PMH
were comparable at the indicated dosages. However, all potency adjusted dosages (100
U/kg, IV) of all UFHs produced comparable TFPI antigen levels. TFPI functional levels
showed that, all UFHs (0.5 mg/kg and 100 U/kg) produced comparable TFPI functional
levels in non-human primate model.
4. Pharmacodynamic (PD) profiles as determined by the TFPI antigen and functional levels
assays showed that, all LMWHs (1 mg/kg, SC) produced comparable release in nonhuman primate model.
5. Pharmacokinetic (PK) parameters as determined by the concentrations derived from the
anti-Xa and anti-IIa activities showed that, both the gravimetric-based and USP potency
adjusted-based BMH dosages exhibited relatively longer half -life (t1/2) compared to PMH
and OMH dosages. No significant differences were noted in AUC, Vd and Cl parameters.
All LMWHs dosages (1 mg/kg, SC) exhibited comparable PK profiles in terms of t1/2,
AUC, Cmax, Vd and Cl.
6. Absolute PK parameters as determined by the Heparin Red assays showed that, all
gravimetric-based UFHs dosages (0.5 mg/kg, IV) exhibited comparable PK profiles with
minor differences in terms of t1/2, AUC, Cmax, Vd and Cl. The USP potency adjustedbased BMH (100 U/kg, IV) exhibited relatively higher AUC and slower Cl rate compared
PMH and OMH (100 U/kg, IV) whereas, no differences were noted in t1/2 and Vd
parameters. All LMWHs (1 mg/kg, SC) exhibited comparable PK profiles with minor
differences in terms of t1/2, AUC, Cmax, Vd and Cl.
7. In vivo PS neutralization profile in non-human primates as determined by the anti-Xa,
anti-IIa and Heparin Red assays showed that, PMH, BMH and OMH at various dosages
(0.5 mg/kg and 100 U/kg, IV) exhibited comparable PS neutralization profiles as
determined by all assays. However, slightly higher residual levels observed in the BMH
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(100 U/kg, IV) in comparison to PMH and OMH. All LMWHs at dosages of 1 mg/kg
(IV) were partially yet comparably neutralized by PS (0.5 mg/kg) as determined by all
assays.

CHAPTER SEVEN
CONCLUSIONS
The primary purpose of this dissertation was to compare the structural and functional
characteristics of BMH, OMH and PMH and their depolymerized derivatives (LMWHs).
Furthermore, to test the hypothesis that “Despite molecular components distribution and
minor structural differences, potency referenced heparins of different animal origins
and their depolymerized derivatives may exhibit similar pharmacological activities”. To
validate this hypothesis, the currently available heparins which are under development were
investigated. This offered an integrated platform to scientifically address the structural and
functional characteristics of these agents and to explore the means to harmonize their
biological activites which may translate to their clinical effects.
Mammalian tissues such as the intestinal mucosa have provided sizable sources for
the manufacture of heparins. Besides bovine, ovine and porcine sources, other animals such
as goat and buffalo may also be useful in the manufacture of heparins. The depolymerization
of these agents results in process based LMWHs with comparable profiles.
The studies presented in this dissertation have demonstrate that despite minor
molecular and structural differences, heparins obtained from various species including
bovine, ovine and porcine sources mediate their anticoagulant effects primarily via AT
binding consensus sequences in the component chains. This Serpin interaction is also the
basis for the potency standardization and cross-referencing heparins. pharmacodynamic
actions contributing to the anticoagulant effects of heparins independent of Serpin
interactions include TFPI release, protease generation inhibition and vascular modulations.
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Functional methods such as the inhibition of factor Xa and thrombin can be used for
the standardization and cross-referencing of UFHs utilizing a pharmacopeial reference. The
functional potency adjustment provides guidance to equate anticoagulant potency of UFHs.
The potency adjusted UFHs demonstrate comparability in various functional assays utilized
which are commonly used to evaluate heparins. The LMWHs of various origins are also
standardized using an international NIBSC standard employing the anti-Xa method. Prestandardized enoxaparins of various origins exhibit comparable biologic profiles.
Heparinase-I digestion revealed that, both the UFHs and LMWHs are digested
comparably resulting in a complete loss of their anticoagulant and antiprotease activities. PS
and PF4 differentially neutralized UFHs in an assay dependent manner and required higher
amounts of these agents for the BMH at potency adjusted levels. The LMWHs are not
effectively neutralized by PS and PF4 due to composition differences including charge
density and chain distribution.
These studies did not demonstrate any differences between the various UFHs and
LMWHs in their platelet modulatory effects in the AIPA. More importantly, in the HIT
antibody mediated aggregation of platelet, no differences were noted among the UFHs. This
finding does not support the notion that, BMH produces stronger HIT mediated responses.
The LMWHs exhibit relatively lower effects in the Hit mediated studies at comparable levels.
The primate model provides physiologically relevant platform to validate the PK/PD
response at both the gravimetric and potency adjusted dosing and PS neutralization profiles
of these agents. The primate’s coagulation profile and anticoagulant responses of various
agents are similar when compared to human blood plasma. The heparinization sensitivity of
both primate and human plasmas are found to be identical in multiple assays.
Potency adjustment of UFHs and subsequent IV dosing validates the hypothesis that,
the biological actions of UFHs are comparable. This is evident with the BMH where the mass
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dosing comparisons show weaker in vivo effects which are not observed with this agent when
administrated at potency equated dosing in the functional assays. However, the absolute
quantification of GAG contents confirms higher levels of circulating BMH which is
proportional to the increased amounts of this agent used for potency adjustment. Moreover,
higher amounts of PS are required for potency adjusted BMH. The behavior of pre
standardized enoxaparins is comparable in the PK/PD and neutralization studies.
In conclusion, these studies have underscored the concept that the minor structural
differences with the exception of pentasaccharide binding sequence in heparins may not
influence the overall anticoagulant activity. These studies have also provided new
information on the interaction of Serpins in mediating the functional activities which may be
helpful in the developing of newer heparins and heparinomimetics. This will lead to designer
heparins with adjustable anti-Xa and anti-IIa activities and desirable PK/PD priorities.
Moreover, these studies also support the notion that pharmacopeial potency adjustment may
result in bioequivalent product with comparable clinical profiles.
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APPENDIX A
SUPPLEMENTAL DATA TABLES
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TABLE 1
COMPARATIVE MOLECULAR WEIGHT PROFILES OF BOVINE, OVINE AND
PORCINE HEPARINS AS MEASURED BY THE NRC METHOD
A- Detector/Method: UV (205 nm)/NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

Porcine heparin (PMH)

15504±757

18911±580

1.21±0.12

Bovine heparin (BMH)

17003±845

21634±654

1.39±0.13

Ovine heparin (OMH)

12639±781

17311±604

1.22±0.11

B- Detector/Method: RI /NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

Porcine heparin (PMH)

16354±686

19919±627

1.22±0.15

Bovine heparin (BMH)

17468±662

22002±654

1.37±0.17

Ovine heparin (OMH)

12894±640

17469±599

1.23±0.12

All results represent the mean (±) standard deviation (n=3). The molecular weights of various
unfractionated heparins were determined by gel permeation chromatography. Mw is the weight
average molecular weight, and Mn is the number average molecular weight. The calculated
MWs were comparable between the UV and RI detectors NRC, narrow range calibrators; SD,
standard deviation.
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TABLE 2
COMPARATIVE MOLECULAR WEIGHT PROFILES OF BOVINE, OVINE AND
PORCINE LOW MOLECULAR WEIGHT HEPARINS AS MEASURED BY THE NRC
METHOD
A- Detector/Method: UV (205 nm)/NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

Porcine LMWH

3497±133

4171±75

1.18±0.11

Bovine LMWH

3447±128

4114±79

1.19±0.13

Ovine LMWH

3499±121

4139±84

1.16±0.11

B- Detector/Method: RI /NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

Porcine LMWH

3972±101

4465±98

1.15±0.12

Bovine LMWH

3926±98

4391±87

1.12±0.12

Ovine LMWH

3948±108

4389±102

1.14±0.13

All results represent the mean (±) standard deviation (n=3). The molecular weights of various
low molecular weight heparins were determined by gel permeation chromatography. Mw is the
weight average molecular weight, and Mn is the number average molecular weight. The
calculated MWs were comparable between the UV and RI detectors NRC, narrow range
calibrators; SD, standard deviation.
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TABLE 3
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR VARIOUS HEPARINS
PRE AND POST HEPARINASE-I DIGESTION AS MEASURED BY THE NRC
METHOD
A- Detector/Method: UV (205 nm)/NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

PMH-Pre

15159±218

18247±208

1.24±0.12

BMH-Pre

16389±221

21986±251

1.31±0.14

OMH-Pre

13430±248

16654±234

1.21±0.13

PMH-Post

3115±122

3147±196

1.03±0.12

BMH-Post

3130±113

3086±163

1.05±0.11

OMH-Post

2994±102

3312±189

1.03±0.12

B- Detector/Method: RI /NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

PMH-Pre
BMH-Pre
OMH-Pre
PMH-Post
BMH-Post

16156±349
17154±419
15003±447
3152±157
3254±137

19146±208
22282±258
17088±242
3223±159
3361±188

1.32±0.15
1.23±0.17
1.28±0.16
1.09±0.13
1.05±0.12

OMH-Post

3209±140

3427±197

1.06±0.13

All results represent the mean (±) standard deviation (n=3). The molecular weights of various
heparins pre and post heparinase-I digestion (FC : 1 U) were determined by gel permeation
chromatography. Mw is the weight average molecular weight, and Mn is the number average
molecular weight. The calculated MWs were comparable between the UV and RI detectors.
NRC, narrow range calibrators.
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TABLE 4
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR VARIOUS LOW
MOLECULARE WEIGHT HEPARINS PRE AND POST HEPARINASE-I DIGESTION
AS MEASURED BY THE NRC METHOD
A- Detector/Method: UV (205 nm)/NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

P. LMWH-Pre

3384±149

4008±187

1.18±0.13

B. LMWH-Pre

3542±165

4126±159

1.16±0.14

O. LMWH-Pre

3630±139

4187±171

1.15±0.11

P. LMWH-Post

2145±87

2289±111

1.06±0.1

B. LMWH-Post

2125±99

2249±134

1.05±0.12

O. LMWH-Post

2152±65

2282±126

1.06±0.13

B- Detector/Method: RI /NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity Index

P. LMWH-Pre
B. LMWH-Pre
O. LMWH-Pre
P. LMWH-Post
B. LMWH-Post

3942±166
3840±179
3663±142
2072±77
2028±65

4362±213
4526±222
4150±198
2162±101
2095±98

1.1±0.11
1.12±0.15
1.13±0.13
1.04±0.12
1.03±0.15

O. LMWH-Post

2068±99

2114±79

1.01±0.11

All results represent the mean (±) standard deviation (n=3). The molecular weights of various
low molecular weight heparins pre and post heparinase-I digestion (FC : 1 U) were determined
by gel permeation chromatography. Mw is the weight average molecular weight, and Mn is the
number average molecular weight. The calculated MWs were comparable between the UV and
RI detectors. NRC, narrow range calibrators.
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TABLE 5
COMPOSITION OF VARIOUS HEAPRINS AND LOW MOLECULAR WEIGHT
HEPARINS FROM DIFFERENT ANIMAL SOURCES USING ONE-DIMENSIONAL
(1D) PROTON AND CARBON NMR ANALYSIS

Agents

GlcNS6X

GlcNAc6X

GlcNX3S6X

GlcNY6S IdoA2S

IdoA

GlcA

PMH
St. Dev

84.5%
±0.92%

15.5%
±0.27%

5.4%
±0.92%

92.5%
±0.07%

62.4%
±0.88%

7.2%
±0.37%

30.3%
±0.92%

BMH
St. Dev
OMH
St. Dev

91.6%
±0.44%
90.7%
±0.66%

8.4%
±0.01%
9.3%
±0.09%

19.4%
±0.44%
2.6%
±0.66%

95.8%
±0.09%
92.9%
±0.16%

74.9%
±0.35%
65.6%
±0.53%

5.7%
±0.10%
4.6%
±0.15%

19.5%
±0.79%
29.8%
±0.43%

P. LMWH
St. Dev

91.6%
±0.47%

8.4%
±0.03%

17.5%
±0.47%

94.7%
±0.20%

69.8%
±0.32%

3.9%
±0.02%

26.2%
±0.18%

B. LMWH
St. Dev

92.6%
±0.47%

7.4%
±0.09%

5.0%
±0.47%

94.7%
±0.20%

70.9%
±0.63%

5.6%
±0.45%

23.5%
±0.55%

O. LMWH
St. Dev

90.8%
±0.54%

9.2%
±0.11%

17.7%
±0.54%

94.7%
±0.20%

74.5%
±0.52%

6.8%
±0.35%

18.7%
±0.45%

All results represent the mean (±) standard deviation (n=3). All samples were analyzed using
one-dimensional (1D) proton and carbon NMR at 800 MHz of D2O exchanged heparin in D2O
on a Bruker Advance II 800 MHz spectrometer (Bruker Bio Spin, Billerica, Massachusetts) with
Topsin 3.2.6 software (Bruker Bio Spin) NMR spectrometer for signal integration. GlcN,
Glucosamine; IdoA, Iduronic acid; GlcA, Glucuronic acid; Ac, Acetyl; S, Sulfate.
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TABLE 6
COMPARATIVE ANTICOAGULANT EFFECTS OF VARIOUS HEPARINS AND
LMWHs IN WHOLE HUMAN BLOOD AS MEASURED BY THE ACT SYSTEM
Agents
UFHs
10 ug/ml
Mean±SD
Agents
UFHs
1 U/ml
Mean±SD
Agents
LMWHs
25 ug/ml
Mean±SD

PMH
Sec
293
290
288
352
383
321±9
PMH
Sec
310
322
318
318
301
313±11
P. LMWH
Sec
217
230
237
220
219
224±8

BMH
Sec
263
253
254
247
251
253±9
BMH
Sec
325
311
317
301
298
310±10
B. LMWH
Sec
222
213
226
217
239
223±12

OMH
Sec
330
303
312
371
328
328±12
OMH
Sec
321
328
323
305
288
313±9
O. LMWH
Sec
208
228
225
215
203
215±9

Saline
Sec
132
140
125
140
135
134±8
Saline
Sec
136
128
125
140
135
132±9
Saline
Sec
123
134
119
138
105
123±7

All results represent the mean (±) standard deviation (n=3). Comparative anticoagulant effects of
various heparins and LMWHs in whole human blood as measured by the ACT system (n = 5-7).
ACT; activated clotting time. PMH; porcine mucosal heparin, BMH; bovine mucosal heparin,
OMH; ovine mucosal heparin, LMWH; low molecular weight heparin.
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TABLE 7
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARINS (µg/ml)
IN BLOOD BANK PLASMA (BBP) AS MEASURED BY APTT AND TT ASSAYS
A- Activated Partial Thromboplastin Time (aPTT) Assay
Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

PMH
Time (sec)

BMH
Time (sec)

OMH
Time (sec)

300±0.0
300±0.0
108±9.8
60±4.9
32.5±2.8
28.45±3.7

300±0.0
207±13.7
78.5±6.9
45.9±7.4
28.95±4.2
28.45±3.7

300±0.0
300±0.0
137.5±15.3
65.5±4.8
38.8±5.9
28.45±3.7

B- Thrombin Time (TT) Assay
Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

PMH
Time (sec)

BMH
Time (sec)

OMH
Time (sec)

300±0.0
300±0.0
300±0.0
300±0.0
18.6±3.2
9.4±1.5

300±0.0
300±0.0
300±0.0
82±0.0
13±2.9
9.4±1.5

300±0.0
300±0.0
300±0.0
300±0.0
17.7±3.2
9.4±1.5

All results represent the mean (±) standard deviation (n=3). All agents were supplemented in the
BBP over a concentration range of 0 to 10 µg/ml. Comparative anticoagulant effects in blood
bank plasma (BBP) as measured by the APTT (A) and TT (B) assays.
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TABLE 8
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARINS (U/ml) IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY APTT AND TT ASSAYS
A- Activated Partial Thromboplastin Time (aPTT) Assay
Concentration
(U/ml)
1
0.5
0.25
0.125
0.062
0

PMH
Time (sec)

BMH
Time (sec)

OMH
Time (sec)

300±0.0
300±0.0
46.35±4.3
35.5±4.3
32±6.3
29.95±4.4

300±0.0
300±0.0
48.75±5.3
36.1±3.8
32.5±2.5
29.95±4.4

300±0.0
300±0.0
43.85±4.5
34.6±5.1
31.7±4.2
29.95±4.4

B- Thrombin Time (TT) Assay
Concentration
(U/ml)
1
0.5
0.25
0.125
0.062
0

PMH
Time (sec)

BMH
Time (sec)

OMH
Time (sec)

300±0.0
300±0.0
300±0.0
19±2.2
15.15±4.1
14.1±2.1

300±0.0
300±0.0
300±0.0
25.75±3.1
16.2±3.3
14.1±2.1

300±0.0
300±0.0
300±0.0
16.45±3.3
16.6±2.5
14.1±2.1

All results represent the mean (±) standard deviation (n=3). All agents were supplemented in the
BBP over a concentration range of 0 to 1 U/ml. Comparative anticoagulant effects in blood bank
plasma (BBP) as measured by the APTT (A) and TT (B) assays.
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TABLE 9
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS LMWHs (ug/ml) IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY APTT AND TT ASSAYS
A- Activated Partial Thromboplastin Time (aPTT) Assay
Concentration
(ug/ml)
10
5
2.5
1.25
0.625
0

P. LMWH
Time (sec)

B. LMWH
Time (sec)

O. LMWH
Time (sec)

300±0.0
300±0.0
46.35±4.3
35.5±4.3
32±6.3
29.95±4.4

300±0.0
300±0.0
48.75±5.3
36.1±3.8
32.5±2.5
29.95±4.4

300±0.0
300±0.0
43.85±4.5
34.6±5.1
31.7±4.2
29.95±4.4

B- Thrombin Time (TT) Assay
Concentration
(ug/ml)
10
5
2.5
1.25
0.625
0

P. LMWH
Time (sec)

B. LMWH
Time (sec)

O. LMWH
Time (sec)

300±0.0
300±0.0
300±0.0
19±2.2
15.15±4.1
14.1±2.1

300±0.0
300±0.0
300±0.0
25.75±3.1
16.2±3.3
14.1±2.1

300±0.0
300±0.0
300±0.0
16.45±3.3
16.6±2.5
14.1±2.1

All results represent the mean (±) standard deviation (n=3). All agents were supplemented in the
BBP over a concentration range of 0 to 1 U/ml. Comparative anticoagulant effects in blood bank
plasma (BBP) as measured by the APTT (A) and TT (B) assays.
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TABLE 10
COMPARATIVE ANTICOAGULANT EFFECTS VARIOUS HEPARINS AND LOW
MOLECULAR WEIGHT HEPARINS IN POOLED HUMAN PLASMA OF AS
MEASURED BY THE PICT ASSAY
A- UFHs – ug/ml
Concentration
(ug/ml)
10
5
2.5
1.25
0.625
0
Concentration
(U/ml)
1
0.5
0.25
0.125
0.062
0
Concentration
ug/ml)
10
5
2.5
1.25
0.625
0

PMH
BMH
Sec
Sec
280±12
265±14
209±13
194±12
111±9
95±10
63±5
57±9
30±6
34±3
24±2
24±2
B- UFHs – U/ml
PMH
BMH
Sec
Sec
246±16
254±15
204±12
205±12
115±9
115±9
59±3
60±7
37±5
35±4
23±3
23±3
C- LMWHs – ug/ml
P. LMWH
Sec
173±9
108±8
73±8
52±6
37±4
26±3

B. LMWH
Sec
177±12
104±8
74±5
53±5
37±4
26±3

OMH
Sec
281±10
218±11
112±9
58±5
37±4
24±2
OMH
Sec
245±12
220±10
118±8
57±7
36±6
23±3
O. LMWH
Sec
184±9
108±10
71±7
52±6
38±3
26±3

All results represent the mean (±) standard deviation (n=3). All heparins were supplemented in
the pooled human plasma over a concentration range of 0-10 µg/ml (A) and 0-1 U/ml (B). All
LMWHs were supplemented in the pooled human plasma over a concentration range of 0-10
µg/ml (C).
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TABLE 11
COMPARATIVE THROMBIN GENERATION INHIBITORY (TGA) PROFILE OF
VARIOUS HEPARINS (ug/ml) IN TERMS OF PEAK THROMBIN , AREA UNDER THE
CURVE, AND LAG TIME
UFHs – ug/ml
Concentration
PMH
BMH
OMH
ug/ml
0
134.36±12
134.36±11
134.36±13
0.62
99.36±8
102.21±12
102.59±12
Peak Thrombin
1.25
21.53±3.2
40.35±3.2
24.39±3.8
nM
2.5
5.37±1.2
12.98±1.3
5.63±1.1
5
0.74±.01
2.31±0.7
1.13±0.1
10
0.31±0.01
0.59±0.02
0.12±0.03
Concentration
PMH
BMH
OMH
ug/ml
0
704.13±64
704.13±76
704.13±79
0.62
571.94±46
545.08±54
594.29±44
AUC
1.25
382.83±33
431.07±39
428.67±32
nM*min
2.5
165.25±12
228.81±19
192.30±21
5
0.00±0
123.70±14
0.00±0
10
0.00±0
0.00±0
0.00±0
Concentration
PMH
BMH
OMH
ug/ml
0
2.73±0.3
2.73±0.1
2.73±0.3
0.62
2.77±0.2
2.41±0.3
2.77±0.4
Lag Time
1.25
3.98±0.7
2.87±0.2
3.89±0.7
min
2.5
8.01±1.1
4.81±0.8
8.53±1.4
5
11.59±2.7
8.06±1.8
11.97±2.1
10
61.94±6.4
26.28±2.8
59.89±7.4
All results represent the mean (±) standard deviation (n=3). Inhibition of thrombin generation
was measured by Fluoroskan ascent fluorimeter, calibrated automated thrombogram (CAT;
Diagnostica Stago). All heparins were supplemented in normal pooled plasma over a
concentration range of 0 – 10 µg/ml.
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TABLE 12
COMPARATIVE THROMBIN GENERATION INHIBITORY (TGA) PROFILE OF
VARIOUS HEPARINS (U/ml) IN TERMS OF PEAK THROMBIN , AREA UNDER THE
CURVE, AND LAG TIME
UFHs – U/ml
Concentration
PMH
BMH
OMH
U/ml
145.36±12
151.36±11
149.36±13
0
114.8±8
118.21±12
116.59±12
0.0625
Peak Thrombin
28.54±3.2
24.35±3.2
25.39±3.8
nM
0.125
9.77±1.2
10.98±1.3
11.63±1.1
0.25
1.75±.01
1.31±0.7
1.93±0.1
0.5
0.31±0.01
0.59±0.02
0.12±0.03
1
Concentration
PMH
BMH
OMH
U/ml
729.13±64
766.13±76
734.13±79
0
588.94±46
574.08±54
584.29±44
0.0625
AUC
421.83±33
432.7±39
433.67±32
nM*min
0.125
165.25±12
182.81±19
187.30±21
0.25
0.00±0
0.00±0
0.00±0
0.5
0.00±0
0.00±0
0.00±0
1
Concentration
PMH
BMH
OMH
U/ml
2.74±0.3
2.83±0.1
2.83±0.3
0
2.71±0.2
2.91±0.3
2.67±0.4
0.0625
Lag Time
3.88±0.7
3.87±0.2
4.19±0.7
min
0.125
7.81±1.1
9.81±0.8
7.53±1.4
0.25
11.29±2.7
10.06±1.8
11.07±2.1
0.5
60.94±6.4
66.28±2.8
69.89±7.4
1
All results represent the mean (±) standard deviation (n=3). Inhibition of thrombin generation
was measured by Fluoroskan ascent fluorimeter, calibrated automated thrombogram (CAT;
Diagnostica Stago). All heparins were supplemented in normal pooled plasma over a
concentration range of 0 - 1 U/ml.
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TABLE 13
COMPARATIVE THROMBIN GENERATION INHIBITORY (TGA) PROFILE OF
VARIOUS LMWHs (ug/ml) IN TERMS OF PEAK THROMBIN , AREA UNDER THE
CURVE, AND LAG TIME
LMWHs – ug/ml
Concentration
P. LMWH
B. LMWH
O. LMWH
ug/ml
0
134.36±12
136.36±11
144.36±13
0.62
127.36±18
133.21±12
132.59±12
Peak Thrombin
1.25
120±13.2
129.35±16
124.39±13.8
nM
2.5
104±9.2
109.98±7
105.63±9.1
5
49.84±7
55.31±6.7
51.13±5.1
10
14.9±4
16.9±4
17.2±3
Concentration
P. LMWH
B. LMWH
O. LMWH
ug/ml
0
695.13±64
704.13±76
704.13±79
0.62
641.94±46
645.08±54
664.29±44
AUC
1.25
580.83±33
561.9±39
558.67±32
nM*min
2.5
546.25±12
528.8±19
522.30±21
5
446.9±14
443.6±14
453.6±12
10
266±12
271.4±14.3
259.4±13.3
Concentration
P. LMWH
B. LMWH
O. LMWH
ug/ml
0
2.73±0.3
2.79±0.1
2.53±0.3
0.62
2.77±0.2
2.41±0.3
2.37±0.4
Lag Time
1.25
2.98±0.7
2.87±0.2
2.89±0.7
min
2.5
3.01±1.1
3.21±0.8
3.53±1.4
5
3.59±1.7
3.56±1.8
3.97±1.1
10
4.94±1.4
5.28±1.8
5.89±1.4
All results represent the mean (±) standard deviation (n=3). Inhibition of thrombin generation
was measured by Fluoroskan ascent fluorimeter, calibrated automated thrombogram (CAT;
Diagnostica Stago). All LMWHs were supplemented in normal pooled plasma over a
concentration range of 0 – 10 µg/ml.
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TABLE 14
THE INHIBITION OF FACTOR XA AND THROMBIN BY VARIOUS HEPARINS
(µg/ml) IN BLOOD BANK PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC
ANTI-XA AND ANTI-IIA ASSAYS
A- Anti-Xa Assay
Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

PMH
% Inhibition
93.7±6.4
87±3.2
64.45±2.7
32.95±4.1
19.3±2.1
0±0.0

BMH
% Inhibition
84.7±5.2
72.25±4.9
50.4±3.3
30.75±4.4
16.95±2.4
0±0.0

OMH
% Inhibition
96.8±5.7
90.9±6.3
71.2±4.3
35.65±3.9
20.35±1.9
0±0.0

B- Anti-IIa Assay
Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

PMH
% Inhibition

BMH
% Inhibition

OMH
% Inhibition

84.2±4.4
77.35±3.9
68.35±5.5
54.3±3.1
47.45±3.3
0±0.0

75.9±7.3
65.6±5.3
57.95±4.4
42.3±2.2
32.2±3.2
0±0.0

89.05±5.9
83.85±6.4
72.7±7.3
57.5±4.1
48.65±2.9
0±0.0

All results represent the mean (±) standard deviation (n=3). All agents were supplemented in the
BBP over a concentration range of 0 to 10 µg/ml. The inhibition of factor Xa in blood bank
plasma (BBP) as measured by the amidolytic anti-Xa (A) and anti-IIa (B) assays.
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TABLE 15
THE INHIBITION OF FACTOR XA AND THROMBIN BY VARIOUS HEPARINS
(U/ml) IN BLOOD BANK PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC
ANTI-XA AND ANTI-IIA ASSAYS
A- Anti-Xa Assay
Concentration
(U/ml)
1
0.5
0.25
0.125
0.062
0

PMH
% Inhibition
88.85±4.8
67.35±5.9
38.4±4.8
21.8±2.4
14.3±2.2
0±0.0

BMH
% Inhibition
87.85±7.7
64.1±5.6
34.95±4.4
21.65±3.9
13.9±3.1
0±0.0

OMH
% Inhibition
90.2±6.9
66.25±7.7
37.75±5.1
21.2±3.7
14.65±3.2
0±0.0

B- Anti-IIa Assay
Concentration
(U/ml)
1
0.5
0.25
0.125
0.062
0

PMH
% Inhibition

BMH
% Inhibition

OMH
% Inhibition

83.4±7.1
68.1±6.8
32.85±4.5
11.1±2.2
3.9±1.1
0±0.0

81.95±6.7
66.05±4.6
33.05±6.4
12.8±2.6
4.65±1.9
0±0.0

85.65±7.6
70.85±6.3
33.05±4,1
10.3±2.4
4.85±1.7
0±0.0

All results represent the mean (±) standard deviation (n=3). All agents were supplemented in the
BBP over a concentration range of 0 to 1 U /ml. The inhibition of factor Xa in blood bank
plasma (BBP) as measured by the amidolytic anti-Xa assay (A).The inhibition of thrombin
(Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay (B).
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TABLE 16
THE INHIBITION OF FACTOR XA AND THROMBIN BY VARIOUS LMWHs
(µg/ml) IN BLOOD BANK PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC
ANTI-XA AND ANTI-IIA ASSAYS
A- Anti-Xa Assay
Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

P. LMWH
% Inhibition
82.7±6.4
67±3.2
44.45±2.7
32.95±4.1
19.3±2.1
0±0.0

B. LMWH
% Inhibition
81.7±5.2
62.25±4.9
40.4±3.3
30.75±4.4
19.95±2.4
0±0.0

O. LMWH
% Inhibition
80.8±5.7
64.9±6.3
38.2±4.3
35.65±3.9
20.35±1.9
0±0.0

B- Anti-IIa Assay
Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

P. LMWH
% Inhibition

B. LMWH
% Inhibition

O. LMWH
% Inhibition

44.2±4.4
37.35±3.9
30.35±5.5
14.3±3.1
8.45±3.3
0±0.0

45.9±7.3
35.6±5.3
27.95±4.4
18.3±2.2
9.2±3.2
0±0.0

49.05±5.9
33.85±6.4
26.7±7.3
17.5±4.1
8.65±2.9
0±0.0

All results represent the mean (±) standard deviation (n=3). All agents were supplemented in the
BBP over a concentration range of 0 to 10 µg/ml. The inhibition of factor Xa in blood bank
plasma (BBP) as measured by the amidolytic anti-Xa (A) and anti-IIa (B) assays.
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TABLE 17
POTENCY COMARISON FOR VARIOUS HEPARINS AND LOW MOLECULAR
WEIGHT HEPARINS WHEN SUPPLEMENTED IN PURIFIED ANTITHROMBIN
SYSYTEM AS MEAUSERED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA
ASSAYS
A- UFHs – ug/ml
Anti-Xa

Anti-IIa

IC50 (µg/ml)

IC50 (µg/ml)

PMH

2.05±0.34

2.14±0.21

BMH

3.06±0.25

3.05±0.31

OMH

1.92±0.27

2.09±0.28

Drug

B- UFHs – U/ml
Anti-Xa

Anti-IIa

IC50 (U/ml)

IC50 (U/ml)

PMH

0.20±0.03

0.27±0.01

BMH

0.23±0.02

0.28±0.02

OMH

0.21±0.03

0.27±0.02

Drug

B- LMWHs – ug/ml
Anti-Xa

Anti-IIa

IC50 (µg/ml)

IC50 (µg/ml)

3.90±0.53

14.8±.098

B. LMWH

3.78±0.36

14.7±1.03

O. LMWH

3.83±0.48

14.6±1.02

Drug
P. LMWH

All results represent the mean (±) standard deviation (n=3). All heparins were supplemented in
the AT purified system over a concentration range of 0-10 µg/ml (A) and 0-1 U/ml (B). All
LMWHs were supplemented in the AT purified system over a concentration range of 0-20 µg/ml
(C).
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TABLE 18
POTENCY COMARISON FOR VARIOUS HEPARINS AND LOW MOLECULAR
WEIGHT HEPARINS WHEN SUPPLEMENTED IN HEPARIN COFACTOR - II
SYSYTEM AS MEAUSERED BY THE AMIDOLYTIC ANTI-IIA ASSAY

Drug

Anti-IIa

Drug

Anti-IIa

Drug

Anti-IIa

ug/ml

IC50 (ug/ml)

U/ml

IC50 (U/ml)

ug/ml

IC50 (ug/ml)

PMH

4.23±0.21

PMH

0.41±0.03

P. LMWH

13.9±1.1

BMH

4.53±0.31

BMH

0.43±0.06

B. LMWH

13.8±1.1

OMH

4.35±0.28

OMH

0.42±0.05

O. LMWH

14.1±1.2

All results represent the mean (±) standard deviation (n=3). All heparins were supplemented in
the HCII system over a concentration range of 0-20 µg/ml and 0-2 U/ml. All LMWHs were
supplemented in the HCII system over a concentration range of 0-20 µg/ml.
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TABLE 19
THE INHIBITION OF FACTOR XA AND THROMBIN OF VARIOUS HEPARINS IN
ANTITHROMBIN DEPLETED PLASMA (AT-DP) AS MEASURED BY THE
AMIDOLYTIC ANTI-XA AND ANTI-IIA ASSAYS

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

PMH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
91.6±3.4
86.7±4.6
90.5±4.4
84.5±5.1
68.5±3.9
75.4±4.3
47.5±2.7
64.5±3.2
24.5±3.5
46.6±3.7
0±0.0
0±0.0

PMH + AT-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
2.2±0.4
9.7±2.2
1.9±0.4
8.9±1.1
2.3±0.5
7.4±1.3
2.1±0.4
8.5±1.2
1.9±0.3
7.6±1.3
0±0.0
0±0.0

BMH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
80.5±4.4
79±6.7
67.2±3.8
73±5.5
40.3±3.4
66.5±3.7
18.9±2.2
52.9±3.2
4.55±1.8
36.5±4.2
0±0.0
0±0.0

BMH + AT-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
2.1±0.3
8.7±2.4
1.8±0.4
7.9±2.1
2.1±0.5
8.4±1.9
2.1±0.3
7.5±1.2
1.2±0.4
8.6±1.3
0±0.0
0±0.0

OMH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
93.4±5.7
89±8.8
89.9±4.4
87±7.8
74.6±4.3
77.5±8.1
49.75±5.4
70.5±5.3
23.6±3.3
44±5.1
0±0.0
0±0.0

OMH + AT-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
2.2±0.4
9.7±2.4
1.9±0.4
9.9±1.9
2.2±0.6
10.4±2.3
2.3±0.5
10.5±2.2
2.2±0.4
9.6±1.9
0±0.0
0±0.0

All results represent the mean values (±) standard deviation (n=3). All agents were supplemented
in AT-DP over a concentration range of (0 - 10) µg/ml. PMH; porcine mucosal heparin, BMH;
bovine mucosal heparin, OMH; ovine mucosal heparin, AT; antithrombin, DP; depleted plasma.
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TABLE 20
THE INHIBITION OF FACTOR XA AND THROMBIN OF VARIOUS LMWHs IN
ANTITHROMBIN DEPLETED PLASMA (AT-DP) AS MEASURED BY THE
AMIDOLYTIC ANTI-XA AND ANTI-IIA ASSAYS

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

P. LMWH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
82.7±6.4
44.2±4.4
67±3.2
37.35±3.9
44.45±2.7
30.35±5.5
32.95±4.1
14.3±3.1
19.3±2.1
8.45±3.3
0±0.0
0±0.0

P. LMWH + AT-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
1.2±0.4
7.7±2.2
1.9±0.4
8.9±1.1
2.2±0.5
8.4±1.3
3.1±0.4
9.5±1.2
2.9±0.3
9.6±1.3
0±0.0
0±0.0

B. LMWH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
81.7±5.2
45.9±7.3
62.25±4.9
35.6±5.3
40.4±3.3
27.95±4.4
30.75±4.4
18.3±2.2
19.95±2.4
9.2±3.2
0±0.0
0±0.0

B. LMWH + AT-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
2.1±0.3
9.7±2.4
1.8±0.4
8.9±2.1
2.1±0.5
9.4±1.9
2.1±0.3
10.5±1.2
1.2±0.4
10.6±1.3
0±0.0
0±0.0

O. LMWH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
80.8±5.7
49.05±5.9
64.9±6.3
33.85±6.4
38.2±4.3
26.7±7.3
35.65±3.9
17.5±4.1
20.35±1.9
8.65±2.9
0±0.0
0±0.0

O. LMWH + AT-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
2.2±0.4
8.7±2.4
1.9±0.4
8.9±1.9
2.2±0.6
9.4±2.3
2.3±0.5
9.5±2.2
2.2±0.4
10.6±1.9
0±0.0
0±0.0

All results represent the mean values (±) standard deviation (n=3). All agents were supplemented
in AT-DP over a concentration range of (0 - 10) µg/ml. LMWH; low molecular weight heparin,
AT; antithrombin, DP; depleted plasma.
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TABLE 21
THE INHIBITION OF FACTOR XA AND THROMBIN OF VARIOUS HEPARINS IN
HEPARIN COFACTOR-II DEPLETED PLASMA (HCII-DP) AS MEASURED BY THE
AMIDOLYTIC ANTI-XA AND ANTI-IIA ASSAYS

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

PMH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
91.6±3.4
89.7±4.6
90.5±4.4
84.5±5.1
68.5±3.9
75.4±4.3
47.5±2.7
64.5±3.2
24.5±3.5
46.6±3.7
0±0.0
0±0.0

PMH + HCII-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
44±7.4
55.4±6.2
36.7±5.4
50.9±5.1
17.3±3.5
43.4±3.3
9.1±1.4
32.5±4.2
3.9±1.3
20.6±1.3
0±0.0
0±0.0

BMH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
80.5±4.4
79±6.7
67.2±3.8
73±5.5
40.3±3.4
66.5±3.7
18.9±2.2
52.9±3.2
4.55±1.8
36.5±4.2
0±0.0
0±0.0

BMH + HCII-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
42.1±0.3
52.7±2.4
37.8±0.4
47.9±2.1
16.1±0.5
40.4±1.9
8.1±0.3
31.5±1.2
4.2±0.4
19.6±1.3
0±0.0
0±0.0

OMH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
93.4±5.7
89±8.8
89.9±4.4
87±7.8
74.6±4.3
77.5±8.1
49.75±5.4
70.5±5.3
23.6±3.3
44±5.1
0±0.0
0±0.0

OMH + HCII-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
41.2±0.4
61.7±2.4
35.9±0.4
49.9±1.9
18.2±0.6
40.4±2.3
9.3±0.5
30.5±2.2
5.2±0.4
18.6±1.9
0±0.0
0±0.0

All results represent the mean values (±) standard deviation (n=3). All agents were supplemented
in AT-DP over a concentration range of (0 - 10) µg/ml. PMH; porcine mucosal heparin, BMH;
bovine mucosal heparin, OMH; ovine mucosal heparin, HCII; heparin cofactor-II, DP; depleted
plasma.
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TABLE 22
THE INHIBITION OF FACTOR XA AND THROMBIN OF VARIOUS LMWHs IN
HEPARIN COFACTOR-II DEPLETED PLASMA (HCII-DP) AS MEASURED BY THE
AMIDOLYTIC ANTI-XA AND ANTI-IIA ASSAYS

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

P. LMWH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
82.7±6.4
44.2±4.4
67±3.2
37.35±3.9
44.45±2.7
30.35±5.5
32.95±4.1
14.3±3.1
19.3±2.1
8.45±3.3
0±0.0
0±0.0

P. LMWH + HCII-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
1.2±0.4
7.7±2.2
1.9±0.4
8.9±1.1
2.2±0.5
8.4±1.3
3.1±0.4
9.5±1.2
2.9±0.3
9.6±1.3
0±0.0
0±0.0

B. LMWH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
81.7±5.2
45.9±7.3
62.25±4.9
35.6±5.3
40.4±3.3
27.95±4.4
30.75±4.4
18.3±2.2
19.95±2.4
9.2±3.2
0±0.0
0±0.0

B. LMWH + HCII-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
2.1±0.3
9.7±2.4
1.8±0.4
8.9±2.1
2.1±0.5
9.4±1.9
2.1±0.3
10.5±1.2
1.2±0.4
10.6±1.3
0±0.0
0±0.0

O. LMWH + Saline
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
80.8±5.7
49.05±5.9
64.9±6.3
33.85±6.4
38.2±4.3
26.7±7.3
35.65±3.9
17.5±4.1
20.35±1.9
8.65±2.9
0±0.0
0±0.0

O. LMWH + HCII-DP
Anti-Xa
Anti-IIa
(% Inhibition)
(% Inhibition)
2.2±0.4
8.7±2.4
1.9±0.4
8.9±1.9
2.2±0.6
9.4±2.3
2.3±0.5
9.5±2.2
2.2±0.4
10.6±1.9
0±0.0
0±0.0

All results represent the mean values (±) standard deviation (n=3). All agents were supplemented
in AT-DP over a concentration range of (0 - 10) µg/ml. LMWH; low molecular weight heparin,
HCII; heparin cofactor-II, DP; depleted plasma.
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TABLE 23
COMPARATIVE USP POTECIES FOR VARIOUS HEPARINS AS MEASURED BY
THE CHROMOGENIC ANTI-XA AND ANTI-IIA ASSAYS USING HYPHEN BIOMED
KITS

Agents

Xa (U/mg)

IIa (U/mg)

Xa/IIa Ratio

PMH

185±4.1

184±4.6

1.03

BMH

136±3.7

135±5.1

1.01

OMH

190±6.4

188±6.3

1.02

All results represent the mean (±) standard deviation (n=3). Comparative USP potencies as
measured by the chromogenic anti-Xa and Anti-IIa assays (Hyphen Kits).

TABLE 24
COMPARATIVE USP POTECIES FOR VARIOUS LOW MOLECULAR WEIGHT
HEPARINS AS MEASURED BY THE CHROMOGENIC ANTI-XA AND ANTI-IIA
ASSAYS USING HYPHEN BIOMED KITS

Agents

Xa (U/mg)

IIa (U/mg)

Xa/IIa Ratio

P. LMWH

99.3±3.5

39.3±1.5

2.54

B. LMWH

95.6±3.2

37.7±3.2

2.51

O. LMWH

99.1±4.6

38.3±1.5

2.63

All results represent the mean (±) standard deviation (n=3). Comparative USP potencies as
measured by the chromogenic anti-Xa and Anti-IIa assays (Hyphen Kits).
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TABLE 25
NEUTRALIZATION PROFILE OF PORCINE HEPARIN (µg/ml) USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

PMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

91.6±3.4

86.7±4.6

5

271±13.5

300±0.0

90.5±4.4

84.5±5.1

2.5

166±11.4

300±0.0

68.5±3.9

75.4±4.3

1.25

79.9±7.8

300±0.0

47.5±2.7

64.5±3.2

0.625

45.7±6.3

18.5±2.9

24.5±3.5

46.6±3.7

0

33±4.4

11.05±3.1

0±0.0

0±0.0

Concentration

PMH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

47.5±5.6

300±0.0

15.25±2.2

12.7±1.9

5

36.5±4.3

13.3±2.2

1.3±0.23

6.85±1.9

2.5

36.1±3.2

12.95±3

1.75±0.31

6.65±1.2

1.25

38.2±3.4

13.25±2.5

2.4±0.23

6.55±1.9

0.625

34.9±3.4

13.3±1.1

2.35±0.36

7.25±2.1

0

34.2±3.8

10.35±1.5

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). PMH, porcine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 26
NEUTRALIZATION PROFILE OF BOVINE HEPARIN (µg/ml) USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

BMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

80.5±4.4

79±6.7

5

192.5±12,3

300±0.0

67.2±3.8

73±5.5

2.5

139.9±13.4

300±0.0

40.3±3.4

66.5±3.7

1.25

59.45±7.7

20±2.2

18.9±2.2

52.9±3.2

0.625

37.35±3.9

15.7±1.8

4.55±1.8

36.5±4.2

0

33±4.4

11.05±3.1

0±0.0

0±0.0

Concentration

BMH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

73.5±5,8

300±0.0

24.05±2.2

22.5±3.1

5

37.3±3.9

13.1±1.2

0.85±0.14

4.25±1.3

2.5

37.6±4.1

12.6±2.2

0.95±0.19

5.4±2.3

1.25

37.3±2.9

11.9±3.3

0.9±0.17

6.95±2.7

0.625

34.2±4.1

11.1±1.9

0.8±0.11

8.2±3.3

0

34.2±3.8

10.35±1.5

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). BMH, bovine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 27
NEUTRALIZATION PROFILE OF OVINE HEPARIN (µg/ml) USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

OMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

95.4±5.7

89±8.8

5

300±0.0

300±0.0

89.9±4.4

87±7.8

2.5

173±12.8

300±0.0

74.6±4.3

77.5±8.1

1.25

78.2±11.6

300±0.0

49.75±5.4

70.5±5.3

0.625

48.55±6.7

18.7±2.6

23.6±3.3

44±5.1

0

33±4.4

11.05±3.1

0±0.0

0±0.0

Concentration

OMH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

55.5±6.4

300±0.0

11.3±2.1

14.85±3.3

5

37.1±4.3

12.1±3.2

0.79±0.21

7.35±1.2

2.5

35.2±3.9

12.3±2.8

0.95±0.31

7.57±2.1

1.25

35.3±4.7

11.05±2.1

0.95±0.27

8.35±3.2

0.625

36.1±5.5

13.4±3.1

1.25±0.43

9.37±3.8

0

34.2±3.8

10.35±1.5

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). OMH, ovine mucosal heparin;
aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 28
NEUTRALIZATION PROFILE OF PORCINE HEPARIN (U/ml) USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

PMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

300±0.0

300±0.0

94.5±5.6

90.7±7.9

0.5

300±0.0

300±0.0

87.3±3.3

85.3±4.8

0.25

124±11.1

300±0.0

75.9±4.1

72.7±6.1

0.125

59±9.88

300±0.0

45.6±2.9

55.3±4.2

0.062

42.5±6.2

36.9±7.7

26.1±3.1

30.9±2.7

0

30.8±3.3

13.8±1.2

0±0.0

0±0.0

Concentration

PMH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

85.8±5.6

300±0.0

11.65±1.2

8.26±1.43

0.5

31.5±2.2

21.9±3.1

1.71±0.11

2.16±0.21

0.25

31.6±1.9

20.1±1.2

1.03±0.18

1.53±0.18

0.125

32.7±3.4

19.7±2.1

1.22±0.21

1.83±0.19

0.062

31.5±4.1

17.5±3.3

1.43±0.14

1.63±0.09

0

29.3±2.6

16.5±2.2

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). PMH, porcine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 29
NEUTRALIZATION PROFILE OF BOVINE HEPARIN (U/ml) USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

BMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

300±0.0

300±0.0

87.4±4.3

84.5±4.8

0.5

213±12.2

300±0.0

78.8±5.1

79.8±3.9

0.25

87.5±8.9

300±0.0

60.6±2.8

62±2.4

0.125

51.5±5.8

61.2±3.9

34.3±3.8

38.2±3.1

0.062

38.4±6.5

22.3±2.8

23.2±4.1

17.8±2.4

0

30.8±3.3

13.8±1.2

0±0.0

0±0.0

Concentration

BMH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

182±11.2

300±0.0

44.7±5.5

43.93±6.3

0.5

31.5±4.5

21.3±2.2

1.41±0.23

1.83±0.43

0.25

31.8±3.9

18.9±2.8

1.82±0.12

1.93±0.32

0.125

31.7±4.1

18.6±3.4

0.99±0.34

2.06±0.22

0.062

31.7±3.6

17.9±3.3

1.21±0.29

2.43±0.19

0

29.3±2.6

16.5±2.2

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). BMH, bovine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 30
NEUTRALIZATION PROFILE OF OVINE HEPARIN (U/ml) USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

OMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

300±0.0

300±0.0

95.3±4.1

90.8±3.8

0.5

300±0.0

300±0.0

86.6±3.2

86.9±2.2

0.25

133.7±13.3

300±0.0

77.6±2.9

80.1±2.9

0.125

66.6±9.4

300±0.0

52.2±3.4

58.8±3.1

0.062

41.7±5.5

33.7±3.9

33.3±2.2

34.7±2.3

0

30.8±3.3

13.8±1.2

0±0.0

0±0.0

Concentration

OMH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

70.3±4.9

300±0.0

10.9±1.73

7.34±1.2

0.5

32.1±3.2

19.7±2.2

1.82±0.19

1.83±0.33

0.25

32.3±4.2

18.8±3.1

1.73±0.21

2.23±0.23

0.125

32.1±3.1

17.9±3.3

1.93±0.31

1.62±0.19

0.062

32.2±2.2

18.3±2.9

2.01±0.22

1.64±0.17

0

29.3±2.6

16.5±2.2

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). OMH, ovine mucosal heparin;
aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 31
NEUTRALIZATION PROFILE OF PORCINE LOW MOLECULAR WEIGHT
HEPARIN USING PROTAMINE SULFATE AS DETERMINED BY VARIOUS
ANTICOAGULANT AND ANTIPROTEASE ASSAYS

P. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

87.1±6.9

300±0.0

76.9±6.1

45.3±5.6

5

57.6±4.9

300±0.0

71.7±6.4

37.1±4.4

2.5

42.8±3.2

30.1±3.7

47.8±5.2

30.2±2.9

1.25

36.4±3.4

19.6±2.6

30.8±3.2

18.3±2.8

0.625

33.3±2.7

16.8±2.1

22.3±2.6

6.94±1.8

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

Concentration

P. LMWH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

52.1±4.9

21.7±3.7

62.9±7.4

31.3±2.9

5

37.9±4.6

20.5±2.6

44.6±4.9

18.8±3.2

2.5

34.8±3.6

18.4±2.2

27.6±3.3

13.2±2.9

1.25

32.8±2.9

19.5±2.2

18.9±3.3

5.3±1.7

0.625

31.5±3.1

18.5±3.2

12.3±1.8

2.9±0.9

0

29.3±3.8

16.1±2.1

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). P. LMWH, porcine low
molecular weight heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa,
factor Xa; IIa, thrombin.
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TABLE 32
NEUTRALIZATION PROFILE OF BOVINE LOW MOLECULAR WEIGHT HEPARIN
USING PROTAMINE SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT
AND ANTIPROTEASE ASSAYS

B. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

91.7±11.2

300±0.0

77.5±7.4

46.6±3.9

5

53.7±4.9

300±0.0

70.3±6.4

35.9±4.3

2.5

43.6±4.4

29.9±3.3

53.6±5.5

30.6±2.9

1.25

35.2±3.9

22.3±2.2

35.2±4.3

15.3±2.2

0.625

33.1±2.8

17.3±2.8

15.3±2.4

8.4±1.8

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

Concentration

B. LMWH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

49.3±4.4

19.7±2.1

63.4±5.9

33.3±4.4

5

36.7±4.2

18.5±3.1

42.6±3.6

19.9±3.1

2.5

32.7±3.9

18.2±2.8

25.1±3.3

10.8±1.9

1.25

31.6±2.9

18±1.5

15.8±2.1

4.1±1.2

0.625

31.1±3.1

18.2±2.8

12.7±1.8

2.5±0.58

0

29.3±3.8

16.1±2.1

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). B. LMWH, bovine low
molecular weight heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa,
factor Xa; IIa, thrombin.
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TABLE 33
NEUTRALIZATION PROFILE OF OVINE LOW MOLECULAR WEIGHT HEPARIN
USING PROTAMINE SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT
AND ANTIPROTEASE ASSAYS

O. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

94.7±7.8

300±0.0

77.4±6.6

46.3±5.5

5

58.1±4.4

300±0.0

72.2±5.5

37.1±3.3

2.5

45.7±4.2

30.2±4.3

52.1±3.5

30.1±4.3

1.25

35.2±3.3

20.7±2.4

31.6±3.3

16.3±2.6

0.625

32.7±4.1

17.1±2.1

16.3±2.8

5.8±1.3

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

Concentration

O. LMWH + Protamine Sulfate
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

49.6±4.9

21.1±2.2

63.3±5.4

32.6±4.2

5

36.4±4.2

19.6±2.5

43.3±3.2

19.6±3.2

2.5

33.9±3.9

19.2±2.5

26.9±2.9

12.3±2.2

1.25

33.4±4.3

19.1±3.1

17.7±2.2

4.1±2.1

0.625

31.2±3.7

18.7±1.9

14.4±1.7

1.7±0.5

0

29.3±3.8

16.1±2.1

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). O. LMWH, ovine low
molecular weight heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa,
factor Xa; IIa, thrombin.
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TABLE 34
NEUTRALIZATION PROFILE OF PORCINE HEPARIN USING HEPARINASE-I AS
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS

PMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

92.1±5.3

84.3±1.1

5
2.5
1.25

283.5±7.8
103.8±2.8
54.9±2.6

300±0.0
300±0.0
300±0.0

82.7±4.4
63.7±3.9
39.8±4.1

78.5±3.7
66.7±2.4
53.6±2.9

0.625
0

38.1±1.3
26.2±2.6

19.7±2.9
13.7±1.6

21.2±2.1
0.0±0.0

44.9±2.7
0.0±0.0

PMH + Heparinase-I
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

34.85±3.5

16.9±2.8

5.3±1.7

7.9±2.8

5
2.5

31.75±2.9
29.35±2.3

17.2±2.0
16.8±3.6

6.8±2.4
5.8±1.9

6.8±1.6
7.4±2.6

1.25
0.625
0

28.66±3.2
27.85±1.9
26.2±2.6

16.9±3.5
15.1±2.7
13.7±1.6

6.0±1.4
5.8±2.3
0.0±0.0

5.4±1.8
5.9±1.5
0.0±0.0

All results represent the mean values (±) standard deviation (n=3). Heparinase-I (1 U/ml final
concentration) was incubated with each agent (10 mg/ml, pH = 5.0) at 37°C for 30 min. PMH,
porcine mucosal heparin; FC, final concentration; aPTT, activated partial thromboplastin time;
TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 35
NEUTRALIZATION PROFILE OF BOVINE HEPARIN USING HEPARINASE-I AS
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS

BMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

87.6±5.9

77.1±5.9

5
2.5
1.25

196.5±6.9
66.8±5.4
39.7±4.9

300±0.0
300±0.0
45.2±3.8

75.9±6.3
53.9±4.4
33.5±4.9

73.6±4.3
57.3±5.1
30.2±3.8

0.625
0

31±3.7
26.2±2.6

20.3±2.9
13.7±1.6

21.2±2.3
0.0±0.0

13±1.8
0.0±0.0

BMH + Heparinase-I
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

34.1±2.3

14.9±2.3

6.8±1.1

7.4±1.9

5
2.5

35.5±2.1
33.6±1.3

15.1±1.8
15.5±3.1

7.6±1.5
6.8±2.1

6.2±1.6
7.5±2.6

1.25
0.625
0

33.3±1.1
32.4±1.9
26.2±2.6

16.1±3.6
16.3±0.3
13.7±1.6

5.9±1.7
5.9±2.1
0.0±0.0

6.3±1.1
5.9±1.5
0.0±0.0

All results represent the mean values (±) standard deviation (n=3). Heparinase-I (1 U/ml final
concentration) was incubated with each agent (10 mg/ml, pH = 5.0) at 37°C for 30 min. BMH,
bovine mucosal heparin; FC, final concentration; aPTT, activated partial thromboplastin time;
TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 36
NEUTRALIZATION PROFILE OF OVINE HEPARIN USING HEPARINASE-I AS
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS

OMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

94.3±6.7

89.9±5.3

5
2.5
1.25

300±0.0
125±1.4
62.5±3.5

300±0.0
300±0.0
300±0.0

86.9±5.9
68.2±4.3
43.0±3.2

85.4±5.8
73.1±4.9
56.5±3.3

0.625
0

41.1±1.3
26.2±2.6

22.7±2.3
13.7±1.6

23.7±1.2
0.0±0.0

47.9±2.9
0.0±0.0

OMH + Heparinase-I
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

32.1±3.2

17.9±2.3

13.8±0.1

8.6±2.9

5
2.5

33.5±2.1
33.6±1.3

18.1±1.8
16.5±3.1

7.6±1.5
3.8±0.1

7.2±3.1
7.5±2.6

1.25
0.625
0

33.3±3.1
32.4±3.4
26.2±2.6

17.1±3.6
16.3±2.1
13.7±1.6

4.9±1.7
0.9±0.1
0.0±0.0

6.8±1.1
8.0±1.9
0.0±0.0

All results represent the mean values (±) standard deviation (n=3). Heparinase-I (1 U/ml final
concentration) was incubated with each agent (10 mg/ml, pH = 5.0) at 37°C for 30 min. OMH,
ovine mucosal heparin; FC, final concentration; aPTT, activated partial thromboplastin time; TT,
thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 37
NEUTRALIZATION PROFILE OF PORCINE LOW MOLECULAR WEIGHT
HEPARIN USING HEPARINASE-I AS DETERMINED BY VARIOUS
ANTICOAGULANT AND ANTIPROTEASE ASSAYS

P. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

87.1±5.9

300±0.0

86.5±3.1

51.3±7.6

5

57.6±3.9

300±0.0

71.7±6.4

37.1±3.4

2.5

42.8±4.2

30.1±3.7

47.8±2.2

30.2±5.9

1.25

36.4±2.4

19.6±2.6

30.8±4.2

18.3±3.8

0.625

33.3±2.7

16.8±2.1

22.3±2.6

6.94±1.8

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

Concentration

P. LMWH + Heparinase-I
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

32.1±4.9

15.7±3.7

2.9±0.9

3.3±0.9

5

33.9±4.6

14.5±2.6

4.6±0.9

2.8±0.7

2.5

32.8±3.6

14.1±2.2

2.6±0.3

3.2±0.9

1.25

32.8±2.9

15.5±2.2

1.9±0.3

3.3±0.4

0.625

31.5±3.1

14.5±3.2

2.3±0.8

2.9±0.7

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). Heparinase-I (1 U/ml final
concentration) was incubated with each agent (10 mg/ml, pH = 5.0) at 37°C for 30 min. P.
LMWH, porcine low molecular weight heparin; FC, final concentration; aPTT, activated partial
thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa, thrombin.

314
TABLE 38
NEUTRALIZATION PROFILE OF BOVINE LOW MOLECULAR WEIGHT HEPARIN
USING HEPARINASE-I AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

B. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

88.4±6.9

300±0.0

88.5±6.1

49.3±5.6

5

58.6±4.9

300±0.0

73.7±6.4

35.1±4.4

2.5

44.1±3.2

35.1±3.7

51.8±5.2

28.2±2.9

1.25

37.4±3.4

21.6±2.6

32.8±3.2

19.3±2.8

0.625

34.3±2.7

13.8±2.1

22.3±2.6

6.94±1.8

0

31.3±3.8

11.9±2.4

0±0.0

0±0.0

Concentration

B. LMWH + Heparinase-I
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

34.1±4.9

13.7±3.7

3.9±0.9

2.3±0.9

5

32.9±4.6

12.5±2.6

2.6±0.9

1.8±0.7

2.5

33.8±3.6

13.1±2.2

3.6±0.3

2.2±0.9

1.25

33.8±2.9

13.5±2.2

2.9±0.3

2.3±0.4

0.625

32.5±3.1

12.5±3.2

2.3±0.8

3.9±0.7

0

31.3±3.8

11.9±2.4

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). Heparinase-I (1 U/ml final
concentration) was incubated with each agent (10 mg/ml, pH = 5.0) at 37°C for 30 min. B.
LMWH, bovine low molecular weight heparin; FC, final concentration; aPTT, activated partial
thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 39
NEUTRALIZATION PROFILE OF OVINE LOW MOLECULAR WEIGHT HEPARIN
USING HEPARINASE-I AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

O. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

85.9±3.9

300±0.0

89.9±6.1

51.3±5.6

5

55.6±3.8

300±0.0

73.7±6.4

37.1±4.4

2.5

46.1±3.2

37.1±3.7

57.8±5.2

25.2±2.9

1.25

38.4±3.4

24.6±2.6

37.8±3.2

17.3±2.8

0.625

33.3±2.7

15.8±2.1

25.3±2.6

9.9±1.8

0

32.3±3.8

13.1±2.4

0±0.0

0±0.0

Concentration

O. LMWH + Heparinase-I
aPTT
TT
Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

33.1±4.9

14.7±3.7

2.5±0.9

2.4±0.9

5

33.9±4.6

14.5±2.6

2.1±0.9

1.8±0.7

2.5

32.8±3.6

15.1±2.2

2.6±0.3

1.2±0.9

1.25

32.8±2.9

15.5±2.2

2.9±0.3

2.3±0.4

0.625

33.5±3.1

14.5±3.2

2.3±0.8

2.9±0.7

0

32.3±3.8

13.1±2.4

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). Heparinase-I (1 U/ml final
concentration) was incubated with each agent (10 mg/ml, pH = 5.0) at 37°C for 30 min. O.
LMWH, ovine low molecular weight heparin; FC, final concentration; aPTT, activated partial
thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 40
NEUTRALIZATION PROFILE OF PORCINE HEPARIN (µG/ML) USING PLATELET
FACTOR 4 (PF4) AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

PMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

91.6±3.4

86.7±4.6

5

271±13.5

300±0.0

90.5±4.4

84.5±5.1

2.5

166±11.4

300±0.0

68.5±3.9

75.4±4.3

1.25

79.9±7.8

300±0.0

47.5±2.7

64.5±3.2

0.625

45.7±6.3

18.5±2.9

24.5±3.5

46.6±3.7

0

33±4.4

11.05±3.1

0±0.0

0±0.0

Concentration

aPTT

PMH + PF4
TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

32.5±5.6

300±0.0

36.25±2.2

27.7±3.9

5

31.5±4.3

22.3±2.2

1.3±0.23

6.85±3.9

2.5

32.1±3.2

20.95±3

1.75±0.31

5.65±1.2

1.25

32.2±3.4

21.25±2.5

1.4±0.23

6.55±1.9

0.625

31.9±3.4

18.3±1.1

1.35±0.36

5.25±2.1

0

32.2±3.8

14.35±1.5

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). PMH, porcine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 41
NEUTRALIZATION PROFILE OF BOVINE HEPARIN (µg/ml) USING PLATELET
FACTOR 4 (PF4) AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

BMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

80.5±4.4

79±6.7

5

192.5±12,3

300±0.0

67.2±3.8

73±5.5

2.5

139.9±13.4

300±0.0

40.3±3.4

66.5±3.7

1.25

59.45±7.7

20±2.2

18.9±2.2

52.9±3.2

0.625

37.35±3.9

15.7±1.8

4.55±1.8

36.5±4.2

0

33±4.4

11.05±3.1

0±0.0

0±0.0

Concentration

aPTT

BMH + PF4
TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

31.5±5.6

300±0.0

33.25±2.2

25.7±4.9

5

32.5±4.3

21.3±2.2

2.3±1.23

7.85±2.9

2.5

32.1±3.2

22.95±3

2.75±1.31

4.65±1.2

1.25

32.2±3.4

23.25±2.5

2.4±1.23

4.55±1.9

0.625

31.9±3.4

19.3±1.1

1.35±0.36

5.25±2.1

0

32.2±3.8

15.35±1.5

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). BMH, bovine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 42
NEUTRALIZATION PROFILE OF OVINE HEPARIN (µg/ml) USING PLATELET
FACTOR 4 (PF4) AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

OMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300±0.0

300±0.0

95.4±5.7

89±8.8

5

300±0.0

300±0.0

89.9±4.4

87±7.8

2.5

173±12.8

300±0.0

74.6±4.3

77.5±8.1

1.25

78.2±11.6

300±0.0

49.75±5.4

70.5±5.3

0.625

48.55±6.7

18.7±2.6

23.6±3.3

44±5.1

0

33±4.4

11.05±3.1

0±0.0

0±0.0

Concentration

aPTT

OMH + PF4
TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

33.5±5.6

300±0.0

33.25±2.2

28.7±6.9

5

30.5±4.3

24.3±2.2

3.3±1.23

8.85±2.9

2.5

33.1±3.2

23.95±3

3.75±1.31

6.65±1.2

1.25

31.2±3.4

21.25±2.5

3.4±1.23

5.55±1.9

0.625

32.9±3.4

18.3±1.1

2.35±1.36

5.25±2.1

0

30.2±3.8

16.35±1.5

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). OMH, ovine mucosal heparin;
aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 43
NEUTRALIZATION PROFILE OF PORCINE HEPARIN (U/ml) USING PLATELET
FACTOR 4 (PF4) AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

PMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

300±0.0

300±0.0

94.5±5.6

90.7±7.9

0.5

300±0.0

300±0.0

87.3±3.3

85.3±4.8

0.25

124±11.1

300±0.0

75.9±4.1

72.7±6.1

0.125

59±9.88

300±0.0

45.6±2.9

55.3±4.2

0.062

42.5±6.2

36.9±7.7

26.1±3.1

30.9±2.7

0

30.8±3.3

13.8±1.2

0±0.0

0±0.0

Concentration

aPTT

PMH + PF4
TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

46.8±5.6

300±0.0

34.65±1.2

29.26±3.43

0.5

32.5±2.2

23.9±3.1

7.71±1.11

5.16±1.21

0.25

31.6±1.9

22.1±1.2

5.03±1.18

4.53±2.18

0.125

32.7±3.4

21.7±2.1

5.22±2.21

5.83±2.19

0.062

33.5±4.1

19.5±3.3

3.43±1.14

5.63±1.09

0

32.3±2.6

18.5±2.2

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). PMH, porcine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 44
NEUTRALIZATION PROFILE OF BOVINE HEPARIN (U/ml) USING PLATELET
FACTOR 4 (PF4) AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

BMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

300±0.0

300±0.0

87.4±4.3

84.5±4.8

0.5

213±12.2

300±0.0

78.8±5.1

79.8±3.9

0.25

87.5±8.9

300±0.0

60.6±2.8

62±2.4

0.125

51.5±5.8

61.2±3.9

34.3±3.8

38.2±3.1

0.062

38.4±6.5

22.3±2.8

23.2±4.1

17.8±2.4

0

30.8±3.3

13.8±1.2

0±0.0

0±0.0

Concentration

aPTT

BMH + PF4
TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

49.7±11

300±0.0

31.7±5.5

38.93±6.3

0.5

32.5±4.5

25.3±4.2

4.41±1.23

4.83±1.43

0.25

33.8±3.9

19.9±3.8

5.82±1.12

5.93±1.32

0.125

29.7±4.1

20.6±3.4

5.99±1.34

3.06±1.22

0.062

30.7±3.6

17.9±3.3

4.21±1.29

5.43±2.19

0

29.3±2.6

14.5±2.2

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). BMH, bovine mucosal
heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa,
thrombin.
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TABLE 45
NEUTRALIZATION PROFILE OF OVINE HEPARIN (U/ml) USING PLATELET
FACTOR 4 (PF4) AS DETERMINED BY VARIOUS ANTICOAGULANT AND
ANTIPROTEASE ASSAYS

OMH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

300±0.0

300±0.0

95.3±4.1

90.8±3.8

0.5

300±0.0

300±0.0

86.6±3.2

86.9±2.2

0.25

133.7±13.3

300±0.0

77.6±2.9

80.1±2.9

0.125

66.6±9.4

300±0.0

52.2±3.4

58.8±3.1

0.062

41.7±5.5

33.7±3.9

33.3±2.2

34.7±2.3

0

30.8±3.3

13.8±1.2

0±0.0

0±0.0

Concentration

aPTT

OMH + PF4
TT

Anti-Xa

Anti-IIa

(U/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

1

47.3±6.9

300±0.0

28.9±1.73

32.34±1.2

0.5

31.1±3.2

24.7±4.2

4.82±2.19

4.83±1.33

0.25

30.3±4.2

18.8±3.1

5.73±1.21

5.23±1.23

0.125

31.1±3.1

19.9±3.3

6.93±1.31

4.62±2.19

0.062

29.2±2.2

17.3±2.9

3.01±1.22

3.64±1.17

0

29.3±2.6

14.5±2.2

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). OMH, ovine mucosal heparin;
aPTT, activated partial thromboplastin time; TT, thrombin time; Xa, factor Xa; IIa, thrombin.
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TABLE 46
NEUTRALIZATION PROFILE OF PORCINE LOW MOLECULAR WEIGHT
HEPARIN USING PLATELET FACTOR 4 (PF4) AS DETERMINED BY VARIOUS
ANTICOAGULANT AND ANTIPROTEASE ASSAYS

P. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

87.1±6.9

300±0.0

76.9±6.1

45.3±5.6

5

57.6±4.9

300±0.0

71.7±6.4

37.1±4.4

2.5

42.8±3.2

30.1±3.7

47.8±5.2

30.2±2.9

1.25

36.4±3.4

19.6±2.6

30.8±3.2

18.3±2.8

0.625

33.3±2.7

16.8±2.1

22.3±2.6

6.94±1.8

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

Concentration

aPTT

P. LMWH + PF4
TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

49.1±4.9

22.7±3.7

61.9±7.4

21.3±2.9

5

38.9±4.6

20.5±2.6

44.6±4.9

18.8±3.2

2.5

33.8±3.6

19.4±2.2

32.6±3.3

11.2±2.9

1.25

32.8±2.9

18.5±2.2

24.9±3.3

9.3±1.7

0.625

30.5±3.1

17.5±3.2

13.3±1.8

4.9±0.9

0

29.3±3.8

15.1±2.1

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). P. LMWH, porcine low
molecular weight heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa,
factor Xa; IIa, thrombin.
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TABLE 47
NEUTRALIZATION PROFILE OF BOVINE LOW MOLECULAR WEIGHT HEPARIN
USING PLATELET FACTOR 4 (PF4) AS DETERMINED BY VARIOUS
ANTICOAGULANT AND ANTIPROTEASE ASSAYS

B. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

91.7±11.2

300±0.0

77.5±7.4

46.6±3.9

5

53.7±4.9

300±0.0

70.3±6.4

35.9±4.3

2.5

43.6±4.4

29.9±3.3

53.6±5.5

30.6±2.9

1.25

35.2±3.9

22.3±2.2

35.2±4.3

15.3±2.2

0.625

33.1±2.8

17.3±2.8

15.3±2.4

8.4±1.8

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

Concentration

aPTT

B. LMWH + PF4
TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

50.3±7.4

21.7±2.1

63.4±7.9

23.3±5.4

5

36.7±4.2

18.5±3.1

48.6±5.6

16.9±3.1

2.5

32.7±3.9

18.2±2.8

28.1±3.3

12.8±2.9

1.25

29.6±2.9

19±3.5

24.8±3.1

10.1±3.2

0.625

30.1±3.1

18.2±2.8

13.7±1.8

4.5±0.58

0

29.3±3.8

14.1±2.1

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). B. LMWH, bovine low
molecular weight heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa,
factor Xa; IIa, thrombin.
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TABLE 48
NEUTRALIZATION PROFILE OF OVINE LOW MOLECULAR WEIGHT HEPARIN
USING PLATELET FACTOR 4 (PF4) AS DETERMINED BY VARIOUS
ANTICOAGULANT AND ANTIPROTEASE ASSAYS

O. LMWH + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

94.7±7.8

300±0.0

77.4±6.6

46.3±5.5

5

58.1±4.4

300±0.0

72.2±5.5

37.1±3.3

2.5

45.7±4.2

30.2±4.3

52.1±3.5

30.1±4.3

1.25

35.2±3.3

20.7±2.4

31.6±3.3

16.3±2.6

0.625

32.7±4.1

17.1±2.1

16.3±2.8

5.8±1.3

0

30.8±3.8

13.8±2.2

0±0.0

0±0.0

Concentration

aPTT

O. LMWH + PF4
TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

45.6±4.9

23.1±2.2

64.3±6.4

24.6±6.2

5

34.4±4.2

20.6±2.5

48.3±5.2

17.6±4.2

2.5

34.9±3.9

19.2±2.5

31.9±6.9

12.3±3.2

1.25

33.4±4.3

20.1±3.1

23.7±4.2

10.1±2.1

0.625

31.2±3.7

17.7±1.9

12.4±2.7

4.7±1.5

0

31.3±3.8

14.1±2.1

0±0.0

0±0.0

All results represent the mean values (±) standard deviation (n=3). O. LMWH, ovine low
molecular weight heparin; aPTT, activated partial thromboplastin time; TT, thrombin time; Xa,
factor Xa; IIa, thrombin.
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TABLE 49
COMPARATIVE EFFECTS OF VARIOUS HEPARINS (ug/ml) ON AGONIST INDUCED PLATELET AGGREGATION
FC=10 µg/ml
FC=1 µg/ml
FC=0.1 µg/ml
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
93.8±4.5
81±5.5
94.4±3.6
75±4.5
96±4.7
78.2±4.5
ADP
AA
94.6±5.4
72±4.3
93.6±4.2
78±3.4
95.4±5.6
80.6±6.7
96.8±4.5
78±3.9
94±4.4
83±2.5
94.2±6.6
72.8±4.2
Collagen
Epinephrine
96.6±3.9
45.8±4.3
94.4±5.5
51.8±3.5
95.4±5.9
55.6±6.2
FC=10 µg/ml
FC=1 µg/ml
FC=0.1 µg/ml
BMH
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
96.8±7.5
79±4.5
96.4±4.6
73±4.5
94±4.5
73±6.5
ADP
AA
95.6±6.4
75±3.3
94.6±3.2
77.6±5.4
96±3.6
70±7.7
93.8±4.5
83±5.9
95±4.4
80.6±4.5
93±4.6
77.8±6.2
Collagen
Epinephrine
96.6±3.9
47.8±3.5
96.4±5.1
46.8±2.5
94±4.1
50.6±5.2
FC=10 µg/ml
FC=1 µg/ml
FC=0.1 µg/ml
OMH
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
95.8±4.5
80±4.5
94.4±4.6
80±5.5
96±5.5
81±5.5
ADP
AA
96.6±5.4
71±5.3
93.6±3.2
73.6±3.4
95.4±6.6
72±4.7
97.8±4.5
79±6.9
94±5.4
76.6±2.9
94.2±4.6
72.6±6.2
Collagen
97.6±3.9
49.8±3.3
94.4±3.5
43.8±4.5
95.4±3.9
47±7.2
Epinephrine
All results represent the mean (±) standard deviation (n=5). FC; final concentration, AGG; aggregation , AIPA; agonist induced
platelet aggregation.
PMH
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TABLE 50
COMPARATIVE EFFECTS OF VARIOUS HEPARINS (U/ml) ON AGONIST INDUCED PLATELET AGGREGATION
FC=1 U/ml
FC=0.5 U/ml
FC=0.1 U/ml
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
93.8±4.5
60±5.5
94±3.6
72±4.5
96±4.7
78.2±4.5
ADP
AA
95.6±5.4
76±4.3
96±4.2
75±3.4
95.4±5.6
83±6.7
97.8±4.5
65±3.9
97±4.4
81±2.5
94.2±6.6
72.8±4.2
Collagen
Epinephrine
93.6±3.9
46±4.3
95±5.5
54±3.5
95.4±5.9
55.6±6.2
FC=1 U/ml
FC=0.5 U/ml
FC=0.1 U/ml
BMH
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
92.8±7.5
73±4.5
95±4.6
72±4.5
94±4.5
79±6.5
ADP
AA
93.6±6.4
75±3.3
94±3.2
77±5.4
96±3.6
80±7.7
96.8±4.5
83±5.9
94±4.4
82±4.5
93±4.6
77.8±6.2
Collagen
Epinephrine
96.6±3.9
48±3.5
96±5.1
49±2.5
94±4.1
50.6±5.2
FC=1 U/ml
FC=0.5 U/ml
FC=0.1 U/ml
OMH
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
93.8±4.5
80±6.5
94.4±4.6
72.9±5.5
96±5.5
83±5.5
ADP
AA
94.6±5.4
76±5.3
93.6±3.2
83±3.4
95.4±6.6
72±4.7
93.8±4.5
78±6.9
94±5.4
74±2.9
94.2±4.6
72.6±6.2
Collagen
93.6±3.9
44±3.3
94.4±3.5
50±4.5
95.4±3.9
49±7.2
Epinephrine
All results represent the mean (±) standard deviation (n=5). FC; final concentration, AGG; aggregation , AIPA; agonist induced
platelet aggregation.
PMH
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TABLE 51
COMPARATIVE EFFECTS OF VARIOUS LMWHs (ug/ml) ON AGONIST INDUCED PLATELET AGGREGATION
FC=10 µg/ml
FC=1 µg/ml
FC=0.1 µg/ml
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
96±5.5
73±5.5
95±3.6
80±4.5
96±4.7
76.2±4.5
ADP
AA
95±6.4
72±4.3
92±4.2
76±3.4
95.4±5.6
70.6±6.7
93±4.5
84±3.9
94±4.4
78±2.5
94.2±6.6
72.8±4.2
Collagen
Epinephrine
95±3.9
45.8±4.3
93±5.5
51.8±3.5
95.4±5.9
55.6±6.2
FC=10 µg/ml
FC=1 µg/ml
FC=0.1 µg/ml
B. LMWH
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
94±7.5
71±4.5
95±4.6
79±4.5
94±4.5
74±6.5
ADP
AA
92±7.4
75±3.3
93±3.2
81±5.4
96±3.6
71±7.7
95±5.5
73±5.9
95±4.4
76.6±4.5
93±4.6
82±6.2
Collagen
Epinephrine
94±6.9
47.8±3.5
96±5.1
46.8±2.5
94±4.1
50.6±5.2
FC=10 µg/ml
FC=1 µg/ml
FC=0.1 µg/ml
O. LMWH
AGG %
AGG Rate
AGG %
AGG Rate
AGG %
AGG Rate
Saline
5±1.2
3±1.1
5±1.2
3±1.1
5±1.2
3±1.1
93±4.5
74±4.5
94±4.6
79±5.5
96±5.5
75±5.5
ADP
AA
97±5.4
71±5.3
95±3.2
77±3.4
95.4±6.6
72±4.7
96±4.5
74±6.9
94±5.4
75±2.9
94.2±4.6
81±6.2
Collagen
94±3.9
49.8±3.3
93±3.5
49±4.5
95.4±3.9
47±7.2
Epinephrine
All results represent the mean (±) standard deviation (n=5). LMWH; low molecular weight heparin, FC; final concentration, AGG;
aggregation, AIPA; agonist induced platelet aggregation.
P. LMWH
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TABLE 52
THE EFFECT OF VARIOUS HEPARINS (µg/ml) ON HIT POSITIVE ANTIBODY MEDIATED PLATELET
AGGREGATION

FC=10 µg/ml
Agent

FC=1 µg/ml

FC=0.1 µg/ml

% Aggregation

Slope

% Aggregation

Slope

% Aggregation

Slope

Saline

5±1.2

1.2±0.4

5±1.2

1.2±0.4

5±1.2

1.2±0.4

AA

81±5

46.8±4.1

81±5

46.8±4.1

81±5

46.8±4.1

PMH

59.4±3

9.9±2.9

62.4±8.6

10.8±6.9

4.9±1.4

1.9±0.4

BMH

61.9±7

10.2±3.4

59.4±5.4

11.3±6.7

4.4±1.3

2.1±0.9

OMH

63.2±8

11±1.9

64.6±7.4

10.4±6.4

5.1±2.3

2.2±0.8

All results represent the mean (±) standard deviation (n=10). FC, final concentration; HIT, heparin induced thrombocytopenia

328

329
TABLE 53
THE EFFECT OF VARIOUS HEPARINS (U/ml) ON HIT POSITIVE ANTIBODY MEDIATED PLATELET
AGGREGATION

FC=1 U/ml
Agent

FC=0.5 U/ml

FC=0.1 U/ml

% Aggregation

Slope

% Aggregation

Slope

% Aggregation

Slope

Saline

6.3±1.9

1.4±0.6

6.3±1.9

1.4±0.6

6.3±1.9

1.4±0.6

AA

51.9±2.9

48.2±6.1

79±3.8

48.2±6.1

79±3.8

48.2±6.1

PMH

49.4±4.3

7.9±1.9

24.5±4.6

5.8±5.9

6.9±2.4

2.9±0.7

BMH

53.1±5.5

8.2±2.4

27.4±6.4

6.3±4.7

7.4±3.3

3.1±0.9

OMH

63.2±8

8.1±2.3

28.6±5.9

7.4±5.4

6.1±2.5

2.2±0.8

All results represent the mean (±) standard deviation (n=11). FC, final concentration; HIT, heparin induced thrombocytopenia.
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TABLE 54
THE EFFECT OF VARIOUS LOW MOLECULAR WEIGHT HEPARINS ON HIT POSITIVE ANTIBODY MEDIATED
PLATELET AGGREGATION

FC=10 µg/ml
Agent

FC=1 µg/ml

FC=0.1 µg/ml

% Aggregation

Slope

% Aggregation

Slope

% Aggregation

Slope

Saline

5±1.2

1.2±0.4

5±1.2

1.2±0.4

5±1.2

1.2±0.4

AA

81±5

46.8±4.1

81±5

46.8±4.1

81±5

46.8±4.1

P. LMWH

39.8±3.3

5.5±1.9

14.8±2.6

3.2±0.9

5.2±1.4

2.3±0.4

B. LMWH

41.1±5.6

4.9±1.4

15.1 ±3.4

2.9±0.7

4.9±2.2

1.9±0.3

O. LMWH

40.9±4.2

5.2±1.7

13.9 ±2.4

3.3±0.9

4.5±1.3

2.1±0.6

All results represent the mean (±) standard deviation (n=13). FC, final concentration; HIT, heparin induced thrombocytopenia.
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TABLE 55
THE EFFECT OF VARIOUS HEPARINS PRE AND POST HEPARINASE-1 DIGESTION ON HIT POSITIVE ANTIBODY
PLATELET AGGREGATION
Heparins + Saline
Agent
Saline
AA
PMH
BMH
OMH

FC=10 µg/ml
% Aggregation
Slope
3.2±1.8
1.0±0.0
77±5.8
46.2±3.6
76.6±7.9
20.5±3.0
71.1±5.2
23.6±3.3
69.6±9.1
16.5±1.7

FC=1 µg/ml
% Aggregation
Slope
3.2±1.8
1.0±0.0
77±5.8
46.2±3.6
69.8±11.7
15.4±2.3
70.4±6.6
20.4±2.3
64.8±4.9
22.4±4.0

FC=0.1 µg/ml
% Aggregation
Slope
3.2±1.8
1.0±0.0
77±5.8
46.2±3.6
3.3±0.8
2±1.0
3.6±0.8
2.2±0.8
4.8±1.1
1.8±0.8

Heparins + Heparinase-1
Agent
Saline
AA
PMH
BMH
OMH

FC=10 µg/ml
% Aggregation
Slope
3.2±1.8
1.0±0.0
77±5.8
46.2±3.6
4.8±1.5
1.8±0.8
6.8±1.3
1.8±0.8
5.4±2.4
2.0±0.9

FC=1 µg/ml
% Aggregation
Slope
3.2±1.8
1.0±0.0
77±5.8
46.2±3.6
4±1.0
2±1.0
4.2±2.2
2±1.0
4.8±2.2
2.6±1.1

FC=0.1 µg/ml
% Aggregation
Slope
3.2±1.8
1.0±0.0
77±5.8
46.2±3.6
4.2±1.1
1.4±0.5
2.4±0.5
1.8±0.8
3.8±0.8
1.4±0.5

All results represent the mean (±) standard deviation (n=5). FC, final concentration; HIT, heparin induced thrombocytopenia.
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TABLE 56
THE EFFECT OF VARIOUS LOW MOLECULAR WEIHGT HEPARINS PRE AND POST HEPARINASE-1 DIGESTION
ON HIT POSITIVE ANTIBODY PLATELET AGGREGATION
Low molecular weight heparins + Saline
Agent
Saline
AA
P. LMWH
B. LMWH
O. LMWH

FC=10 µg/ml
% Aggregation
Slope
3.9±1.4
1.0±0.0
82±6.8
58.2±3.6
34.8±4.3
18.5±3.0
39.1±3.6
15.6±3.3
35.9±5.2
17.5±1.7

FC=1 µg/ml
% Aggregation
Slope
3.9±1.4
1.0±0.0
82±6.8
58.2±3.6
13.8±1.6
12.4±1.3
14.7 ±2.4
13.4±3.3
15.2 ±3.4
16.4±3.4

FC=0.1 µg/ml
% Aggregation
Slope
3.9±1.4
1.0±0.0
82±6.8
58.2±3.6
3.2±1.4
2±1.0
3.9±2.2
2.2±0.8
5.1±1.3
1.8±0.8

Low molecular weight heparins + Heparinase-1
Agent
Saline
AA
P. LMWH
B. LMWH
O. LMWH

FC=10 µg/ml
% Aggregation
Slope
3.9±1.4
1.0±0.0
82±6.8
58.2±3.6
3.8±1.5
1.2±0.8
4.8±1.3
1.5±0.8
3.4±2.4
1.0±0.9

FC=1 µg/ml
% Aggregation
Slope
3.9±1.4
1.0±0.0
82±6.8
58.2±3.6
3.2±1.0
1.2±1.0
2.2±2.2
2.1±1.0
2.8±2.2
2.3±1.1

FC=0.1 µg/ml
% Aggregation
Slope
3.9±1.4
1.0±0.0
82±6.8
58.2±3.6
2.2±1.1
1.4±0.5
3.4±0.5
1.8±0.8
1.8±0.8
1.2±0.5

All results represent the mean (±) standard deviation (n=5). FC, final concentration; HIT, heparin induced thrombocytopenia.
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TABLE 57
COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF VARIOUS HEPARINS AS DETERMINED BY
VARIOUS ANTIPROTEASE AND ANTICOAGULANT ASSAYS AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN
PRIMATES
Drug

Time

Anti-Xa

Anti-IIa

aPTT

TT

0.5 mg/kg IV

(Minutes)

(% Inhibition)

(% Inhibition)

(Seconds)

(Seconds)

0
15
30
60

0.0±0.0
88.5±5.5
85.5±6.5
73.0±9.8

0.0±0.0
89.5±3.4
77.0±3.9
69.8±2.5

24.7±1.8
38.8±1.0
35.2±3.7
30.9±2.8

22.3±1.3
300±0.0
300±0.0
300±0.0

120

47.0±7.2

52.0±3.8

25.7±1.8

23.7±1.4

0
15
30
60

0.0±0.0
79.3±6.3
64.8±8.8
52.5±6.1

0.0±0.0
80.5±2.6
68.5±5.8
51.5±4.2

24.8±1.0
33.6±2.9
31.5±0.9
28.2±1.4

18.1±3.1
300±0.0
300±0.0
27.0±1.8

120

42.5±4.4

41.3±5.7

26.2±1.4

19.9±2.1

0
15
30
60

0.0±0.0
90.5±7.1
87.3±7.2
78.3±9.1

0.0±0.0
92.3±2.5
81.0±2.9
70.8±4.3

24.4±1.6
39.8±2.3
36.4±1.5
29.9±1.9

19.7±2.1
300±0.0
300±0.0
300±0.0

120

49.8±7.6

57.0±6.1

25.8±2.2

21.5±1.4

PMH

BMH

OMH

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin; aPTT, activated partial thromboplastin time;
TT, thrombin time.
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TABLE 58
COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF VARIOUS HEPARINS AS DETERMINED BY
VARIOUS ANTIPROTEASE AND ANTICOAGULANT ASSAYS AT A DOSE OF 100 U/KG IV IN NON-HUMAN
PRIMATES
Drug

Time

Anti-Xa

Anti-IIa

aPTT

TT

100 U/kg IV

(Minutes)

(% Inhibition)

(% Inhibition)

(Seconds)

(Seconds)

0
15
30
60

0.0±0.0
89.3±6.5
86.5±7.5
75.0±7.8

0.0±0.0
87.5±3.4
75.0±3.9
70.1±2.5

27.7±1.8
40.8±1.0
36.2±3.7
32.9±2.8

19.3±1.3
300±0.0
300±0.0
300±0.0

120

48.0±6.2

56.3±3.8

28.7±1.8

22.9±1.4

0
15
30
60

0.0±0.0
90.1±6.3
88.8±8.8
73.5±6.1

0.0±0.0
88.5±2.6
78.5±5.8
69.5±4.2

26.3±1.0
42.6±2.9
36.5±0.9
33.2±1.4

19.1±3.1
300±0.0
300±0.0
300±0.0

120

49.5±4.4

54.3±5.7

27.2±1.4

21.9±2.1

0
15
30
60

0.0±0.0
91.2±7.1
88.3±7.2
68.3±9.1

0.0±0.0
89.9±2.5
77.0±2.9
69.8±4.3

25.4±1.6
38.8±2.3
35.4±1.5
28.9±1.9

20.2±2.1
300±0.0
300±0.0
300±0.0

120

51.8±7.6

53.0±6.1

26.8±2.2

23.5±1.4

PMH

BMH

OMH

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin; aPTT, activated partial thromboplastin time;
TT, thrombin time.
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TABLE 59
COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF VARIOUS LOW MOLECULAR WEIGHT HEPARINS
AS DETERMINED BY VARIOUS ANTIPROTEASE AND ANTICOAGULANT ASSAYS AT A DOSE OF 1 MG/KG SC IN
NON-HUMAN PRIMATES
Drug

Time

Anti-Xa

Anti-IIa

aPTT

TT

1 mg/kg SC

(Hours)

(% Inhibition)

(% Inhibition)

(Seconds)

(Seconds)

0

0.0±0.0

0.0±0.0

27.7±1.8

19.3±1.3

2

84.3±5.5

43.5±3.4

40.8±1.0

300±0.0

4

76.5±3.5

31.9±3.9

36.2±3.7

300±0.0

6

59.6±4.2

15.3±3.8

28.7±1.8

21.9±1.4

0

0.0±0.0

0.0±0.0

26.3±1.0

21.1±3.1

2

86.1±6.3

44.8±2.6

41.6±2.9

300±0.0

4

76.8±8.8

33.3±5.8

35.5±0.9

300±0.0

6

61.8±4.4

14.8±5.7

29.2±1.4

23.1±2.1

0

0.0±0.0

0.0±0.0

25.4±1.6

20.2±2.1

2

88.2±7.1

45.9±2.5

39.8±2.3

300±0.0

4

78.3±7.2

34.0±2.9

33.4±1.5

300±0.0

6

51.8±7.6

16.0±6.1

27.8±2.2

22.5±1.4

P. LMWH

B. LMWH

O. LMWH

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin; aPTT, activated partial thromboplastin time;
TT, thrombin time.
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TABLE 60
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS HEPARINS AS DETERMINED BY
VARIOUS ANTIPROTEASE ASSAYS AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES

Drug
0.5 mg/kg IV

PMH

BMH

OMH

Time
(Minutes)
0
15
30
60
120
0
15
30
60
120
0
15
30
60
120

Anti-Xa
Concentration (U/ml)
0.0±0.0
2.2±0.1
1.5±0.3
1.2±0.3
0.6±0.3
0.0±0.0
1.5±0.1
1.0±0.2
0.8±0.2
0.6±0.2
0.0±0.0
2.3±0.1
1.7±0.1
1.0±0.2
0.4±0.1

Anti-IIa
Concentration (U/ml)
0.0±0.0
1.9±0.3
1.7±0.3
1.3±0.3
0.6±0.3
0.0±0.0
1.2±0.2
0.8±0.1
0.3±0.2
0.2±0.1
0.0±0.0
2.2±0.1
1.7±0.2
1.0±0.2
0.4±0.1

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin.
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TABLE 61
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS HEPARINS AS DETERMINED BY
VARIOUS ANTIPROTEASE ASSAYS AT A DOSE OF 100 U/KG IV IN NON-HUMAN PRIMATES

Drug
100 U/kg IV

PMH

BMH

OMH

Time
(Minutes)
0
15
30
60
120
0
15
30
60
120
0
15
30
60
120

Anti-Xa
Concentration (U/ml)
0.0±0.0
2.3±0.13
1.4±0.31
1.1±0.33
0.6±0.34
0.0±0.0
2.5±0.1
1.5±0.2
1.2±0.2
0.8±0.2
0.0±0.0
2.4±0.1
1.6±0.1
1.1±0.2
0.6±0.1

Anti-IIa
Concentration (U/ml)
0.0±0.0
2.0±0.3
1.8±0.3
1.2±0.3
0.7±0.3
0.0±0.0
2.1±0.2
1.7±0.1
1.3±0.2
0.9±0.1
0.0±0.0
2.1±0.1
1.6±0.2
1.2±0.2
0.6±0.1

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin.
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TABLE 62
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS LOW MOLECULAR WEIGHT
HEPARINS AS DETERMINED BY VARIOUS ANTIPROTEASE ASSAYS AT A DOSE OF 1 MG/KG SC IN NON-HUMAN
PRIMATES

Drug
1 mg/kg SC

P. LMWH

B. LMWH

O. LMWH

Time
(Hours)

Anti-Xa
Concentration (U/ml)

Anti-IIa
Concentration (U/ml)

0
2
4
6

0.0±0.0
1.2±0.13
0.8±0.31
0.6±0.34

0.0±0.0

0
2
4
6

0.0±0.0
1.1±0.12
0.7±0.15
0.5±0.13

0
2
4
6

0.0±0.0
1.0±0.14
0.8±0.15
0.5±0.11

0.15±0.02
0.11±0.01
0.03±0.002
0.0±0.0
0.17±0.02
0.13±0.01
0.03±0.004
0.0±0.0
0.16±0.02
0.12±0.01
0.03±0.003

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin.
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TABLE 63
COMPARATIVE THROMBIN GENERATION INHIBITORY (TGA) PROFILE OF
VARIOUS HEPARINS IN TERMS OF PEAK THROMBIN , AREA UNDER THE
CURVE AND LAG TIME AT A DOSE OF 0.5 mg/kg IV IN NON-HUMAN PRIMATES
UFHs – 0.5 mg/kg

Peak Thrombin
nM

AUC
nM*min

Lag Time
min

Time
(Minutes)
0
15
30
60
120
Time
(Minutes)
0
15
30
60
120
Time
(Minutes)
0
15
30
60
120

PMH

BMH

OMH

234±23
0.21±0.03
0.26±0.05
0.12±0.04
33±4

227±21
0.61±0.08
0.66±0.07
1.9±0.2
103±9

250±29
0.49±0.09
0.45±0.06
1.8±0.3
46±5

PMH

BMH

OMH

1992±56
6.7±1.2
0±0
0±0
462±23

1921±79
9.8±2.1
9.6±2.1
35.8±4
422±28

2009±112
0±0
0±0
51.7±7
525±35

PMH

BMH

OMH

1.8±0.2
0.67±-.1
13.5±2.1
0.34±0.03
2.8±0.3

1.8±0.4
2.6±0.2
17±3.2
0.92±0.04
2.6±0.4

1.8±0.3
6.9±1.1
19.8±4.7
1.4±0.2
2.9±0.3

All results represent the mean (±) standard deviation (n=4). Inhibition of thrombin generation
was measured by Fluoroskan ascent fluorimeter, calibrated automated thrombogram (CAT;
Diagnostica Stago). All heparins were administered at a dose of 0.5 mg/kg IV, in non-human
primates.
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TABLE 64
COMPARATIVE THROMBIN GENERATION INHIBITORY (TGA) PROFILE OF
VARIOUS HEPARINS IN TERMS OF PEAK THROMBIN , AREA UNDER THE
CURVE AND LAG TIME AT A DOSE OF 100 U/kg IV IN NON-HUMAN PRIMATES
UFHs – 100 U/kg

Peak Thrombin
nM

AUC
nM*min

Lag Time
min

Time
(Minutes)
0
15
30
60
120
Time
(Minutes)
0
15
30
60
120
Time
(Minutes)
0
15
30
60
120

PMH

BMH

OMH

257±9
0.27±0.03
0±0
0±0

246±10
1.1±0.07
0±0
0±0

241±12
0.21±0.03
0±0
0±0

31±4

33±6

40±5

PMH

BMH

OMH

1937±131
0±0
0±0
0±0

2079±145
4.9±0.8
0±0
0±0

2057±158
11.3±1.2
0±0
0±0

430±25

315±15

412±23

PMH

BMH

OMH

1.6±0.3
21±4
0±0
0±0

1.7±0.2
17±4
0±0
0±0

1.8±0.4
18±3
0±0
0±0

1.8±0.4

1.1±0.2

1.5±0.3

All results represent the mean (±) standard deviation (n=4). Inhibition of thrombin generation
was measured by Fluoroskan ascent fluorimeter, calibrated automated thrombogram (CAT;
Diagnostica Stago). All heparins were administered at a dose of 100 U/kg IV, in non-human
primates.
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TABLE 65
COMPARATIVE THROMBIN GENERATION INHIBITORY (TGA) PROFILE OF
VARIOUS LMWHs IN TERMS OF PEAK THROMBIN , AREA UNDER THE CURVE
AND LAG TIME AT A DOSE OF 1 mg/kg SC IN NON-HUMAN PRIMATES
LMWHs – 1 mg/kg

Peak Thrombin
nM

AUC
nM*min

Lag Time
min

Time
(Minutes)
0
15
30
60
120
Time
(Minutes)
0
15
30
60
120
Time
(Minutes)
0
15
30
60
120

P. LMWH

B. LMWH

O. LMWH

240±19
33±6
34±4
116±9
240±19

230±21
46±9
43±6
120±10
230±14

249±18
36±7
50±4
123±11
249±12

P. LMWH

B. LMWH

O. LMWH

2094±154
628±34
601±35
1048±99
2094±121

2056±176
724±52
615±44
1155±132
2055±134

2047±177
690±43
652±21
1203±112
2047±133

P. LMWH

B. LMWH

O. LMWH

1.5±0.3
2.2±0.3
2.2±0.4
1.6±0.2
1.6±0.3

1.5±0.2
2.2±0.4
2.1±0.4
1.8±0.2
1.5±0.3

1.6±0.4
2.1±0.6
2.1±0.4
1.7±0.2
1.5±0.3

All results represent the mean (±) standard deviation (n=4). Inhibition of thrombin generation
was measured by Fluoroskan ascent fluorimeter, calibrated automated thrombogram (CAT;
Diagnostica Stago). All LMWHs were administered at a dose of 1 mg/kg SC, in non-human
primates.
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TABLE 66
COMPARATIVE TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ANTIGEN
RELEASE PROFILE OF VARIOUS HEPARINS AND LMWHS IN NON-HUMAN
PRIMATES
Time
PMH
BMH
OMH
(Minutes)
ng/ml
ng/ml
ng/ml
0
64±4
59±5
68±8
Heparins
15
264±18
223±16
255±21
(0.5 mg/kg)
30
206±12
180±11
213±16
60
154±16
152±14
161±12
120
91±5
88±7
82±5
Time
PMH
BMH
OMH
(Minutes)
ng/ml
ng/ml
ng/ml
0
89±7
89±5
88±8
Heparins
15
258±27
245±26
257±21
(100 U/kg)
30
222±21
220±19
222±17
60
173±16
171±15
166±13
120
115±9
119±6
110±8
Time
P. LMWH
B. LMWH
O. LMWH
(Hours)
ng/ml
ng/ml
ng/ml
0
49±4
55±4
51±7
LMWHs
(1 mg/kg)
2
98±9
102±7
98±8
4
75±7
81±5
82±7
6
56±5
56±5
56±4
All results represent the mean (±) standard deviation (n=4). The pharmacodynamic effects of
various heparins and LMWHs administered to primates as measured by the TFPI antigen release
level assay. The TFPI antigen release profile of various heparins (0.5 mg/kg and 100 U/kg IV)
and LMWHs (1 mg/kg SC) in primates were determined by using commercially available
Sandwich ELISA kits.
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TABLE 67
COMPARATIVE TISSUE FACTOR PATHWAY INHIBITOR (TFPI) FUNCTIONAL
PROFILE OF VARIOUS HEPARINS AND LMWHS IN NON-HUMAN PRIMATES
Time
PMH
BMH
OMH
(Minutes)
U/ml
U/ml
U/ml
0
1.23±0.3
1.27±0.1
1.3±0.2
Heparins
15
2.1±0.4
2.5±0.3
2.1±0.3
(0.5 mg/kg)
30
1.9±0.2
1.98±0.2
2±0.2
60
1.9±0.3
1.93±0.1
1.98±0.3
120
1.4±0.1
1.5±0.2
1.43±0.2
Time
PMH
BMH
OMH
(Minutes)
U/ml
U/ml
U/ml
0
1.21±0.2
1.26±0.3
1.23±0.3
Heparins
15
2.11±0.4
2.14±0.5
2.16±0.4
(100 U/kg)
30
1.94±0.4
1.89±0.2
2±0.2
60
1.6±0.3
1.63±0.3
1.54±0.2
120
1.35±0.1
1.34±0.2
1.41±0.3
Time
P. LMWH
B. LMWH
O. LMWH
(Hours)
U/ml
U/ml
U/ml
0
1.27±0.2
1.24±0.1
1.28±0.1
LMWHs
(1 mg/kg)
2
1.76±0.2
1.76±0.3
1.83±0.2
4
1.63±0.1
1.63±0.3
1.65±0.2
6
1.46±0.2
1.52±0.2
1.55±0.3
All results represent the mean (±) standard deviation (n=4). The pharmacodynamic effects of
various heparins and LMWHs administered to primates as measured by the TFPI functional level
assay. The TFPI functional level profile of various heparins (0.5 mg/kg and 100 U/kg IV) and
LMWHs (1 mg/kg SC) in primates were determined by using commercially available
ACTICHROME® TFPI kits.
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TABLE 68
ESTAMATION OF PHARMACOKINETIC PARAMETERS OF VARIOUS HEPARINS CALCULATED FROM PLASMA
CONCENTRATION TIME CURVES AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES

Test

Drug

Half-life; mins

AUC; (ug*ml)/min

Vd; ml/kg

Cl; ml/kg/min

Anti-Xa

PMH

59±7.9

210±13

39±4.8

0.54±0.12

BMH

96±11

185±9

48±5.3

0.48±0.13

OMH

54±7

205±10.6

34±4.9

0.51±0.11

PMH

58±8.4

181±8.9

38±4.4

0.52±0.14

BMH

105±12.7

155±7.3

47±5.3

0.43±0.12

OMH

59±5.9

178±9

34±4.9

0.55±0.11

IV 0.5 mg/kg

Anti-IIa
IV 0.5 mg/kg

All results represent the mean (±) standard deviation (n=4). AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa,
factor Xa; IIa, thrombin.
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TABLE 69
ESTAMATION OF PHARMACOKINETIC PARAMETERS OF VARIOUS HEPARINSCALCULATED FROM PLASMA
CONCENTRATION TIME CURVES AT A DOSE OF 100 U/KG IV IN NON-HUMAN PRIMATES

Test

Drug

Half-life; mins

AUC; (ug*ml)/min

Vd; ml/kg

Cl; ml/kg/min

Anti-Xa

PMH

61±7

143±15

60±7

0.8±0.06

BMH

97±11

156±11

65±6

0.6±0.08

OMH

57±6

145±8

59±5

0.7±0.09

PMH

56±9

139±10

57±8

0.72±0.12

BMH

89±8

152±11

65±6

0.65±0.13

OMH

60±7

144±6

61±7

0.75±0.12

IV 100 U/kg

Anti-IIa
IV 100 U/kg

All results represent the mean (±) standard deviation (n=4). AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa,
factor Xa; IIa, thrombin.
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TABLE 70
ESTAMATION OF PHARMACOKINETIC PARAMETERS OF VARIOUS LOW MOLECULAR WEIGHT HEPARINS
CALCULATED FROM PLASMA CONCENTRATION TIME CURVES AT A DOSE OF 1 MG/KG SC IN NON-HUMAN
PRIMATES

Test

Drug

Half-life; hrs

AUC; (ug*ml)/hr

Vd; ml/kg

Cl; ml/kg/hr

Anti-Xa

P. LMWH

4.1±0.27

72±5.3

84±3.3

18±2.4

B. LMWH

3.8±0.49

76±8.2

81±4.7

20±3.3

O. LMWH

3.7±0.62

71±5.3

79±5.4

21±1.9

P. LMWH

1.9±0.1

23±2.1

119±7.4

59±4.8

B. LMWH

1.65±0.2

22±3.2

121±8.5

57±6.9

O. LMWH

1.67±0.2

21±2.3

118±9.3

61±5.8

SC 1 mg/kg

Anti-IIa
SC 1 mg/kg

All results represent the mean (±) standard deviation (n=4). AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa,
factor Xa; IIa, thrombin.
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TABLE 71
ABSOLUTE QUANTIFICATION OF GAG CONTENTS OF VARIOUS HEPARINS AND LOW MOLECULAR WEIGHT
HEPARINS AT VARIOUS DOSES IN NON-HUMAN PRIMATES USING HEPRIN RED METHOD
Time
PMH
BMH
OMH
(Minutes)
ug/ml
ug/ml
ug/ml
0
0±0
0±0
0±0
Heparins
15
7.6±0.6
7.9±0.8
7.5±0.6
(0.5 mg/kg)
30
5.4±0.2
5.3±0.4
5.3±0.3
60
2.7±0.2
2.8±0.3
2.8±0.2
120
1.2±0.1
1.5±0.2
1.2±0.1
Time
PMH
BMH
OMH
(Minutes)
ug/ml
ug/ml
ug/ml
0
0±0
0±0
0±0
Heparins
15
7.7±0.5
9.8±0.9
7.7±0.6
(100 U/kg)
30
5.2±0.4
6.5±0.7
5.5±0.4
60
2.8±0.2
3.1±0.2
2.6±0.4
120
1.4±0.1
1.7±0.2
1.3±0.2
Time
P. LMWH
B. LMWH
O. LMWH
(Hours)
ug/ml
ug/ml
ug/ml
0
0±0
0±0
0±0
LMWHs
(1 mg/kg)
2
5.4±0.7
5.6±0.4
5.3±0.6
4
3.4±0.4
3.1±0.2
3.3±0.3
6
1.5±0.2
1.6±0.1
1.4±0.2
All results represent the mean (±) standard deviation (n=4). The absolute quantification of GAG contents of various heparins (0.5
mg/kg and 100 U/kg IV) and LMWHs (1 mg/kg SC) in primates were determined by using Heparin Red kits.
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TABLE 72
ABSOLUTE PHARMACOKINETIC PARAMETERS OF VARIOUS HEPARINS AND LOW MOLECULAR WEIGHT
HEPARINS AT VARIOUS DOSES IN NON-HUMAN PRIMATES USING HEPRIN RED METHOD

Test

Drug

Half-life; mins

AUC; (ug*ml)/min

Vd; ml/kg

Cl; ml/kg/min

UFHs

PMH

39±3.8

458±9.3

62±3.3

1.1±0.14

IV 0.5 mg/kg

BMH

45±4.6

504±8.2

64±4.7

1.0±0.13

OMH

41±5.1

463±8.3

63±5.4

1.1±0.19

UFHs

PMH

43±4.1

483±9.1

130±4.4

2.1±0.38

IV 100 U/kg

BMH

48±5.2

624±13

121±5.5

1.6±0.19

OMH

41±4.2

470±2.3

124±7.3

2.1±0.18

Test

Drug

Half-life; hrs

AUC; (ug*ml)/hr

Vd; ml/kg

Cl; ml/kg/hr

LMWHs

P. LMWH

2.2±0.4

24±2.1

131±8.4

42.3±3.8

SC 1 mg/kg

B. LMWH

2.2±0.3

24±3.2

131±3.5

41.7±2.9

O. LMWH

2.1±0.2

23±2.3

133±7.3

43.6±4.8

All results represent the mean (±) standard deviation (n=4). AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa,
factor Xa; IIa, thrombin.
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TABLE 73
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS UNFRACTIONATED HEPARINS POST
SALINE IV INJECTION AS DETERMINED BY VARIOUS ANTIPROTEASE ASSAYS IN NON-HUMAN PRIMATES
Drug

Time Points
Anti-Xa
Anti-IIa
(Minutes)
Concentration (U/ml)
Concentration (U/ml)
0
0.0±0.0
0.0 ±0.0
15 Post Drug
1.2±0.26
1.19±0.24
BMH (100 U/Kg)
15 Post Saline
1.08±0.14
1.05 ±0.09
45 Post Saline
0.8±0.07
0.81±0.0)
120 Post Saline
0.45±0.03
0.43±0.01
0
0.0±0.0
0.0±0.0
15 Post Drug
1.22±0.21
1.26±0.25
OMH (100 U/Kg)
15 Post Saline
1.2±0.15
1.05±0.15
45 Post Saline
0.77±0.02
0.82±0.08
120 Post Saline
0.39±0.01
0.41±0.05
0
0.0±0.0
0.0±0.0
15 Post Drug
1.25±0.2
1.21±0.29
PMH (100 U/Kg)
15 Post Saline
1.08±0.13
1.10±0.18
45 Post Saline
0.80±0.09
0.83±0.12
120 Post Saline
0.38±0.04
0.37±0.015
0
0.0±0.0
0.0±0.0
15 Post Drug
1.01±0.11
0.97±0.14
BMH (0.5 mg/Kg)
15 Post Saline
0.81±0.09
0.79±0.12
45 Post Saline
0.56±0.02
0.58±0.09
120 Post Saline
0.23±0.01
0.35±0.03
All results represent the mean (±) standard deviation (n=4). BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, PMH;
porcine mucosal heparin, Xa; factor Xa, IIa; thrombin.
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TABLE 74
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS UNFRACTIONATED HEPARINS POST
PROTAMINE SULFATE (PS) IV INJECTION AT A DOSE OF 0.5 (mg/kg) AS DETERMINED BY VARIOUS
ANTIPROTEASE ASSAYS IN NON-HUMAN PRIMATES
Drug

Time Points
Anti-Xa
Anti-IIa
(Minutes)
Concentration (U/ml)
Concentration (U/ml)
0
0.0±0.0
0.0±0.0
15 Post Drug
1.22±0.09
1.20±0.13
BMH (100 U/Kg)
15 Post PS
0.14±0.01
0.14±0.02
45 Post PS
0.09±0.009
0.07±0.008
120 Post PS
0.04±0.008
0.03±0.007
0
0.0±0.0
0.0±0.0
15 Post Drug
1.15±0.08
1.16±0.06
OMH (100 U/Kg)
15 Post PS
0.05±0.006
0.05±0.01
45 Post PS
0.04±0.007
0.01±0.003
120 Post PS
0.01±0.003
0.0±0.0
0
0.0±0.0
0.0±0.0
15 Post Drug
1.13±0.07
1.22±0.15
PMH (100 U/Kg)
15 Post PS
0.07±0.005
0.09±0.01
45 Post PS
0.05±0.004
0.02±0.003
120 Post PS
0.01±0.001
0.01±0.001
0
0.0±0.0
0.0±0.0
15 Post Drug
0.96±0.04
0.92±0.01
BMH (0.5 mg/Kg)
15 Post PS
0.05±0.006
0.02±0.002
45 Post PS
0.01±0.001
0.01±0.002
120 Post PS
0.0±0.0
0.0±0.0
All results represent the mean (±) standard deviation (n=4). BMH; bovine mucosal heparin, OMH; ovine mucosal heparin, PMH;
porcine mucosal heparin, Xa; factor Xa, IIa; thrombin.
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TABLE 75
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS LOW MOLECULAR WEIGHT
HEPARINS POST SALINE IV INJECTION AS DETERMINED BY VARIOUS ANTIPROTEASE ASSAYS IN NONHUMAN PRIMATES
Drug

Time Points
(Minutes)

P. LMWH (1 mg/Kg)

B. LMWH (1 mg/Kg)

O. LMWH (1 mg/Kg)

Anti-Xa
Concentration (U/ml)

Anti-IIa
Concentration (U/ml)

0

0.0±0.0

0.0±0.0

15 Post Drug

1.29±0.19

0.31±0.03

15 Post Saline

1.21±0.21

0.28±0.01

45 Post Saline

1.14±0.18

0.26±0.03

120 Post Saline

0.98±0.13

0.22±0.02

0

0.0±0.0

0.0±0.0

15 Post Drug

1.21±0.13

0.31±0.02

15 Post Saline

1.19±0.25

0.27±0.01

45 Post Saline

1.11±0.19

0.25±0.06

120 Post Saline

0.96±0.11

0.21±0.03

0

0.0±0.0

0.0±0.0

15 Post Drug

1.23±0.18

0.32±0.01

15 Post Saline

1.20±0.11

0.28±0.02

45 Post Saline

1.13±0.14

0.26±0.01

120 Post Saline
0.99±0.09
0.22±0.02
All results represent the mean (±) standard deviation (n=4). P; porcine, B; bovine, O; ovine, LMWH; low molecular weight heparin,
Xa; factor Xa, IIa; thrombin.
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TABLE 76
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS LOW MOLECULAR WEIGHT
HEPARINS POST PROTAMINE SULFATE (PS) IV INJECTION AT A DOSE OF 0.5 (mg/kg) AS DETERMINED BY
VARIOUS ANTIPROTEASE ASSAYS IN NON-HUMAN PRIMATES
Drug

Time Points
Anti-Xa
Anti-IIa
(Minutes)
Concentration (U/ml)
Concentration (U/ml)
0
0.0±0.0
0.0±0.0
15 Post Drug
1.07±0.16
0.21±0.04
P. LMWH (1 mg/Kg)
15 Post PS
0.97±0.13
0.14±0.03
45 Post PS
0.88±0.09
0.11±0.01
120 Post PS
0.79±0.06
0.06±0.003
0
0.0±0.0
0.0±0.0
15 Post Drug
1.01±0.18
0.21±0.06
B. LMWH (1 mg/Kg)
15 Post PS
0.96±0.12
0.15±0.01
45 Post PS
0.85±0.09
0.11±0.02
120 Post PS
0.78±0.05
0.05±0.001
0
0.0±0.0
0.0±0.0
15 Post Drug
1.05±0.17
0.2±0.01
O. LMWH (1 mg/Kg)
15 Post PS
0.94±0.14
0.16±0.02
45 Post PS
0.83±0.13
0.11±0.01
120 Post PS
0.74±0.08
0.05±0.001
All results represent the mean (±) standard deviation (n=4). P; porcine, B; bovine, O; ovine, LMWH; low molecular weight heparin,
Xa; factor Xa, IIa; thrombin.
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TABLE 77
ABSOLUTE QUANTIFICATION OF GAG CONTENTS OF VARIOUS
HEPARINS POST SALINE IV INJECTION AS DETERMINED BY THE
HEPARIN RED METHOD IN NON-HUMAN PRIMATES
Drug

Time Points
Concentration
(Minutes)
(ug/ml)
0
0.0±0.0
15 Post Drug
8.22±1.2
PMH (100 U/Kg)
15 Post Saline
5.41±0.6
45 Post Saline
2.79±0.4
120 Post Saline
1.34±0.2
0
0.0±0.0
15 Post Drug
9.99.±1.3
BMH (100 U/Kg)
15 Post Saline
6.35±1.6
45 Post Saline
3.4±0.9
120 Post Saline
2.1±0.6
0
0.0±0.0
15 Post Drug
7.73±1.2
OMH (100 U/Kg)
15 Post Saline
5.34±1.5
45 Post Saline
2.56±0.9
120 Post Saline
1.28±0.3
0
0.0±0.0
15 Post Drug
7.99±1.3
BMH (0.5 mg/Kg)
15 Post Saline
5.54±1.1
45 Post Saline
2.82±0.5
120 Post Saline
1.7±0.9
All results represent the mean (±) standard deviation (n=4). BMH; bovine mucosal
heparin, OMH; ovine mucosal heparin, PMH; porcine mucosal heparin.
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TABLE 78
ABSOLUTE QUANTIFICATION OF GAG CONTENTS OF VARIOUS
HEPARINS POST PROTAMINE SULFATE (PS) IV INJECTION AT A DOSE OF
0.5 (mg/kg) AS DETERMINED BY THE HEPARIN RED METHOD IN NONHUMAN PRIMATES
Drug

Time Points
Concentration
(Minutes)
(ug/ml)
0
0.0±0.0
15 Post Drug
8.22±1.2
PMH (100 U/Kg)
15 Post PS
1.41±0.9
45 Post PS
0.89±0.4
120 Post PS
0.74±0.2
0
0.0±0.0
15 Post Drug
9.99.±1.3
BMH (100 U/Kg)
15 Post PS
2.35±0.9
45 Post PS
1.4±0.4
120 Post PS
0.89±0.6
0
0.0±0.0
15 Post Drug
7.73±1.2
OMH (100 U/Kg)
15 Post PS
1.34±1.5
45 Post PS
0.86±0.9
120 Post PS
0.68±0.3
0
0.0±0.0
15 Post Drug
7.99±1.3
BMH (0.5 mg/Kg)
15 Post PS
1.24±1.1
45 Post PS
0.99±0.1
120 Post PS
0.43±0.06
All results represent the mean (±) standard deviation (n=4). BMH; bovine mucosal
heparin, OMH; ovine mucosal heparin, PMH; porcine mucosal heparin, PS; protamine
sulfate.
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TABLE 79
ABSOLUTE QUANTIFICATION OF GAG CONTENTS OF VARIOUS LOW
MOLECULAR WEIGHT HEPARINS POST SALINE IV INJECTION AT A
DOSE OF 0.5 (MG/KG) AS DETERMINED BY THE HEPARIN RED METHOD
IN NON-HUMAN PRIMATES
Drug

P. LMWH
(1 mg/Kg)

B. LMWH
(1 mg/Kg)

O. LMWH
(1 mg/Kg)

Time Points

Concentration

(Minutes)

(ug/ml)

0

0.0±0.0

15 Post Drug

5.72±0.9

15 Post Saline

4.41±0.6

45 Post Saline

3.79±0.4

120 Post Saline

2.04±0.2

0

0.0±0.0

15 Post Drug

5.45±1.3

15 Post Saline

4.35±1.6

45 Post Saline

3.48±0.9

120 Post Saline

1.9±0.6

0

0.0±0.0

15 Post Drug

5.73±1.2

15 Post Saline

4.34±1.5

45 Post Saline

3.56±0.9

120 Post Saline

1.28±0.3

All results represent the mean (±) standard deviation (n=4). P; porcine, B; bovine, O;
ovine, LMWH; low molecular weight heparin.
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TABLE 80
ABSOLUTE QUANTIFICATION OF GAG CONTENTS OF VARIOUS LOW
MOLECULAR WEIGHT HEPARINS POST PROTAMINE SULFATE IV
INJECTION AT A DOSE OF 0.5 (MG/KG) AS DETERMINED BY THE
HEPARIN RED METHOD IN NON-HUMAN PRIMATES
Drug

P. LMWH
(1 mg/Kg)

B. LMWH
(1 mg/Kg)

O. LMWH
(1 mg/Kg)

Time Points

Concentration

(Minutes)

(ug/ml)

0

0.0±0.0

15 Post Drug

5.72±0.9

15 Post PS

3.41±0.6

45 Post PS

2.19±0.4

120 Post PS

1.0±0.2

0

0.0±0.0

15 Post Drug

5.45±1.3

15 Post PS

3.35±1.6

45 Post PS

2.4±0.9

120 Post PS

1.21±0.6

0

0.0±0.0

15 Post Drug

5.73±1.2

15 Post PS

3.34±1.5

45 Post PS

2.16±0.9

120 Post PS

1.01±0.3

All results represent the mean (±) standard deviation (n=4). P; porcine, B; bovine, O;
ovine, LMWH; low molecular weight heparin, PS; protamine sulfate.
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APPENDIX B
ADDITIONAL DATA TABLES AND FIGURES
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B1- MOLECULAR WEIGHT PARAMETERS OF VARIOUS UFHS AND
LMWHS (DETECTION: UV)

Agent

Mn

Mw

MP

Mz

Mz+1

Polydispersity

PMH - 1st Run

15337

17953

15756

20038

24947

1.176938

PMH – 2nd Run
PMH – 3rd Run

16578
15641

18648
18829

16453
16716

20464
20801

24873
25372

1.186111
1.179650

BMH - 1st Run

17754

19978

16336

23118

28093

1.252401

BMH – 2 Run

18511

22416

17837

24864

29260

1.240799

BMH – 3rd Run

17811

20532

16889

24059

28832

1.235353

OMH - 1st Run

11966

16889

14322

22302

28930

1.422974

OMH – 2nd Run

12795

17590

14530

22124

28869

1.444153

OMH – 3rd Run

12841

17594

14202

22066

28749

1.438394

P. LMWH - 1st Run

3475

4122

2755

4334

5908

1.162711

P. LMWH– 2nd Run

3252

4134

2813

4653

5762

1.178976

P. LMWH – 3 Run

3334

4003

2819

4590

5633

1.176081

B. LMWH - 1st Run

3574

3979

2810

4732

5883

1.184880

B. LMWH – 2nd Run

3418

4221

2756

4298

5180

1.161255

B. LMWH – 3 Run

3397

4176

2816

4574

5648

1.181248

O. LMWH - 1st Run

3570

3925

2807

4471

5448

1.175120

O. LMWH – 2nd Run

3341

4135

2830

4523

5440

1.177827

O. LMWH – 3rd Run

3340

4099

2816

4917

5834

1.197454

nd

rd

rd
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B2- MOLECULAR WEIGHT PARAMETERS OF VARIOUS UFHS AND
LMWHS (DETECTION: RI)

Agent

Mn

Mw

MP

Mz

Mz+1

Polydispersity

PMH - 1st Run

16735

19524

16664

21167

25659

1.189294

PMH – 2 Run
PMH – 3rd Run

16837
16774

18806
19057

16812
16335

20709
20328

24909
25553

1.173084
1.157030

BMH - 1st Run

18084

21545

19579

27600

33151

1.235577

BMH – 2nd Run

17812

22556

16627

24471

30073

1.236796

BMH – 3rd Run

17492

21901

18539

26527

32368

1.273409

OMH - 1st Run

12919

17386

14175

21865

29347

1.409118

OMH – 2nd Run

13583

17017

13834

21395

28747

1.418894

OMH – 3rd Run

13883

18445

14568

22036

29552

1.419131

P. LMWH - 1st Run

3987

4335

3210

5058

5946

1.144717

P. LMWH– 2nd Run

3841

4424

3226

5203

6174

1.151769

P. LMWH – 3rd Run

3909

4481

3237

5225

6120

1.146321

B. LMWH - 1st Run

3914

4283

3196

5026

5930

1.153081

B. LMWH – 2nd Run

3776

4322

3222

5031

5895

1.143862

B. LMWH – 3rd Run

3868

4589

3204

4967

5794

1.138776

O. LMWH - 1st Run

3811

4361

3230

5091

6002

1.144374

O. LMWH – 2nd Run

3905

4516

3246

5315

6274

1.156566

O. LMWH – 3rd Run

3883

4445

3568

5036

5552

1.139131

nd
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B3- MOLECULAR WEIGHT DISTRIBUTION OF VARIOUS UFHS AND
LMWHS (DETECTOR: UV)

Agent
PMH - 1st Run
PMH – 2nd Run
PMH – 3rd Run
BMH - 1st Run
BMH – 2nd Run
BMH – 3rd Run
OMH - 1st Run
OMH – 2nd Run
OMH – 3rd Run
P. LMWH - 1st Run
P. LMWH– 2nd Run
P. LMWH – 3rd Run
B. LMWH - 1st Run
B. LMWH – 2nd Run
B. LMWH – 3rd Run
O. LMWH - 1st Run
O. LMWH – 2nd Run
O. LMWH – 3rd Run

> 12
kDa
68
69
65
73
77
78
56
54
54
0
0
0
0
0
0
0
0
0

Molecular Weight Components
8-12
1.5-2.5
5-8 kDa 2.5-5 kDa
kDa
kDa
23
8
1
0
22
8
1
0
24
10
1
0
19
6
0
0
19
4
0
0
18
4
0
0
22
17
5
0
22
18
6
0
22
18
6
0
3
15
63
17
3
15
63
17
3
16
62
17
2
13
63
20
2
15
63
18
2
15
62
19
2
17
65
15
4
17
61
16
3
16
63
16

<1.5
kDa
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
1
2
2
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B4- MOLECULAR WEIGHT DISTRIBUTION OF VARIOUS UFHS AND
LMWHS (DETECTOR: UV)
Agent
PMH - 1st Run
PMH – 2nd Run
PMH – 3rd Run
BMH - 1st Run
BMH – 2nd Run
BMH – 3rd Run
OMH - 1st Run
OMH – 2nd Run
OMH – 3rd Run
P. LMWH - 1st Run
P. LMWH– 2nd Run
P. LMWH – 3rd Run
B. LMWH - 1st Run
B. LMWH – 2nd Run
B. LMWH – 3rd Run
O. LMWH - 1st Run
O. LMWH – 2nd Run
O. LMWH – 3rd Run

Molecular Weight Components
> 7.5 kDa
< 7.5 kDa
93
7
93
7
91
9
98
2
98
2
97
3
79
21
80
20
81
19
4
96
4
96
5
95
3
97
4
96
3
97
3
97
5
95
4
96
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B5- MOLECULAR WEIGHT DISTRIBUTION OF VARIOUS UFHS AND
LMWHS (DETECTOR: RI)

Agent
PMH - 1st Run
PMH – 2nd Run
PMH – 3rd Run
BMH - 1st Run
BMH – 2nd Run
BMH – 3rd Run
OMH - 1st Run
OMH – 2nd Run
OMH – 3rd Run
P. LMWH - 1st Run
P. LMWH– 2nd Run
P. LMWH – 3rd Run
B. LMWH - 1st Run
B. LMWH – 2nd Run
B. LMWH – 3rd Run
O. LMWH - 1st Run
O. LMWH – 2nd Run
O. LMWH – 3rd Run

> 12
kDa
67
68
67
75
76
76
53
51
53
0
0
0
0
0
0
0
0
0

Molecular Weight Components
8-12
1.5-2.5
5-8 kDa 2.5-5 kDa
kDa
kDa
25
8
0
0
26
6
0
0
24
9
0
0
20
5
0
0
21
3
0
0
19
5
0
0
23
19
5
0
24
19
6
0
24
18
5
0
4
23
65
8
5
24
63
8
5
25
63
7
4
22
63
11
4
23
64
9
4
22
65
9
4
23
65
8
6
25
61
8
5
25
60
10

<1.5
kDa
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
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B6- MOLECULAR WEIGHT DISTRIBUTION OF VARIOUS UFHS AND
LMWHS (DETECTOR: RI)
Molecular Weight Components
Agent
> 7.5 kDa
< 7.5 kDa
st
PMH - 1 Run
96
4
nd
PMH – 2 Run
97
3
PMH – 3rd Run
97
3
st
BMH - 1 Run
96
4
BMH – 2nd Run
97
3
rd
BMH – 3 Run
97
3
OMH - 1st Run
77
23
OMH – 2nd Run
79
21
rd
OMH – 3 Run
80
20
P. LMWH - 1st Run
6
94
nd
P. LMWH– 2 Run
7
93
P. LMWH – 3rd Run
7
93
st
B. LMWH - 1 Run
6
94
B. LMWH – 2nd Run
6
94
rd
B. LMWH – 3 Run
5
95
st
O. LMWH - 1 Run
6
94
O. LMWH – 2nd Run
8
92
rd
O. LMWH – 3 Run
7
93
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B7- MOLECULAR WEIGHT PARAMETERS OF VARIOUS LMWHS – EP
METHOD (DETECTION: UV)
Agent

Mn

Mw

MP

Mz

Mz+1

Polydispersity

P. LMWH - 1st Run
P. LMWH– 2nd Run
P. LMWH – 3rd Run
B. LMWH - 1st Run
B. LMWH – 2nd Run
B. LMWH – 3rd Run
O. LMWH - 1st Run
O. LMWH – 2nd Run
O. LMWH – 3rd Run

3975
3973
4007
3997
3711
3811
3966
3795
3841

4622
4628
4672
4708
4616
4732
4889
4690
4594

3755
3752
3756
3729
3837
3789
3322
3530
3202

5334
5345
5400
5496
5564
5559
5302
5424
5466

6108
6119
6181
6345
6260
6132
6230
6369
6349

1.162711
1.164808
1.165996
1.177995
1.150799
1.165353
1.172974
1.164153
1.168394

B8- MOLECULAR WEIGHT DISTRIBUTION OF VARIOUS LMWHS – EP
METHOD (DETECTION: UV)
Agent
P. LMWH - 1st Run
P. LMWH– 2nd Run
P. LMWH – 3rd Run
B. LMWH - 1st Run
B. LMWH – 2nd Run
B. LMWH – 3rd Run
O. LMWH - 1st Run
O. LMWH – 2nd Run
O. LMWH – 3rd Run
Agent
P. LMWH - 1st Run
P. LMWH– 2nd Run
P. LMWH – 3rd Run
B. LMWH - 1st Run
B. LMWH – 2nd Run
B. LMWH – 3rd Run
O. LMWH - 1st Run
O. LMWH – 2nd Run
O. LMWH – 3rd Run

> 12
kDa
0
0
0
0
0
0
0
0
0

Molecular Weight Components
8-12
1.5-2.5
5-8 kDa 2.5-5 kDa
kDa
kDa
5
28
60
6
5
29
58
7
6
29
58
6
6
30
56
7
5
30
57
7
5
32
56
6
5
29
58
7
6
29
58
6
5
28
60
6
Molecular Weight Components
> 7.5 kDa
< 7.5 kDa
7
93
8
92
8
92
9
91
7
93
8
92
8
92
9
91
7
93

<1.5
kDa
1
1
1
1
1
1
1
1
1
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B9- CHROMATOGRAMS OF VARIOUS LOW MOLECULAR WIGHT
HEPARINS AS DETERMINED BY GEL PERMEATION CHROMATOGRAPHY
(GPC) USING THE EP METHOD

Elution profiles of various LMWHs as measured by gel permeation chromatography
(GPC) using the EP method. Only the UV 234 nm was used in this method.
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B10- CALIBRATIONS CURVES FOR THE THIRTEEN NARROW RANGE
CALIBRATORS AS GENERATED BY THE UV AND RI DETECTORS
A. Calibration Curve – UV Detector
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B. Calibration Curve - RI Detector
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Calibration curves as measured by gel permeation chromatography (GPC) using the
13 narrow range calibrators (NRC method). Both the UV 205 nm (A) and RI (B)
detector methods were used. Panel A, shows the UV calibration curve whereas the
panel B, shows the RI calibration curve.
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B11- NORMAL DONOR BLOOD COLLECTION FOR PLATELET
ACTIVATION AND COAGULATION ASSAYS
Justification:
The following assays of platelet function and blood coagulation are performed in
the Hemostasis and Thrombosis Research Laboratory. Each of these assays requires the
use of fresh, normal donor blood as part of the procedure.
Assays:
1. Heparin-induced platelet antibody test
2. Agonist* induced platelet aggregation (*e.g., collagen, ADP and arachidonic
acid)
3. Activated clotting time (ACT)
4. Thromboelastography (TEG)
For platelet activity assays, there exist several limitations which need to be
adhered to in order to obtain meaningful results. Platelets, processed from whole blood,
must be obtained fresh from a healthy donor. Platelets must be tested within 4 hours from
the time of blood collection. Platelet activity is inhibited by common drugs such as
aspirin and ibuprofen, common foods such as garlic and monosodium glutamate. Blood
from donors who ingested these agents in the 7 previous days cannot be used. Platelet
activity is dependent on platelet genotype and other factors. Thus, only specific donors
can be used for these assays.
The coagulation assays ACT and TEG are designed to use freshly collected
normal human whole blood to study blood clotting activities. Blood must be placed on
the assay instrument immediately after collection.
Protocol
The protocol used for venipuncture and blood collection is provided below.
Typically, 10 ml of whole blood is collected at any one venipuncture time. At a
maximum, no more than 50 ml of whole blood would be collected at any one time.
Because the blood and/or platelets of only certain donors function well in the
above assays, it will be necessary to periodically collect blood from the same donor. Any
one individual would not be used more than twice per month. We are constantly
searching for new donors with platelets reactive in our assays. As the donor pool
becomes larger, a given individual will be used less frequently.
Thus, typically, one person would be asked to donate 10 ml of whole blood twice
a month for a total of 20 ml per month. At a maximum, one person would be asked to
donate 50 ml of whole blood once a month for a total of 50 ml per month.
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B12- DONOR BLOOD COLLECTION PROCEDURES
METHOD
- 2 Syringe Butterfly Technique was used to obtain fresh whole blood or fresh
platelets to perform specific assays of hemostatic activation.
PROCEDURE
1.
Selection of Blood Donor
1.1
Only normal healthy volunteers are to be used as blood donors.

2.

1.2

Informed consent document is to be signed and kept on file for each donor.

1.3

Because all platelets are not reactive in these assays, new donors are tested
for activity prior to use in an assay.

Venipuncture
2.1

The anticoagulant (ACD) to blood ratio is 1 part to 5 parts. For most
assays, collect blood into sodium citrate at a ratio of 9 parts blood to 1 part
citrate. Certain assays use whole blood collected via syringe without
anticoagulant.

2.2

A 21-gauge butterfly needle and plastic syringes are used for the
venipuncture of the antecubital vein of the arm.

2.3

Using sterile technique, perform a clean, free-flowing venipuncture. Swab
the area of the venipuncture with a sterile alcohol pad prior to blood collection.
Use of a tourniquet is allowed.

2.4

Using a 3 ml plastic syringe, draw and discard 3.0 ml of blood to avoid a
pre-activated blood sample.

2.5

With a 10 ml plastic syringe, draw the amount of blood required for the
assay. If more than 10 ml of blood is to be collected, use multiple clean
syringes.

2.6

The tourniquet is to be removed prior to completing the blood draw;
pressure is applied to the puncture site immediately after removing the needle
to avoid bleeding.

2.7

Immediately, gently transfer blood to the tube containing the anticoagulant,
or hold the blood-filled syringe on the side for use in the assay.

2.8

Cap tube containing blood and anticoagulant and mix gently but well.

2.9

Dispose of the needle in a sharp’s container. Any other visibly contaminated equipment should be disposed of in a biohazardous waste bag. Disinfect
any blood contaminated surfaces and assure the donor is in good condition
before releasing him or her.
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B13- COMPLETE BLOOD COUNTS (CBC) FOR NON-HUMAN PRIMATES INCLUDED IN THE PK/PD STUDIES
(UFHS)
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B14- COMPLETE BLOOD COUNTS (CBC) FOR NON-HUMAN PRIMATES INCLUDED IN THE PK/PD STUDIES
(LMWHS)
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B15- CORRELATION STUDIES OF VARIOUS UFHs IN TERMS OF ANTI-Xa POTENCY, TFPI ANTIGEN (TFPI a),
TFPI FUNCTIONAL (TFPI f) LEVELS AND GAG CONTENTS IN NON-HUMAN PRIMATES

Correlation studies of various UFHs as determined by Pearson’s Correlation analysis. The anti-Xa potency of various heparins (0.5
mg/kg and 100 U/kg IV) in primates was measured by the chromogenic anti-Xa assay using Hyphen Biomed kits. The TFPI antigen
and functional levels of all agents were determined by using commercially available Sandwich ELISA kits. The absolute
quantification of GAG contents of all agents was determined by using Heparin Red kits. All results represent the mean (±) standard
deviation (n=4).
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B16- CORRELATION STUDIES OF VARIOUS LMWHs IN TERMS OF ANTI-Xa POTENCY, TFPI ANTIGEN (TFPI a),
TFPI FUNCTIONAL (TFPI f) LEVELS AND GAG CONTENTS IN NON-HUMAN PRIMATES

Correlation studies of various LMWHs as determined by Pearson’s Correlation analysis. The anti-Xa potency of various LMWHs (1
mg/kg, SC) in primates was measured by the chromogenic anti-Xa assay using Hyphen Biomed kits. The TFPI antigen and functional
levels of all agents were determined by using commercially available Sandwich ELISA kits. The absolute quantification of GAG
contents of all agents was determined by using Heparin Red kits. All results represent the mean (±) standard deviation (n=4).
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APPENDIX C
IRB AND IACUC APPROVAL INFORMATION
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C1- Blood Draw from Healthy Human Volunteers
-

LU# 9191051098
Approved 5/1/1998, continuing approval granted 07/08/2020
Title: Normal Donor Blood Collection for Platelet Activity and Coagulations Assays

C2- Non-Human Primate Studies
-

LU#208582 (1.05); P/D#022-19; IACUC#; “Characterization of bovine heparin”;
10/D NHP
Approval Date: July 29, 2019
Expiration Date: July 29, 2022
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APPENDIX D
NIBSC/USP STANDARDS INFORMATION
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D1- WHO International Standard The 3rd International Standard for Low Molecular
Weight Heparin NIBSC code: 11/176 Instructions for use (Version 1.0, Dated 27/06/2013)
1. INTENDED USE
The 3rd International Standard for Low Molecular Weight Heparin, consists of ampoules, coded
11/176, containing aliquots of a freeze-dried material prepared from porcine mucosa. This
preparation was established as the 3rd International Standard for Low Molecular Weight Heparin
by the Expert Committee on Biological Standardisation of the World Health Organisation in
2012. It is intended for anti-Xa and anti-IIa potency estimation of low molecular weight heparin.
2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.
The material is not of human or bovine origin. As with all materials of biological origin, this
preparation should be regarded as potentially hazardous to health. It should be used and
discarded according to your own laboratory's safety procedures. Such safety procedures should
include the wearing of protective gloves and avoiding the generation of aerosols. Care should be
exercised in opening ampoules or vials, to avoid cuts.
3. UNITAGE
The standard was calibrated by 22 laboratories from 13 countries against the 2nd International
Standard for Low Molecular Weight Heparin (01/608). Anti-Xa and anti-IIa chromogenic
methods were used in the study. Twenty-two laboratories performed anti-Xa assays (100 assays
in total) and anti-IIa assays (80 assays in total). The following potencies were assigned based on
the geometric mean of all the valid assay results:
- 1068 International Units of anti-Xa activity per ampoule
- 342 International Units of anti-IIa activity per ampoule
Uncertainty: the assigned unitage does not carry an uncertainty associated with its
calibration. The uncertainty may therefore be considered to be the variance of the ampoule
content and was determined to be +/- 0.1%.
4. CONTENTS
Country of origin of biological material: France.
The mean weight of liquid content of 879 check weight ampoules was 1.0068g, with a
coefficient of variation of 0.097%. The mean weight of the freeze-dried plug was 9.22mg, with a
coefficient of variation of 1.39%. The mean residual moisture was 3.41%.
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D2- WHO International Standard 6th International Standard for Unfractionated Heparin
NIBSC code: 07/328 Instructions for use (Version 2.0, Dated 12/07/2013)
1. INTENDED USE
The 6th International Standard for Unfractionated Heparin, consists of ampoules, coded 07/328,
containing aliquots of freeze-dried heparin prepared from porcine mucosa. This preparation was
established as the 6th International Standard for Unfractionated Heparin, by the Expert Committee on
Biological Standardisation of the World Health Organisation in 2009, with labelled potency of 2145
IU/ampoule.
2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.The material is
not of human or bovine origin. As with all materials of biological origin, this preparation should be
regarded as potentially hazardous to health. It should be used and discarded according to your own
laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves
and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid
cuts.
3. UNITAGE
The standard was calibrated by 33 laboratories in 18 countries against the 5th International Standard for
Unfractionated Heparin (97/578). Twelve different methods were employed in the study: anti-Xa
chromogenic assay using purified antithrombin, anti-IIa chromogenic assay using purified antithrombin,
anti-Xa chromogenic assay using human plasma, anti-IIa chromogenic assay using human plasma, antiXa clotting assay, activated partial thromboplastin time (APTT), the European Pharmacopoeial (EP)
assay, the United States Pharmacopoeial (USP) sheep plasma assay*, the Chinese Pharmacopoeial (CP)
assay, the Japanese Pharmacopoeial (JP) assay, Thrombin Time and Prothrombinase induced clotting
time. A total of 690 assays were carried out. The potency of 2145 IU/ampoule was assigned by taking the
geometric mean of all the valid assay results. The details of the collaborative study is documented in
WHO/BS 09.2124.
* Uncertainty: the assigned unitage does not carry an uncertainty associated with its calibration. The
uncertainty may therefore be considered to be the variance of the ampoule content and was determined to
be ±0.12%.
* The USP sheep plasma assay was the official USP potency assay for Heparin Sodium and Heparin
Calcium until the end of September 2009. The current USP potency assay for Heparin Sodium and
Heparin Calcium is an anti-IIa chromogenic assay using purified antithrombin and 9 participants carried
out this current USP anti-IIa chromogenic assay.
4. CONTENTS
Country of origin of biological material: USA.
The bulk starting material consisted of a single batch of porcine mucosal sodium heparin. 275.0 g of dried
powder were dissolved in 26 L of sterile distilled water. The solution was distributed at room temperature
into 24,000 ampoules, coded 07/328. The contents of the ampoules were then freeze-dried under
conditions normally used for international biological standards (1).The mean weight of the liquid content
of 99 checkweight samples was 1.0050g, with coefficient of variation 0.12%. The mean weights of the
freeze dried plug was 10.7 ± 0.39 mg (mean of 6 estimates).
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D3- USP Statement on Heparin Potency Unit Assignment and Harmonization with the
International Standard for Unfractionated Heparin
In response to the heparin adulteration crisis of 2007/2008, USP has worked swiftly to
improve the standards for unfractionated heparin (UFH) in order to secure the supply of safe
heparin and heparin products in the US.
As part of the Stage 2 revisions to the Heparin Sodium monograph, USP has adopted a
new potency assay for heparin, the chromogenic anti-Factor IIa test. The high specificity of this
assay provides an additional safeguard against potential adulterants that may display heparin-like
activity in the previous USP plasma-based assay. Transition to the new assay and parallel
introduction of a new potency reference standard, USP Heparin Sodium for Assays Reference
Standard, has given the USP the opportunity to calibrate the new material relative to the
International Standard (IS) for UFH issued by the World Health Organization (WHO).
Over the past 30 years, there has been an estimated drift of 10% between the USP heparin
unit and the international unit for UFH. The calibration of the new USP Heparin Sodium for
Assays Reference Standard eliminates this difference since the standard is directly traceable to
the 5th IS for UFH.
USP does not anticipate that the change in the USP heparin unit resulting from its
harmonization with the IS has clinical significance. Due to the inherently low and extremely
variable bioavailability of heparin, finished drug product potencies are generally specified with
±10% of the potency values. In addition, therapeutic dosing of heparin is generally monitored by
aPTT. However, USP encourages industry stakeholders to work closely with the Food and Drug
Administration and the medical community in communicating the change in potency assignment.
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